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Abstract 
There is an urgent need for the development of novel antibacterial agents to combat the 
insidious proliferation of multi-drug resistant bacteria. Cationic antimicrobial peptides 
represent a naturally occurring class of compounds which have been used for millennia 
by many organisms to counter bacterial infections with little resistance. However, 
cationic antimicrobial peptides are not commonly used in the clinic as they have a number 
of associated drawbacks including poor metabolic stability, high molecular complexity 
(making them difficult to manufacture) and in some cases toxic side-effects.  
This project focuses on the development of a new class of antibacterial agent that employs 
the norbornane scaffold to mimic cationic antimicrobial peptides. A range of anion 
recognition groups and hydrophobic groups are included to assess the structure activity 
relationship of these compounds with respect to antibacterial activity. Importantly, these 
groups are well separated by the rigid norbornane core to generate a library of amphiphilic 
peptidomimetics. The norbornane-based analogues were evaluated for their antibacterial 
activity and cytotoxicity properties. Two fluorescently tagged analogues were also 
prepared with a view to elucidating a mode of action for these compounds. 
Finally, the use of appropriately functionalised norbornane derivatives as organogelating 
agents was investigated. The most potent organogelator was characterised using 1H NMR 
spectroscopy and both atomic force microscopy and transmission electron microscopy to 
gain an insight into its mode of assembly. 
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Plain English Summary 
There is a very real and imminent threat that in the future there will be no effective 
antibiotics available to treat some bacterial infections. As multi-drug resistant bacteria 
have rendered a number of antibiotics ineffective, doctors have recently turned towards 
antibiotics which were previously avoided, due to toxic side-effects, to treat bacterial 
infections. This project focuses on the development of new antibacterial agents to treat 
bacterial infections and combat the increasing prevalence of multi-drug resistant bacteria. 
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Chapter 1 
This Chapter begins with a history of antibiotics and their current role in modern 
medicine. The bacterial membrane is an excellent target for antibacterial agents and as 
such its properties will be detailed. A discussion on how bacteria develop resistance to 
antibiotics follows.  
Cationic antimicrobial peptides (AMPs) represent a class of potent antibacterial agents 
for which minimal bacterial resistance has been observed. The modes of action employed 
by cationic AMPs to kill bacteria and efforts to develop synthetic mimetics of cationic 
AMPs will be discussed. The norbornane framework is then introduced as a scaffold 
which warrants investigation for the development of cationic AMP mimetics and a 
potential pharmacophore is then proposed. The aims of this thesis are then outlined. 
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Introduction 
1.1 Antibiotics: A History 
Infectious diseases are the second leading cause of mortality worldwide and are directly 
responsible for fifteen million deaths annually.1,2 The term ‘antimicrobial’ refers to 
compounds that either kill or slow the growth of microorganisms such as Gram-positive 
and Gram-negative bacteria and fungi.3 Antimicrobials therefore encompass multiple 
classes of compounds including antibiotics and antifungals. Antibiotics can be sourced 
from living organisms such as plants and bacteria, synthetically produced or a 
combination of the two.4  
In 1910 a team led by the famous German scientist and Nobel Prize winner, Paul Ehrlich, 
provided the first example of a synthetically developed antibiotic; the arsenic-containing 
Salvarsan (Figure 1).5,6 Salvarsan is effective against a narrow range of diseases such as 
syphilis and sleeping sickness, and was the most frequently prescribed drug until the 
production of Penicillin begun on industrial scales.6,7 The mode of action of Salvarsan is 
still unknown and the correct molecular structure of the drug has only recently been 
elucidated; a mixture of 3 and 5-membered rings (Figure 1).5 
 
Figure 1: Structure of Salvarsan.5 
The sulfonamides are another early example of synthetically developed antibiotics.8 In 
1935 Gerhard Domagk demonstrated that the diazo sulfonamide Prontosil (3, Figure 2),9 
which was originally synthesised by Friedrich Mietzsch and Joseph Klarer in 1932,10 was 
an effective treatment of Gram-positive bacterial infections.11 Gerhard Domagk was 
subsequently awarded the Nobel Prize in 1939 for his work.12 Following the discovery of 
Prontosil, a large number of sulfonamide derivatives were synthesised such as 
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sulfapyridine 4 (Figure 2). Sulfonamide antibiotics are associated with a number of side-
effects including urinary tract infections and allergic reactions,12,13 and as a result, the 
clinical use of sulfonamides was quickly superseded by the β-lactam antibiotics.8  
 
Figure 2: Structures of Prontosil (3) and sulfapyridine (4). 
The importance of available and effective antibiotics is irrefutable. From the early 20th 
century to today, the life expectancy throughout most of the world has increased from 40 
to 77 years.4 The breakthrough discoveries of the sulfonamides and Penicillin in the 1930s 
and 40s have saved countless lives and sparked what is commonly referred to as the 
‘Golden Age’ of antibiotic research.14 
 
1.1.1: Discovery of Penicillin 
Alexander Fleming’s somewhat serendipitous discovery of Penicillin in September 1928 
changed the medical landscape.6,15 However, it took a further twelve years after this initial 
observation before a group from Oxford University, led by Howard Florey and Ernest 
Chain, were able to isolate Penicillin from the bacterium Penicillium in sufficient 
quantities and purity for clinical testing.  
The large number of bacterial-related fatalities during World War I (1914–1918) made 
the development of antibiotics a high priority. An intensified effort toward antibiotic 
development ensued and by World War II (1939–1945) Penicillin was used to treat 
bacterial infections.7 By 1945 Penicillin was being mass produced and assumed the status 
of number one drug for bacterial infections.6 
 
1.1.2: The Golden Age 
Despite all its hype, the ‘Golden Age’ of antibiotic discovery is restricted to a mere twenty 
year period (1940–1960).16 Following this, a fifty-year long period which Walsh refers to 
as the ‘Golden Age’ of antibacterial medicinal chemistry ensued, where revisions to 
existing drug classes were made to combat antibacterial resistance (Figure 3).  
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Figure 3: Timeline of antibiotic history (adapted from Walsh and Wencewicz, 2014).16 
Most ‘new’ drug classes synthesised during the ‘Golden Age’ of medicinal chemistry are 
in fact reincarnated versions of previously discovered scaffolds including the 
tetracyclines and macrolides.16 For example, the important discovery of the glycopeptides 
in the 1950s ultimately gave rise to a number of Vancomycin-like drugs.17 Whilst there 
has been steady progress in continually altering molecular scaffolds of known 
antibacterial agents to generate new drugs, there is a pressing need for the discovery 
and/or development of totally new classes of antibiotics.  
 
1.2 Antibiotics: The Current Climate 
“The future of humanity and microbes likely will unfold as a suspense thriller that could 
be titled Our Wits Versus Their Genes” 
(Joshua Lederberg, Science, 2003)18 
With the above quote, Nobel Laureate Joshua Lederberg succinctly summarised the 
current situation facing humankind with respect to infectious diseases. It has become a 
throw-away line in the literature to refer to humans as being at ‘war’ with bacteria.19-21 
This term is disliked by Spellberg who states “It is absurd to believe that we could ever 
claim victory in a war against organisms that outnumber us by a factor of 1022, that 
outweigh us by a factor of 108, that have existed for 1000 times longer than our species, 
and that can undergo as many as 500,000 generations during 1 of our generations.”2  
5 | P a g e  
 
There is a continuous need for iterative cycles of antibiotic discovery and development to 
combat the continued emergence of resistant bacterial pathogens to currently available 
pharmaceuticals.16 Whilst Gram-positive bacteria such as Vancomycin-resistant 
Enterococcus faecium and Methicillin-resistant Staphylococcus aureus (MRSA) pose a 
major global concern, it is the Gram-negative bacterial species which largely make up the 
so called ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella 
pneumoniae, Acinetobacter baumanii, Pseudomonas aeruginosa and Enterobacter 
species)22 and present an even more immediate treatment challenge.23 There has not been 
a new class of antibiotic to treat Gram-negative bacterial infections in decades16 and as a 
result medical practitioners have turned to polymyxins (such as Colistin) as a front-line 
therapy in recent times, despite being eschewed as too toxic many years ago.16,24,25 
The current antibiotic crisis has been a major discussion point in recent years.7,23,26-28 
There is a consensus among health professionals that a scenario is imminent whereby 
strains of pathogenic bacteria will be resistant to all current antibiotics.23,29,30 An increase 
in the instances of multi-drug resistant (MDR) bacteria, compounded by the current 
decline in novel drug development, only serves to bring this prediction closer to a reality 
(Figure 4).26  
 
Figure 4: A decline in antibacterial development in the face of increased bacterial resistance 
(taken from Cooper and Shales, 2011).26 
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1.2.1: A Decline in Antibacterial Development 
The human race finds itself in somewhat of a paradox; there is an urgent need for new 
antibacterial agents to be developed, however, many companies have withdrawn their 
efforts in this field.31 Since 1990 there has been a 78% decrease in the number of 
companies researching novel antibiotics32 invariably leading to a significant drop in the 
number of new antibiotics reaching the market. Today there are only four large 
pharmaceutical companies actively engaged in antibacterial research; AstraZeneca and 
GSK (London, UK), Novartis (Basel, Switzerland) and Sanofi-Aventis (Paris, France).14 
It should also be noted that AstraZeneca announced in 2013 that they would be scaling 
back their investment in antibiotic discovery.14 The move by pharmaceutical companies 
away from antibiotic discovery is due to a combination of medical, business and scientific 
reasons.33  
Pharmaceutical companies are reluctant to invest in antibiotic research as the financial 
return is much lower than that of other therapeutics. For example, anti-hypertensive 
agents are taken for many years whilst antibiotics are typically only administered for a 
few weeks.14,31 Also of concern is the minimal cost of antibiotics (e.g. Vancomycin costs 
$7 for one gram)34 when compared to other treatments such as anticancer drugs (often > 
$10 000 per treatment).14 The inevitable emergence of bacterial resistance to a new 
antibiotic lowers the drugs validity and ultimately leads to decreased profits. 
Another deterrent is the effort required to have a new drug approved by the Food and 
Drug Administration (FDA),35 as depicted in Figure 5.16 It has been well argued that 
regulatory restrictions currently in place are overly stringent to get a new drug through 
clinical trials to market.36-38 The cost of these tight regulations for the manufacturing, 
clinical trials and efficacy of new drugs has been passed onto the pharmaceutical 
companies; a further discouragement when financial returns are likely to be low.38  
 
Figure 5: Antibacterial drug development timeline (adapted from Walsh and Wencewicz, 
2014).16 
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1.2.2: An Increase in Bacterial Resistance 
Wright defines antibiotic resistance as “the continued growth of microorganisms in the 
presence of cytotoxic concentrations of antibioitcs.”17 The insidious proliferation of 
bacterial resistance to currently available therapeutics has been labelled by Dr Tom 
Frieden (Director of U.S Centers for Disease Control and Prevention) as “one of our most 
serious health threats.”27 Resistance has now been observed for every antibiotic in current 
clinical use.39 The ESKAPE pathogens are responsible for a large majority of the 
nosocomial infections encountered by medical practioners.22 The factors attributed to 
bacterial resistance, as well a discussion on the molecular pathways bacteria employ to 
develop resistance, is provided in section 1.4. 
 
1.2.3: Recent Developments 
Public awareness of the antibiotic crisis has risen significantly through popular media 
outlets in recent times.28,40,41 As a result there has been a renewed push from Governments 
and academics alike to pursue novel antibacterial agents. A number of recent private-
public partnerships and large financial awards,14 in combination with the expedited 
approval of some new drugs by the FDA, such as Bedaquiline (6, Figure 6),42 is evidence 
of a change in mindset. 
Twenty-two new antibiotics were launched between 2000 and 2013. Five of these 
antibiotics belonged to new classes; Linezolid (5, oxazolidinones), Daptomycin 
(lipopeptides), Retapamulin (pleuromutilins), Fidaxomicin (tiacumicins) and Bedaquiline 
(6, diarylquinolines).14 Furthermore, a number of prospective drugs are currently 
undergoing clinical trials.14,43 
In early 2015 much fanfare accompanied the newly discovered antibacterial agent 
Teixobactin (7, Figure 6).44 This antibacterial agent exhibits low minimum inhibitory 
concentration (MIC) values (< 0.5 μg/mL) against a number of Gram-positive bacterial 
strains, and its dual mode of action makes it challenging for bacteria to develop resistance 
against it.44 Of even greater interest was the method employed that led to the discovery 
of Teixobactin; a multi-channelled device45 that simultaneously isolates and grows 
previously unattainable bacteria from soil extracts.44  
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Figure 6: Structures of Linezolid (5), Bedaquiline (6) and Teixobactin (7). 
 
1.3 The Bacterial Cellular Envelope 
Bacteria are classified as prokaryotic organisms; unicellular with no intracellular 
organelles or a membrane-bound nucleus.46 In 1884 Danish scientist Hans Christian Gram 
developed a bacterial staining technique to make bacteria more visible in stained sections 
of lung tissue.47 This eponymous stain is now used to distinguish bacteria based on 
structural characteristics of their cellular envelope; namely the amount of peptidoglycan 
(also known as murein sacculus)48 in the bacterial cell wall.49 Gram-positive bacteria, 
which contain a thick layer of peptidoglycan in their cell wall, are stained purple, whereas 
Gram-negative bacteria, which contain only a thin layer of peptidoglycan in their cellular 
envelope, are unable to retain the stain.50 A third category of bacteria exist—the 
Corynebacterineae group—whose cellular envelope exhibit both Gram-positive and 
Gram-negative characteristics.51 This class of bacteria includes important pathogens such 
as Mycobacterium tuberculosis and Mycobacterium leprae and it is the complexity of 
their cellular envelope that gives rise to their virulence.52 Whilst it is not within the scope 
of this thesis to discuss this third class of bacteria, a number of excellent publications 
exist on the topic.51,53-57 
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1.3.1: Gram-positive Bacteria 
Gram-positive bacteria rely on a thick peptidoglycan layer (up to 100 nm) as their first 
line of protection (Figure 7).58,59 Peptidoglycan is a polymer consisting of repeating β-1,4 
linked units of N-acetylglucosamine and N-acetylmuramic acid which are cross-linked by 
short peptides.60,61 The four-amino acid peptide chain, which is attached through an amide 
bond from the ᴅ-lactoyl moiety of the N-acetylmuramic monomer, is typically comprised 
of ʟ-Ala-γ-ᴅ-Glu-meso-A2pm*-ᴅ-Ala,61 however variations are known to exist.49  
 
Figure 7: Schematic of the Gram-positive bacterial cellular envelope (taken from Collin 
College, 2015).62 
Lipid II, which is a disaccharide comprised of a five-amino acid peptide chain, is the pre-
cursor to peptidoglycan (Figure 8). The synthesis of Lipid II takes place on the inner 
surface of the plasma membrane before being  translocated by enzymes called ‘flippases’ 
to the exterior of the plasma membrane.63 The Lipid II unit is then further modified, 
including hydrolysis of the terminal ᴅ-Ala residue, and incorporated into the 
peptidoglycan polymer.  
                                                 
* A2pm is the abbreviation for 2,6-diaminopimelic acid  
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Figure 8: Structure of Lipid II.16  
In addition to thick assemblies of peptidoglycan, the Gram-positive bacterial cellular 
envelope is comprised of polyanionic teichoic acids; macromolecular structures 
composed of wall teichoic acids and lipoteichoic acids.58 The wall teichoic acids and 
lipoteichoic acids vary considerably between bacterial species and are either covalently 
bound to the peptidoglycan unit (wall teichoic acids) or to a lipid anchor near the interface 
between the cell wall and cellular membrane (both wall teichoic and lipoteichoic acids).64 
 
1.3.2: Gram-negative Bacteria 
Gram-negative bacteria encompass some of the most troublesome pathogenic bacterial 
species including Salmonella typhimurium, Heliobacter pylori, Chlamydia trachomatis, 
as well as ESKAPE pathogens P. aeruginosa, E. coli, K. pneumoniae and A. 
baumanii.23,65 The complexity of the Gram-negative bacterial cellular envelope is an 
important consideration in antibacterial design. There are three main sections to the 
cellular envelope of Gram-negative bacteria; the inner plasma membrane, the cell wall 
comprised of a thin peptidoglycan layer and the outer membrane (Figure 9).52,59,66-70  
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Figure 9: Schematic of the Gram-negative bacterial cellular envelope (taken from Collin 
College, 2015).62 
The inner membrane is a bilayer predominately comprised of well-defined domains of 
phospholipids, chiefly phosphatidyl ethanolamine and phosphatidyl glycerol,71,72 as well 
as a variety of lipoproteins.52 The inner membrane, along with the cytoplasm, is the site 
for which all essential elements for maintaining the cellular-envelope are synthesised 
such as periplasmic, peptidoglycan and outer membrane components.52 These key 
components are then transported from the inner membrane to their required destination 
within the cellular envelope.  
Whilst the inner membrane follows the fluid mosaic model, the cell wall (which is 
comprised of peptidoglycan) provides structural rigidity to the cellular envelope. The 
main role of the cell wall is to resist turgor. So important is the role of the cell wall that 
cell lysis occurs if there is any disruption to its biosynthesis or functionality.52,61,73  
Gram-negative bacteria possess a thick outer-membrane which acts as the cell’s first line 
of defence. This outer-membrane is largely comprised of endotoxins (roughly 50%)65 
which, upon entering the mammalian blood stream, can cause a life-threatening response 
from the hosts immune system.74,75 These endotoxins are lipopolysaccharides (LPS)—a 
complex glycolipid unique to Gram-negative bacteria.76,77 The LPS unit consists of three 
sections: the O-antigen, core and lipid A (Figure 10).78 Whilst the O-antigen and the outer 
and inner core components vary between bacterial species, the lipid A molecule is 
conserved across all Gram-negative bacteria; hence it is a useful target for antibacterial 
agents.79,80 Altering the lipid A group would be a very costly evolutionary process, as the 
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bacteria would have to redesign its membrane composition. As such, it is less likely that 
bacterial resistance would develop against drugs that target lipid A.81 
 
Figure 10: Generic LPS structure highlighting the conserved lipid A unit.79,82 
Lipid A is a covalently β-1,6-linked disaccharide of ᴅ-glucosamine, as shown in 
Figure 10.79,80,83 Two anionic phosphate groups are present on the α-glycosidic position 
1 and the nonglycosidic position 4ʹ. Additionally, ester (positions 3 and 3ʹ) and amide 
(positions 2 and 2ʹ) groups, of which two are typically further acylated at the hydroxyl 
position, give rise to six long alkyl chains resulting in an overall amphiphilic structure.84 
Typically these hydrophobic chains are fully saturated allowing for tighter packing which 
strengthens its function as a protective barrier.52 The role of the two phosphate groups is 
to bind strongly through ionic interactions with Ca2+ and Mg2+ to create a stable and 
selectively permeable membrane and to help anchor the LPS unit to the outer 
membrane.78,85  
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1.4 Antibacterial Resistance: A Major Global Concern 
“There is the danger that the ignorant man may easily underdose himself and by 
exposing his microbes to non-lethal quantities of the drug make them resistant.” 
(Alexander Fleming, Nobel lecture, 1945)86 
It is commonly accepted that the misuse of antibiotics, including sub-lethal dosage 
concentrations,87 overuse in both clinical and agricultural settings, as well as availability 
without prescription in some countries (such as Brazil),46 are responsible for the level of 
antibacterial resistance prevalent today.14 Recent studies have also pointed towards 
resistomes—a collection of antibacterial resistant genes that have likely been present in 
bacterial populations for a millennia—as the major cause of antibacterial resistance.17,88,89 
However, it is more than likely that both factors work in concert to give rise to drug-
resistant bacterial pathogens.17,88  
 
1.4.1: Extent of the Problem 
History indicates that resistance against all new antibacterial agents will occur at some 
point. Resistance against Penicillin was observed within three years of clinical use 
(Table 1).16 More recently, bacterial resistance against Linezolid, Daptomycin, 
Retapamulin and Fidaxomicin occurred within one year of use (Table 1). Vancomycin is 
an exception to this trend, but the fact that the drug was used sparingly probably aided in 
the slower emergence of resistance. 
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Table 1: Emergence of resistance to clinical antibiotics16 
Antibiotic Year deployed Clinical resistance observed Reference 
Sulfonamides 1930s 1940s 90 
Penicillin 1943 1946 90 
Streptomycin 1943 1959 90 
Chloramphenicol 1947 1959 90 
Tetracycline 1948 1953 90 
Erythromycin 1952 1988 90 
Vancomycin 1956 1988 90 
Cephalosporins 1960s Late 1960s 90 
Methicillin 1960 1961 90 
Ampicillin 1961 1973 90 
Nalidixic acid 1962 1962 91 
Fluoroquinolones 1980s 1980s 92 
Linezolid 1999 1999 93 
Daptomycin 2003 2003 94 
Retapamulin 2007 2007 95 
Fidaxomicin 2011 2011 96 
Bedaquiline 2013 ? 42 
 
1.4.2: Antibacterial Resistance Mechanisms 
From a molecular viewpoint, bacteria can develop resistance to antibacterial agents 
through three general mechanisms: i) the molecular target of the drug can be modified so 
that the target is no longer sensitive to the drug; ii) an enzyme can be produced that 
destroys the drug; or iii) concentration of the drug within the bacteria can be reduced, for 
example, by actively pumping the drug out of the pathogen or by decreasing the 
permeability of the membrane to the antibiotic (Figure 11).32,46,97 
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Figure 11: General mechanisms of antibiotic resistance (taken from Abreu, McBain and 
Simões, 2012).32 
Beta-lactam antibiotics, such as Penicillin V,98 Methicillin99 and Cephalosporins100 
(Figure 12), bind covalently to bacterial proteins that are required for the biosynthesis of 
peptidoglycan.101,102 Bacteria that are resistant to Penicillins often contain the mecA gene 
which encodes for a protein that has a reduced binding affinity to all β-lactam antibiotics 
and consequently is able to perform its biosynthetic function unhindered.103-105 
Alternatively, bacterial strains which are resistant to β-lactam antibiotics can express β-
lactamases which hydrolyse the β-lactam ring.106 
 
Figure 12: Beta-lactam antibiotics; Penicillin V, Methicillin and Ceftobiprole (a type of 
cephalosporin). The β-lactam moiety for each example is highlighted in red. 
Bacterial resistance against Vancomycin is due to an alteration of the target site. 
Vancomycin recognises the ᴅ-Ala-ᴅ-Ala dipeptide sequence present in Lipid II,107 
ultimately leading to inhibition of peptidoglycan cross-linking and cell wall synthesis 
(Figure 13).108,109 Vancomycin-resistant strains of Enterococci (VRE) are known to 
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produce a protein (VanA) which is responsible for the synthesis of the ᴅ-Ala-ᴅ-Ala 
dipeptide. However, the VanA protein also synthesises similar dipeptides ᴅ-Ala-ᴅ-Lac, 
ᴅ-Ala-ᴅ-Phe and ᴅ-Ala-ᴅ-Met, which replace the natural ᴅ-Ala-ᴅ-Ala dipeptide, resulting 
in a 1000-fold lower affinity to Vancomycin.110   
 
Figure 13: Binding of Vancomycin with the D-Ala-D-Ala terminus of Lipid II (adapted from 
Walsh, 2000).111 
Cationic antimicrobial peptides (AMPs) are a class of compounds which have 
demonstrated activity against most microbes including bacteria, fungi and viruses, with 
only minimal resistance being observed to date.112 As such, they represent an excellent 
starting point for the design of new antibacterial agents. 
 
1.5 Cationic Antimicrobial Peptides 
Antimicrobial peptides are naturally occurring compounds that differ in size (12–
50 amino acid residues) and sequence.113 AMPs are part of the human innate immune 
system114 and can be sourced from multiple origins such as plants, mammals and snake 
venom.115 AMPs are often categorised into four groups based on their structure; α-helices, 
β-sheets, peptides with extended structures and peptides with loop structures.116-118 There 
are also additional sub-groups of AMPs such as lipopeptides.25 In order to interact with 
the negatively charged groups of the bacterial cytoplasmic membrane, such as the lipid A 
moiety present on Gram-negative bacteria, a specific class of AMP—cationic AMPs—
are required.119  
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Cationic AMPs were first reported by Steiner et al. in 1981, with the isolation of a 37 
amino acid cationic peptide from the haemolymph of a moth (Hyalophora cecropia).120 
This cationic AMP was found to be active against both Gram-negative (E. coli) and Gram-
positive (Bacillus megaterium) bacterial pathogens using disk diffusion assay at 
0.13 mM; zones of inhibition (ZOI) of 14.0 and 10.0 mm were observed respectively.120  
In recent years cationic AMPs have received much attention as promising antibacterial 
agents that could overcome the bacterial resistance problems encountered by other 
antibiotics.117,121,122 The mode of action employed by these compounds, which will be 
discussed in section 1.6, justifies this optimistic view.123 Cationic AMPs adopt an 
amphiphilic topology whereby hydrophobic and cationic segments are located in well 
separated regions of the overall peptide.113,124 They are typified by a net positive charge 
of at least +2 due to the presence of arginine and lysine residues which are protonated at 
physiological pH.118,122 
 
1.5.1: Alpha Helical Cationic AMPs 
Structurally amphiphilic α-helices are a commonly encountered secondary structure in 
bioactive  proteins.125 One of the first known antimicrobial peptides, Magainin, falls 
within this group.126 Magainin was first isolated from the skin of the African clawed frog 
Xenopus laevis.127 The structure of Magainin II was elucidated using NMR spectroscopy 
and was shown to adopt an α-helical formation in solution.128 The facial amphipilicity of 
Magainin II was also confirmed (as depicted in Figure 14) using nuclear Overhauser 
effect spectroscopy (NOESY).128  
 
Figure 14: Structure of Magainin II in solution. Hydrophobic, cationic and anionic residues are 
highlighted in green, blue and red respectively (taken from Haney et al., 2009).126 
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1.5.2: Beta Sheet Cationic AMPs 
The structural rigidity of β-sheet peptides can be enhanced by the inclusion of 2–4 
disulfide bridges between cysteine residues.121 This group of peptides includes such 
compound classes as human defensins, protegrins and plectasin.121 
Defensins, which include human β-defensins 1,129 2130 and 3,131 are part of the innate 
immune system and exhibit antibacterial activity against both Gram-positive and Gram-
negative bacteria.132 Human β-defensin 3 (Figure 15) is a large cationic AMP consisting 
of 45 amino acids. The structural integrity of human β-defensin 3 is maintained through 
a triple stranded antiparallel β-sheet and three disulfide bonds. Interestingly, it has been 
shown that removing the disulfide bonds does not abolish antibacterial activity, however 
the ability of the linear analogue to respond to pathogenic stimuli is significantly 
impaired.133,134 
 
Figure 15: Structure of human β-defensin 3 in solution. Hydrophobic, cationic and anionic 
residues are highlighted in grey, blue and red respectively (taken from Nguyen, Haney and 
Vogel, 2011).135 
 
1.5.3: Extended Cationic AMPs 
Extended cationic AMPs are a group of peptides that don’t form a regular secondary 
structure. Compounds of this group are typically abundant in glycine, proline, tryptophan, 
arginine and in some cases histidine amino acids.121  
Indolicidin is an example of a peptide that falls within this category. Indolicidin is a 
relatively small cationic AMP (13 amino acids) that is found naturally in bovine 
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neutrophils.136 Antibacterial activity against both Gram-positive and Gram-negative 
bacteria has been observed for Indolicidin.136,137 The structure of Indolicidin was 
elucidated using NMR spectroscopy and no classical secondary structure was 
identified.138 Instead, Indolicidin formed a ‘wedge’ shape which was attributed to two β-
turns located at the lysine-5 and tryptophan-8 amino acid residues (Figure 16). 
 
Figure 16: Structure of Indolicidin in solution. Hydrophobic and cationic residues are 
highlighted in grey and blue respectively (taken from Nguyen, Haney and Vogel, 2011).135 
 
1.5.4: Cyclic Cationic AMPs 
Another group of peptides are the cationic AMPs which contain a peptide loop.121 A 
commonly cited example is that of bactenecin; a 12-amino acid peptide containing two 
cysteine residues which bind to form a cycle through a disulfide bridge.139,140  
Another example are the rhesus θ-defensins which are derived from rhesus macaque 
leukocytes.141 There have been three rhesus θ-defensins isolated from rhesus leukocytes 
(RTD1, RTD2 and RTD3) to date. Given isolation and purification of these macrocyclic 
peptides is not a trivial task, and humans are unable to transcribe the θ-defensins due to a 
premature stop codon, three synthetic mimics (retrocyclins 1, 2 and 3) have since been 
constructed.142,143 These rigid peptides are locked in a cyclic formation through multiple 
disulfide bridges (Figure 17) and have demonstrated potent antimicrobial behaviour.141  
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Figure 17: Structure of retrocyclin-1 (11).144 
 
1.5.5: Lipopeptides  
An important sub-group of cationic AMPs are lipopeptides which are comprised of both 
peptide and fatty acid portions.25 A well-known family of lipopeptides are the polymyxins 
which consist of five different compounds (polymyxins A–E).25,145 Of these compounds 
only polymyxins B and E (otherwise known as Colistin) have been clinically used.  
Commercial Colistin is comprised of two structurally related compounds; Colistin A and 
B (Figure 18).146 Furthermore, there are two forms of commercially available Colistin; 
Colistin sulfate (oral and topical use) and Colistimethate sodium (parenteral use).146 
Throughout the 1960’s Colistin was used worldwide for the treatment of Gram-negative 
bacterial infections, but owing to high levels of nephrotoxicity its use fell out of favour 
in the 1970s.146-149 Due to the current lack of available options to treat MDR bacterial 
infections, the use of Colistin has been reconsidered in recent years.25  
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Figure 18: Structure of Colistimethate sodium. 
Colistimethate sodium is readily hydrolysed under aqueous physiological conditions to 
form Colistin and a mixture of partially sulfomethylated derivatives. A hydrophobic fatty 
acid chain connected to a hydrophilic polypeptide ring, gives Colistin an overall 
amphiphilic structure which is crucial to its antibacterial activity.150 Colistin has a net 
positive charge of +5 due to the presence of five lysine amino acid residues.  
 
1.6 Cationic AMP Mode of Action 
Multiple theories have been proposed to explain how cationic AMPs kill bacteria 
including the barrel-stave and ‘carpet’ models.150 Common to these theories is that an 
electrostatic interaction facilitates the initial association of the cationic AMP with the 
anionic regions of the bacterial cellular envelope.116,119,150,151 For example, the ionic 
interaction between the cationic AMPs and the anionic phosphate groups of lipid A result 
in the displacement of the Ca2+ and Mg2+ cations.122,152 As the cationic AMP is invariably 
bulkier than the displaced Ca2+ and Mg2+ ions, the affected membrane develops transient 
‘cracks’.25 Hydrophobic interactions, provided by the non-polar residues in the cationic 
AMP, act to disrupt the structural integrity of the membrane in a detergent-like manner, 
leading to cell death.25,137,153 
Colistin provides an excellent example of membrane lysis by this general mechanism. 
Initially, the positively charged groups of Colistin coordinate with the negatively charged 
phosphate anions of the LPS group of Gram-negative bacteria. The hydrophobic portion 
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of Colistin then penetrates the membrane which ultimately leads to membrane 
degradation and cell lysis.150,154,155    
 
1.6.1: Barrel-stave Model 
The barrel-stave model proposes that prior to interaction with the outer membrane the 
cationic AMPs aggregate to form bundles of α-helices that are able to embed themselves 
within the membrane.118,156 These new assemblies form pores (barrels) that increase the 
permeability of the cell, essentially allowing all molecules to pass freely through the 
membrane resulting in lysis (Figure 19).151,156 
 
Figure 19: The barrel-stave model (taken from Brogden, 2005).151 
An example of an AMP acting in a barrel-stave fashion is Alamethicin (12, Figure 20); a 
20-amino acid long peptide, derived from the fungus Trichoderma viride.157 The α-helical 
Alamethicin is comprised of eight hydrophobic α-aminoisobutyric acid residues and is 
acylated at the N-terminus. Alamethicin is able to attach, aggregate and insert into the 
membrane bilayer; as evidenced by orientated circular dichroism, neutron scattering and 
synchrotron-based X-ray scattering experiments.158,159 The hydrophobic regions of 
Alamethicin then induce transmembrane pores which leads to cell death.159   
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Figure 20: Structure of Alamethicin (12).157 
 
1.6.2: Carpet Model 
In the carpet model cationic peptides individually carpet the membrane surface.121,160 
After enough of these molecules have coated the membrane a critical local concentration 
is reached and the peptides can ‘dissolve’ portions of the membrane which results in the 
formation of pores.156 These pores destabilise the membrane again leading to cell lysis 
(Figure 21).151,156  
 
Figure 21: The carpet layer model (taken from Brogden, 2005).151 
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The 26-amino acid cationic peptide Melittin (13, Figure 22) is found in the venom of 
European honey bees (Apis mellifera).161 Melittin has five amino acids which are 
protonated at physiological pH (three lysine and two arginine residues) as well as a 
number of hydrophobic components.161-163 Melittin carpets the membrane of pathogenic 
bacteria to ultimately disrupt the structural integrity of the membrane.118 The Ladokhin 
group has used fluorescent markers and circular dichroism experiments to demonstrate 
that Melittin acts in a ‘detergent-like’ fashion as opposed to the previously postulated 
barrel-stave model.164 
 
Figure 22: Structure of Melittin (13).162,163 
 
1.7 Cationic AMP Mimetics 
Despite overwhelming optimism in the literature for the application of cationic AMPs as 
new generation antibiotics, very few of these compounds have reached a clinical 
setting.112 There are two main problems associated with peptide drugs: 
1. Peptides are prone to hydrolysis in vivo and cationic derivatives are even more 
susceptible.112 Cationic AMPs are excellent substrates for the chymotrypsin 
family of endoproteases.165 
2. Cationic AMPs are generally cross-linked and high molecular weight peptide 
structures that are costly to construct synthetically. 
Therefore, the development of simpler, cheaper and more metabolically stable 
antimicrobial agents that mimic cationic AMP activity is an important pursuit.166,167 The 
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essential features for antibacterial activity are the topologically defined hydrophobic and 
cationic regions that create facial amphiphilicity.† Selected examples of cationic AMP 
mimetics from the past fifteen years will now be briefly discussed. 
 
1.7.1: Lipopolyamines 
Work from David et al., showed that lipopolyamines bind strongly to the LPS group of 
Gram-negative bacteria.168 The affinity of commercially available 1,3-di-oleoyloxy-2-(6-
carboxspermyl)-propylamide) (DOSPER) to LPS is approximately 10% compared to 
Polymyxin B. However, as DOSPER (Figure 23) is already FDA-approved for other 
medicinal purposes, and has an excellent toxicity profile, it represents an attractive class 
of cationic amphiphile for the treatment of bacterial infections.169 David et al., propose 
that DOSPER could be administered with other antibacterial agents to bind and trap LPS 
units as it is relatively non-toxic and does not appear to inhibit the antibacterial effects of 
other antibitoics.168 
 
Figure 23: Structure of DOSPER.168 
 
1.7.2: Calixarenes 
Calixarenes are structurally rigid molecules and can be selectively functionalised in a pre-
organised fashion. The calixarene-based compounds from the Mayo group are excellent 
examples of facially amphiphilic compounds.82 In the case of calixarene 15 (Figure 24) 
the hydrophobic tert-butyl groups are well separated from the cationic guanidine 
moieties. 
                                                 
† Throughout the remainder of this document hydrophobic and cationic regions will be coloured red and 
blue respectively. 
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Figure 24: Structure of calixarene 15.82 
Compounds such as 15 were shown to form β-sheets and bind to LPS in vitro.82 The IC50 
values of 15 for LPS binding in E. coli (0.04 μM) are comparable to polymyxin B 
(0.03 μM).82 NMR titrations with lipid A using 15, in combination with total correlation 
spectroscopy (TOCSY), indicated initial binding was due to electrostatic interactions 
between the positively charged groups located on the calixarene framework and the 
negatively charged phosphate groups of LPS.82 
 
1.7.3: Functionalised Triaryl Scaffolds 
Thaker and co-workers evaluated a series of diaminium and diguanidinium functionalised 
triaryl frameworks.170 Broad spectrum activity was observed in this study with the most 
potent diguanidine 16 (Figure 25) exhibiting a minimum inhibitory concentration (MIC) 
of 0.78 μg/mL against S. aureus. For this series there was no significant difference in 
antibacterial activity between guanidine and amine functionalised compounds. Altering 
the length of the alkyl linker between the charged moieties and the triaryl scaffold resulted 
in no observable differences in antibacterial potency. Indeed, MIC values of 6.25 and 
12.5 μg/mL were observed against E. coli and K. pneumoniae respectively for all 
analogues (16–18). The authors determined that the hydrophobic tert-butyl groups were 
crucial for these triaryl compounds to elicit antibacterial activity.170  
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Figure 25: Triaryl-based cationic AMP mimetics 16–18.170 
 
1.7.4: Binapthyl-based Compounds 
Bremner and co-workers reported the binapthyl-based diguanidine 19 (Figure 26) which 
exhibits antibacterial activity against a range of Gram-positive and Gram-negative 
isolates, highlighted with an MIC value of 4 μg/mL against S. aureus.171 The authors 
reported a second generation binapthyl-based cationic amphiphile (20, Figure 26) which 
possessed slightly improved antibacterial activity; MIC = 2 μg/mL against S. aureus.172 
This second generation compound was much more selective for Gram-positive bacteria 
with only modest activity against Gram-negative bacteria observed.172 
 
Figure 26: Binapthyl-based cationic AMP mimics 19 and 20.171,172 
These selected examples clearly illustrate that cationic AMP mimetics can be successfully 
developed as antibacterial agents. However, despite advances in this area, there is still a 
pressing need for novel cationic AMP mimetics using molecular frameworks which allow 
for custom functionalisation and promote facial amphiphilicity.  
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1.8 Norbornane-based Cationic AMP Mimetics 
The bicyclo[2.2.1]heptane (norbornane) scaffold is an ideal framework from which 
cationic AMP mimetics can be constructed. Its rigid structure ensures a pre-organised 
system; groups can be attached with the expectation that they will orientate in a 
predictable three-dimensional arrangement. The norbornane framework also represents 
one of the most accessible, pre-organised frameworks available and has a history of use 
in many areas of chemistry. 
 
1.8.1: Applications of Norbornane Compounds 
The norbornane scaffold features in a number of pharmaceuticals used to treat a variety 
of disease states.173 For example, Biperiden 21 (Figure 27) is used for the treatment of 
mild cases of Parkinson’s disease,174 cyclothiazide 22 is administered in Japan and 
throughout Europe as an orally available treatment of hypertension175 and more recently 
(in 2013), Lurasidone (23) was approved for the treatment of bipolar I depression.176  
 
Figure 27: Examples of pharmaceutically active norbornenes 21–23. 
In the field of asymmetric synthesis, chiral auxiliaries based on the norbornane scaffold 
have been successfully employed. Norbornane 24 has been used as a ligand for the 
enantioselective addition of diethylzinc to benzaldehyde in quantitative yields and good 
enantiomeric excess (66% ee).177 Camphor-based compounds such as 25,178 26179 and 
sultam 27180 (Figure 28) have also been used to generate chiral products.181  
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Figure 28: Examples of norbornane-based compounds. 
Functionalised norbornanes have been used for a wide variety of applications in the field 
of supramolecular chemistry. Work by the Ranganathan group using X-ray 
crystallography and circular dichroism have shown that in the solid state norbornene 28 
(Figure 28) can self-assemble into ‘column-type’ arrays through hydrogen bonding 
interactions.182  
The norbornane scaffold has also found use in both cation and anion recognition. The 
Ranganathan group has demonstrated that cyclic peptidomimetics, such as 29 (Figure 29) 
which was shown by 1H NMR and circular dichroism spectroscopic analysis to adopt a 
β-sheet conformation, can transport metal cations across biological membranes.183 
Furthermore, the Pfeffer group have employed norbornane 30 as an anion host, which 
was shown to bind in a 1:2 fashion to dihydrogen phosphate anions (Figure 29).184 
 
Figure 29: Cation sensor norbornene 29183 and norbornene 30 binding to two equivalents of 
phosphate.184 
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1.8.2: Norbornanes as AMP Mimetics 
Given norbornene 30 can bind two phosphate anions, and lipid A has a bisphosphonate 
structure, facially amphiphilic norbornane 31 (Figure 30) was synthesised as a lipid A 
binder.185 Hydrophobicity was installed to the norbornane framework using an acetal 
group, while the thiourea groups of 30 were replaced with charged guanidine moieties, to 
make norbornane trifluoroacetate salt 31 as a facially amphiphilic cationic AMP mimetic. 
Norbornane 31 was evaluated for its antibacterial activity using disk diffusion assay at 
100 μg/disk and was shown to inhibit P. aeruginosa with a ZOI of 19 mm.185 
Furthermore, norbornane 31 was non-haemolytic when tested against healthy human red 
blood cells.185  
 
Figure 30: Norbornane cationic AMPs 31 and 32. 
Subsequent work within the Pfeffer group focused on the synthesis and evaluation of a 
series of diaminium and diguanidinium norbornane hydrochloride salts. This work used 
i) the guanidine or amine functional groups to impart a cationic charge and ii) a range of 
hydrophobic groups attached to the norbornane framework via an acetal linkage.186 It was 
found that acetals linked directly to an aryl group (such as 32, Figure 30) degraded under 
acidic conditions and many of the compounds evaluated for antibacterial activity were 
not spectroscopically pure.186 It was proposed that an acid-mediated ring opening event 
took place to ultimately give an oxonium cation.185 In instances when an aryl group was 
bound directly to the acetal, the oxonium cation (such as 38, Scheme 1) would be 
resonance stabilised; unlike its alkyl counterpart thereby making alkyl acetals less prone 
to hydrolysis.186  
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Scheme 1: Alkyl acetal (top) and aryl acetal (bottom) degradation under acidic conditions. 
 
1.9 Project Aims 
Given the previous generation of compounds were prone to acetal hydrolysis under acidic 
conditions186 a true structure-activity relationship (SAR) is yet to be established. Based 
on the work by Pfeffer et al.,185 40 was identified as a useful general design for cationic 
AMP mimetics based on the norbornane framework (Scheme 2). Hence the principal aim 
of this thesis is to generate SAR data for compounds of the general structure 40. In order 
to achieve this, variations to both the anion recognition and hydrophobic groups is 
required. The synthesis of fluorescent analogues will be also be pursued as fluorescence 
microscopy studies may provide an insight into the mode of action of these compounds. 
Finally, biological evaluation of all norbornane-based peptidomimetics against 
pathogenic bacterial strains is a key requirement of this thesis. 
 
Scheme 2: General structure 40 and an overview of the key project aims. 
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1.9.1: The Role of the Anion Recognition Group 
The electrostatic interactions between cationic AMPs and the phosphate groups of the 
bacterial cellular envelope are the first step in the MOA of cationic AMPs.81 A range of 
anion recognition groups will be included in this project including charged moieties such 
as guanidinium, aminium, imidazolium and pyridinium groups (Figure 31). Substituted 
guanidines have also been shown to have antibacterial activity185 and therefore will also 
be included in this study. Charge-neutral functional groups which have shown to be 
capable of anion recognition, such as thioureas184 and squaramides,187 will also be 
investigated (Figure 31). The importance of a net cationic charge will be explored by 
attaching one, two or three of these charged species to the norbornane framework. 
 
Figure 31: Anion recognition groups to be investigated in this project. 
 
1.9.2: Synthesis of Aminoethylguanidine 41 
Previous work employed aminoethylguanidine 41 (Figure 32) to attach guanidinium 
functionality to the norbornane framework (31, Figure 30).185 The cost of 
aminoethylguanidine 41‡ results in many research groups opting to synthesise 41 in-
house. As such, an operationally simple and reliable synthesis that gives access to 
aminoethylguanidine 41 (and related compounds) in large quantities is required.
                                                 
‡ $305/gram, Sigma Aldrich catalogue (7/11/2015). 
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Figure 32: Aminoethylguanidine 41. 
 
1.9.3: The Role of the Hydrophobic Group 
Hydrophobicity plays a vital role in the antibacterial activity of cationic AMPs.117 As 
such, a selection of alkyl, aryl and alkyl/aryl hydrophobic groups will be attached to the 
norbornane framework. An acetal linkage has previously been used to attach 
hydrophobicity to the norbornane scaffold185,186 and it is an aim of this project to optimise 
this process to furnish compounds of the general structure 42 (Figure 33) which avoid the 
direct attachment of aryl moieties to the acetal group.  
 
Figure 33: Hydrophobic groups to be investigated for general structures 42 and 43. 
Compounds of the general structure 43 (Figure 33) are comprised of two hydrophobic 
groups attached to the norbornane scaffold through ether bonds. As bisalkylation of the 
norbornane framework has previously failed using standard Williamson ether 
protocols,186 additional methods will be investigated to access norbornane bisethers 43. 
 
1.9.4: Synthesis of Fluorescent Analogues 
The attachment of a fluorescent tag to the norbornane scaffold would allow for 
fluorescence microscopy studies to be performed and potentially confirm a MOA. As 
such, the synthesis of fluorescently tagged norbornane-based analogues of the general 
structure 44 (Figure 34) is also a key aim of this thesis. 
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Figure 34: General structure of fluorescently tagged norbornane-based peptidomimetics. 
 
1.9.5: Biological Evaluation of Norbornane Peptidomimetics 
Evaluation of the norbornane-based AMP mimetics is required to gain the essential SAR 
data for this project. Disk diffusion studies to elucidate the ZOI of these analogues, as 
well as micro-broth dilution assays to determine the MIC values against a range of Gram-
positive and Gram-negative bacterial strains will be carried out by project collaborators. 
The cytotoxicity of the most potent compounds will also be investigated against human 
cell lines. 
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Chapter 2 
It has been established that the guanidine moiety is present in many cationic 
antimicrobial peptides and as such, the inclusion of guanidine groups in the design of 
peptidomimetics as antibacterial agents is a logical decision. Pre-built guanidine-
containing building blocks are useful reagents to install guanidine functionality to 
molecular scaffolds. The facile synthesis of such building blocks is therefore a key 
requirement of this project. 
This Chapter begins with a discussion on the properties and applications of the guanidine 
group. The advantages and drawbacks of current protocols used to introduce the 
guanidine functional group are also detailed.  
The value of aminoethylguanidine 41 as a means to introduce guanidine functionality in 
the context of this project will be outlined. A scalable and operationally simple synthetic 
protocol which gives access to aminoethylguanidine 41 and its subsequent conversion to 
a shelf-stable salt is then reported. The synthesis of analogous aminoalkylguanidines as 
shelf-stable salts is also described. The guanidinylating methodology used to synthesise 
41 is then applied to a range of substrates to furnish a small series of guanidines tethered 
to a variety of synthetically useful functional groups.  
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Preparation of Guanidine-
containing Building Blocks 
The key aims of this Chapter are to; 
x Develop a high-yielding methodology that gives access to large quantities of 
aminoethylguanidine 41. 
x Convert aminoethylguanidine 41 to a shelf-stable salt. 
x Apply the optimised guanidinylation protocol to a variety of other substrates to 
furnish a series of guanidine-containing compounds tethered to a range of 
synthetically useful functional groups. 
 
2.1 Properties and Applications of Guanidines 
The guanidine moiety is ubiquitous throughout nature primarily as the side chain of the 
amino acid arginine.188 The basic guanidine group (pKa = 13.5) is protonated at 
physiologically relevant pH and is capable of forming electrostatic interactions with 
biologically important anions such as phosphates, carboxylates and sulfonates.189 The 
guanidinium group can have up to five hydrogen bond donors,190 and in combination with 
its inherent cationic charge, makes compounds containing guanidinium moieties typically 
water soluble.  
The ability of guanidines to facilitate electrostatic and hydrogen-bond interactions lends 
them to a variety of applications such as anion recognition191,192 and enantioselective 
catalysis.193-196 As mentioned in Chapter 1, guanidines play a critical role in the activity 
of both natural197 and synthetic antimicrobial agents.185 
 
2.1.1: Guanidinium Anion Hosts 
In 1978, Lehn described the first examples of macrocyclic guanidinium receptors (45 and 
46, Figure 35) which bound weakly to phosphate anions.192 Since this seminal report, the 
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importance of having a pre-organised host to improve host-guest interactions has been 
well documented.198,199 For example, rigid scaffolds such as octahydroacridine 47200 and 
calixarene 15 (Figure 35),82 have demonstrated strong binding affinities for 
dibenzylphosphate and lipid A, respectively. 
 
Figure 35: Guanidinium-based anion receptors. 
Work by the Pfeffer group has illustrated how norbornene bisthiourea 30 binds to two 
equivalents of H2PO4- (see Chapter 1).184 In subsequent work positively charged 
guanidine groups were attached in place of the charge-neutral thiourea moieties to 
ultimately synthesise norbornane diguanidine 31 (Scheme 3).185 The guanidine group was 
selected due to both its utility in the field of anion recognition and to provide a cationic 
charge at physiological pH;185 an important characteristic of antimicrobial 
peptidomimetics.  
 
2.1.2: Previously Synthesised Norbornane Diguanidines 
Pfeffer and co-workers used aminoethylguanidine 41, which was synthesised in-house, 
to attach guanidine functionality to norbornane 48 (Scheme 3).185 The choice of tert-
butoxycarbonyl (Boc)-protected guanidine 41 allowed for chromatographic purification 
of the norbornane Boc-protected guanidine product 49. As purification of 
aminoethylguanidine 41 proved troublesome it was used crude in the following reaction 
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making purification of 49 essential. Deprotection of the Boc-groups using trifluoroacetic 
acid (TFA) gave norbornane diguanidine 31 as a trifluoroacetate salt (Scheme 3).185  
 
Scheme 3: Reported pathways to access guanidinium species. 
More recently, work by Khosa at Deakin University synthesised hydrochloride salts such 
as 32 (Scheme 3) using a strategy that focused on late stage derivatisation of the 
hydrophobic group.186 Whilst successful, this approach suffered from multiple 
protection/deprotection steps, difficulty in the purification of key intermediates and 
degradation of the acetal group using the acidic conditions required to remove the Boc-
protecting groups (Scheme 3).186  
Due to the drawbacks of the approach used by Khosa,186 the synthetic route reported by 
Pfeffer et al. was revisited for this project. As aminoethylguanidine 41 is a key reagent in 
this strategy, a reliable and scalable method was required to access 41 in large quantities, 
preferably without the need for chromatographic purification. To develop such a method 
an understanding of the available guanidinylating agents is necessary. 
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2.2 Guanidinylating Agents 
Mono-guanidinylation of 1,2-ethylenediamine (EDA) is required to access 
aminoethylguanidine 41. A range of guanidinylating agents are available for this purpose; 
each with advantages and limitations. A number of recent reviews highlight the 
preparation of guanidines using transition-metal catalysis and carbodiimide-based 
reagents.201-203 However, treatment of an amine with an electrophilic amidine species 
(guanidinylating agent)204 is still the preferred method to synthesise guanidines.191,205 
Many of these guanidinylating agents employ the Boc-protecting group;206 a useful 
strategy to increase the guanidinylating agent’s reactivity through electron-withdrawing 
effects.207  
Reagents such as N,Nʹ-bis(Boc)thiourea (57),208-210 N,Nʹ-bis(Boc)-S-methylisothiourea 
(58),211,212 N,Nʹ-bis(Boc)-Nʺ-triflylguanidine (55),205,213,214 N,Nʹ-bis(Boc)-1H-pyrazole-
1-carboxamidine (59)215,216 and to a lesser extent N,Nʹ-
bis(Boc)benzotriazolecarboxamidine (60)217,218 represent some of the most commonly 
used guanidinylating agents (Figure 36).206 However, there are drawbacks associated with 
many of them.  
 
Figure 36: Guanidinylating agents 55 and 57–60. 
The use of thiourea 57 often requires toxic reagents, such as HgCl2,219 in order to activate 
the sulfinyl carbon. Triflylguanidine 55, although popular, is expensive to purchase,§ 
resulting in most research groups synthesising it in-house. The Boc-protection of 
guanidine hydrochloride 61 gives not only the desired diBoc-product 64, but the mono 
and tri-Boc products as well (62, 63 respectively, Scheme 4). Therefore, chromatographic 
purification is required.205 Attachment of the triflyl group to 64, using 
                                                 
§ $212/gram, Sigma Aldrich catalogue (7/11/2015). 
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trifluoromethanesulfonic anhydride (Tf2O), needs to be performed at −78 °C; conditions 
which are not amenable to large-scale syntheses (Scheme 4).205  
Scheme 4: Synthesis of guanidinylating agent 55 as reported by Feichtinger et al.205 
Another option which has found recent use is pryazole 59, however, its synthesis is quite 
tedious; two separate Boc-protecting steps are required.220 Although not as commonly 
used, benzotriazole derivatives such as 60 have found use, but these non-commercially 
available reagents require toxic additives to synthesise (Scheme 5).217 Furthermore, 
methylisothiourea 58 (a guanidinylating agent in its own right) is often employed as a 
starting material to access benzotriazoles such as 60.217  
 
Scheme 5: Synthesis of guanidinylating agent 60 as reported by Musiol et al.217 
In summary, there are many guanidinylating agents available but due to the ease of 
synthesis, cost of materials and no requirement for the use of toxic additives, 
methylisothiourea 58 was selected as being worthy of further investigation in the 
synthesis of aminoethylguanidine 41. 
 
2.3 Synthesis of Shelf-stable Aminoalkylguanidines 
Current methods to synthesise aminoethylguanidine 41 involve the slow addition of 
methylisothiourea 58 to EDA, presumably to prevent the formation of a bisguanidinylated 
product. The reaction is also often performed at elevated temperatures,185,221,222 which 
results in cyclisation of 41 to form cyclic guanidine 66 (Scheme 6), as reported by 
Castagnolo and co-workers.223 As the formation of cyclic guanidine 66 is undesirable for 
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this project, an improved synthesis of 41 was required which gives access to large 
quantities of material in high yields and without the need for purification. 
 
Scheme 6: Cyclisation of aminoethylguanidine 41 as reported by Castagnolo et al.223 
 
2.3.1: Synthesis of Aminoethylguanidine 41 
Following literature procedure, thiourea 67 was methylated using MeI to give 
methylisothiouronium iodide salt 68 in near-quantitative yield (99%, Scheme 7).224 Using 
a biphasic solvent system (CH2Cl2/H2O, 4:1), iodide salt 68 was Boc-protected to give 
the desired guanidinylating agent 58225 in excellent yield (85%, Scheme 7) on large scale 
(>10 grams). 
 
Scheme 7: Synthesis of methylisothiourea 58. 
The synthetic procedure reported by Carmignani and co-workers to access 
aminoethylguanidine 41 was trialled (Table 2, entry 1); guanidinylating agent 58 was 
added slowly over 90 minutes to a stirring solution of EDA in THF (0.02 M), before 
heating to 50 °C for four hours.221 After extractive work-up, 1H NMR spectroscopic 
analysis of the crude material indicated that the desired product (41) had formed; a triplet 
and an apparent quartet were observed (δ = 2.90 and 3.49 ppm respectively), which 
corresponded to the two sets of methylene protons of 41. The 1H NMR spectra also 
showed a singlet at δ = 3.62 ppm corresponding to the four equivalent methylene protons 
present in cyclic guanidine 66.223 The unwanted cyclic guanidine 66 represented 
approximately 17% of the crude reaction product, as determined by integrations of the 
1H NMR spectra (Table 2). Purification of 41 using column chromatography was 
complicated as both 66 and 41 have similar retention factors (Rf) in a range of solvent 
systems. It was therefore clear that the reaction conditions had to be tailored to limit the 
formation of cyclic guanidine 66. 
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Table 2: Optimisation of aminoethylguanidine 41 synthesis 
 
Entry Scale 
(g) 
Temp. 
(°C) 
Conc. 
(M) 
Addition 
time (min) 
Reaction 
time 
Ratio  
(41/66/51)a 
Yield 
(%)b 
1 0.2 50 0.02 90 4 h 83:17:0 69 
2 0.2 21 0.02 90 24 h 97:3:0 64 
3 0.6 21 0.02 90 24 h 95:5:0 87 
4 0.6 21 0.07 60 5.5 h 99:1:0 74 
5 1.8 21 0.07 90 20 h 86:5:9 78 
6 1.8 21 0.14 - 3.5 h 98:2:0 76 
7 1.8 21 0.27 - 80 min 98:2:0 82 
8 1.8 21 0.67 - 50 min 92:3:5c 55 
9 5.8 21 0.27 - 60 min 98:2:0 91 
10 9.4 21 0.27 - 80 min 97:3:0 90 
11 20.4 21 0.27 - 90 min 98:2:0 97 
a Ratio by mass was determined from integration of the 1H NMR spectra. 
b Isolated yield of 41 after work-up. 
c An additional unidentified product was formed. 
The reaction was performed at room temperature (Table 2, entry 2) using CH2Cl2 as the 
reaction solvent. The use of CH2Cl2 allowed for easy removal of the solvent upon work-
up without the need for heating. These conditions gave the desired product (41) in 64% 
yield with only a small amount of cyclic guanidine 66 (3%) observed in the 1H NMR 
spectra of the crude reaction product. When the reaction was carried out on a larger scale 
(Table 2, entry 3), 41 was isolated in an improved yield of 87% with only a small amount 
(5%) of the cyclic guanidine generated. 
When the reaction was performed at 0.07 M the starting material was consumed in a 
shorter time frame (5.5 hours) to give 41 in 74% yield with only 1% of 66 observed by 
1H NMR analysis (Table 2, entry 4). When the reaction was carried out on a larger scale 
(1.8 grams, Table 2, entry 5), it took 20 hours for the starting material (58) to be fully 
consumed in the reaction, as monitored by thin layer chromatography (TLC) analysis. 
The crude reaction product was analysed using 1H NMR spectroscopy and signals were 
observed at õ = 2.79 and 3.15 ppm which indicated that an additional and unwanted side-
product had formed (Figure 37). The second side-product was isolated using column 
chromatography in 9% yield and identified as 2-(tert-butoxycarbonylamino)ethylamine 
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51 by comparison of the 1H NMR spectra to literature values.226 As the longer reaction 
time (20 hours) correlated with the formation of 51, the slow addition of guanidinylating 
agent 58 was ceased and the reaction was performed in more concentrated conditions 
(0.14 M). When methylisothiourea 58 was added in one portion to the stirring mixture of 
EDA in CH2Cl2 (Table 2, entry 6), consumption of the starting material was complete 
after 3.5 hours and 41 was isolated in a 76% yield after an extractive work-up, with no 
sign of amine 51 (as evidenced by 1H NMR analysis). 
 
Figure 37: 1H NMR spectra (2.55–3.85 ppm) of crude reaction product from Table 2, entry 5 
(top) and entry 11 (bottom).  
When the reaction was conducted using more concentrated conditions (0.27 M) the 
starting material was consumed after only 80 minutes and aminoethylguanidine 41 was 
isolated in 82% yield with only 2% of cyclic guanidine 66 side-product formed (Table 2, 
entry 7). However, when the reaction was carried out at 0.67 M, 41 was isolated in only 
55% yield and amine 51 was again observed in the 1H NMR spectra of the crude reaction 
product in 5% yield (Table 2, entry 8). 
With this in mind the reaction was again performed at 0.27 M using 5.8 grams of 58 to 
ultimately afford 41 in 91% yield (Table 2, entry 9). When the reaction was carried out 
on a 9.4 gram scale, 41 was isolated in 90% yield with only 3% of cyclic guanidine 66 
being observed using 1H NMR spectroscopy (Table 2, entry 10). Similarly, when a 
20.4 gram scale reaction was performed, 41 was isolated in excellent yield (97%, 
Figure 37) with only a small amount of side-product 66 (2%) generated (Table 2, 
entry 11).  
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2.3.2: Conversion to a Shelf-stable Salt 
The stability of aminoethylguanidine 41 was assessed using 1H NMR spectroscopy. It 
was found that 41 slowly cyclised, upon standing, even at 4 °C and consequently had to 
be stored at −20 °C to prevent this intramolecular 5-exo-trig cyclisation. Therefore, the 
conversion of amine 41 to its conjugate salt would prevent cyclisation and as such was 
deemed a worthwhile pursuit. The use of amines as mesylate salts rather than 
hydrochloride salts has become more common in the pharmaceutical industry, due to their 
ease of preparation and the ability to establish anion/cation stoichiometry using 1H NMR 
spectroscopy.227 Similarly, tosylate salts have also found use when a product that is easy 
to handle is desired.228 
Treatment of aminoethylguanidine 41 with an equimolar amount of p-toluenesulfonic 
acid monohydrate (TsOH·H2O) in Et2O for one hour resulted in the formation of tosylate 
salt 69, which was collected as a white solid in a 70% yield using vacuum filtration 
(Table 3, entry 1). The organic filtrate was also analysed using 1H NMR spectroscopy 
and tosylate 69 was observed, indicating its partial solubility in Et2O. When the less 
lipophilic methanesulfonic acid (MsOH) was used, mesylate salt 70 was easily collected 
using vacuum filtration, as a non-hygroscopic white solid in near-quantitative yield 97% 
(Table 3, entry 2). TFA was also investigated (Table 3, entry 3), however, the product 
quickly formed a gum upon exposure to air; indicating a highly hygroscopic nature. When 
formic acid was used a complex mixture of products formed, as evidenced by 1H NMR 
analysis of the crude reaction mixture.  
Table 3: Formation of salts 69–71 
 
Entry AH Product  Hygroscopic Yield (%) 
1 TsOH·H2O 69 No 70 
2 MsOH 70 No 97 
3 CF3CO2H 71 Yes 99 
4a HCO2H - - - 
a The desired product was not isolated. 
Given the success in isolating aminoethylguanidine 41 as a shelf-stable mesylate salt (70), 
analogous aminoalkylguanidine salts were pursued. Tosylate salts of the propyl and butyl 
analogues of 41 were prepared in good yields over two steps—72 (85%) and 73 (74%)—
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from the corresponding diamines (1,3-diaminopropane and 1,4-diaminobutane 
respectively, Scheme 8). While the tosylate salts were non-hygroscopic powders for each 
of these aminoalkylguanidines, when the mesylate salt was formed the product presented 
as a hygroscopic residue. When 1,6-diaminohexane was guanidinylated with 
methylisothiourea 58, followed by treatment with MsOH, mesylate salt 74 was isolated 
in 50% yield over the two steps (Table 3, entry 4); the tosylate version of 74 appeared to 
be hygroscopic. 
 
Scheme 8: Synthesis of sulfonate salts 70 and 72–74 (yields given over two steps). 
 
2.4 Other Guanidine-containing Compounds 
A small series of Boc-protected guanidines connected to synthetically useful handles was 
also pursued using the optimised guanidinylation protocol (Table 4). 
Hydroxyethylguanidine 75 (Table 4, entry 1) has been used to attach Boc-protected 
guanidines to compounds for a variety of applications such as the delivery of small 
interfering RNA (siRNA) into cells229 and antibacterial polymers.230 The synthesis of 
hydroxyethylguanidine 75 is typically achieved using triflylguanidine 55 and 
chromatographic purification.213 Using the previously described methodology, 
ethanolamine was treated with guanidinylating agent 58 in CH2Cl2 at 21 °C for 24 hours 
to give 75 in 83% yield, with no chromatographic purification step necessary (Table 4, 
entry 1). Analogously, hydroxypropylguanidine 76 was synthesised in 81% yield using 
3-amino-1-propanol (Table 4, entry 2).  
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Table 4: Synthesis of guanidines 75–80 
 
Entry R Guanidine Yield (%) 
1  75 83 
2  76 81 
3  77 86 
4a  78 83 
5  79 84 
6b 
 
80 81 
a Reaction was carried out over five hours. 
b Reaction was carried out over two days. 
The Murphy group has used allylguanidine 77 to form cyclic guanidines which are present 
in biological systems such as antibacterial α-mannopeptimycin.231 Previous reports to 
access allylguanidine 77 rely on pyrazole 59232 or thiourea 57 with cyanuric chloride.233 
When guanidinylating agent 58 was used (Table 4, entry 3), allylguanidine 77 was 
isolated in good yield (86%) after an extractive work-up.  
The formation of 1,2,3-triazoles through copper-assisted azide-alkyne cycloaddition 
reactions has made terminal alkynes and azides some of the most used functionalities in 
modern organic chemistry.234-236 The synthesis of alkyne 78 has been previously reported 
using guanidinylating agent 58 at 40 °C for seven hours (83% after column 
chromatography).237 Using the method described earlier, alkyne 78 was also accessed in 
an 83% yield but unlike previously published methods elevated temperatures and 
chromatographic purification were not required (Table 4, entry 4). 
Wei et al. reported the synthesis of glycol guanidine 79, which was used as a building 
block for the formation of polymeric hydrogels, in 81% yield after chromatographic 
purification.238 Using the method described in Table 4, glycol guanidine 79 was accessed 
in a slightly improved yield (84%) without the use of exogenous base or a purification 
step. When 3-amino-1,2-propandiol was reacted with guanidinylating agent 58 for two 
days the novel 1,2 diol guanidine 80 was isolated in 81% yield (Table 4, entry 6).  
As mentioned, the commonly used 1,2,3-triazole system requires both an alkyne and an 
azide to be prepared.234 The previously reported synthesis of azidoethylguanidine 83 
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(76% over two steps, Scheme 9) required the synthesis and distillation of the low 
molecular weight azide 82, using conditions that could potentially generate HN3.237 The 
guanidinylation step was performed under inert conditions and column chromatography 
was required to afford 83.237 With this in mind, diazo transfer reagent 2-azido-1,3-
dimethyl-4,5-dihydro-1H-imidazol-3-ium hexafluorophosphate (ADMP, 86) which was 
prepared following the procedure by Kitamura et al.,239 was used to generate 
azidoethylguanidine 83 (Scheme 9). Although this method involved an additional step, 
and the yields were slightly lower, the aforementioned hazards were not encountered and 
there was no need for inert conditions or chromatographic purification to convert amine 
41 to azide 83 (50%, Scheme 9).  
 
Scheme 9: Synthesis of azidoethylguanidine 83 by Riechers et al. (top),237 synthesis of ADMP 
86 by Kitamura et. al (middle)239 and this work (bottom). 
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2.5 Conclusions 
The operationally simple protocol described in this Chapter has given access to a range 
of Boc-protected guanidine compounds, which are tethered to a variety of functional 
groups, in excellent yields. The guanidinylating agent used for these reactions 
(methylisothiourea 58) is easily synthesised from cheap and readily available starting 
materials, and in all cases pure product was obtained after a simple extractive work-up. 
Moreover, these reactions have proven to be amenable to multi-gram scales (e.g. 41 was 
synthesised on a 20 gram scale in 97% yield). The final products are either stable at room 
temperature, or can be converted to a sulfonate salt (mesylate or tosylate) to form an easy-
to-handle, non-hygroscopic solid which is stable at room temperature. 
With multi-gram quantities of aminoethylguanidine 41, and related aminoalkylguanidines 
(70 and 73) in hand, the synthesis of facially amphiphilic norbornane-based compounds 
could now be pursued.  
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Chapter 3 
Cationic antimicrobial peptides represent a potent class of antibiotics but they are 
typically i) readily degraded in vivo when in the ʟ-isomeric form and ii) relatively difficult 
to synthesise due to their structural complexity. Cationic peptidomimetics offer a 
potential solution to this problem. The norbornane scaffold represents a synthetic core 
which can be functionalised to generate amphiphilic peptidomimetics. 
In this Chapter several key project aims will be achieved. Firstly, the synthesis of a series 
of norbornane-based amphiphiles is performed. A range of hydrophobic groups 
connected through an acetal linker to the norbornane scaffold is explored. The 
installation of different anion recognition groups to the norbornane framework is also 
investigated, including charged and charge neutral functionalities. The optimisation of 
important synthetic steps is also detailed. 
Evaluation of these compounds against both Gram-positive and Gram-negative bacterial 
strains using disk diffusion and micro-broth dilution assays is then described. The most 
potent compounds are assessed for cytotoxicity. Finally, structure-activity relationships 
will be discussed. 
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Norbornane-acetals as 
Peptidomimetic Antibacterial Agents 
The key aims of this Chapter are to; 
x Devise, carry out and optimise a synthetic route to access a small library of 
norbornane-based peptidomimetics that incorporate i) a range of lipophilic 
portions connected to the norbornane scaffold through an acetal group and ii) a 
variety of anion recognition groups, some of which exhibit a cationic charge. 
x Evaluate the compounds for antibacterial activity against a range of Gram-
negative and Gram-positive bacterial strains. 
x Propose reasonable conclusions about the structure-activity relationship data 
obtained. 
 
3.1 Compound Design 
The major focus of this Chapter is to synthesise a series of norbornane-based cationic 
amphiphiles of the general structure 42 (Figure 38) and to probe the SAR of these 
compounds in regards to antibacterial activity. The facial amphipilicity of 42 is governed 
by the norbornane scaffold with hydrophobic and anion recognition groups separated in 
a pre-organised fashion. Recent work at Deakin University identified that aryl acetals 
degrade under acidic conditions,186 and as such only alkyl acetals (such as the previously 
reported 31)185 will be pursued herein.  
A lipophilic region is an essential component of antibacterial agents to cause membrane 
disruption. Hence, the design of compounds of the general structure 42 involves variation 
of the hydrophobic section to include alkyl and mixed alkyl/aryl acetals (as depicted in 
Figure 38).  
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Figure 38: General structure 42 and a summary of the hydrophobic and anion recognition 
groups to be investigated. 
The lead compound (31) is comprised of two guanidinium groups which provide an 
overall charge of +2.185 In this project, the importance of a net cationic charge for 
antibacterial activity will be investigated with charge neutral and +1, +2 and +3–charged 
species targeted.  
To broaden the scope of this SAR study, different anion recognition groups will be 
explored. A range of charged and charge neutral groups, which are able to bind to 
biologically relevant anions,240-243 have been selected (Figure 38). It has been previously 
reported that substituted guanidine groups can increase antibacterial activity185,244 and as 
such, a substituted guanidine analogue will also be pursued.  
 
3.2 Anion Recognition Groups 
Charged moieties (guanidinium, aminium, imidazolium and pyridinium) and charge 
neutral groups (thiourea and squaramide) have been identified as suitable components of 
a new class of peptidomimetic antibacterial agent. A discussion on each of these groups 
follows, apart from the guanidinium group which has been detailed in Chapter 2. 
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3.2.1: Aminium  
The amine functional group is ubiquitous throughout nature as the side chain of the amino 
acid lysine.122 Charged amines have found use in the field of anion recognition with 
lipopolyamine 14168 (Chapter 1) and steroidal 87245 demonstrating strong binding 
affinities for the LPS group of Gram-negative bacteria (Figure 39). Due to the prevalence 
of lysine residues in cationic AMPs (such as Magainin II),126 the amino group is often 
present in antibacterial peptidomimetics; triaryl-based diamine 18 (Figure 39) is one such 
example.170 
 
Figure 39: LPS binders (14 and 87) and antibacterial agent 18. 
Installation of a Boc-protected amine to a molecular scaffold allows for purification of 
the product using standard chromatographic techniques. Removal of the Boc-group can 
be performed as the final step to reveal the charged aminium species. Many research 
groups have used BocEDA (51) for this role.198 As such, BocEDA 51 was synthesised in 
92% yield by adding Boc2O at room temperature to an excess of EDA and stirring the 
reaction for four hours (Scheme 10). 1H NMR spectroscopic analysis of 51 showed key 
resonances which matched literature values;226 δ = 1.43, 2.78 and 3.15 ppm corresponding 
with the t-butyl, CH2NH and CH2NH2 groups respectively. 
 
Scheme 10: Synthesis of BocEDA 51. 
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3.2.2: Imidazolium 
Examples of the charged imidazolium group used for anion recognition applications246,247 
include the macrocyclic cyclophane 88,248 which strongly and selectively binds to 
chloride ions and the 1,1ʹ-Bi-2-naphthol (BINOL) derivative 89, which functions as a 
fluorescent anion sensor (Figure 40).249 Although not as commonly used as its 
guanidinium and aminium counterparts, the imidazolium functionality has shown to be 
an effective component in antibacterial agents. One such example is imidazolium 90 
(Figure 40), which has exhibited antibacterial activity against E. coli and S. aureus with 
MIC values of 4 μg/mL each.250  
 
Figure 40: Examples of imidazolium compounds used for anion recognition (88 and 89) and 
antibacterial (90) purposes. 
 
3.2.3: Pyridinium 
The Beer group has demonstrated the use of the pyridinium moiety in the formation of 
pseudorotaxanes;251-253 unique supramolecular assemblies that have potential use in 
encapsulating and delivering drugs.254 Kawabata and co-workers described the synthesis 
and evaluation of poly(N-benzyl-4-vinylpyridinium halides) as antibacterial agents 
against Gram-positive bacteria (91, Figure 41).255,256 The authors deemed the pyridinium 
cation was vital to elicit an antibacterial response.255,256 Ionic liquids containing a 
pyridinium group have also demonstrated antibacterial activity with N-alkylated 
pyridiniums 92257 and 93258 (Figure 41) inhibiting the growth of Gram-positive bacteria, 
such as Bacillus subtillis. 
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Figure 41: Examples of pyridinium compounds used for anion recognition (91) and 
antibacterial purposes (92 and 93). 
Both the imidazolium and pyridinium groups can be substituted onto large molecular 
frameworks when a good leaving group is present. For example, Gathergood and co-
workers have reported the synthesis of imidazolium ionic liquid 95 in 84% yield, from 
the corresponding α-bromoamide 94 (Scheme 11).259 
 
Scheme 11: Synthesis of ionic liquid 95 as reported by Gathergood et al.259 
 
3.2.4: Thiourea 
The norbornene dithiourea 30 (Figure 42) has previously been shown to bind strongly 
with two equivalents of dihydrogen phosphate.184 The thiourea group is also present in 
antibacterial agents such as benzothiazole 97 and the chitosan derivative 96 which 
exhibits modest activity against E. faecalis (MIC = 15 μg/mL) and P. aeruginosa (MIC 
= 16 μg/mL).260,261 
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Figure 42: Examples of thiourea compounds used for anion recognition (30) and antibacterial 
(96 and 97) purposes. 
 
3.2.5: Squaramide 
Squaramides have found a variety of applications including organocatalysis (such as 
squaramide 98 immobilised on a polystyrene support, Figure 43),262 cation sensing (99 
which binds to copper(II) ions),263 anion sensing (colourimetric 100 which responds to 
fluoride ions)187 and as linkers in biomolecules.264 Recent work by Gale identified 
squaramide 101 and related compounds as effective membrane anion transporters.265,266 
Although no known antibacterial agents currently contain a squaramide, they feature in 
antimalarial compounds such as 102 (Figure 43).267  
 
Figure 43: Examples of squaramides used for organocatalysis (98), ion sensing (99 and 100), 
anion membrane transport (101) and antimalarial (102) purposes. 
To install squaramide functionality onto the norbornane framework a squaramide 
building block was required. Following literature procedure, squaric acid 103 was 
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converted to squaric methyl ester 104 in 72% yield by refluxing in MeOH (Scheme 12).268 
The more commonly used ethyl ester derivative 106 was also synthesised in 65% yield 
using EtOH, however, its use was disfavoured as it is more prone to hydrolytic 
degradation than methyl ester 104.269 The squaric ester 104 was treated with an equimolar 
amount of BnNH2 at room temperature for one hour to give the benzyl substituted 
squaramide 105 in 49% yield (Scheme 12).269 The 1H NMR spectra of 105 matched 
literature values269 with signals observed at δ = 4.46 and 4.68 ppm correlating to the non-
equivalent methylene protons. 
 
Scheme 12: Synthesis of squaramide 105. 
 
3.3 Retrosynthetic Analysis 
A retrosynthetic route allowing for late stage derivatisation of the anion recognition group 
was designed. For the sake of brevity, only the guanidinium group is illustrated in 
Scheme 13, however it was envisaged that analogues bearing other anion recognition 
groups would be accessed using a similar synthetic pathway. For example, the aminium 
group could be installed onto the norbornane framework using BocEDA 51 in place of 
aminoethylguanidine 41. 
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Scheme 13: Retrosynthetic pathway for norbornane peptidomimetics 107. 
The retrosynthetic analysis outlined in Scheme 13 identifies several important steps to 
access norbornane amphiphiles such as 107. The Boc-protecting groups used to mask the 
guanidine moieties are removed to afford the desired product as a hydrochloride salt. 
Alternatively, the Boc-groups could be removed using TFA to generate the 
trifluoroacetate salt derivative. Attachment of the Boc-protected guanidine group 41 via 
an amide coupling reaction with dicarboxylic acid 109 gives diamide 108. The installation 
of a hydrophobic portion to the norbornane scaffold through an acetal connection is a key 
step in this pathway, which requires an aldehyde and norbornane diol 110. The synthesis 
of norbornane diol 110 can be achieved by dihydroxylation of norbornene 112 which is 
in turn constructed using a Diels-Alder cycloaddition (Scheme 13). 
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3.4 Diels-Alder Cycloaddition 
In 1928, Professor Otto Diels and his student Kurt Alder established the identities of 116 
and 117 (Scheme 14) when cyclopentadiene (CPD, 113) and quinone (115) were 
reacted.270 The importance of this discovery was fully recognised in 1950 when they 
shared the Nobel Prize in chemistry.  
 
Scheme 14: The reaction that led to Diels and Alders discovery.270 
The Diels-Alder reaction is a [4 + 2] cycloaddition; a concerted process which can be 
explained by the molecular orbital (MO) interactions between a diene and a dienophile.271-
273 A classic example is the reaction between CPD 113 and maleic anhydride 118 
(Scheme 15). Primary orbital overlap between the highest occupied molecular orbital 
(HOMO) of diene 113 and the lowest unoccupied molecular orbital (LUMO) of 
dienophile 118 forms transition state 119 (as illustrated by red dotted lines in Scheme 15). 
The endo-product 120 is favoured over the exo product due to the stabilising effect of 
secondary orbital overlap between the developing π-bond and the carbonyl orbitals of the 
transition state (as illustrated by blue dotted lines in Scheme 15).274-276  
 
Scheme 15: Diels-Alder cycloaddition. Primary MO overlap is shown in red and secondary 
orbital overlap is shown in blue. 
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3.4.1: Synthesis of Norbornene 112 
Freshly prepared CPD** was reacted with equimolar amounts of dimethyl fumarate 114 
in tetrahydrofuran (THF) to give norbornene 112 in near-quantitative yield (99%, 
Scheme 16). The 1H and 13C NMR spectra of 112 matched literature reports277 and high-
resolution mass spectrometry (HRMS) data supported the identity of 112; a signal was 
observed at 233.0785 m/z which matched the calculated value for [M + Na]+. Although 
this method was both reliable and high-yielding, an alternative strategy was investigated 
which obviated the need to prepare CPD beforehand.  
 
Scheme 16: Synthesis of norbornene 112. 
Dejmek and co-workers recently published a solvent-free Diels-Alder cycloaddition 
approach using microwave irradiation to crack dicyclopentadiene (DCPD, 121) in situ, 
before reacting with an appropriate dienophile in the presence of quinol, to generate 
functionalised norbornenes.278 The conditions described by Dejmek et al.,278 (Table 5, 
entry 1) were trialled and after one hour at 150 °C both DCPD and dimethyl fumarate 
were still present in the reaction mixture (as evidenced by 1H NMR analysis of the crude 
reaction mixture). Dimethyl fumarate could not be separated from norbornene 112 using 
column chromatography due to similar Rf values. Performing the reaction for an extra 
30 minutes also failed to consume all of the dimethyl fumarate (Table 5, entry 2).  
When a slight excess of DCPD (1.2 equivalents, i.e. 2.4 equivalents of CPD) was used, 
and the reaction was performed for one hour (Table 5, entry 3), norbornene 112 was 
obtained in good yield (89%) after chromatographic purification. Increasing the reaction 
time to 1.5 hours (Table 5, entry 4), resulted in norbornene 112 being generated in near-
quantitative yield (99%).  
 
 
                                                 
** CPD was prepared by heating dicyclopentadiene (DCPD) at above 150 °C and collecting the product 
using distillation at −10 °C under an inert atmosphere. Unused CPD was stored in a cold environment (less 
than −20 °C) to prevent dimerization. 
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Table 5: Optimised microwave-assisted synthesis of norbornene 112 
 
Entry Scale 
(mmol) 
Time 
(h) 
121:114 Purification 
method 
Yield 
(%) 
1 1 1 1:2 Column NAa 
2 1 1.5 1:2 Column NA 
3 1 1 1.2:2 Column 89 
4 5 1.5 1.2:2 Column 99 
5 10 1.5 1.2:2 Column NA 
6 10 2 1.2:2 Column NA 
7 10 2 1.6:2 Column 98 
8 20 2 1.6:2 Column 98 
9b 20 2 1.6:2 Distillationc 84 
a NA in all cases refers to the inability to isolate pure norbornene 112.  
b This reaction was repeated three times on a 20 mmol scale due to limitations in reaction vessel size, and 
all resulting material was distilled together. 
c Distillations were performed at 93 °C at 0.1 mbar. 
When the reaction was performed on a 10 mmol scale not all of the dimethyl fumarate 
was consumed (Table 5, entry 5). Again, an increase in reaction time did not ameliorate 
this problem (Table 5, entry 6). When 1.6 equivalents of DCPD was used (Table 5, 
entry 7), norbornene 112 was isolated as a clear viscous oil in excellent yield (98%). 
These conditions also proved to be amenable to a 20 mmol scale, with a 98% yield 
(8.25 grams) of 112 obtained (Table 5, entry 8). 
The microwave-mediated protocol gave norbornene 112 in a more timely fashion than 
the conventional method and obviated the need for organic solvent or the preparation of 
CPD. Its use was somewhat restricted however due to the capacity of available microwave 
vessels (35 mL) and the practicality of purifying large quantities of material using column 
chromatography. Therefore, the reaction was performed in three batches and the crude 
materials were combined and purified using vacuum distillation (93 °C at 0.1 mbar) to 
give 112 in an overall yield of 84% (Table 5, entry 9). 
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3.5 Dihydroxylation of Norbornene 112 
3.5.1: Upjohn Dihydroxylation of Norbornene 112 
A number of transition metals have been employed for the conversion of an alkene to a 
1,2-syn diol including ruthenium,279 iron,280 cobalt,281 manganese,282 molybdenum283 and 
palladium.284 The most popular method is the Upjohn OsO4-mediated method,285,286 
which was reported by the Upjohn chemical company in 1976.287 This initial report 
demonstrated that the co-oxidant N-methylmorpholine N-oxide (NMO, 125) was able to 
oxidise OsO3 (124) to active OsO4 (122) without over-oxidising the substrate or product; 
an inherent disadvantage of many other secondary oxidants such as sodium chlorate and 
hydrogen peroxide.285,288-291  
It is commonly accepted that the addition of an alkene to the OsO4 species occurs in a 
[3 + 2] fashion to give osmate ester 123 (Scheme 17). For a time the Sharpless group 
strongly proposed an alternative pathway which relied on a [2 + 2] addition,292-294 
however several independent groups have used density functional theory to show that a 
[3 + 2] addition is energetically more favourable.295-298  
 
Scheme 17: Mechanistic cycle of Upjohn dihydroxylation of 112.294,297 
Following literature precedent,185 norbornane diol 110 was accessed in 94% yield using 
catalytic OsO4 (0.004 equivalents) and NMO (1.1 equivalents, Scheme 18). An extractive 
work-up was all that was required to give spectroscopically pure product and the reaction 
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was amenable to larger scales (> 4 grams). The 1H NMR spectroscopic data of 110 
matched literature values;185 the chemical shifts of the H5 and H6 endo-protons 
(Scheme 18) were observed at δ = 3.85 and 3.71–3.77 ppm respectively. 
 
Scheme 18: OsO4-mediated dihydroxylation of norbornene 112. 
 
3.5.2: KMnO4-mediated Dihydroxylation of Norbornene 112 
Although the OsO4-mediated dihydroxylation to afford norbornane diol 110 proceeds 
smoothly, a cheaper method was explored. Since the seminal report by Kekule in 1880,299 
KMnO4 has been used extensively in the dihydroxylation of olefins.300-302  
A report by the Donohue group detailed a procedure for the dihydroxylation of related 
norbornene compounds using KMnO4 and NaOH.301 Using these conditions (Table 6, 
entry 1) it was found that norbornene 112 was not fully consumed in the reaction (as 
evidenced by TLC analysis). When the amount of KMnO4 was increased from 1.2 to 
2.0 equivalents (Table 6, entry 2) an increase in yield of 110 (56%) was achieved. It was 
reasoned that the moderate yields could be attributed to hydrolysis of the ester groups by 
the NaOH. When no exogenous base was used in the reaction (Table 6, entry 3) only a 
small amount of norbornane diol 110 (14%) was isolated.  
When a non-nucleophilic base was employed (K2CO3), the desired product was isolated 
in a 58% yield (Table 6, entry 4). As it is well-known that the use of KMnO4 can lead to 
oxidative cleavage of alkenes,300 lower reaction temperatures were trialled in an attempt 
to slow down side reactions of this nature. When the reaction was performed at −10 °C 
(Table 6, entry 5) diol 110 was isolated in a 55% yield. When the reaction was performed 
at 21 and 50 °C (Table 6, entries 6 and 7 respectively) 110 was generated in 52 and 42% 
yield respectively. Adding KMnO4 in one portion to the reaction mixture did not improve 
reaction success with 110 isolated in a 43% yield (Table 6, entry 8). 
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Table 6: Investigation into KMnO4-mediated dihydroxylation of norbornene 112 
 
Entry KMnO4 
(equiv) 
Base 
(equiv) 
Temp. 
(°C) 
Addition 
method 
Timea Yield 
(%) 
1 1.2 NaOH 0 Dropwise 16 h NAb 
2 2.0 NaOH 0 Dropwise 70 min 56 
3 2.0 None used 0 Dropwise 70 min 14 
4 2.0 K2CO3 0 Dropwise 25 min 58 
5 2.0 K2CO3 −10 Dropwise 10 min 55 
6 2.0 K2CO3 21 Dropwise 25 min 52 
7 2.0 K2CO3 50 Dropwise 20 min 42 
8 2.0 K2CO3 0 One addition 40 min 42 
a Time required to consume norbornene 112 (as indicated by TLC analysis). 
b NA = Starting material was not fully consumed in the reaction. 
Although not as high-yielding as the OsO4-mediated synthesis of norbornane diol 110, 
the KMnO4 procedure has some advantages. The decrease in cost, coupled with the much 
faster reaction times, make this method a useful alternative. 
 
3.6 Installation of Hydrophobicity via an Acetal Group 
With diol 110 in hand, attachment of a hydrophobic group to the norbornane framework 
could be pursued. Recent work identified that aryl acetals were prone to degradation 
under acidic conditions.186 To avoid this issue, only aldehydes that would give alkyl 
acetals were selected (Figure 44). 
 
Figure 44: Aldehydes 127–131 selected for use in this project. 
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Linear aliphatic aldehydes 127, 128 and 129 were selected to assess the effect of 
hydrophobicity on antibacterial activity. The use of 3-phenylpropanal 130 was chosen to 
investigate the effect aromatic functionality has on antibacterial activity, whilst aldehyde 
131 has a large non-polar surface area comprised of both alkyl and aryl regions. As 
aldehydes 129 and 131 are not commercially available they had to be synthesised in-
house. 
 
3.6.1: Synthesis of Hexadecanal 129 
The Swern oxidation, originally reported by Daniel Swern in 1978,303 is commonly used 
to transform primary alcohols to aldehydes.304 The Swern oxidation follows the reaction 
mechanism depicted in Scheme 19.305 Intermediate 134 is known to decompose above 
−60 °C and as such, the reaction is often performed at −78 °C (using an EtOAc/liquid N2 
slurry).305 The reaction generates dimethylsulfide 141 as a by-product (Scheme 19); a 
malodorous, flammable and low-boiling liquid.306 
 
Scheme 19: Swern oxidation reaction mechanism.305 
The synthesis of hexadecanal 129 was achieved following the procedure described by the 
Bittman group.307 Oxidation of commercially available hexadecan-1-ol 143, using oxalyl 
chloride and dimethyl sulfoxide (DMSO) in anhydrous CH2Cl2 gave 129 in 81% yield 
(Scheme 20). Hexadecanal 129 was found to decompose if left at room temperature for 
extended periods (monitored by 1H NMR analysis) and was therefore used immediately 
in its crude state.  
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Scheme 20: Swern oxidation of alcohol 143 to give aldehyde 129. 
 
3.6.2: Synthesis of 3-[4-(Octyloxy)phenyl]propanal 131 
Following previously reported methodology,308 Fischer esterification309 of the 
commercially available carboxylic acid 144 gave the methyl ester product 145, which was 
isolated in 88% yield after an extractive work-up (Scheme 21). Standard Williamson 
methodology310 was used to react phenol 145 with 1-iodooctane to generate aryl ether 
146 in 77% yield. Reduction of the methyl ester group using sodium bis(2-
methoxyethoxy)aluminium hydride (Red-Al® or Vitride) in PhMe furnished alcohol 147 
in 89% yield. 1H NMR spectroscopy supported the identity of 147 as the methyl ester 
protons of 146 (δ = 3.67 ppm) were absent and a singlet was observed at δ = 1.51 ppm 
which correlated to the OH group.   
 
Scheme 21: Synthesis of aldehyde 131. 
Swern oxidation conditions (oxalyl chloride and DMSO) were then employed to generate 
the desired aldehyde 131 (Scheme 21). Unfortunately, aldehyde 131 was also shown to 
degrade at room temperature (as evidenced by 1H NMR analysis) and was therefore 
reacted immediately in its crude state. 
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3.6.3: Synthesis of Norbornane-acetals 
The attachment of a heptyl†† chain to diol 110 using octanal and TFA to give norbornane 
acetal 148 has been previously reported on a 400 mg scale in 76% yield.185 When these 
conditions were replicated similar yields were obtained; 70 and 87% on 100 and 400 mg 
scales respectively (Table 7, entries 1 and 2). When the reaction was performed on a one 
gram scale (Table 7, entry 3) 148 was isolated after chromatographic purification in only 
51% yield. The reaction performed even more poorly when carried out on a 3.5 gram 
scale (33%, Table 7, entry 4).  
Table 7: Synthesis of acetal 148 
 
Entry Scale 
(g) 
Acid  
(equiv) 
Solvent Temp. 
(°C) 
Time 
(h) 
Yield 
(%) 
1 0.1 TFA (0.5) CHCl3 21 16 70 
2 0.3 TFA (0.5) CHCl3 21 16 87 
3 1.0 TFA (0.5) CHCl3 21 48 51 
4 3.5 TFA (0.5) CHCl3 21 48 33 
5 0.1 TsOH·H2O (0.05) PhMe 110 2.5 63 
6 0.3 TsOH·H2O (0.05) PhMe 110 2.5 77 
7 1.0 TsOH·H2O (0.05) PhMe 110 2.5 77 
8 3.5 TsOH·H2O (0.05) PhMe 110 3.5 92 
 
A more scalable procedure to access norbornane acetals in high yields was sought. 
Following the method reported by Pandey et al.,311 100 mg of diol 110 was stirred in 
PhMe with octanal, MgSO4 and catalytic TsOH·H2O (0.05 equivalents) at 110 °C to give 
acetal 148 in 63% yield (Table 7, entry 5). When the reaction was performed on a 300 mg 
scale (Table 7, entry 6), acetal 148 was isolated in a 77% yield after chromatographic 
purification. Pleasingly, when the reaction was performed on a one gram scale (Table 7, 
entry 7), 148 was again obtained in a 77% yield. These conditions proved to be amenable 
                                                 
†† Throughout the remainder of this document the acetal chain length will be referred to as the size of the 
substituent of the acetal group. For example, norbornane acetal 148 has a heptyl chain, despite being 
synthesised using octanal. 
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to larger scales; when 3.5 grams of diol 110 was used acetal 148 was isolated in 92% 
yield (Table 7, entry 8). 
The 1H NMR spectrum of acetal 148 revealed a triplet (δ = 4.62 ppm) corresponding with 
the endo methine proton (H4, Figure 45), which matched the reported literature value.185 
Verification of the exo acetal stereochemistry was achieved using Nuclear Overhauser 
effect (NOE) spectroscopy to pinpoint through-space interactions independent of scalar 
coupling between protons.312 Using 1D difference NOE, the endo acetal proton (H4) was 
irradiated and a clear NOE correlation was observed with neighbouring endo norbornane 
protons (H2 and H6, Figure 45). This result confirms that acetal 148 is the desired exo 
product. 
 
Figure 45: 1H NMR spectra of 148 in CDCl3 (0.0–10.0 ppm) with carbons assigned (top) and 
1D difference NMR spectra (3.1–5.2 ppm) where H4 has been irradiated (bottom). 
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With the synthesis of acetal 148 optimised, attention turned towards treating diol 110 with 
other lipophilic aldehydes to generate additional norbornane acetals (Table 8). Using 
commercially available dodecanal 128 and freshly prepared hexadecanal 129, longer 
alkyl chain derivatives 149 and 150 were synthesised in 83 and 60% yields respectively 
(Table 8, entries 2 and 3). The use of 3-phenylpropanal 130 (Table 8, entry 4) gave access 
to norbornane acetal 151 in 79% yield. When aldehyde 131 was employed (Table 8, 
entry 5), norbornane acetal 152, which contained both alkyl and aromatic functionality, 
was obtained in a modest 48% yield.  
Table 8: Synthesis of norbornane acetals using optimised methodology 
 
Entry Aldehyde Time (h) Product Yield (%) 
1 
 
3.5 148 92 
2 
 
2.5 149 83 
3 
 
3.0 150 60 
4 
 
3.0 151 79 
5 
 
2.5 152 48 
 
3.6.4: Hydrolysis of Methyl Esters 
Hydroxide-mediated hydrolysis of an ester is routinely performed to give the 
corresponding carboxylic acid.313,314 Dimethyl esters (148–152) were hydrolysed using 
NaOH in a biphasic THF/H2O solvent system to access norbornane dicarboxylic acids 48 
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and 153–156 (Table 9) in typically good yields (78–86%). These reactions were scalable 
(multi-gram), and after an extractive work-up spectroscopically pure material was 
isolated in every instance. The formation of all norbornane dicarboxylic acids was readily 
confirmed using 1H NMR spectroscopy; the methyl ester groups present in the starting 
material (ca. δ = 3.67 ppm) were absent in the 1H NMR spectra of the dicarboxylic acid 
products. 
Table 9: Synthesis of norbornane dicarboxylic acids 48 and 153–156. 
 
Entry R Product Yield (%) 
1 
 
153 86 
2 
 
154 83 
3 
 
48 80 
4 
 
155 78 
5 
 
156 80 
 
3.7 Dicationic Norbornane-based Amphiphiles 
With a collection of norbornane acetals bearing two carboxylic acid handles now 
synthesised, attaching a range of anion recognition groups to the norbornane scaffold via 
an amide could be pursued. To facilitate the formation of an amide bond without the need 
for high temperatures,315 the carboxy group must first be activated.316 Whilst the 
carboxylic acid can be converted and isolated into a more reactive acylating agent, such 
as an acyl chloride317 or mixed anhydride,318 the most common method is to form the 
reactive acylating agent in situ using activating or coupling agents.319,320  
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3.7.1: Amide Couplings 
In 1965 Sheehan reported the first use of N-3-dimethylaminopropyl-Nʹ-ethyl 
carbodiimide hydrochloride (EDCI, 158) as a coupling agent.321 The use of EDCI as an 
efficient means to generate an amide bond has become routine, partly due to its water 
solubility which allows unreacted EDCI and by-product urea 163 (also water soluble) to 
be removed post-reaction.319 The mechanism for EDCI-mediated peptide coupling 
between a carboxylic acid and an amine is depicted in Scheme 22. After formation of the 
active O-acylisourea 161, a number of products can be generated including the desired 
amide 162, the water soluble urea 163 and the undesirable N-acylurea 164 (Scheme 22). 
 
Scheme 22: EDCI-mediated coupling highlighting possible reaction products. 
To circumvent the formation of N-acylurea 164, additives are often used to react with O-
acylisourea 161 prior to attack from the nucleophilic amine.319,322 One commonly used 
additive is 1-hydroxybenzotriazole hydrate (HOBt, 165) which reacts with O-acylisourea 
161 to give the activated O-benzotriazole ester 166 intermediate (Scheme 23).323 After 
subsequent attack of the nucleophilic amine, the desired amide 162 is formed and HOBt 
is regenerated (Scheme 23).319 
 
Scheme 23: HOBt-mediated mechanism to afford amide 162. 
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3.7.2: Synthesis of Norbornane Diguanidines 
Recent work at Deakin University optimised the formation of two amide bonds, 
connected to the norbornane framework.186 The optimised conditions used EDCI and 
HOBt in DMF and heated the mixture to 50 °C for 30 minutes using microwave 
irradiation.186  
Employing these conditions, norbornane dicarboxylic acids were reacted with 
aminoethylguanidine 41 (prepared in Chapter 2) to give the desired norbornane 
diguanidines 49 and 167–170, after chromatographic purification, in reasonable yields 
(41–74%, Table 10). In some instances the reactions were performed in CHCl3; solvent 
choice was dictated by substrate solubility. 
Table 10: Synthesis of norbornane diguanidines 49 and 167–170  
 
Entry R Solvent Product Yield (%) 
1 
 
DMF 167 64 
2 
 
DMF 168 49 
3 
 
DMF 49 74 
4 
 
CHCl3 169 44 
5 
 
DMF 170 41 
 
Characterisation of all norbornane diguanidines was achieved using 1H and 13C NMR 
spectroscopy. As an example, 168 exhibited characteristic signals at δ = 11.45 and 
11.48 ppm corresponding to the NHBoc protons (Figure 46). The newly formed amide 
bonds were confirmed with the presence of signals at δ = 6.88 and 8.04 ppm 
corresponding to the amide NH protons. A low frequency chemical shift of the H8 proton 
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adjacent to the endo-amide carbonyl group (δ = 2.94 ppm) was also observed when 
compared to the dicarboxylic acid starting material 154; δ = 3.17 ppm. Eight signals were 
observed in the high frequency region of the 13C NMR spectrum of 168 (Figure 46), which 
correspond to the six carbonyl groups and the two guanidine carbons. HRMS data also 
supported the identity of 168 with a signal observed at 951.6131 m/z which matched the 
calculated [M + H]+ value. 
 
Figure 46: 1H and 13C NMR spectra of diguanidine 168 in CDCl3. 
In an earlier communication, computational modelling indicated that an ethyl linker 
between the norbornane scaffold and the guanidine was sufficient for effective binding 
of lipid A.184,324 However, the dependence of activity on spacer length was never 
experimentally tested, therefore propyl and butyl analogues were desired. The heptyl 
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chain dicarboxylic acid 153 was converted to norbornane propyl guanidine 173 in 49% 
yield using freshly prepared aminopropylguanidine 171 (Scheme 24). Analogously, the 
butyl derivative (174) was synthesised in 52% yield using aminobutylguanidine 172 
(Scheme 24). 
 
Scheme 24: Synthesis of propyl (173) and butyl (174) diguanidines. 
 
3.7.3: Synthesis of Norbornane Diamines 
It has been established that the aminium group is present in many cationic AMPs which 
possess antibacterial activity.126,135 As such, norbornane diamines were identified as 
synthetic targets. Employing the microwave-mediated amide-coupling protocol, 
BocEDA 51 was attached to previously synthesised norbornane dicarboxylic acids, and 
following chromatographic purification, diamides 175–178 were isolated (35–61%, 
Table 11).  
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Table 11: Synthesis of norbornane diamines 175–178 
 
Entry R Product Yield (%) 
1 
 
175 57 
2 
 
176 61 
3 
 
177 46 
4 
 
178 35 
 
The diamine series of compounds were characterised using NMR spectroscopy and 
HRMS. For example, 1H NMR spectroscopic analysis of 176 revealed two signals at δ = 
6.63 and 6.77 ppm corresponding to the amide NH protons (Figure 47). The low 
frequency chemical shift of the H8 proton (δ = 2.88 ppm) when compared to starting 
material 154, provided further evidence of the expected transformation. Two signals at δ 
= 156.8 and 157.1 ppm were observed in the 13C NMR spectra of 176 (Figure 47) which 
are indicative of the carbonyl carbons in the Boc groups. HRMS further supported the 
identity of 176 with a signal observed at 723.5263 m/z which matched the calculated value 
for [M + H]+. 
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Figure 47: 1H and 13C NMR spectra of diamine 176 in CDCl3. 
 
3.7.4: Removal of Boc-protecting groups 
Removal of the Boc-protecting groups was required to reveal the desired guanidinium 
and aminium charged species. The use of Brønsted-Lowry acid is the most common 
method to cleave the Boc-protecting group325 and previous work by Pfeffer et al., 
favoured the use of TFA, resulting in a trifluoroacetate salt.185 When this procedure was 
repeated, norbornane diguanidine 31 was accessed in a modest yield of 60% (Scheme 25). 
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Scheme 25: Synthesis of previously reported 31. 
Bioactive pharmaceuticals that contain a cationic charge are commonly prepared as a 
hydrochloride salt.326 As such, the cationic norbornane amphiphiles were synthesised 
herein as hydrochloride salts. When Boc-protected guanidine compounds were treated 
with MeOH and ten equivalents of AcCl, to generate HCl in situ, the guanidinium 
products (179–183) were isolated in typically high yields (74–95%, Table 12) after 
removal of the reaction solvent and two co-evaporations with MeOH. In all instances, the 
reaction progress was monitored by 1H NMR analysis of the reaction mixture; the absence 
of tert-butyl protons (ca. δ = 1.48 ppm) was clear evidence of reaction success. 
Importantly, the acetal methine proton (H4) of all analogues integrated correctly when 
compared to all other protons in the norbornane diguanidinium compounds which 
suggested no degradation of the acetal group occurred under the acidic conditions. 
Table 12: Synthesis of norbornane acetal diguanidine hydrochlorides 
 
Entry R Product Yield (%) 
1 
 
179 95 
2 
 
180 85 
3 
 
181 87 
4 
 
182 93 
5 
 
183 74 
 
The propyl and butyl chain analogues of diguanidine 179, were generated using the same 
AcCl/MeOH procedure; 184 (74%) and 185 (94%) respectively (Scheme 26). Again, the 
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absence of signals corresponding to tert-butyl protons in their respective 1H NMR spectra 
was evidence of reaction success. 
 
Scheme 26: Synthesis of propyl and butyl guanidines (184 and 185 respectively). 
The Boc-protected diamines 175–178 were converted to their corresponding 
hydrochloride salts in excellent yields (94–99%, Table 13). 1H NMR spectroscopic 
analysis of amine hydrochlorides 186–189 confirmed their identity with no tert-butyl 
proton signals observed. 1H NMR analysis also confirmed that the acetal group was again 
stable to the acidic reaction conditions employed (see appendix 11.2 for 1H and 13C NMR 
spectra of diamine 187).  
Table 13: Synthesis of norbornane acetal diamine hydrochlorides 
 
Entry R Product Yield (%) 
1 
 
186 99 
2 
 
187 98 
3 
 
188 94 
4 
 
189 94 
 
3.7.5: Synthesis of Diimidazolium and Dipyridinium Analogues 
To broaden the scope of the SAR study norbornanes functionalised with charged 
imidazolium and pyridinium groups were sought. Gathergood has previously used an α-
bromoamide group as a useful intermediate to facilitate the attachment of imidazolium or 
pyridinium groups to larger scaffolds via a substitution reaction.259 Following literature 
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procedure,259 norbornane diamine 186 was treated with bromoacetyl bromide and Et3N 
and reacted for five hours at −78 °C (Scheme 27). After chromatographic purification, 
the desired α-bromoamide 190 was isolated as a white solid in 65% yield. 1H NMR 
spectroscopy confirmed the formation of 190 with two singlets observed at δ = 3.83 and 
3.84 ppm, corresponding to the methylene protons adjacent to the bromide moiety. 
 
Scheme 27: Synthesis of α-bromoamide 190. 
When 190 was reacted with 1-methylimidazole in THF at −78 °C, starting material still 
remained after five hours. The reaction was subsequently warmed to room temperature 
and after two days complete consumption of 190 was observed by TLC analysis. Organic 
impurities were removed by extractive workup and the desired diimidazolium 191 was 
isolated in 74% yield after lyophilisation (Scheme 28). A considerable high frequency 
shift of the methylene protons of α-bromoamide 190 was observed for diimidazole 191 
(δ = 4.97 ppm) using 1H NMR spectroscopy. 
 
Scheme 28: Synthesis of diimidazolium (191) and dipyridinium (192). 
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The dipyridinium derivative 192 was accessed in 64% yield by heating α-bromoamide 
190 and pyridine in THF at 66 °C for 16 hours (Scheme 28). The structure of 192 was 
also confirmed using 1H NMR spectroscopy, with the methylene protons adjacent to the 
pyridinium group observed as singlets at δ = 5.45 ppm.  
 
3.8 Synthesis of a Substituted Guanidinium Analogue 
Pfeffer et al., have previously described the synthesis of norbornane bisphenylguanidine 
194 from phenylaminonitrile327 and norbornane diamine 193 (Scheme 29).185 Isolation of 
the final bisphenylguanidine product proved troublesome185 and as such, a simpler and 
more robust method to access substituted guanidines such as 194 was required. 
 
Scheme 29: Previously reported synthesis of norbornane bisphenylguanidine 194.185 
 
3.8.1: Substituted Thiourea 195 as a Guanidinylating Agent 
Maki and co-workers have reported the conversion of thiourea 195 to guanidine 197 using 
the Burgess-type reagent 196 (Scheme 30).328 Work by Hamilton also illustrates the use 
of thiourea 195 to access tri-substituted guanidines such as 198, in high yields, using an 
EDCI-mediated approach (Scheme 30).207 
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Scheme 30: Examples of guanidinylation reactions using thiourea 195 as reported by the Maki 
(top)328 and the Hamilton groups (bottom).207  
Following the method reported by the Hamilton group,207 norbornane diamine 
hydrochloride 187 was treated with 195, N,N-diisopropylethylamine (DIPEA) and EDCI 
in CH2Cl2 at 0 °C. After stirring the reaction for two days at 21 °C the desired Cbz-
protected diguanidine 199 was formed (Scheme 31), however, purification of 199 was 
unsuccessful using both column chromatography and recrystallisation and consequently 
the material was used in its crude state in the next step. Hydrogenolysis conditions (Pd/C, 
H2) failed to remove the Cbz group from 199. When strongly acidic conditions were used 
(33% HBr in AcOH), partial removal of the Cbz-group was observed by 1H NMR 
spectroscopic analysis, but this was accompanied by degradation of the acetal group. 
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Scheme 31: Attempted synthesis of bisbenzylguanidine 200. 
 
3.8.2: Substituted Isothiourea 201 as a Guanidinylating Agent  
Guanidinylating agent 201 has previously been used to good effect in the guanidinylation 
of primary amines.329 Following literature procedure,329 Boc-protected methylisothiourea 
58 was treated with BnBr and NaH to generate benzyl methylisothiourea 201 
(Scheme 32). After multiple additions of BnBr and NaH, and stirring the reaction for four 
days, starting material still remained (as indicated by both TLC and NMR spectroscopic 
analysis), and consequently 201 was isolated in a poor yield of 21% after 
chromatographic purification (Scheme 32). The 1H NMR spectra of 201 matched 
literature values329,330 with key resonances observed at δ = 2.28 and 4.78 ppm which 
correlated with the Me and CH2 protons. 
 
Scheme 32: Synthesis of N-benzyl methylisothiourea 201 using BnBr and NaH. 
The Mitsunobu reaction was first reported by Oyo Mitsunobu in 1967 who used diethyl 
azodicarboxylate (DEAD) and Ph3P to acylate secondary alcohols with carboxylic 
acids.331,332 The Mitsunobu reaction is used to substitute primary or secondary alcohols 
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with a variety of nucleophiles in the presence of a dialkyldiazodicarboxylate and a tri-
substituted phosphine.333,334  
The Botta group have described the synthesis of guanidinylating agent 201 from 
methylisothiourea 58 using Mitsunobu conditions.330 By treating methylisothiourea 58 
with benzyl alcohol, diisopropyl azodicarboxylate (DIAD) and Ph3P in THF at reflux for 
16 hours, 201 was obtained in excellent yield (95%, Scheme 33). When DEAD was used 
in place of DIAD the desired 201 was again obtained, albeit in a lower yield (73%). 
 
Scheme 33: Synthesis of N-benzyl methylisothiourea 201 using Mitsunobu conditions. 
It was envisaged that a similar reagent to aminoethylguanidine 41 could be constructed 
to access norbornane dibenzylguanidines in a convergent fashion. When 2.5 equivalents 
of EDA was treated with guanidinylating reagent 201 in CH2Cl2, rapid cyclisation 
occurred to form cyclic guanidine 66 (Scheme 34), as evidenced by the presence of a 
singlet at 3.62 ppm in the 1H NMR spectra. To prevent this cyclisation, the reaction was 
performed at 0 °C, however cyclic guanidine 66 was still observed by 1H NMR 
spectroscopy as the major product of the reaction. It appeared that the benzyl substituent 
promoted rapid intramolecular 5-exo-trig cyclisation of amine 202.  
 
Scheme 34: Attempted guanidinylation to access amine 202. 
In order to obviate the formation of cyclic products, norbornane diamine 186 was reacted 
with guanidinylating agent 201 in the presence of Et3N, and after chromatographic 
purification, norbornane 203 was isolated in a low yield of 30% (Scheme 35). 
Nevertheless, no side-products were observed in the 1H NMR spectra of 203 and the 
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material was of sufficient purity to proceed. Treatment of Boc-protected 203 with an 
AcCl/MeOH mixture generated the desired norbornane dibenzylguanidinium 204 in 
excellent yield (93%, Scheme 35).  
 
Scheme 35: Synthesis of bisbenzylguanidine hydrochloride 204. 
 
3.9 Mono-cationic Norbornane-based Peptidomimetics 
In order to synthesise norbornane-based amphiphiles with a single positive charge, a 
norbornane scaffold containing just one carboxylic acid handle was required. Niwayama 
has previously described the selective hydrolysis of the less sterically hindered exo ester 
of the norbornane scaffold.335 Following this procedure,335 norbornene diester 112 was 
treated with an aqueous KOH/THF system at 0 °C for four hours. Isomers 205 and 206 
were isolated in 88% yield in a ratio of 9:1 in favour of the exo-acid 205. This ratio was 
determined by 1H NMR spectroscopy as the endo methyl ester protons of 205 and exo 
methyl ester protons of 206 have slightly different chemical shifts (δ = 3.64 and 3.72 ppm 
respectively, Scheme 36). Unfortunately, 205 and 206 were completely inseparable using 
standard chromatographic techniques. 
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Scheme 36: Selective hydrolysis of norbornene dimethyl ester 112. 
A different multistep approach, as reported by Hamanaka, uses norbornane iodolactone 
207, to ultimately access norbornene endo carboxylic acid 206 (Scheme 37).336 Using 
standard hydrolysis conditions, norbornene dimethyl ester 112 was converted to 
norbornene dicarboxylic acid 50 in 88% yield.337 Synthesis of the norbornane iodolactone 
207 was achieved following literature procedure;336 treatment of norbornene dicarboxylic 
acid 50 with KI, I2 and NaHCO3 in H2O furnished the desired product in 95% yield.  
 
Scheme 37: Synthesis of norbornene 206. 
Iodolactone 207 was the only exo/endo isomer formed as the exo conformation of the 
carboxylic acid group in 50 precludes interaction with the olefin region. NMR 
spectroscopy confirmed the formation of iodolactone 207 with the H3 proton observed as 
a doublet at δ = 5.16 ppm in the 1H NMR spectra and the corresponding C3 carbon at 
88.7 ppm in the 13C NMR spectra (Figure 48). 
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Figure 48: 1H and 13C NMR spectra of iodolactone 207 in CDCl3.  
With iodolactone 207 in hand, Fischer esterification afforded the desired methyl ester 208 
in 90% yield. A zinc-mediated reductive dehalogenation then generated the requisite 
norbornene endo carboxylic acid 206 in 93% yield.336 Every step depicted in Scheme 37 
only required a simple extractive work-up to obtain spectroscopically pure product. 
Norbornene carboxylic acid 206 was coupled with n-heptylamine using microwave-
mediated conditions to afford norbornene heptylamide 209 in 77% yield (Scheme 38). 
Subsequent dihydroxylation of the alkene using catalytic OsO4 and NMO gave 
norbornane diol 211 in 85% yield. Acetal 213 was synthesised in 94% yield from endo-
heptylamide diol 211 and octanal, using the previously optimised acetal formation 
conditions. Hydrolysis of the exo-methyl ester using NaOH, furnished carboxylic acid 
215 in a 64% yield. Again, using the microwave-mediated amide coupling conditions, 
Boc-protected aminoethylguanidine 41 was attached to the norbornane carboxylic acid 
215 to give guanidine 217 in 30% yield. Subsequent deprotection using an AcCl/MeOH 
mixture, gave the requisite hydrochloride salt 219 in 99% yield.  
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Scheme 38: Synthesis of norbornane guanidine hydrochlorides 219 and 220. 
In an analogous fashion, when n-hexadecylamine was used norbornene hexadecylamide 
210 was isolated in 73% yield (Scheme 38). Subsequent dihydroxylation of the alkene 
gave norbornane diol 212 89% yield, which was then converted to acetal 214 using 
octanal in 45% yield. After subsequent hydrolysis of the methyl ester to give carboxylic 
acid 216 in 93% yield, aminoethylguanidine 41 was attached to access guanidine 218 in 
79% yield. Removal of the Boc-protecting groups afforded the target compound (220) in 
80% yield. 
 
3.10 Charge Neutral Norbornane-based Peptidomimetics 
Two charge-neutral analogues were sought to assess the importance of a net positive 
charge on antibacterial activity. The thiourea and squaramide functionalities were 
selected for this purpose as they have previously found use in anion recognition184 and 
membrane transport265,266 applications respectively.  
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3.10.1: Synthesis of Norbornane Dithiourea 221 
The reaction between a nucleophilic amine and an isothiocyanate leads to the formation 
of a thiourea. Synthesis of the target norbornane dithiourea 221 was achieved by reacting 
norbornane diamine 186 and phenylisothiocyanate at 21 °C for 16 hours (Scheme 39). 
After chromatographic purification, norbornane dithiourea 221 was isolated in 95% yield. 
The structure of 221 was confirmed using NMR spectroscopy with the thiourea NH 
protons observed in the 1H NMR spectrum (δ = 6.68 (2 × H), 8.06 and 8.12 ppm) and the 
thiourea carbons both resonating at δ = 172.9 ppm in the 13C spectrum. HRMS data also 
supported the identity of 221 with a signal observed at 681.3251 m/z which matched the 
calculated value for [M + H]+. 
 
Scheme 39: Synthesis of norbornane dithiourea 221. 
 
3.10.2: Synthesis of Norbornane Disquaramide 222 
To synthesise a norbornane disquaramide derivative, norbornane diamine 186 was 
reacted with two equivalents of squaric ester 105 in MeOH at 21 °C (Scheme 40). Due to 
the difficulty of effectively stirring the thick reaction mixture, the reaction was ceased 
after 2.5 hours, despite not going to completion (as evidenced by TLC analysis). As the 
crude product was insoluble in most organic solvents, chromatographic purification was 
avoided. Instead, the crude material was treated with an excess of EDA, which reacted 
with the remaining squaric ester 105, to form amine 223 (Scheme 40). The mixture of 
products was then triturated in 2 M HCl to dissolve amines 186 and 223. Pure norbornane 
disquaramide 222 was then collected as a white solid in 40% yield using vacuum filtration 
(Scheme 40). Signals in the 1H NMR spectrum of 222 (δ = 7.49 (2 × H), 7.89 (2× H), 
8.11 and 8.16 ppm) which corresponded to the NH protons of 222, as well as the absence 
of the methyl ester protons of 105 (δ = 4.29 ppm), confirmed that 222 had formed. HRMS 
data of 222 also supported this conclusion; a signal was observed at 781.3904 m/z which 
matched the calculated value of [M + H]+. 
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Scheme 40: Synthesis of norbornane disquaramide 222.  
 
3.11 Synthesis of a Tricationic Analogue 
A compound with a net +3 charge was desired for this SAR study, to further probe the 
importance of net charge on antibacterial activity. Although mono-amine diguanidine 224 
(Scheme 41) is not structurally amphiphilic, it is comprised of three positively charged 
groups and was therefore pursued.  
 
Scheme 41: Retrosynthetic route to access tricationic norbornane 224. 
A retrosynthetic analysis of tricationic norbornane 224 is proposed in Scheme 41. As the 
methodology to install two guanidine moieties onto the norbornane framework has been 
established, attention turned to the attachment of an aminium group to the norbornane 
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scaffold through an acetal link. Acetal 225 was identified as a key intermediate which 
could be accessed from diol 112 and aldehyde 226. Aldehyde 226 is not commercially 
available and therefore has to be synthesised in-house.  
 
3.11.1: Synthesis of Aldehyde 226 
The use of NaBH4 and I2 to reduce carboxylic acids to primary alcohols has been 
previously reported.338 When commercially available 12-aminododecanoic acid 227 was 
subjected to these conditions (Scheme 42) none of the desired alcohol was formed and 
only starting material was recovered from the reaction mixture (as evidenced by 1H NMR 
analysis of the crude reaction mixture). 
 
Scheme 42: Attempted reduction of carboxylic acid 227 to alcohol 228. 
Given the conversion of carboxylic acid 227 to alcohol 228 was unsuccessful (Scheme 
42), it was decided that protecting the carboxylic acid with an ester group may ultimately 
allow for easier access to 228. Following literature procedure,339 Fischer esterification 
was used to generate methyl ester 229 as a hydrochloride salt in near-quantitative yield 
(99%, Table 14). The NMR spectroscopic values of 229 matched literature reports.339 
Following literature procedure (Table 14, entry 1), methyl ester 229 was treated with 
2.5 equivalents of Red-Al® in anhydrous PhMe for 16 hours at 21 °C.340 Although TLC 
analysis indicated complete consumption of starting material, 1H NMR spectroscopy of 
the crude reaction mixture confirmed a complex mixture of products had formed. Upon 
closer examination, none of the signals present in the 1H NMR spectrum matched 
literature values for alcohol 228.341  
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Table 14: Reaction conditions trialled for the synthesis of 12-aminododecan-1-ol 228 
 
Entry Reducing agent 
(equiv) 
Solvent Temp. 
(°C) 
Time 
(h) 
Ratio of 
229:228a 
1 Red-Al® (2.5) PhMe 21 16 NAb 
2 LiAlH4 (1.5) Et2O 21 16 1:1 
3 LiAlH4 (3.0) Et2O 21 16 2:8 
4 LiAlH4 (4.0) PhMe 21 48 1:9 
5 LiAlH4 (5.0) PhMe 55 48 1:9 
a As determined by 1H NMR analysis. 
b NA = A mixture of products was formed, as seen by 1H NMR analysis. 
When 229 was treated with 1.5 equivalents of LiAlH4 in anhydrous Et2O (Table 14, 
entry 2) the crude product consisted of a 1:1 ratio of starting material to alcohol 228, as 
observed by 1H NMR analysis. Using additional LiAlH4 (3.0, 4.0 and 5.0 equivalents, 
Table 14, entries 3–5) resulted in an increase in the ratio of starting material to product 
(1:9) being isolated, however increasing the reaction temperature to 55 °C did not 
improve the reaction outcome (Table 14, entry 5). Due to the highly polar nature of amine 
228, purification using column chromatography proved difficult. In light of this, it was 
decided that protection of the primary amine group was required to allow for 
chromatographic purification of key intermediates. 
The procedure by Forbes and co-workers to synthesise N-(Boc)-12-aminododecanoic 
acid (230)342 was adopted successfully (85%, Scheme 43) and was shown to be applicable 
to large scale synthesis (six grams). Following literature precedent,342 carboxylic acid 230 
was treated with 2.5 equivalents of Red-Al®, to generate primary alcohol 231 in 76% 
yield (Scheme 43). This reaction was also amenable to large scales (seven grams). The 
1H and 13C NMR of 231 matched literature spectroscopic values.342  
 
Scheme 43: Synthesis of alcohol 231. 
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With alcohol 231 in hand, the synthesis of aldehyde 226 could now be investigated 
(Table 15). Following previously reported conditions,343 a Swern oxidation of 231 using 
1.2 equivalents of oxalyl acid was carried out at −78 °C for four hours. After this time, 
TLC analysis indicated that starting material was still present in the reaction mixture and 
consequently the reaction was warmed to 21 °C and left to stir for a further 20 hours 
(Table 15, entry 1). After chromatographic purification, aldehyde 226 was isolated in 
35% yield. 1H NMR spectroscopy confirmed the formation of 226 with the aldehyde 
proton observed as a triplet at δ = 9.76 ppm. When the reaction was ceased after 4 hours 
at −78 °C (Table 15, entry 2) the aldehyde 226 was isolated in a lower yield of 18%. 
Increasing the number of equivalents of (COCl2)2 used in the reaction to 2.4, did not 
improve the amount of aldehyde 226 synthesised (20%, Table 15, entry 3). 
Table 15: Synthesis of aldehyde 226 
 
Entry Scale 
(g) 
Oxidising agent 
(equiv) 
Base 
(equiv) 
Temp. 
(°C) 
Time 
(h) 
Yield 
(%) 
1 0.4 (COCl2)2 (1.2) Et3N (5.4) −78–21 24 35 
2 0.4 (COCl2)2 (1.2) Et3N (5.4) −78 4 18 
3 0.4 (COCl2)2 (2.4) Et3N (5.4) −78 3 20 
4 0.1 PCC (1.5) None used 21 3 6 
5 0.1 PCC (3.0) None used 21 24 60 
6 0.1 PCC (3.0) None used 21 3 56 
7 1 PCC (3.0) None used 21 3 79 
8 0.2 TEMPO (0.2) None used 21 48 58 
 
Corey was the first to describe the use of pyridinium chlorochromate (PCC) as an efficient 
means to oxidise a primary alcohol to an aldehyde.344 Since this seminal report PCC has 
been used extensively for this purpose, often in stoichiometric amounts, despite its 
toxicity.345-347  
Following the procedure by Seto,348 alcohol 231 was treated with PCC (1.5 equivalents) 
to give aldehyde 226 in a low yield of 6% after chromatographic purification (Table 15, 
entry 4). When additional PCC (3.0 equivalents) and longer reaction times (24 hours) 
were employed (Table 15, entry 5), aldehyde 226 was isolated in 60% yield after 
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chromatographic purification. Stopping the reaction after three hours did not result in a 
significant change in the amount of 226 which was isolated (Table 15, entry 6). These 
conditions were used on a one gram scale (Table 15, entry 7) to generate aldehyde 226 in 
79% yield. Unfortunately, it was found that aldehyde 226 was shown to slowly degrade 
at room temperature. As such, a procedure which generated spectroscopically pure 226 
without the need for time-consuming chromatographic purification was sought. 
Since the elegant work of Anelli and Montanari just over two decades ago,349 the nitroxyl 
radical (2,2,6,6-tetramethylpiperidin-1-yl)oxyl (TEMPO), has been used for the catalytic 
oxidation of primary alcohols to their corresponding aldehydes.350 The procedure from 
the MacMillan group351 was adopted whereby TEMPO (0.2 equivalents) was used 
catalytically in the presence of iodobenzene diacetate, to generate aldehyde 226 in 58% 
yield (Table 15, entry 8). Although these conditions gave the desired product without the 
need for toxic additives (such as PCC) or low temperatures (such as those required using 
Swern conditions), chromatographic purification was still required.  
The eponymous Weinreb amide has enjoyed widespread use since its discovery by Steven 
Weinreb in 1981,352 to efficiently access both ketones and aldehydes.353,354 The synthesis 
of Weinreb amide 233 was accomplished following literature procedure (Scheme 44).355 
Carboxylic acid 230 was treated with N,O-dimethylhydroxylamine hydrochloride (232), 
EDCI and HOBt to give Weinreb amide 233 in excellent yield (87%) after 
chromatographic purification. A distinctive low frequency shift of the carbonyl carbon in 
amide 233 (δ = 174.9 ppm) when compared to carboxylic acid 230 (δ = 179.2 ppm), using 
13C NMR spectroscopy, is evidence of the successful transformation. 
 
Scheme 44: Synthesis of Weinreb amide 233 and aldehyde 226. 
The reduction of Weinreb amide 233 using LiAlH4 in THF proceeded smoothly to give 
aldehyde 226 in 95% yield (Scheme 44). It was discovered that if the reaction was 
conducted at −78 °C no side-products were formed and spectroscopically pure 226 was 
isolated after an extractive work-up. 
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In summary, a number of different synthetic routes were investigated to access aldehyde 
226. Protection of the primary amine using a Boc group was identified as being essential 
to allow for improved handling and purification of subsequent compounds (Scheme 43). 
The reduction of Weinreb amide 233 using LiAlH4 proved to be the most effective way 
to access aldehyde 226 in excellent yield (95%, Scheme 44) without the need for 
chromatographic purification or toxic additives.  
 
3.11.2: Synthesis of Tricationic Norbornane 224 
Using the previously optimised conditions, diol 110 was reacted with freshly prepared 
aldehyde 226 to give acetal 225 in 78% yield (Scheme 45). The catalytic amount of 
TsOH·H2O used in this reaction did not cleave the Boc-group, as evidenced by the 
1H NMR spectra of 225; a singlet at δ = 1.43 ppm which integrated for nine protons (t-
Bu). Subsequent base-mediated hydrolysis of the methyl ester groups furnished 
norbornane dicarboxylic acid 234 in 88% yield. Attachment of aminoethylguanidine 41 
to dicarboxylic acid 234, using standard microwave-assisted amide coupling conditions, 
gave diamide 235 in 32% yield after chromatographic purification. Removal of all five 
Boc-groups using AcCl/MeOH was achieved in one step to reveal three charged moieties 
(two guanidinium groups and one aminium, 224) in near-quantitative yield (99%, 
Scheme 45). The successful removal of the Boc groups was confirmed using 1H NMR 
spectroscopy; the signals correlating to the tert-butyl protons in 235 (δ = 1.43–1.50 ppm) 
were not present in the 1H NMR spectra of 224.  
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Scheme 45: Synthesis of tricationic norbornane 224. 
 
3.12 Summary of Synthesis 
A total of 19 norbornane-based AMP mimics were synthesised—a key aim of this project. 
These compounds exhibit a range of hydrophobic regions comprised of either alkyl or 
alkyl/aromatic regions of differing sizes. The overall cationic charge was varied with 
analogues possessing either +1, +2 or +3. Two charge-neutral analogues were also 
prepared. The spacer between the norbornane scaffold and the anion recognition group 
was varied to include ethyl, propyl and butyl. A benzyl-substituted guanidine analogue 
was also synthesised. Apart from tricationic norbornane 224, all of the compounds 
reported herein are facially amphiphilic with well separated hydrophobic and anion 
recognition groups. Importantly, the synthetic routes employed have been optimised to 
allow for the generation of analogues on multi-gram scales. 
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3.13 Biological Evaluation of Norbornane-acetals 
The antibacterial activity of all norbornane-based amphiphiles synthesised were 
evaluated using two techniques; disk diffusion assay and micro-broth dilution assay. A 
range of Gram-positive and Gram-negative bacteria were tested, including members of 
the ESKAPE pathogens (E. faecium, S. aureus, K. pneumoniae, A. baumanii, P. 
aeruginosa and Enterobacter species).23 Cytotoxicity studies against human embryonic 
kidney cells (HEK293) and hepatocellular carcinoma (HepG2) cell lines were carried out 
for the most potent compounds. 
All disk diffusion assays were performed at the Monash Institute of Pharmaceutical 
Sciences courtesy of Professor Jian Li. Disk diffusion assays were performed by adding 
50 μg of sample to an agar plate previously swabbed with a suspension of a specific 
bacterial isolate. After incubation for 20 hours at 37 °C, the ZOI was measured which 
determined if the compound warranted further investigation. 
All MIC values were ascertained using micro-broth dilution assays and were performed 
courtesy of The Community for Antimicrobial Drug Discovery (CO-ADD) at The 
University of Queensland. MICs were determined visually after 20 hours of incubation at 
37 °C with the MIC defined as the lowest compound concentration at which no bacterial 
growth was visible.  
 
3.13.1: Bacterial Strains Used in This Study 
Gram-negative bacteria 
Acinetobacter baumannii 
The ATCC 19606 strain of A. baumannii was used in this study. The A. baumannii species 
have become a major cause of nosocomial infections over the last few decades356 and are 
associated with urinary tract and bone infections, and hospital-acquired meningitis.356 
Due to the rise of antibiotic resistant strains of A. baumannii since the 1970s, treatment 
of these infections has proved challenging for medical practitioners.357 The ability of A. 
baumannii to thrive in a hospital environment can be attributed to several factors 
including its ability to form biofilms which prevent the cell from drying out on medical 
devices.358  
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Pseudomonas aeruginosa 
The ATCC 27853 strain of P. aeruginosa was used in this project. The ability of P. 
aeruginosa to survive in non-native environments has facilitated the rapid emergence of 
antibacterial-resistant strains. P. aeruginosa has been identified within hospitals on soaps, 
sinks, mops and medical equipment.359,360 Immunocompromised patients are highly 
susceptible to infection due to the opportunistic nature of P. aeruginosa.359 Moreover, it 
is one of the major causes of respiratory problems in patients.361 
Klebsiella pneumoniae 
Two strains of K. pneumoniae were used in this study: ATCC 13883 and ATCC 700603. 
It has been known for over a century that K. pneumoniae is responsible for pneumonia 
infections outside of a hospital setting.362 Nevertheless, K. pneumoniae is still 
troublesome within hospitals; responsible for some urinary tract, bloodstream and 
pneumonia infections.362,363 Since the 1990s many resistant strains of K. pneumoniae have 
emerged making treatment of such infections difficult. Alarmingly, in the past ten years 
K. pneumoniae infections have led to >9000 cases of liver abscesses throughout Asia.364  
Escherichia coli 
The ATCC 25922 E. coli strain is the final Gram-negative bacterial pathogen tested in 
this study. E. coli is an especially versatile microorganism; it makes up part of the natural 
microflora of human intestines, is used as a host to clone recombinant DNA and in some 
instances can be pathogenic with deadly consequences.365 Pathogenic E. coli can result in 
diarrhoea, urinary tract infections and sepsis.366  
 
Gram-positive bacteria 
Staphylococcus aureus 
Several bacterial isolates of S. aureus were used in this project including Methicillin 
resistant S. aureus ATCC 43300 (MRSA), multi-resistant MRSA, glycopeptide 
intermediate S. aureus and Vancomycin-intermediate S. aureus. MRSA is a leading cause 
of bacterial infection worldwide. MRSA is the most common pathogen linked to skin and 
soft tissue infections,367 and is the cause of more severe infections such as infective 
endocarditis.368 Currently MRSA infections are responsible for an estimated $3–4 billion 
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expenditure of health care costs per year.369 The ability for S. aureus to quickly become 
resistant is concerning. For example, strains of  S. aureus were resistant to Penicillin 
within two years of clinical use.370 S. aureus strains are also resistant to antibiotics 
Methicillin368 and Vancomycin.105,371 As such, clinicians now have very few tools at their 
disposal to combat this pathogen. 
Enterococcus faecium and Enterococcus faecalis 
The compounds synthesised in this project were also tested against the Vancomycin-
resistant strains of E. faecium (VRE) ATCC 700221 and E. faecalis. Both of these strains 
are commonly found in human feces,372 with E. faecalis making up for roughly 90% of 
Enterococcus clinical isolates.373 VRE is a major cause of nosocomial infections, 
particularly in immunocompromised patients.372 They are versatile microorganisms that 
can survive in extreme temperatures and in the presence of chemical detergents.374 Due 
to their ability to survive in such harsh conditions, instances of resistance to most anti-
enterococcal antibiotics has increased making the treatment of these infections 
challenging. This difficulty has led clinicians to rely upon a cocktail of antibiotics to treat 
patients with Enterococcus infections.375  
Streptococcus pneumoniae 
The final bacteria to be tested in this study is the MDR bacteria S. pneumoniae. Typically, 
S. pneumoniae infections target the respiratory tract and for a long period of time these 
were treated with Penicillins with the belief that resistance would not occur.376 
Unfortunately, several independent studies have now proven this belief to be flawed and 
consequently S. pneumoniae strains that are resistant to multiple drug classes, including 
Fluoroquinolones, now exist.376,377 S. pneumoniae is responsible for the second most 
common cause of bacterial meningitis with a mortality rate of 25–29%.378 Due to the 
difficulty of effectively treating S. pneumoniae infections, there is a pressing need to 
develop new antibacterials to combat this harmful pathogen.379 
 
3.13.2: Disk Diffusion Assay 
Diguanidine compounds comprised of heptyl (179) and undecyl (180) chains were active 
against all Gram-negative and Gram-positive bacterial isolates tested in this study apart 
from A. baumannii (Table 16). Diguanidine 183, which possesses a 2-[4-
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(octyloxy)phenyl]ethyl chain, showed activity against A. baumannii (ZOI = 9 mm) and 
both K. pneumoniae and VRE (ZOI = 8 mm each). The effect of the linker between the 
norbornane framework and the guanidinium moiety was minimal as the three related 
diguanidine analogues 179 (ethyl), 184 (propyl) and 185 (butyl), each had a ZOI ≥ 12 mm 
against P. aeruginosa, K. pneumoniae and MRSA (Figure 49). When benzyl-substituted 
diguanidine 204 was evaluated, activity against all bacterial strains was observed, 
including E. faecium (ZOI = 18 mm), MRSA (17 mm) and K. pneumoniae (15 mm). 
 
Figure 49: Antibacterial activity of diguanidines 179 (marked as “SMH003”), 184 (marked as 
“12”) and 185 (marked as “13”) against MRSA. 
When a single cationic charge was present only moderate, or no, activity was observed 
e.g. 219 (ZOI = 8 and 7 mm for MRSA and VRE respectively, Table 16) and 220 
(inactive). However, tricationic 224 showed activity against most bacterial pathogens 
tested e.g. (ZOI = 14.5 and 14 mm for K. pneumoniae and MRSA respectively).  
Compounds bearing two aminium groups displayed similar activity to their 
diguanidinium counterparts; diamines 186, 187 and 189 were comparable to diguanidines 
179, 180 and 183 respectively (Table 16). However, only minor inhibition was observed 
for the imidazolium (191) and pyridinium (192) analogues (ZOI = 7 and 8 mm 
respectively against MRSA). The importance of an overall positive charge was reinforced 
with poor antibacterial activity observed for the charge neutral analogues; dithiourea 221 
and disquaramide 222 (Table 16). 
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Table 16: ZOI as measured (in mm) using disk diffusion assaya 
 
 
 
Compound 
A. baumannii 
ATCC 19606 
P. aeruginosa  
ATCC  
27853 
K. pneumoniae  
ATCC  
13883 
S. aureus 
MRSA 
ATCC 
43300 
E. faecium 
VRE  
ATCC 
700221 
Guanidines      
179 NTb 15 12 13 12 
180 - 8 8 9 10 
181 - - - - - 
182 10 - - - - 
183 9 - 8 8 - 
184 - 14 12 16 - 
185 - 14 14 14 8 
204 10 13 15 17 18 
219 - - - 8 7 
220 - - - - - 
224 12 12 14.5 14 - 
Diamines      
186 - 16 11 8 - 
187 - 10 12 12 14 
188 - - - - - 
189 9 - 7 9 - 
Other anion recognition groups 
191 - - - 7 - 
192 - - - 8 - 
221 - - - 8 - 
222 - - - 7 - 
COLc 20 19 20 - - 
a Measured after incubation of disk (6 mm diameter, 50 μg/disk) at 37 °C for 20 hours. 
b NT = Not tested. 
c Tested at 10 μg/disk. 
 
3.13.3: Micro-broth Dilution Assay 
The norbornane acetals which showed promising results in the disk diffusion assay along 
with the more lipophilic analogues (181, 188 and 220) were subject to a micro-broth 
dilution assay to quantify MICs (Table 17). The activity between the aminium and 
guanidinium analogues was again comparable. For example, analogues with a pentadecyl 
chain (diguanidine 181 and diamine 188) showed almost identical MIC values against all 
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bacterial pathogens (32 μg/mL against E. coli and 0.5 and 1 μg/mL against MRSA 
respectively, Table 17).‡‡ Similarly, analogues with an undecyl tail (diguanidine 180 and 
diamine 187) also showed near-identical MIC values against all bacterial isolates tested 
(e.g. 4 and 4–8 g/mL against E.coli respectively and 2 μg/mL against MRSA, Table 17). 
Analogues with a heptyl chain (diguanidines 179, 184 and 185 and diamine 186) showed 
either weak, or no activity at all. However, benzyl-substituted diguanidine 204 which also 
contains a heptyl chain, showed improved activity with MIC values of 8 and 2 μg/mL 
against E. coli and MRSA respectively. 
Table 17: MIC values (μg/mL) 
 
 
 
Compound 
A. baumannii 
ATCC 19606 
P. aeruginosa  
ATCC  
27853 
K. pneumoniae  
ATCC  
700603 
E. coli 
ATCC 
25922 
S. aureus 
MRSA 
ATCC 43300 
Guanidines      
179 >32 >32 >32 >32 32 
180 >32 16 >32 4 2 
181 16–32 >32 >32 32 1 
31 8–16 >32 >32 32 0.5 
182 >32 >32 >32 >32 >32 
183 32 16 32 4–8 1 
184 >32 >32 >32 >32 >32 
185 >32 >32 >32 >32 32 
204 >32 32 >32 8 2 
219 32 32 32 32 4 
220 >32 >32 >32 >32 32 
224 >32 >32 >32 >32 16 
Amines      
186 >32 >32 >32 >32 >32 
187 >32 16–32 >32 4–8 2 
188 32 >32 >32 32 0.5 
189 >32 16–32 16 1–2 1 
COL 0.06 0.25 0.03 0.06 >32 
 
                                                 
‡‡ While there is no explicit explanation in the literature to explain the discrepancy between disk diffusion 
results and MIC values (as seen for analogues 181 and 188), after consultation with project collaborators, 
the phenomenon is known and it is suggested that analogues bearing larger lipophilic groups are less soluble 
in the aqueous agar environment used in the disk diffusion assay and as a result the compounds do not 
diffuse from the disk. As such, false negatives can be obtained for these experiments. 
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The importance of the net cationic charge was again emphasised with singularly charged 
guanidines 219 and 220 showing only modest potency; 219 displayed MIC values of 
32 μg/mL against all strains tested apart from MRSA (4 μg/mL), whilst 220 was only 
active against MRSA (32 μg/mL, Table 17). Tricationic analogue 224 only showed 
activity against MRSA (MIC = 16 μg/mL) reinforcing that structural amphiphilicity is 
important for these compounds to elicit antibacterial activity. 
Diamines 188 (pentadecyl chain) and 189 (2-[4-(octyloxy)phenyl)ethyl chain) both had 
MIC values of 1 μg/mL against MRSA. Indeed, compound 189 was active against most 
isolates tested with MIC values of 2, 16 and 32 μg/mL against E. coli, K. pneumoniae and 
P. aeruginosa respectively (Table 17). Diguanidine 183, which contains both alkyl and 
aryl portions, was active against every bacterial isolate tested; highlighted by an MIC 
value of 1 μg/mL against MRSA. It should also be noted that the effect of counter ion 
was minimal with homologous compounds hydrochloride 181 and TFA salt 31 exhibiting 
almost identical MIC values (Table 17).  
Compounds with MIC values ≤ 2 μg/mL against MRSA (Table 17), were subject to a 
second round of micro-broth dilution assay against additional Gram-positive bacterial 
isolates.§§ Compounds with an undecyl chain attached (diguanidine 180 and diamine 187) 
exhibited good activity against Gram-positive bacterial strains shown in Table 18 with 
MIC values ranging from 2–8 μg/mL. The pentadecyl-substituted analogues 
(diguanidines 181 and 31 and diamine 188) showed excellent activity with MIC values ≤ 
2 μg/mL for all bacterial isolates tested in this assay. Of particular note were diamines 
188 and 189 which showed MIC values against all strains tested which are comparable 
to, or better than, Vancomycin (Table 18).  
 
 
 
 
 
                                                 
§§ At the time of submission 204 had not been tested against these additional bacterial strains or evaluated 
for cytotoxicity. 
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Table 18: MIC values (μg/mL) of most potent analogues 
 
Compound 180 181 31 183 187 188 189 VANa 
S. aureus  
mMRSA 
4 2 2 2 8 2 1 1 
S. aureus  
GISA, NRS 17 
2 1 0.5 1 2 0.5 1 4  
S. aureus  
VISA, NRS 1 
4 2 1 2 4 1 1 8 
S. aureus  
MRSA  
4 2 2 2 8 1 1 2 
S. pneumoniae  
MDR ATCC 
700677 
2 1 0.5 1 2 0.5 1 2 
E. faecalis  
VanA 
4 1 1 2 8 0.5 2 >32 
a VAN = Vancomycin. 
 
3.13.4: Cytotoxicity Studies 
The most potent compounds were then evaluated for cytotoxicity against HEK293 and 
HepG2 cell lines with 100 μM the most concentrated dose investigated (Table 19). In all 
cases the compounds exhibited a degree of cytotoxicity to both HEK293 and HepG2. 
Nevertheless, selectivity for bacterial cells over human cells for the compounds tested 
was apparent. For example, compound 189 which demonstrated MIC values of 1–
2 μg/mL against all Gram-positive bacterial pathogens investigated, exhibited a CC50 = 
12 μM which is equivalent to 7 μg/mL—a higher concentration than the observed MIC 
(see Appendix 11.1 for calculation). 
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Table 19: Cell line cytotoxicity (CC50)a  
 
Compound 180 181 31 183 187 188 189 TAMb 
HEK293  
ATCC CRL-1573 
7 12 6 13 9 7 12 11.1 
HepG2  
ATCC HB-8065 
10 11 9 14 11 6 12 18.7  
a CC50 values are given as μM. 
b TAM = Tamoxifen. 
 
3.14 Conclusions 
Herein, a high-yielding and scalable (to multi-gram amounts) method to access highly 
functionalised norbornane frameworks has been developed. A series of cationic 
norbornane-based amphiphiles have been synthesised which possess a variety of 
guanidinium, aminium, imidazolium and pyridinium groups. Analogues were also 
prepared bearing charge neutral anion recognition groups such as thioureas and 
squaramides.  
Biological evaluation of these compounds indicate that dicationic species were 
significantly more active than monocationic species, which in turn were more active than 
charge neutral compounds. The relationship between activity and cationic group follows 
the trend guanidinium ≈ aminium > imidazolium ≈ pyridinium. The nature of the 
counterion appears to have, at best, a minor influence on activity.  
Improved antibacterial activity was observed for benzyl-substituted guanidine 204 (MIC 
= 32, 8 and 2 μg/mL against P. aeruginosa, E. coli and MRSA, respectively) when 
compared to unsubstituted guanidine analogues 179 (MIC = 32 μg/mL against MRSA), 
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184 (no activity observed) and 185 (MIC = 32 μg/mL against MRSA). The importance 
of structural amphipilicity was also reinforced with non-amphiphilic tricationic 224 
exhibiting only modest activity against MRSA (MIC = 16 μg/mL) despite possessing 
three cationic moieties. 
Compounds containing hydrophobic groups with a greater non-polar surface area 
typically possessed increased antibacterial activity. The pentadecyl analogues 
(diguanidine 181 and diamine 188) and 2-[4-(octyloxy)phenyl]ethyl analogues 
(diguanidine 183 and diamine 189) were the most potent compounds in this series with 
MIC values ≤ 2 μg/mL against all Gram-positive bacterial isolates tested. The relationship 
between activity and lipophilic group follows the trend 2-[4-(octyloxy)phenyl]ethyl ≈ 
pentadecyl > undecyl > heptyl ≈ phenylethyl. 
The norbornane-based peptidomimetics described here require a net cationic charge to 
elicit antibacterial activity. An increase in activity was observed for benzyl-substituted 
guanidine 204 when compared to unsubstituted guanidine analogues of similar structure. 
The potency of these analogues is primarily dictated by the size of the hydrophobic 
portion attached to the norbornane scaffold; the greater the lipophilicity, the greater the 
antibacterial activity. In light of these conclusions, a logical means to increase 
lipophilicity whilst still retaining a dual cationic charge, would be the installation of two 
hydrophobic groups to the norbornane scaffold; the focus of Chapter 4. 
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Chapter 4 
The synthesis of a novel family of compounds—norbornane bisethers—is described in this 
Chapter. Previous unsuccessful attempts to alkylate norbornane diol 110 are outlined, 
followed by a detailed discussion of the Ag2O-mediated approach employed in this work. 
The norbornane bisether diacids were converted to their corresponding diguanidine 
hydrochloride salts using methodology described earlier in this thesis.  
The biological evaluation of this family of cationic amphiphiles against a panel of Gram-
negative and Gram-positive bacterial strains is also covered. Finally, the SAR data 
obtained for these cationic peptidomimetics will be discussed and conclusions will be 
drawn. 
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Norbornane Bisethers as 
Peptidomimetic Antibacterial Agents 
The key aims of this Chapter are to; 
x Synthesise a series of norbornane bisether diguanidine hydrochlorides. The key 
step in this synthesis—bisalkylation of norbornane diol 110—needs to be 
developed. 
x Evaluate these cationic amphiphiles as antibacterial agents against a range of 
Gram-negative and Gram-positive bacterial strains. 
x Propose reasonable SAR conclusions from the data obtained. 
 
4.1 Compound Design 
Two major conclusions were made from the SAR study performed in Chapter 3. Firstly, 
a net positive charge is required for antibacterial activity; preferably in the form of a 
guanidinium or aminium group. Secondly, an increase in hydrophobicity correlated with 
greater antibacterial potency. In light of these findings, a new family of norbornane-based 
amphiphiles was designed that incorporate two hydrophobic groups tethered to the 
norbornane framework through ether linkages. It is known that ethers typically 
demonstrate good in vivo stability380 and as such, compounds that follow the general 
structure of 236 (Figure 50) were considered attractive targets for this project. Subsequent 
functionalisation of the norbornane framework would ultimately furnish a new family of 
norbornane-based cationic amphiphiles. 
 
Figure 50: General structure of proposed norbornane bisether diguanidinium 236. 
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4.2 Retrosynthetic Analysis 
A retrosynthetic pathway, similar to the one outlined in Chapter 3, was devised to access 
norbornane bisether analogues of the general structure 236 (Scheme 46). The necessary 
Boc-deprotection, amide coupling and hydrolysis steps to ultimately afford compounds 
of the general structure 236 have all been detailed in Chapter 3. The installation of two 
hydrophobic groups to the norbornane scaffold is the key step in this retrosynthetic 
analysis. In order to achieve this, bisalkylation of norbornane diol 110 with an appropriate 
alkyl halide (238) is required to give norbornane bisether 237. The synthesis of 
norbornane diol 110 has already been outlined in Chapter 3.  
 
Scheme 46: Retrosynthetic route to norbornane bisether diguanidinium 236. 
 
4.3 Bisalkylation of Diol: Early Attempts 
4.3.1: Williamson Ether Synthesis 
The Williamson ether synthesis involves alkylation of an alcohol.310 Previous work at 
Deakin University investigated the bismethylation of diol 110 using standard Williamson 
conditions (MeI, NaH, DMF).381 However, this approach failed to generate bismethyl 
ether 239a and it was proposed that a Grob-type fragmentation382 occurred to give enolate 
241 (Scheme 47).381  
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Scheme 47: Failed attempt to access bisether 239a and the possible enolate 241 product. 
When the bismethylation of diol 110 using NaH and MeI was repeated, a complex mixture 
of products formed (as evidenced using 1H NMR spectroscopy). The reaction was also 
unsuccessful when n-BuLi in THF (−78 to 0 °C) was employed. 
In some cases alkylation of alcohols using typical Williamson protocols gives lower than 
expected yields, or no desired product at all.383,384 In circumstances where a stabilised 
leaving group can be formed, the basic conditions employed can lead to an elimination 
event.385,386 An example of competitive elimination in a fused cyclic system has been 
described by Hergueta et al. (Scheme 48); alkoxide 242, derived from a norbornane fused 
to a quinoxaline, undergoes elimination to give carbanion 243 which is resonance 
stabilised by the aromatic heterocycle.387 This example supports the hypothesis that a 
Grob-type fragmentation may be occurring from norbornane alkoxide 240 (Scheme 47).  
 
Scheme 48: Ring-opening to give stabilised ‘benzylic’ carbanion 243 as reported by Hergueta et 
al.387 
 
4.3.2: Reduction of Acetyl Groups 
As base-mediated conditions required for the Williamson ether synthesis were not 
conducive to the bisalkylation of diol 110, a more pH-neutral method was sought. The 
Sakai group have described the reduction of esters to ethers using Et3SiH in the presence 
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of catalytic InBr3.388 As it has been previously reported that diol 110 can be readily 
acetylated using AcCl,301 it was envisaged that reduction of the acetyl groups could be 
achieved, using the Sakai method, to furnish norbornane bisethers.  
The synthesis of benzyl ethyl ether 247 in 69% yield was reported by the Sakai group 
using the InBr3-mediated conditions.388 In order to validate this protocol, the synthesis of 
247 was repeated using the conditions described by Sakai et al.388 Benzyl alcohol was 
treated with neat acetic anhydride at 100 °C for 15 minutes to afford benzyl acetate 246 
in 58% yield (Scheme 49). When 246 was reacted with InBr3 and Et3SiH in CHCl3 at 
60 °C for 24 hours (Scheme 49), none of the desired product formed, as evidenced by 
1H NMR analysis of the crude reaction mixture. As such, this approach was abandoned. 
 
Scheme 49: Attempted reduction of benzyl acetate 246 to benzyl ethyl ether 247. 
 
4.4 Bisalkylation of Diol: Silver (I) Oxide-mediated Approach  
The use of silver (I) oxide (Ag2O) for the transformation of an alcohol to an alkyl ether 
has been known for well over a century.389 The seminal report by Thomas Purdie and 
William Pitkeathly in 1899 described the conversion of diethyl ᴅ-malate 248 to diethyl 
ᴅ-ethoxy ether 249 using neat EtI and Ag2O in 43% yield (Scheme 50).390  
 
Scheme 50: Alkylation of ᴅ-malate ester 248 using Ag2O.390 
 
4.4.1: Silver (I) Oxide-mediated Alkylations 
Many examples using Ag2O and an appropriate alkyl halide to convert alcohols to the 
corresponding ether have been reported since Purdie’s initial publication.390 Purdie was 
quick to continue his work and with the help of James Irvine, reported the alkylation of a 
small series of lactic acid derivatives; e.g. alcohol 250 was converted to methyl ether 251 
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in 65% yield using Ag2O and neat MeI (Scheme 51).391 Around the same time, McKenzie 
reported the preparation of alkoxymendelic acids, such as 253 (Scheme 51) in low yields, 
again using neat alkylating agent.392 Another early example is the methylation of 
salicylaldehyde 254 to give methyl ether 255 in 90% yield; again the reaction was 
performed in neat MeI (Scheme 51).393 It was Purdie who also described the first per-
methylation of carbohydrates when he converted α-methylglucoside 256 to tetramethyl 
α-methylglucoside 257 in 55% yield, using a large excess and two separate treatments of 
MeI (2 × 10 equivalents) in the presence of Ag2O (Scheme 51).394  
 
Scheme 51: Early uses of Ag2O to alkylate alcohols. 
Since that time the method developed by Purdie has been used to achieve 1) mono-
alkylations;395-399 2) bisalkylation of unhindered diols such as cyclohexanediol;400 and 3) 
per-methylation of other carbohydrates such as galactose and fructose.401 Due to reaction 
conditions such as multiple additions of the alkylating agent,394,398 or carrying the reaction 
out in neat alkylating agent,390,391,394 the Purdie method is often overlooked for 
Williamson methodology. Nevertheless, due to the neutral conditions employed, the 
Purdie method is still used in the alkylation of carbohydrates.402,403  
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4.4.2: Synthesis of Norbornane Bisether Diacid 258a 
Bisalkylation of eclipsed 1,2-syn diols using Ag2O has not been previously reported. 
However, when norbornane diol 110 was reacted with Ag2O (1.6 equivalents) and MeI 
(4.6 equivalents) in DMF at 21 °C for 48 hours, bismethylether 239a was isolated in good 
yield (67%, Scheme 52) after chromatographic purification. Bismethylether 239a was 
characterised using 1H NMR spectroscopy with singlets observed at δ = 3.37 and 
3.42 ppm which correlated to the protons of the methyl ether groups. A low frequency 
shift of the nearby endo protons (H5 and H6, Scheme 52) of 239a (δ = 3.29 and 3.46 ppm, 
respectively), when compared to norbornane diol 110 (δ = 3.85 and 3.71–3.77 ppm, 
respectively) was also observed. HRMS data also supported the identity of 239a with a 
signal at 273.1328 m/z which matched the calculated value of [M + H]+. 
 
Scheme 52: Synthesis of bisether diacid 258a.  
Hydrolysis of diester 239a using NaOH in THF/H2O gave the required diacid 258a in a 
73% yield (Scheme 52). Spectroscopically pure material was obtained after an extractive 
work-up and the structure was confirmed using 1H NMR spectroscopy by the absence of 
the methyl ester protons (δ = 3.70 and 3.72 ppm) in 239a. With the desired bisether diacid 
258a now synthesised, efforts were directed to improving the yield of the bisalkylation 
step. 
When diol 110 was reacted with MeI in the presence of Ag2O for 24 hours (Table 20, 
entry 2), a lower yield of 239a was obtained (49%). When the reaction was stirred for 
three days (Table 20, entry 3) and after chromatographic purification, bisether 239a was 
isolated in a 57% yield. None of the desired product was formed when THF was used as 
the reaction solvent or when the reaction was performed in more dilute conditions 
(Table 20, entries 4 and 5). 
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Table 20: Alkylation of norbornane diol 110 with MeI 
 
Entry Silver 
source 
MeI 
(equiv) 
Solvent Temp. 
(°C) 
Time Yield 
(%) 
1 Ag2O 4.6 DMF 21 2 d 67 
2 Ag2O 4.6 DMF 21 1 d 49 
3 Ag2O 4.6 DMF 21 3 d 57 
4 Ag2O 4.6 THF 21 2 d N.Ra 
5b Ag2O 4.6 DMF 21 2 d N.R 
6c Ag2O 4.6 × 2 DMF 21 2 d 62 
7d Ag2O 4.6 DMF 50 30 min N.R 
8 AgBF4 4.6 DMF 21 2 d N.R 
9 AgPF6 4.6 DMF 21 2 d N.R 
10 Ag2CO3 4.6 DMF 21 2 d N.R 
a N.R = No reaction. 
b Reaction performed at 0.1 M with respect to diol 110. All other reactions were carried out at 1.53 M. 
c The reaction was subjected to two separate additions of MeI at 24 hour intervals. 
d Microwave irradiation was employed. 
An extra portion of MeI (4.6 equivalents) added to the reaction mixture after 24 hours 
(Table 20, entry 6) did not significantly improve the yield of 239a (62%). When 
microwave irradiation was used to heat the reaction mixture (Table 20, entry 7) none of 
the desired product was observed in the 1H NMR spectrum of the crude reaction product. 
Different silver salts were also trialled including AgBF4, AgPF6 and Ag2CO3 (Table 20, 
entries 8–10), however only starting material was recovered from the reaction mixture 
when these were used. 
Although the best yield of bisether 239a was a modest 67%, the ability to synthesise these 
previously inaccessible norbornane bisethers was considered noteworthy. With 
methodology developed to access target bisether diacids such as 258a, a variety of alkyl 
halides were investigated to furnish a series of analogues comprised of two hydrophobic 
regions. 
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4.4.3: Synthesis of Bisether Diacid Analogues 
Using BnBr (Table 21, entry 2), bisether diacid 258b was obtained over two steps in an 
overall yield of 18% on a 300 mg scale. The 1H NMR spectrum of 258b showed a 
chemical shift of the endo H5 and H6 norbornane protons (δ = 3.63 ppm) and the absence 
of the methyl ester protons (δ = 3.60 and 3.69 ppm) which were present in the 1H NMR 
spectra of diester 239b. HRMS further supported the structure of 258b with a signal 
observed at 395.1504 m/z which correlated to [M − H]−. When the reaction was performed 
on a larger scale (900 mg of 110), the yield increased to 37%. A Finkelstein approach 
using NaI, in an effort to replace the bromide atom with an iodine,404 did not improve the 
yield of 258b.  
Treating norbornane diol 110 with 2-methybenzyl bromide and subsequent hydrolysis of 
the methyl ester groups afforded 258c in 19% yield over the two steps (Table 21, entry 3). 
When fluorinated benzyl bromides 4-(trifluoromethyl)benzyl bromide, 3-fluorobenzyl 
bromide and  4-flurobenzyl bromide were employed, good yields of the desired bisether 
diacid products 258d (51%), 258e (55%) and 258f (25%) were obtained using the two-
step process (Table 21, entries 4–6).  
Bisether diacids 258g and 258h were accessed over two steps using 3-bromobenzyl 
bromide and 4-bromobenzyl bromide in 24 and 28% yields respectively (Table 21, 
entries 7 and 8). When allyl bromide was used as the alkylating agent, and after hydrolysis 
of the methyl esters, bisether diacid 258i was obtained in 25% yield over the two steps 
(Table 21, entry 9).  
When 3-phenylbenzyl bromide was used none of the desired product was formed 
(Table 21, entry 10) and a mixture of mono-alkylated regioisomers was observed in the 
1H NMR spectra of the crude reaction product (this will be further discussed in section 
4.4.4). When 4-methoxybenzyl chloride and 4-nitrobenzyl bromide were trialled 
(Table 21, entries 11 and 12), only starting material was recovered from the reaction 
mixture. The bisalkylation step also failed when 1-iodooctane was used (Table 21, 
entry 13). 
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Table 21: Synthesis of bisether diacids 258a–i 
 
Entry R1X Diacid Yielda (%) 
1 MeI 258a 48 
2 
 
258b 37 
3 
 
258c 19 
4 
 
258d 51 
5 
 
258e 55 
6 
 
258f 25 
7 
 
258g 24 
8 
 
258h 28 
9b  258i 25 
10 
 
N.Rc N.R 
11 
 
N.R N.R 
12 
 
N.R N.R 
13  N.R N.R 
14 
 
N.R N.R 
15 
 
N.R N.R 
a Yield calculated over two steps. 
b Reaction was stirred for four days. 
c N.R. = None of the desired bisether product was isolated. 
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Two benzyl bromides comprised of both alkyl and aromatic functionality were sought to 
generate norbornane bisethers with larger hydrophobic groups attached. Firstly, 
alkylation of ethyl-4-hydroxybenzoate 259 with 1-iodooctane, using basic conditions, 
gave octyl ether 260 in 88% yield. Reduction of the ethyl ester using Red-Al® gave 
alcohol 261 in 75% yield following literature procedure.405 Purification of 261 was 
achieved by trituration with petroleum spirits. Following literature procedure,406 benzyl 
alcohol 261 was converted to benzyl bromide 262 in 59% yield using PBr3.  
 
Scheme 53: Synthesis of benzyl bromide 262. 
The synthesis of a second benzyl bromide began with a Sonogashira cross-coupling of 4-
bromobenzaldehyde 263 using PdCl2(PPh3)2 and 1-octyne,407,408 to give alkyne 264 in 
67% yield. The two-step, one-pot hydrogenation of the alkyne and reduction of the 
aldehyde, as described by Yagi,409 gave benzyl alcohol 265 in 21% yield. Finally, 
bromination using PBr3 in CH2Cl2 afforded the desired benzyl bromide 266 in 80% yield 
(Scheme 54) which matched previously reported spectroscopic data.410  
 
Scheme 54: Synthesis of benzyl bromide 266. 
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Unfortunately, when benzyl bromides 262 and 266 were used to alkylate diol 110 
(Table 21, entries 14 and 15), only starting material was recovered from the reaction 
mixture in each instance.  
 
4.4.4: Structure of Norbornane Bisether Diacids 
The low yields for the bisalkylation step can be rationalised somewhat by the steric bulk 
introduced as a result of the first alkylation; the reaction with the second equivalent of 
benzyl halide is considerably inhibited. As previously mentioned, when 3-phenylbenzyl 
bromide was used (Table 21, entry 10) only mono-alkylated products were isolated. 
Indeed, in every instance a mixture of mono alkylated regioisomers was generated, and 
in some cases were isolated in appreciable amounts using column chromatography. As an 
example, regioisomers 267a and 267b (Figure 51) were isolated using column 
chromatography in 39% yield after treating norbornane diol 110 with 2-methylbenzyl 
bromide. When 267a and 267b were reacted with additional equivalents of 2-
methylbenzyl bromide only small quantities of the desired bisether product was isolated. 
 
Figure 51: Regioisomers 267a and b. 
Analysis of bisether diacid 258d using 1H NMR spectroscopy showed four doublets as 
two sets of AB pairs; δ = 4.58 and 4.62 ppm with coupling constants of 12.7 Hz each, and 
δ = 4.63 and 4.68 ppm with coupling constants of 12.5 Hz each (Figure 52). The observed 
splitting pattern is due to geminal coupling between the diastereotopic methylene protons 
of C1ʹ and C2ʹ.  
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Figure 52: 1H NMR (500 MHz) spectra (top) and expansion (4.48–4.77 ppm, bottom) of 258d 
in DMSO-d6. 
In some cases the 1H NMR signals associated with the methylene protons could not be 
resolved into four distinguishable doublets, presumably due to second order coupling 
effects.411 When the chemical shift difference (in Hz) between two coupled nuclei is 
similar to that of the coupling constant, the peak intensities can change, resulting in the 
spectra being difficult to interpret as the signals are poorly resolved.411 When 258c was 
analysed by 1H NMR spectroscopy (performed at 20 °C), the two diastereotopic 
methylene groups were observed as two doublets (δ = 4.45 and 4.48 ppm, 2JHH = 11.8 Hz 
each) and a singlet (δ = 4.53 ppm, Figure 53).  
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Figure 53: 1H NMR (500 MHz) spectra (top) and expansion (4.39–4.64 ppm) of variable 
temperature 1H NMR spectra (bottom) of 258c in DMSO-d6. 
When the 1H NMR experiment of 258c was performed at 100 °C two sets of AB pairs 
were observed with a high frequency shift of the methylene proton resonances (ca. ∆δ = 
0.04 ppm, Figure 53). This result indicates that the methylene protons reside in a less 
shielded chemical environment when heated to 100 °C. A high frequency chemical shift 
of the endo-protons (H5 and H6) and the two sets of ArCH3 protons was also observed 
when the 1H NMR experiment was performed at 100 °C; ∆δ = 0.06 ppm and ∆δ = 
0.04 ppm respectively. This phenomena was found to be reversible; after heating a sample 
of 258c to 100 °C and then cooling to 20 °C, the 1H NMR spectra matched that of the 
initial 20 °C experiment (Figure 53). This trend was observed for all norbornane 
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bisbenzyl ethers in this study. As the chemical shift of non-exchangeable protons in a 
freely-rotating system are typically independent of temperature in 1H NMR spectroscopy 
experiments,412-414 these results suggest the molecule may be undergoing a 
conformational change when the temperature is increased. 
Crystals suitable for X-ray diffraction were obtained for bisether diacid 258h after 
recrystallisation from EtOH/pet. spirits. X-ray crystallography was performed at The 
University of Melbourne courtesy of Professor Jonathan White. The resulting structure 
contained a unit cell comprised of two conformational isomers with the two benzyl groups 
residing in a non-symmetrical orientation to each other (Figure 54). The O···O distance 
(which is measured from the nucleus of each atom) was calculated to be approximately 
2.6 Å. The van der Waals radius for oxygen is approximately 1.6 Å,415 suggesting the van 
der Waals radii of the oxygen atoms would be overlapping. Given the oxygen atoms are 
locked in a 1,2-syn conformation they are unable to reorientate, however, it would be 
reasonable to assume that substituents on the two oxygen atoms would repel each other 
as a direct result of the van der Waals radii overlap. This would result in the molecule 
adopting an overall non-symmetric conformation; as supported by the X-ray crystal 
structure of 258h (Figure 54). 
 
Figure 54: Thermal ellipsoid plot of the two independent molecular confirmations (ellipsoids at 
20% probability level) of compound 258h. Hydrogen atoms have been omitted for clarity. 
The X-ray crystal structure of 258h supports the 1H NMR data which suggests that the 
norbornane bisether compounds are forced to adopt non-symmetric conformations. As 
the chemical shift of the methylene protons in the 1H NMR spectra of 258c changed when 
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the experiment was performed at 100 °C, it is tentatively suggested that heating allows 
for the formation of a number of previously inaccessible conformers.  
As well as the formation of mono-alkylated side-products, in six of the alkylation 
reactions (239b and 239d–h) transesterification also occurred to a small extent (6–12%, 
as determined by 1H NMR spectroscopy). This mixed-ester side-product (example 268 
from the synthesis of 239b, Figure 55) was difficult to separate from the desired dimethyl 
ester product using column chromatography. The presumption that the more sterically 
accessible exo methyl ester was affected is based on a previous report by Niwayama who 
illustrated how the exo face is less hindered than the endo face of related norbornane 
diesters.335 Despite the presence of small amounts of mixed-ester by-products, hydrolysis 
of the crude mixture proceeded smoothly to afford the desired bisether diacid products in 
every instance. 
 
Figure 55: Structure of proposed mixed-ester 268. 
 
4.4.5: Limitations in the Methodology 
Part A: Alkylation 
To further investigate the scope of the Ag2O-mediated bisalkylation reaction, a more 
complex diol substrate was sought. Norbornene diacid 50 was reacted with 
aminoethylguanidine 41, using previously described microwave-mediated coupling 
conditions, to access diamide 269 in 68% yield (Scheme 55). Norbornene 269 was then 
converted to diol 270 using a catalytic amount of OsO4 in the presence of NMO, however 
the material was unable to be purified using column chromatography.*** Nonetheless for 
the purpose of this study, crude diol 270 was treated with MeI in the presence of Ag2O, 
however only starting material was recovered from the reaction. Similarly, when a less 
complex substrate was used, such as norbornane diol 273 which was synthesised from the 
                                                 
*** The inability to obtain spectroscopically pure diol 270 is further justification for employing synthetic 
routes that focus on late stage derivatisation of the anion recognition groups for both the acetal and ether 
series of compounds. 
121 | P a g e  
 
dihydroxylation of norbornene 272 in 45% yield (Scheme 55), the desired bismethyl ether 
274 was not formed, as evidenced by 1H NMR spectroscopic analysis of the crude 
reaction product.  
 
Scheme 55: Failed Ag2O-mediated methylations of norbornane diols 270 and 273. 
Part B: Pd(II)-catalysed Aromatic Substitution 
It has been well established in the literature that hydrophobicity plays an important role 
in the activity of antibacterial agents.25 As such, the introduction of longer alkyl groups 
to the norbornane scaffold was desired. Given the inability to alkylate diol 110 with bulky 
alkyl halides, a Sonogashira cross-coupling approach to install an alkyl chain to the 
bisbenzyl ethers was investigated. Adopting the method by Ezoe et al.,409 bisether 239h 
was stirred with 1-octyne, Et3N, a catalytic amount of PdCl2(PPh3)2 and CuI for two days 
at 50 °C, however only starting material was recovered from the reaction mixture 
(Scheme 56). 
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Scheme 56: Attempted Sonogashira cross-coupling of bisether 239h. 
Despite these limitations, the Ag2O-mediated approach to alkylate diol 110 is the first 
known procedure to successfully synthesise the norbornane bisether family of 
compounds. This protocol requires only 4.6 equivalents of the appropriate alkyl halide 
and the reaction is performed using pH-neutral conditions.  
 
4.5 Dicationic Norbornane Bisether Peptidomimetics 
The installation of two guanidine units to the norbornane framework was achieved using 
the same protocol described for the acetal series of compounds (Chapter 3). Using EDCI 
and HOBt, aminoethylguanidine 41 was attached to the norbornane bisether diacids 
(258a–i, Table 22). The reactions were performed in either DMF or CHCl3 and after 
chromatographic purification, norbornane bisether diguanidines (271a–i) were isolated in 
yields of 26–72% (Table 22). Characterisation of these compounds was achieved using 
1H NMR spectroscopy. For example, the 1H NMR spectra of bismethyl ether diguanidine 
271a showed the two amide NH resonances as triplets at δ = 6.69 and 8.02 ppm. The low 
frequency shifts of H2 and H3 in 271a (δ = 2.45 and 2.82 ppm, respectively) when 
compared to bismethyl ether diacid 258a (δ = 2.67–2.76 and 3.25 ppm, respectively) is 
evidence of reaction success. Examination of the 13C NMR spectra of 271a revealed a 
low frequency chemical shift (ca. ∆δ = 5.3 ppm) of the amide carbonyl carbons when 
compared to diacid 258a. 
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Table 22: Formation of guanidine hydrochloride salts 276a–i 
 
Diacid R1X Diamide Yield (%) Diguanidinium Yield (%)a 
258a Me 271a 72 276a 96 
258bb 
 
271b 57 276b 96 
258c 
 
271c 54 276c 24 
258d 
 
271d 56 276d 66 
258e 
 
271e 26 276e 99 
258fb 
 
271f 45 276f 77 
258gb 
 
271g 53 276g 97 
258h 
 
271h 26 276h 99 
258i  271i 63 276i 31 
a Product was isolated as a hydrochloride salt. 
b Reaction was performed in CHCl3. 
Removal of the Boc-protecting groups was carried out using the previously employed 
AcCl/MeOH conditions (Chapter 3). Synthesis of the required diguanidine hydrochloride 
salts (276a–i) was achieved in typically good yields of 24–99% (Table 22) and pure 
material was obtained after removal of the reaction solvent and two co-evaporations with 
MeOH. The absence of any tert-butyl protons in the 1H NMR spectra of these compounds 
(ca. δ = 1.49 ppm) as well as the absence of signals in the 13C NMR spectra of these 
compounds that related to the Boc-protecting groups (ca. δ = 28.1–28.4 and 156.0–
164.0 ppm) confirmed reaction success.  
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4.6 Biological Evaluation of Norbornane Bisethers  
The bisether diguanidinium analogues 276a–i (Table 22), were evaluated against the 
same panel of bacterial pathogens described in Chapter 3. Disk diffusion assays were used 
to calculate the ZOI and micro-broth dilution assays were employed to ascertain MIC 
values. The cytotoxicity of the most potent compounds were evaluated against HEK293 
and HepG2 cell lines. 
 
4.6.1: Disk Diffusion Assay 
Bismethyl ether 276a and bisallyl ether 276i did not show any activity in the disk 
diffusion assay (Table 23). For the bisbenzyl ether 276b, a noticeable ZOI was observed 
(11 mm) against P. aeruginosa. An increase in activity was seen for substituted benzyl 
analogues. For example, 16, 14 and 15 mm zones of inhibition against P. aeruginosa, K. 
pneumoniae and MRSA respectively were observed for the 2-methyl derivative 276c 
(Table 23).  
Table 23: ZOI as measured (in mm) using disk diffusion assaya 
 
 
 
Compound 
A. baumannii 
ATCC 19606 
P. aeruginosa  
ATCC  
27853 
K. pneumoniae  
ATCC  
13883 
S. aureus 
MRSA 
ATCC 
43300 
E. faecium 
VRE  
ATCC 
700221 
276a NTb - - - - 
276b NT 11 - - - 
276c - 16 14 15 - 
276d - 15 16 17 18 
276e - 16 14 11 - 
276f - 15 14 11 - 
276g 15 16 15 17 7 
276h - 15 8 18 16 
276i - - - - - 
COLc 20 19 20 - - 
a Measured after incubation of disk (6 mm diameter, 50 μg/disk) at 37 °C for 20 hours. 
b NT = Not tested. 
c Tested at 10 μg/disk. 
The 4-(trifluoromethyl)benzyl analogue 276d was one of the most potent compounds in 
this study with a ZOI ≥ 15 mm against all bacterial isolates tested except for A. baumannii 
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(Table 23). Analogues bearing a fluoro substituent in the 3-position (276e) and 4-position 
(276f) showed almost identical activity against P. aeruginosa (16 and 15 mm 
respectively), K. pneumoniae (14 mm) and MRSA (11 mm). 
The 3-bromobenzyl analogue 276g was the most effective inhibitor of bacterial growth 
in the disk diffusion assay (Table 23); highlighted by a ZOI of 16 and 17 mm against P. 
aeruginosa and MRSA respectively (Figure 56). Similarly, the 4-bromobenzyl analogue 
276h showed inhibition against all of the strains tested (except A. baumannii), including 
excellent activity against Gram-positive isolates MRSA (18 mm) and VRE (16 mm).  
 
Figure 56: Antibacterial activity of compound 276g (as indicated by ‘5’) against P. aeruginosa 
(LHS) and MRSA (RHS) using disk diffusion assay. 
From the results in Table 23, the substituent on the benzyl group influences antibacterial 
activity (e.g. bromo-substituted analogues > fluoro-substituted analogues > unsubstituted 
benzyl analogue 276b). This is a similar trend to what was seen with the acetal family of 
compounds discussed in Chapter 3.  
 
4.6.2: Micro-broth Dilution Assay 
Substituted benzylethers (276c–h) were subject to micro-broth dilution studies to 
determine MIC values. For smaller ether substituents—2-methyl (276c), 3-fluoro (276e) 
and 4-fluoro (276f)—no activity was observed against any of the bacterial strains tested 
(Table 24). However, when larger substituents were included on the benzyl groups, such 
as the 4-trifluoromethyl group (276d), good activity was observed against most bacterial 
strains evaluated; 32 μg/mL against A. baumannii and 8 μg/mL against P. aeruginosa, E. 
coli and MRSA. When bromo-groups were present on the phenyl rings in the 3-position 
(276g) and 4-position (276h), activity was observed against MRSA with MIC values of 
16 and 32 μg/mL respectively (Table 24). 
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Table 24: MIC values (μg/mL) for bisether diguanidinium compounds 276c–h 
Compound 276c 276d 276e 276f 276g 276h COLa VANb 
A. baumannii 
ATCC 19606 
>32 32 >32 >32 >32 >32 0.06 NT 
P. aeruginosa 
ATCC 27853 
>32 8 >32 >32 32 >32 0.25 NT 
K. pneumoniae 
ATCC 700603 
>32 >32 >32 >32 >32 >32 0.03 NT 
E. coli 
ATCC 25922 
>32 8 >32 >32 >32 >32 0.06 NT 
S. aureus 
MRSA ATCC 43300 
>32 8 >32 >32 16 32 NT 1 
a COL = Colistin sulphate. 
b VAN = Vancomycin. 
Compounds 276d and 276g showed good activity against MRSA and were consequently 
evaluated against seven additional Gram-positive bacterial isolates (Table 25). The 4-
(trifluoromethyl)benzyl analogue 276d was again the most active compound; 
antibacterial activity (MIC = 8–16 μg/mL) against all eight Gram-positive strains was 
observed (Table 25). Activity was also observed for the 3-bromobenzyl analogue 276g 
against all eight Gram-positive strains tested, albeit it was not as potent as 276d 
(Table 25). 
Table 25: MIC values (μg/mL) for bisether diguanidinium compounds 276d and 276h 
Compound 276d 276g VANa 
S. aureus MRSA ATCC 43300 8 16 1 
S. aureus mMRSA 16 32 1 
S. aureus GISA, NRS 17 8 16 4 
S. aureus VISA, NRS 1 16 32 8 
S. aureus MRSA 16 32 2 
S. aureus NARSA VRS 10 8 16 2 
S. pneumoniae MDR ATCC 700677 8 8 2 
E. faecalis VanA 8 32 >32 
a VAN = Vancomycin. 
4.6.3: Cytotoxicity Studies 
The two most potent compounds (276d and 276g) were evaluated for cytotoxicity against 
HEK293 and HepG2 cell lines with the maximum concentration investigated 100 μM. 
The 4-(trifluoromethyl)benzyl ether analogue 276d exhibited moderate cytotoxicity with 
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CC50 values of 43 and 56 μM against HEK293 and HepG2 respectively (Table 26). 
Compound 276g showed good cytotoxicity with CC50 values of 90 and 96 against the 
same cell lines (Table 26). Much like the acetal analogues described in Chapter 3, the 
bisether compounds seemed to have a degree of selectivity for bacterial cells over human 
cells.  
Table 26: Cell line cytotoxicity (CC50)a 
Compound 276d 276g TAMb 
HEK293  
ATCC CRL-1573 
43 90 11.1 
HepG2  
ATCC HB-8065 
56 96 18.7  
a CC50 values given as μM. 
b TAM = Tamoxifen. 
 
4.7 Conclusions 
The key aims of this Chapter were to i) attach two hydrophobic groups to the norbornane 
framework via the bisalkylation of diol 110; and ii) evaluate the facially amphiphilic 
bisether diguanidinium compounds for their antibacterial activity.  
The low yields of the Ag2O-mediated bisalkylation step were rationalised by the 
inherently congested nature of the ether groups which was supported by NMR studies and 
X-ray crystallography. Although the methodology was somewhat restricted in regards 
substrate specificity, subsequent functionalisation with aminoethylguanidine 41 
ultimately furnished a series of facially amphiphilic cationic compounds (276a–i). 
Results from the biological evaluation of these compounds reinforce the notion that larger 
hydrophobic groups typically lead to greater antibacterial activity, with analogues bearing 
4-(trifluoromethyl)benzyl (276d) and bromo-substituted benzyl groups (276g and h) the 
most potent compounds in the series. The two most potent bisether analogues (276d and 
276g) also exhibited an encouraging cytotoxicity profile. 
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Chapter 5 
The synthesis of fluorescent norbornane-based antibacterial agents would enable 
fluorescence microscopy studies which may give some insight into a possible mode of 
action. This Chapter begins with an introduction to fluorescence and a discussion of some 
selected examples of small fluorescent compounds which have demonstrated biomedical 
applications. The preparation of two fluorescent norbornane-based peptidomimetics 
follows. The two analogues are then assessed for photophysical properties and biological 
activity. 
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Fluorescent Norbornane-based 
Peptidomimetics 
The key aims of this Chapter are to; 
x Design and synthesise two fluorescently tagged norbornane-based cationic 
amphiphiles. 
x Assess the photophysical properties of the two fluorescent analogues. 
x Evaluate the two fluorescent compounds for antibacterial activity. 
 
5.1 An Introduction to Fluorescence 
Fluorescence occurs when a photon is emitted from an excited singlet state.416,417 A 
Jabłoński diagram, as illustrated in Figure 57,418 is often used to explain the transitions of 
an electron which can ultimately lead to fluorescence. A photon is absorbed by a 
fluorophore in the ground state (So) to give an excited state (either S1 or S2). Once in this 
excited state energy can be lost through a number of processes. Although emission of a 
photon from the S2 state is theoretically possible (which would result in fluorescence) 
energy is preferentially lost through vibrational relaxation in a non-radiative manner; a 
much more rapid process. Once in the S1 excited state a photon can then be emitted to 
give fluorescence. Alternatively, the energy can dissipate in a non-radiative fashion from 
an excited electron in the S1 state to the ground state (as depicted in Figure 57). This 
process is called internal conversion and no fluorescence is observed as a result.416 
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Figure 57: A simplified Jabłoński diagram.418  
The term ‘fluorescence’ was conceived by Sir George Stokes in 1852 when he reported 
the visible emission of light by quinine 277.419 Stokes concluded that dispersed light is 
always of a longer wavelength then absorbed light when fluorescence occurs.419 The 
difference (in nm) between the absorption maximum (λmax) and the emission maximum 
(λem) was subsequently coined the Stokes shift (Figure 58).416 The most useful 
fluorophores have large Stokes shifts, as it is easier to distinguish absorption and emission 
wavelengths.420  
 
Figure 58: Structure of quinine 277 and a diagram illustrating the Stokes shift (taken from 
Lavis and Raines, 2008).416 
Fluorescence efficiency is determined by measuring the quantum yield (ɸf) of a particular 
fluorophore. The quantum yield is the ratio of photons emitted to those that are absorbed 
by the fluorophore.416 
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5.1.1: Fluorescent Compounds and Their Applications 
There are many examples of natural compounds which exhibit measurable fluorescence, 
such as tryptophan 278 and quinine 277 (Figure 59). The amino acid tryptophan 278 has 
a number of bioanalysis applications including investigations into protein folding,421 
whilst quinine 277 is commonly used as a fluorescence standard.422 The oxazine-based 
fluorophore resorufin (282, Figure 59) is an anionic fluorophore which is used in 
biological assays such as enzyme-linked immunosorbent assay (ELISA).423 A more 
recently reported class of fluorophores are the squaraine compounds, such as 283 which 
absorbs and emits light at near-IR wavelengths.424 These are appealing fluorophores due 
to their ease of synthesis, however, squaraine derivatives are inherently susceptible to 
nucleophilic attack and are prone to aggregation. Recent work by the Smith group has 
overcome these drawbacks by protecting squaraine fluorophores with rotaxanes.424,425 
 
Figure 59: Plot of fluorescent quantum yield (ɸf) versus maximum absorption (λmax) for selected 
fluorophores. The position of the compound number relates to the quantum yield and the colour 
of the structure indicates its maximum emission (λem) wavelength.416,424,426  
A number of fluorescent molecules have found use in fluorescence microscopy which in 
turn has facilitated a greater understanding of biological systems.420,427 Small fluorescent 
markers have been used to reveal information about the morphology of the cellular 
cytoskeleton428 and the lipid membrane composition.429 The boron difluoride 
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dipyrromethene (BODIPY-FL®) dye (281) is a commonly used fluorophore for this 
purpose due to its high quantum yields (ca. ɸf = 0.94).430 For example, a perception that 
Daptomycin performed poorly against biofilms of Staphylococcus epidermidis because it 
was unable to penetrate the biofilm layer was challenged by the Stewart group.431 
Daptomycin tagged with BODIPY-FL® 281 was clearly visualised, using fluorescence 
microscopy, to penetrate the S. epidermidis biofilm cell cluster within two minutes 
(Figure 60).431  
 
Figure 60: Images of the S. epidermidis biofilm cell cluster before and after treatment with 
BODIPY-tagged Daptomycin (images taken from Stewart et al.).431 
Two notable examples illustrated in Figure 59 are the naphthalimide (279) and 4-
nitrobenz-2-oxa-1,3-diazole (NBD, 280) fluorophores. These fluorophores have found 
use as fluorescent anion sensors426,432 (such as naphthalimide 284, Figure 61)433 and lipid-
penetrating probes434,435 (such as NBD 285).436 Both the naphthalimide and NBD 
fluorophores are known to exhibit large Stokes shifts, high quantum yields and emit light 
typically in the green part of the UV-visible spectrum (495–570 nm).416,437  
 
Figure 61: Naphthalimide 284 and NBD 285. 
The fluorescence of both the naphthalimide and NBD fluorophores is reliant on electron 
donating and electron withdrawing substituents to facilitate a ‘push-pull’ internal charge 
transfer (ICT).438 In the case of 4-amino naphthalimides (Scheme 57), this push-pull 
character is governed by the electron-donating amino moiety and the electron-
withdrawing imide group.439 Both the naphthalimide and NBD fluorophores are 
intrinsically sensitive to changes in their environment; a useful feature of fluorescent 
probes and sensors.438  
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Scheme 57: Example of ‘push-pull’ mechanism of naphthalimide 279.426 
The 4-amino naphthalimide and NBD fluorophores were selected for this project due to 
their favourable fluorescent properties (large Stokes shifts and high quantum yields) and 
their applicability in anion recognition (naphthalimide) and lipid permeability (NBD).  
 
5.2 Compound Design 
Enhanced antibacterial activity was observed for the norbornane-based compounds 
described in Chapters 3 and 4, when hydrophobic groups with a greater non-polar surface 
area were attached to the norbornane scaffold. The ability of cationic AMPs to penetrate 
the lipid membrane of bacterial cells is considered crucial to antibacterial activity.151 It is 
therefore reasonable to suggest that these compounds may act by disrupting the bacterial 
cellular envelope.  
In order to investigate if the norbornane-based antibacterial agents detailed in this thesis 
penetrate the lipid membrane, fluorescent analogous were desired to facilitate future 
fluorescence microscopy studies. The two proposed targets (287 and 288, Figure 62) are 
comprised of two guanidinium moieties and a fluorescent tag††† connected to the 
norbornane framework through an undecanyl linker and an acetal group.  
 
Figure 62: Proposed fluorescent norbornane cationic peptidomimetics 287 and 288.  
                                                 
††† For the remainder of this document the fluorophore will be coloured green. 
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5.3 Synthesis of Fluorescent Cationic Peptidomimetics 
Compounds 289 and 290 (Figure 63) were identified as key intermediates to access 
naphthalimide 287 and NBD 288. The dimethyl ester functional groups of 289 and 290 
can be converted to the desired guanidine hydrochloride salts, over three steps, using 
methodology described in Chapters 3 and 4.  
 
Figure 63: Naphthalimide (289) and NBD (290). 
 
5.3.1: Pathway A – Convergent Synthetic Route 
Strategy 
An approach to build the naphthalimide portion of 289 before attaching it to the 
norbornane framework was initially investigated. The retrosynthetic analysis, as depicted 
in Scheme 58, highlights the key disconnection of norbornane naphthalimide 289 to give 
norbornane diol 110 and aldehyde 291. Aldehyde 291 can be accessed from the oxidation 
of alcohol 292 which in turn can be synthesised by amination of 4-bromo naphthalimide 
293 with propylamine. Nucleophilic acyl substitution of commercially available 4-
bromo-1,8-naphthalic anhydride 294 with amine 295 is the final step of this retrosynthetic 
analysis (Scheme 58). 
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Scheme 58: Retrosynthetic pathway to construct norbornane naphthalimide 289. 
Synthesis 
The synthesis of Boc-protected 231 has been detailed in Chapter 3. Removal of the Boc-
protecting group from 231 was achieved using HCl (generated in situ from AcCl and 
MeOH) to give 295 in near-quantitative yield (99%, Scheme 59).  
 
Scheme 59: Synthesis of 12-aminododecan-1-ol hydrochloride 295. 
An equimolar amount of 295 and Et3N was heated with commercially available 4-bromo-
1,8-naphthalic anhydride 294 in EtOH for 45 minutes at 100 °C using microwave 
irradiation (Scheme 60). The desired naphthalimide 293 was isolated in 91% yield after 
an extractive workup. A high frequency shift of the methylene protons adjacent to the 
amine group in 295 (δ = 2.69–2.77 ppm) was observed in the 1H NMR spectra of imide 
293 (δ = 4.15 ppm) which is evidence of the desired transformation.  
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Scheme 60: Attempted synthesis of aldehyde 291. 
The Buchwald-Hartwig amination is used to form carbon-nitrogen bonds between an 
amine and an aryl halide via palladium cross-coupling. The procedure was originally 
developed by John Hartwig in 1994440 and later improved by Stephen Buchwald in 
1996.441  
Pfeffer et al., recently described the amination of 4-bromo naphthalimide derivatives 
using optimised Buchwald-Hartwig conditions.442 Using this procedure, 4-bromo 
naphthalimide 295 was treated with three equivalents of propylamine, Cs2CO3 and 
catalytic amounts (0.04 equivalents) of both tris(dibenzylideneacetone)dipalladium(0)-
CHCl3 adduct (Pd2(dba)3·CHCl3) and 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene 
(xantphos) in PhMe for 24 hours at 70 °C (Scheme 60). After chromatographic 
purification, the fluorescent naphthalimide 292 was obtained in 38% yield. 
Naphthalimide protons (H5 and H7, Scheme 60) of 292 displayed considerably low 
frequency shifts in the 1H NMR spectrum (δ = 6.71 and 8.08 ppm, respectively) when 
compared to the bromo-substituted naphthalimide 293 (δ = 8.04 and 8.56 ppm, 
respectively). Conversely, a noticeable high frequency shift of the C6 carbon in the 
13C NMR spectra of amino naphthalimide 292 was observed (δ = 149.5 ppm) when 
compared to bromo naphthalimide 293 (δ = 130.3 ppm). This chemical shift was 
attributed to the steric shielding imparted on the C6 carbon by the large bromo group. 
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When the oxidation of alcohol 292 to form aldehyde 291 was attempted using oxalyl 
chloride and DMSO (Scheme 60) only starting material was recovered from the reaction 
mixture. As the oxidation of 292 failed and the previous Buchwald-Hartwig step gave 
292 in only 38% yield, an alternative approach which gave access to norbornane 
naphthalimide 289 in high yields was sought. 
 
5.3.2: Pathway B – Linear Synthetic Route 
Strategy 
A more linear approach was investigated to construct norbornane naphthalimide 289 
(Scheme 61). Amination of 4-bromo naphthalimide 296 with propylamine would give the 
fluorescent 4-amino substituted 289. Attachment of the naphthalimide group to the 
norbornane scaffold could be achieved via nucleophilic acyl substitution of 4-bromo-1,8-
naphthalic anhydride 294 and norbornane amine hydrochloride 297 which could be 
prepared from the previously synthesised Boc-protected 225.  
 
Scheme 61: Revised retrosynthetic pathway to construct norbornane naphthalimide 289. 
Synthesis 
The synthesis of norbornane 225 has been previously detailed in Chapter 3. The 
corresponding hydrochloride salt 297 was generated in a near-quantitative yield (99%, 
Scheme 62) by treating 225 with and AcCl/MeOH mixture.  
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Scheme 62: Synthesis of amine hydrochloride 297. 
Reacting norbornane amine 297 with 4-bromo-1,8-naphthalic anhydride 294 gave the 
desired naphthalimide 296 in a near-quantitative yield (99%, Scheme 63). The methylene 
protons adjacent to the imide group of 296 were expected to present as a triplet in the 
1H NMR spectra. Instead, three peaks of the same intensity were observed with a shoulder 
peak either side of the centre signal. This phenomenon was attributed to the magnetic 
inequivalence of the methylene protons. Due to geminal coupling between these two 
protons a doublet of triplets multiplicity was therefore expected to be observed. However, 
due to second order coupling effects the correct coupling constants could not be 
determined and consequently these protons were reported as a multiplet (δ = 4.12–
4.18 ppm). This phenomenon was observed for all subsequent naphthalimide-based 
compounds. HRMS data also supported the identity of 296 with a signal observed at 
706.1972 m/z which matched the calculated value for [M + Na]+. 
 
Scheme 63: Synthesis of norbornane naphthalimide 289. 
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Using the Buchwald-Hartwig amination conditions reported by Pfeffer et al.,442 296 was 
treated with propylamine to give the desired fluorescent norbornane naphthalimide 289 
in very good yield (88%, Scheme 63). 1H NMR analysis of 289 (Figure 64) showed a low 
frequency shift of the H5ʺ and H7ʺ naphthalimide protons (δ = 6.72 and 8.08 ppm, 
respectively) when compared to bromo naphthalimide 296 (δ = 8.02 and 8.55 ppm, 
respectively). The NH proton of 289 was also observed at δ = 5.26 ppm. Again, a high 
frequency shift was observed for the naphthalimide carbon connected to the amino 
substituent in 289 (δ = 149.5 ppm) when compared to the bromo derivative 296 (δ = 
129.1 ppm), using 13C NMR spectroscopy. 
 
Figure 64: 1H and 13C NMR spectra of iodolactone 289 in CDCl3. 
140 | P a g e  
 
The proton and carbon signals of 289 were assigned with the aid of HSQC and HMBC 
NMR experiments. Key HSQC correlations are depicted in Figure 65 which clearly 
distinguish the naphthalimide protons and C-H carbons. Two signals in the 13C spectra 
were observed with very similar chemical shifts (δ = 104.4 and 104.5 ppm). These signals 
were able to be distinguished with clear HSQC correlations being observed with the acetal 
methine (H4) proton (δ = 4.65 ppm) and the H5ʺ proton (δ = 6.73 ppm) respectively. The 
H11ʹ protons at δ = 4.12–4.16 ppm showed a clear correlation with a signal at δ = 
40.4 ppm which was subsequently identified as the C11ʹ carbon of 289.   
 
Figure 65: Key HSQC correlations for 289 in CDCl3. 
The HMBC NMR experiment (Figure 66) allowed additional assignments of key proton 
and carbon resonances to be made. HMBC correlations were observed between the 
methylene protons H11ʹ (δ = 4.12–4.16 ppm) and two signals at δ = 164.3 and 164.8 ppm 
in the 13C spectra of 289. These carbon resonances were therefore attributed to the imide 
carbonyl carbons. HMBC correlations were also observed between the naphthalimide 
proton H4ʺ (δ = 8.45 ppm) and the signal located at δ = 164.3 ppm which was 
subsequently assigned to the C3 carbon. This was further confirmed with a correlation 
observed between the H9ʺ resonance (δ = 8.57 ppm) and the C1ʺ carbon (δ = 164.8 ppm). 
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Correlations between both the H4ʺ and H7ʺ (δ = 8.08 ppm) naphthalimide protons and a 
signal at δ = 149.5 ppm was also observed, which indicated that this signal corresponded 
to the C6ʺ carbon. 
 
Figure 66: Key HMBC correlations for 289 in CDCl3. 
Hydrolysis of the methyl ester groups of 289 gave dicarboxylic acid 298 in 88% yield 
(Scheme 64). The attachment of two units of aminoethylguanidine 41 to dicarboxylic acid 
298 was carried out using microwave-mediated amide coupling conditions (50 °C for 
30 minutes), however, only small quantities of crude material were obtained which could 
not be purified using column chromatography. When the reaction was performed at 
ambient temperature for two days diamide 299 was isolated in 82% yield, after 
chromatographic purification (Scheme 64). Subsequent removal of the Boc-protecting 
groups using AcCl and MeOH gave the desired diguanidinium product (287) in 97% 
yield. With the synthesis of naphthalimide 287 complete, attention turned towards the 
construction of the NBD analogue 288. 
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Scheme 64: Synthesis of norbornane naphthalimide diguanidine hydrochloride 287. 
Commercially available NBD-Cl 300 was reacted with freshly prepared amine 
hydrochloride 297 under basic conditions to give fluorescent norbornane NBD 290 in 
68% yield (Scheme 65). The 1H NMR spectra of 290 displayed two aromatic protons (δ 
= 6.17 and 8.48 ppm) as an AB pair. The NH proton was also observed as a triplet at δ = 
6.33 ppm. The identity of 290 was further supported by HRMS analysis; a signal was 
observed at 589.2883 m/z which matched the calculated value for [M + H]+.  
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Scheme 65: Synthesis of norbornane NBD analogue 288.  
Hydrolysis of the methyl ester groups using NaOH gave the requisite dicarboxylic acid 
301 in 78% yield (Scheme 65). As was the case with the naphthalimide analogue, when 
dicarboxylic acid 301 was treated with aminoethylguanidine 41 using microwave-assisted 
amide coupling conditions (50 °C for 30 minutes) small amounts of 302 were formed 
which could not be purified using column chromatography. Stirring 301 with 
aminoethylguanidine 41, EDCI and HOBt at ambient temperature for three days gave the 
desired diamide 302 in a 65% yield which was isolated after chromatographic 
purification. Removal of the Boc-protecting groups proceeded smoothly using an 
AcCl/MeOH mixture to give NBD diguanidinium 288 in excellent yield (95%, Scheme 
65). 
 
5.4 Photophysical Evaluation of Fluorescent Analogues 
The naphthalimide ICT transition state is known to be influenced by solvent,443,444 and as 
such, the photophysical properties of naphthalimide diguanidinium 287 and NBD 
diguanidinium 288 were evaluated in both DMSO and H2O. The Boc-protected pre-
cursors to these compounds (299 and 302 respectively) were also evaluated (in DMSO) 
to assess if the charged guanidinium groups affected the photophysical properties of 287 
and 288. 
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The Boc-protected naphthalimide compound 299 showed a large Stokes shift (84 nm) and 
a high quantum yield of 0.89 (Table 27). Similarly, guanidinium naphthalimide 287 
showed a Stokes shift of 91 nm and a quantum yield of 0.88 when evaluated in DMSO. 
When 287 was tested in H2O a slightly larger Stokes shift was observed (100 nm), 
however, the quantum yield recorded was significantly lower (ɸf = 0.16) when compared 
to 287 in DMSO. This result matches previous reports which state that the fluorescence 
of the naphthalimide fluorophore is quenched in H2O.426 
Table 27: Photophysical properties of naphthalimide and NBD compounds 
Compound Solvent λmax (nm)a λem (nm)a Stokes shift (nm) ɸf 
299 DMSO 442 526 84 0.89 
287 DMSO 437 528 91 0.88 
287 H2O 449 549 100 0.16 
302 DMSO 475 538 63 0.55 
288 DMSO 472 538 66 0.55 
288 H2O 475 550 75 0.02 
a Wavelength of maximum absorbance (λmax) and emission (λem) intensity. 
When Boc-protected NBD 302 was evaluated, a Stokes shift of 63 nm and a quantum 
yield of 0.55 nm was recorded (Table 27). The diguanidinium NBD 288 displayed very 
similar photophysical properties to 302 with Stokes shift and quantum yield values of 
66 nm and 0.55 respectively. Again, the presence of the charged guanidinium groups had 
only a minimal effect on the photophysical properties. When 288 was evaluated in H2O, 
a slightly larger Stokes shift (75 nm) was observed but there was a significant decrease 
in the quantum yield (ɸf = 0.02) when compared to 288 in DMSO. This suggests that the 
fluorescence of the NBD fluorophore may also be quenched in H2O. As the fluorescent 
properties of the NBD fluorophore are known to be influenced by its environment, the 
trends seen in Table 27 are expected. Indeed, these results are encouraging for potential 
future applications of both the NBD and naphthalimide fluorophores to be used in 
fluorescence microscopy studies.  
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5.5 Biological Evaluation of Fluorescent Analogues 
The naphthalimide and NBD diguanidinium analogues (287 and 288 respectively) were 
evaluated against the same panel of bacterial pathogens described in Chapters 3 and 4, 
using the aforementioned disk diffusion and micro-broth dilution assays.  
 
5.5.1: Disk Diffusion Assay 
Naphthalimide 287 did not show any activity against any of the bacterial strains tested in 
the disk diffusion assay (Table 28). The NBD analogue (288) showed moderate activity 
against both Gram-negative and Gram-positive bacterial pathogens; ZOI = 9 mm against 
A. baumannii and MRSA and 8.5 mm against K. pneumoniae. Despite these modest 
results, further evaluation of 287 and 288 to ascertain their MIC values against a range of 
bacterial pathogens was investigated.   
Table 28: ZOI as measured (inn mm) using disk diffusion assaya 
 
 
 
Compound 
A. baumannii 
ATCC 19606 
P. aeruginosa  
ATCC  
27853 
K. pneumoniae  
ATCC  
13883 
S. aureus 
MRSA 
ATCC 
43300 
E. faecium 
VRE  
ATCC 
700221 
287 - - - - - 
288 9 - 8.5 9 - 
COLb 20 19 20 - - 
a Measured after incubation of disk (6 mm diameter, 50 μg/disk) at 37 °C for 20 h. 
b Tested at 10 μg/disk. 
 
5.5.2: Micro-broth Dilution Assay  
Naphthalimide 287 was inactive against all Gram-negative bacterial strains tested in the 
micro-broth dilution assay but an MIC value of 4 μg/mL was observed against MRSA 
(Table 29). The NBD analogue (288) showed activity against all bacterial strains tested 
except K. pneumoniae. Pleasingly, MIC values of 8 and 4 μg/mL were observed against 
E. coli and MRSA respectively. When compared to norbornane diguanidine 180, which 
is comprised of an undecanyl hydrophobic chain, a slight decrease in potency was evident. 
For example, MIC values of 4 and 2 μg/mL were observed against E. coli and MRSA 
respectively for 180—slightly lower values then those recorded for NBD 288 against the 
same bacterial pathogens. 
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Table 29: MIC values (μg/mL) for fluorescent analogues 
 
 
Compound 
A. baumannii 
ATCC 19606 
P. aeruginosa  
ATCC  
27853 
K. pneumoniae  
ATCC  
700603 
E. coli 
ATCC 
25922 
S. aureus 
MRSA 
ATCC 43300 
287 >32 >32 >32 >32 4 
288 32 32 >32 8 4 
COLa 0.06 0.25 0.03 0.06 NTb 
VANc NT NT NT NT 1 
a COL = Colistin sulphate. 
b NT = Not tested. 
c VAN = Vancomycin. 
 
5.6 Conclusions 
The key aims of this Chapter were to i) synthesise two fluorescent norbornane-based 
peptidomimetics; and ii) evaluate the photophysical properties and antibacterial activity 
of these compounds. 
The synthesis of two norbornane-based diguanidinium peptidomimetics that have either 
a naphthalimide (287) or NBD (288) fluorophore attached was successful. Norbornane 
amine hydrochloride 297 was the common starting material for both analogues and was 
used in either a nucleophilic acyl substitution reaction to generate naphthalimide 296 in 
99% yield, or an aromatic substitution reaction to form NBD 290 in 68% yield. 
Subsequent functionalisation furnished the two desired products (naphthalimide 287 and 
NBD 288) in overall yields of 61 and 32% from the common starting material 297.  
The naphthalimide derivatives possessed larger Stokes shifts and quantum yields than 
their NBD counterparts. The choice of solvent was found to have a dramatic effect on the 
quantum yield recorded for both the naphthalimide (287) and NBD (288) analogues with 
much higher quantum yields observed in DMSO compared to H2O. Nevertheless, both 
fluorophores showed photophysical properties that are suitable for imaging applications. 
NBD 288 exhibited better antibacterial activity than the naphthalimide derivative (287), 
however both compounds had identical potency against MRSA; MIC = 4 μg/mL. 
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Chapter 6 
Organogelating agents based on the norbornane framework are yet to be reported. In an 
earlier study it was noticed that some norbornane carboxylic acids caused gelation in 
particular organic solvents. This Chapter details the rational design and synthesis of 
related norbornane-based compounds as potential organogelating agents.  
The Chapter first provides a brief overview of organogelators followed by the design and 
synthesis of a new class of norbornane-based organogelating agents. Their gelation 
properties are evaluated in a range of organic solvents. 
Detailed characterisation of the most effective organogelator using both NMR 
spectroscopic and imaging techniques will be described. From these results a mode of 
assembly is proposed to account for the observed gel formation.  
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Norbornane-based Organogelators 
The key aims of this Chapter are to; 
x Design and synthesise a series of norbornane-based compounds containing 
functional groups likely to elicit gel formation. 
x Investigate the gelation properties of these compounds in a range of organic 
solvents. 
x Characterise the most effective organogel using 1H NMR spectroscopy in 
combination with rheometry and imaging techniques.  
 
6.1 Organogels: An Introduction 
Colloidal solid-like “jellies”, as originally described by Thomas Graham in 1861, are the 
first description of a gel within the literature.445 Nearly seventy years later Dorothy Lloyd 
stated that “… the colloid condition, the gel, is easier to recognize than to define.”446 The 
definition of a gel was refined in 1974 by Nobel Laureate Paul Flory; a gel 1) has a 
continuous structure with macroscopic dimensions that is permanent on the time scale of 
an analytical experiment; and 2) is solid-like in its rheology.447 To complement Flory’s 
description of gels,447 organogels are a colloidal state of matter that are comprised of an 
organic liquid and low concentrations (typically <2% weight) of low molecular weight 
molecules known as gelators.448 
Gels are often classified by the fluid component; a hydrogel is comprised of H2O whilst 
an organogel is comprised of an organic solvent.449 Other types of gels (beyond the scope 
of this thesis), include aerogels which employ a gas as the fluid phase instead of a 
liquid450,451 and metallogels where the fibril components are linked together by metal ions 
such as silver, copper and iron.452 
It is widely acknowledged that thermally reversible low molecular weight organogelators 
(<3000 g/mol) have use in applications such as drug delivery,453-456 cosmetics,448,455-457 
enzyme immobilisation455,456,458 and separation science.455,456,459 The discovery of gels is 
often serendipitous.460 For example, the Weiss group (now a major contributor to the field 
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of organogelation) began investigating organogels when they observed the unexpected 
gelation of a variety of organic solvents using compound 303 (Figure 67).461  
 
Figure 67: Organogelator 303 reported by Weiss and co-workers.461 
 
6.1.1: Organogel Properties 
The solid-like physical state of an organogel is due to the entrapment of liquid in a three-
dimensional matrix formed by polymeric strands of molecules assembled through 
intermolecular forces.462,463 Ionic, π-π stacking, hydrogen-bonding and hydrophobic 
interactions are typically the intermolecular forces involved in gel formation.455,456,464-466 
Given the reversible nature of these interactions, supramolecular gels have an inherent 
ability to respond reversibly to external stimuli such as light, temperature, pH and 
chemical entities.462,465 An example of a photo-responsive organogel is illustrated in 
Figure 68, with isomerization from the trans to cis isomers of diazo 304 in PhMe leading 
to a change in state from gel to solution respectively.456  
 
Figure 68: Example of a photo-responsive gel formed from 304 and PhMe, as reported by 
Rajaganesh et al.456 
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6.1.2: Key Structural Features of Organogelators 
The design of effective organogelators is not a trivial task.467 Organogelators self-
assemble to form the three-dimensional networks required for gel formation and great 
diversity exists in terms of potential molecular structures which can achieve this.468,469 
Typically organogelators are comprised of a core unit that is functionalised with groups 
to facilitate intermolecular interactions. For example, the Schmidt group have reported 
the organogelator 305 (Figure 69) which is comprised of both hydrophobic and hydrogen-
bonding regions.470 Organogelators commonly rely on hydrogen-bonding interactions 
and therefore functional groups such as alcohols471 amides,472 ureas473 and carboxylic 
acids474 are often employed (306–309).  
 
Figure 69: Previously reported organogelators 305–309. 
The Ranganathan group have used X-ray crystallography and circular dichroism analysis 
to show that in the solid state the norbornene scaffold can form column-type arrays 
through hydrogen-bonding interactions.182 Despite the inherent ability of the norbornane 
framework to self-assemble, functionalised norbornanes as organogelators have not been 
previously reported.  
During previous work towards the synthesis of norbornene-based peptidomimetics, it was 
discovered that the crude mixture of exo/endo isomers 310 and 311 (Figure 70), in a 
9:1 ratio, formed a partial gel in CDCl3.475 In light of this observation and given the work 
reported by Ranganathan,182 it was envisaged that the conformationally rigid norbornane 
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scaffold could be functionalised in a pre-organised fashion to furnish a novel family of 
organogelating agents.  
 
Figure 70: Isomers 310 and 311 which formed a partial gel in CDCl3.475 
 
6.2 Compound Design  
To establish a correlation between functional group and organogelation ability, a range 
of norbornane and norbornene compounds were designed (Figure 71). Given that 
norbornenes 310 and 311 both contained a carboxylic acid group (Figure 70), 
norbornenes of the general structure 312, where R is either a heptyl or hexadecyl chain, 
were targeted to assess the importance of the carboxylic acid moiety for these compounds 
to gelate organic solvents. 
The use of carboxylic acids to enhance hydrogen-bonding interactions in gel formation 
has been previously reported.469 As such, norbornenes of the general structures 313 and 
314, which are comprised of a carboxylic acid and a hydrophobic chain, were pursued 
(Figure 71). The effect of the relative exo/endo positioning of the carboxylic acid with 
respect to the alkyl chain will also be evaluated using norbornenes 313 and 314.  
 
Figure 71: General structures 312–315. 
To increase potential hydrophobic interactions, compounds with an additional heptyl 
chain connected through an acetal group were also sought (315, Figure 71). Norbornanes 
of the general structure 315 also contain a carboxylic acid in the exo-position and an alkyl 
chain in the endo-position connected through an amide bond. 
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6.3 Synthesis of Potential Organogelators 
6.3.1: Synthesis of Norbornene Diamides 
A microwave-assisted EDCI/HOBt-mediated amide coupling was used to attach 
heptylamine to norbornene diacid 50, and after chromatographic purification, norbornene 
diheptyl amide 316 was isolated in 42% yield (Scheme 66). The slightly broad signals 
observed in the 1H NMR spectra of 316 at δ = 6.02 and 6.44 ppm were assigned to the 
NH amide protons. The H2 and H3 protons of 316 were more shielded when compared 
to the starting material diacid 50, due to the presence of the heptyl chains; H2 shifted from 
δ = 2.42 to 2.37 ppm and H3 shifted from δ = 3.15 to 2.97 ppm. In an analogous fashion, 
dihexadecyl amide 317 was accessed in a 35% yield by coupling diacid 50 and 
hexadecylamine (Scheme 66).  
 
Scheme 66: Synthesis of norbornene diamides 316 and 317. 
 
6.3.2: Synthesis of Norbornene endo-carboxylic acid, exo-amides 
Niwayama et al., has previously reported the selective hydrolysis of the exo methyl ester 
of norbornene 112.335 Following this procedure, diester 112 was stirred in a dilute aqueous 
KOH/THF system at 0 °C for four hours (Scheme 67). After an extractive work-up, 
isomers 205 and 206 (88%) were isolated in a ratio of 9:1 in favour of exo-carboxylic acid 
205.  
 
Scheme 67: Selective hydrolysis of norbornene dimethyl ester 112. 
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Isomers 205 and 206 could not be separated using typical chromatographic techniques. 
When a 9:1 mixture of mono acids 205 and 206 were coupled with heptylamine using 
EDCI and HOBt, exo-heptylamide 318 was isolated as a single isomer in 49% yield, after 
chromatographic purification (Scheme 68). 1H NMR analysis of 318 confirmed that only 
one isomer was isolated. A singlet corresponding to the three methyl ester protons was 
observed at δ = 3.66 ppm. There were no signals observed in the 1H NMR spectra of 318 
that corresponded with the endo-heptylamide product. Subsequent hydrolysis of the endo-
methyl ester gave the requisite endo-carboxylic acid 320 in 77% yield (Scheme 68). 
 
Scheme 68: Synthesis of norbornene endo-carboxylic acid, exo-amides 320 and 310. 
Similarly, when hexadecylamine was used (Scheme 68), exo-hexadecylamide 319 was 
isolated in 31% yield after column chromatography. Hydrolysis of the endo-methyl ester 
gave the corresponding acid 310 in 69% yield. With two norbornene endo-carboxylic 
acid, exo-amides synthesised (320 and 310), attention turned towards accessing the endo-
amide, exo-carboxylic acid isomers. 
 
6.3.3: Synthesis of Norbornene endo-amide, exo-carboxylic acids  
The synthesis of endo-heptylamide 209, via an iodolactone, was described in Chapter 3. 
With 209 in hand, hydrolysis of the exo-methyl ester was carried out to give exo-
carboxylic acid 321 in 87% yield (Scheme 69). In a similar fashion the previously 
synthesised endo-hexadecylamide 210 was treated with aqueous NaOH in THF to give 
the requisite exo-carboxylic acid 311 in excellent yield (90%). 
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Scheme 69: Synthesis of endo-amide, exo-carboxylic acid analogues 321 and 311. 
 
6.3.4: Previously Synthesised Norbornane Acetals 
An extra hydrophobic region on the norbornane scaffold was desired in an effort to 
enhance lipophilic interactions. The synthesis of norbornane acetals 215 and 216 (Figure 
72) which bear a carboxylic acid group in the exo position and two aliphatic chains, was 
described in Chapter 3.  
 
Figure 72: Previously synthesised norbornane acetals 215 and 216. 
 
6.4 Evaluation of Organogelators 
To assess the organogelation properties of a compound, an accurately weighed amount of 
the material is warmed in an organic solvent until dissolution occurs. The solution is then 
slowly cooled to below the gelation transition temperature (typically 4 °C will suffice).448   
Following this protocol, the compounds synthesised herein were evaluated as 
organogelators in a range of solvents including CHCl3, CH2Cl2, EtOH, PhMe, THF, Et2O, 
anisole, 1,4-dioxane, i-PrOH, MeCN and o-xylene (Table 30). These solvents were 
selected based on availability and their previously reported use in organogelation 
studies.457 The compound/solvent mixture was heated until a clear homogenous solution 
was observed and then slowly cooled to 4 °C and left unagitated for no more than 
16 hours.  
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Table 30: Norbornane compounds in organic solvents (amounts in mg/mL) 
 
 Compound 
Solvent 316 317 320 310 321 311 215 216 
CHCl3 S S S I I I S S 
CH2Cl2 S I I I I I S S 
EtOH S I S I I I S S 
PhMe S P P G (40.3) G (51.2) G (15.6) S S 
THF S S S I S S S S 
Et2O S I I I I I S S 
Anisole S I P I G (33.9) I P C 
1,4-Dioxane S I C I I I S S 
i-PrOH S I S I S C S S 
MeCN S I I I C I C S 
o-Xylene S P P G (42.3) G (51.0) G (20.6) S S 
Abbreviations: G = gel, minimum gelation concentration (mg/mL); P = partial gel; S = soluble; I 
= insoluble; C = crystallised 
 
When a gel was observed it was subject to the ‘six-hour inversion test’—the standard 
assessment of gel viability—at room temperature.457,476 In numerous instances (Table 30), 
partial gelation was observed where the gel was not maintained when left inverted at room 
temperature for 6 hours. 
Compounds which did not contain a carboxylic acid (316 and 317) failed to form a gel in 
any of the organic solvents tested. Norbornane acetals 215 and 216 also failed to gelate 
any of the solvents investigated; the increased lipophilicity of these compounds correlated 
with solubility in most solvents (Table 30). 
Norbornene endo-carboxylic acid, exo-heptylamide 320 formed a number of partial gels 
(PhMe, anisole and o-xylene). When norbornene endo-carboxylic acid, exo-
hexadecylamide 310 was tested, gelation occurred in PhMe (Figure 73) and o-xylene with 
minimum gelation concentrations (MGCs) of 40.3 and 42.3 mg/mL respectively 
(Table 30). 
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When endo-heptylamide, exo-carboxylic acid 321 was tested, gelation was observed in 
PhMe (Figure 73), anisole and o-xylene, with MGC values of 51.2, 33.0 and 51.0 mg/mL 
respectively (Table 30). The endo-hexadecylamide derivative (311) proved to be the most 
potent organogelator with gelation observed under five minutes in PhMe (MGC = 
15.6 mg/mL, Figure 73) and o-xylene (MGC = 20.6 mg/mL, Figure 73). 
 
Figure 73: Organogels from left: 311 (PhMe), 311 (o-xylene), 321 (PhMe) and 310 (PhMe). 
All effective organogelators contained a carboxylic acid group. Improved MGC values 
were observed when the carboxylic acid group resided in the exo-position. For example, 
endo-carboxylic acid 310 and exo-carboxylic acid 311, formed a gel in PhMe with a MGC 
of 40.3 and 15.6 mg/mL respectively.  
Lipophilic balance was important as compounds with three alkyl chains (such as acetals 
215 and 216) failed to form a gel in any of the solvents used in this study (Table 30). The 
most effective organogelator in this series—norbornene endo-hexadecylamide, exo-
carboxylic acid 311—which formed a gel in PhMe (MGC = 15.6 mg/mL), was selected 
for further characterisation. 
 
6.4.1: 1H NMR Spectroscopy of Organogelator 311 
Due to the presence of the exo-carboxylic acid and endo-amide groups, it was suspected 
that hydrogen-bonding was contributing to the self-assembly of 311 which resulted in a 
gel being formed in PhMe. The NH amide proton of 311, which was observed in the 
1H NMR spectra at δ = 5.25 ppm in PhMe-d8, was monitored in a series of 1H NMR 
spectroscopic experiments which probed the effect of concentration, temperature and 
added base.  
When the concentration of norbornene 311 was increased from 10.0–15.6 mg/mL a high 
frequency shift (∆δ = 0.15 ppm) of the NH resonance at was observed (Figure 74). As 
15.6 mg/mL is the MGC of 311 in PhMe, less concentrated samples were a solution at 
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20 °C. As 311 in PhMe-d8 becomes more gel-like the NH resonance experiences a high 
frequency chemical shift change. This suggests that the NH proton of 311 may play a role 
in gel formation, perhaps through hydrogen bonding interactions. 
 
Figure 74: Variable concentration 1H NMR spectra of 311 in PhMe-d8 (4.60–6.50 ppm) at 
20 °C; i: 15.6 mg/mL; ii: 12.0 mg/mL; iii: 10.0 mg/mL. 
Using variable temperature (VT) 1H NMR experiments, the NH resonance underwent a 
low frequency shift (∆δ = 0.06 ppm) as the temperature was increased from 20–40 °C and 
the sample became more solution-like (Figure 75). These results are further evidence that 
the NH proton plays a role in the formation of this gel.   
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Figure 75: VT 1H NMR spectra of 311 in PhMe-d8 (4.60–6.50 ppm) at 15.6 mg/mL; i: 40 °C; ii: 
30 °C; iii: 20 °C. 
The pH sensitivity of gels is often investigated to assess the role of hydrogen bonding.465 
Complete dissolution of the organogel formed between 311 and PhMe occurred within 
five minutes after Et3N (10 μL) was added. The NH proton resonance was absent in the 
1H NMR spectra of 311 in PhMe-d8 which had been treated with Et3N (Figure 76). This 
suggests that the Et3N is deprotonating the carboxylic acid proton of 311, which in turn 
directly influences its ability to self-assemble. This ultimately leads to a collapse of the 
gelled state of 311 in PhMe. A high frequency chemical shift change of the alkene proton 
resonances (H5 and H6, Figure 76) was also observed, which may indicate a relatively 
ordered arrangement of PhMe with the alkene through π-π interactions. 
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Figure 76: 1H NMR spectra of 311 (5.05–6.75 ppm) in PhMe-d8; i) compound 311 with 
addition of Et3N; and ii) compound 311. 
Based on these results, organogelator 311 may be initially self-assembling through 
hydrogen-bonding interactions to form structures such as that shown in Figure 77. It is 
proposed that the carboxylic acid in the exo-position is hydrogen bonding with the amide 
group in the endo-position of nearby 311 molecules. Work by the Ranganathan group 
supports this proposed assembly as they have previously confirmed the formation of 
molecular ribbons with related norbornene structures similar to that illustrated in 
Figure 77.182  
 
Figure 77: Proposed hydrogen-bond-mediated assembly of 311. 
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6.4.2: Physical Characteristics of Gelator 311 in PhMe 
Rheology is the study of a samples resistance to flow under an applied stress.477-479 In 
order to quantify this property, the sample is placed between two plates and an oscillatory 
(repetitive variation) stress is applied to one of them. The elastic storage modulus (Gʹ) 
and the elastic loss modulus (Gʺ) can be quantified as a function of the applied stress.465 
Typically for gels, Gʹ should be greater than Gʺ with respect to applied pressure 
(measured in Pa), independent of the oscillatory frequency (measured in rad/s).476 
The mechanical characteristics of the gel formed from norbornene 311 in PhMe were 
determined using parallel plate rheometry. A fixed shear frequency sweep analysis 
revealed the organogel to be stable over a range of frequencies, with an elastic modulus 
of approximately 2200 Pa (Figure 78). The Gʹ value was greater than Gʺ throughout the 
experiment which is characteristic of a gelled sample.465 
 
Figure 78: Fixed shear frequency sweep analysis of organogel 311. 
Differential scanning calorimetry (DSC) was used to determine the temperature at which 
the solution-gel transition occurred. In a DSC experiment the sample undergoes a 
physical transformation (e.g. gel → solution) and the heat required to maintain its new 
state is compared to that of a reference sample at the same temperature.480 If less heat is 
required than the reference sample the process is endothermic and if more heat is required 
the process is exothermic.465 In the case of a gel, an exothermic process (which is 
indicated by a negative peak in the DSC thermogram) is expected as the gel converts to a 
solution.481 
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When organogel 311 was heated a negative peak was seen in the resulting thermogram 
(Figure 79); indicating a gel-solution transition. The sharp transition indicated the melting 
point (Tgel) of norbornene 311 in PhMe is approximately 93 °C.  
 
Figure 79: DSC thermogram of organogel 311. 
 
6.4.3: AFM and TEM Imaging of Organogelator 311 in PhMe 
Gels formed from small molecular organogelators typically display highly ordered 
assemblies which give rise to a three-dimensional network of fibers.482 In order to 
determine whether organogel 311 was due to the formation of an ordered structure (as 
postulated in Figure 77) as opposed to disordered aggregation or crystallisation, the 
underpinning structures were visualised at both the micro and nanoscale level.483 
Atomic force microscopy (AFM) is a vital tool for the imaging and measurement of 
matter on the micro or nanoscale. High resolution in conjunction with the ability to view 
materials without pre-treatment that could potentially damage the sample, make AFM an 
important imaging technique.465  
AFM analysis of compound 311 in PhMe (0.78 mg/mL) on a highly ordered pyrolytic 
graphite (HOPG) surface displayed large linear structures (Figure 80a). Closer 
examination of these revealed longitudinal striations broadly indicative of an inter-
twining linear fibrillar assembly (Figure 80b and c).   
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Figure 80: AFM images of norbornene 311 in PhMe; (a) linear structures (scale bar 0.5 μm); 
(b) and (c) close up of one of the linear features showing striations longitudinally in both peak 
force analysis and height respectively. 
Transmission electron microscopy (TEM) allows for higher resolution than AFM. In 
TEM, beams of electrons interact with the sample as they pass through it which gives rise 
to an image. Typically, TEM is used for the characterisation of supramolecular systems 
such as micelles and vesicles but has also been used to determine the morphology of 
peptides and nucleotides.465  
TEM was employed to probe the structures gained from the AFM imaging on the 
nanoscale. The same linear features were observed at the same scale as the AFM analysis 
(Figure 81a), suggesting that these are indeed the principal structures that underpin the 
organogel. Upon closer analysis, these structures consisted of a number of striated 
features 100 nm in width. These striations were consistently observed to be 25 nm in 
width, suggesting that this may be the basic structure formed by the assembly of 
compound 311. The interface of these structures showed that there was a clear and well-
defined boundary, suggesting that these are fibrillar micelle structures formed from the 
assembly of compound 311 (Figure 81b). 
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Figure 81: TEM images of norbornene 311 in PhMe; (a) linear structures; and (b) magnified 
region showing the interface between the larger fibrillar structures. 
 
6.5 Conclusions 
Eight norbornane-based compounds comprised of a mixture of hydrophobic and 
hydrogen-bonding groups, were synthesised as potential organogelators. These 
compounds were tested in eleven different organic solvents with gelation occurring in the 
aromatic solvents (PhMe, anisole and o-xylene). It was apparent that a carboxylic acid 
group (preferably in the exo-position) was required for these compounds to induce 
gelation. Compounds with three alkyl chains (such as acetals 215 and 216) or no 
carboxylic acid groups (such as diamides 316 and 317) did not gelate any of the solvents 
tested.  
The most effective organogelator in the series was norbornene 311 (15.6 mg/mL in PhMe) 
which bore a hexadecylamide in the endo-position and a carboxylic acid in the exo-
position. This gel was found to have a Tgel of approximately 93 °C and its rheological 
properties (Gʹ ≈ 2200 Pa) were determined. Analysis of norbornene 311 in PhMe-d8 using 
1H NMR spectroscopy suggests that hydrogen-bonding is likely responsible for gel 
formation.  
AFM and TEM imaging indicate that this particular organogel is formed by the assembly 
of an individual fibrillar micelle approximately 25 nm in diameter. These fibrils are 
observed to arrange longitudinally to give a micro scale network of bundles. 
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Chapter 7 
Conclusions 
The chief aim of this project was to investigate the SAR within a library of norbornane-
based peptidomimetic amphiphiles and their antibacterial activity. The norbornane-based 
compounds described herein are comprised of different hydrophobic and anion 
recognition groups. As such, there were a number of other aims that had to be addressed 
in this study. 
1. The synthesis of Boc-protected guanidine reagents. 
In Chapter 2 a guanidinylation method was optimised to access aminoethylguanidine 41 
in excellent yields (97%) on large scales (20 grams) without the need for chromatographic 
purification (Scheme 70). This operationally simple protocol relied on the cheap and 
readily available guanidinylating agent 58 which was synthesised in-house in 85% yield.  
 
Scheme 70: Optimised synthesis of aminoethylguanidine 41. 
The subsequent conversion of 41 and related aminoalkylguanidines to shelf-stable 
sulfonate salts (such as 70, 72 and 73) proceeded smoothly (Scheme 71). The 
guanidinylation protocol was also applied to a number of other substrates to generate a 
collection of Boc-protected guanidines tethered to a range of synthetically useful 
functional groups including alcohol, alkene, alkyne and 1,2-diol functionality.  
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Scheme 71: Synthesis of aminoalkylguanidine sulfonate salts (70, 72 and 73) and other Boc-
protected guanidine analogues (75–80). 
2. The synthesis and evaluation of norbornane peptidomimetics incorporating a 
range of hydrophobic groups (attached to the norbornane scaffold through an 
acetal linker) and anion recognition groups. 
Chapter 3 described the synthesis and evaluation of norbornane acetal peptidomimetics. 
A total of fifteen norbornane acetal analogues of the general structure 42 were synthesised 
(Figure 82). These compounds were comprised of different hydrophobic groups including 
alkyl, aryl and alkyl/aryl combinations. Two anion recognition groups were also installed 
to the norbornane framework including guanidinium, aminium, imidazolium and 
pyridinium moieties as well as charge neutral thiourea and squaramide groups.  
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Figure 82: General structure of norbornane-based peptidomimetic amphiphiles comprised of 
two anion recognition groups. 
Norbornane diguanidinium compounds with ethyl (179), propyl (184) and butyl (185) 
length linkers between the norbornane scaffold and the cationic group were prepared to 
broaden the scope of the SAR study (Figure 83). Analogues consisting of one (219 and 
220, Figure 83) and three charged groups (224) were also synthesised to further 
investigate the effect of net cationic charge on antibacterial activity.  
 
Figure 83: Ethyl, propyl and butyl analogues (179, 184 and 185), mono-charged analogues (219 
and 220) and tricationic 224. 
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Biological evaluation of the acetal series of compounds (using disk diffusion and micro-
broth dilution assays) determined that a net positive charge was crucial to elicit 
antibacterial activity. Charge neutral compounds displayed no antibacterial activity whilst 
analogues with one charge exhibited only modest activity. Tricationic norbornane 224 
also showed only modest activity (MIC = 16 μg/mL against MRSA) but this may be 
attributed to 224 not being structurally amphiphilic. The most potent compounds in this 
study (such as 181, 188 and 189, Figure 84) possessed two charged moieties. There did 
not appear to be any significant difference in the antibacterial activity of guanidinium and 
aminium analogues. However, compounds functionalised with guanidinium or aminium 
groups were more potent than the imidazolium (191) and pyridinium (192) derivatives. 
The effect of linker length between the norbornane framework and guanidinium groups 
proved to be minimal at best, with similar antibacterial activity observed for related 
analogues ethyl (179), propyl (184) and butyl (185); each exhibited a ZOI in the range of 
12–16 mm against P. aeruginosa, K. pneumoniae and MRSA. 
 
Figure 84: A selection of the most potent compounds in this study. 
The results from this study suggest that hydrophobicity was responsible for potency. For 
example, antibacterial activity followed the trend of pentadecyl chain > undecyl chain > 
heptyl chain (as illustrated in Figure 85). When the guanidine moiety was substituted with 
a hydrophobic benzyl group an increase in antibacterial was observed. For example, 
benzyl-substituted guanidine 204 was more potent against S. aureus (MIC = 2 μg/mL) 
than structurally similar 179 (MIC = 32 μg/mL, Figure 85).  
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Figure 85: Effect of hydrophobic groups on antibacterial activity. 
3. The synthesis and evaluation of a novel family of norbornane diguanidinium 
peptidomimetics which contained two hydrophobic groups linked to the 
norbornane core through ether bonds. 
Chapter 4 detailed the synthesis and evaluation of a novel family of compounds—
norbornane bisether diguanidine hydrochlorides. The key synthetic step was the 
bisalkylation of diol 110 which was achieved using Ag2O and an appropriate alkyl halide. 
Subsequent functionalisation of the norbornane framework furnished a total of nine 
norbornane bisether diguanidine hydrochlorides.  
A similar trend to the acetal series of compounds was observed for the bisether analogues 
with regards to antibacterial activity. Norbornane bisethers comprised of larger 
hydrophobic groups, such as trifluoromethyl-substituted and bromo-substituted benzyl 
analogues (276d and 276g, respectively) were the most potent antibacterial agents in this 
series; MIC values of 8 and 16 μg/mL against MRSA were observed for 276d and 276g 
respectively (Figure 86).  
 
Figure 86: The most potent bisether antibacterial agents. 
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4. The synthesis and evaluation of fluorescent norbornane-based peptidomimetics. 
In Chapter 5 two fluorescently tagged analogues were prepared; 4-amino naphthalimide 
norbornane diguanidinium (287) and NBD norbornane diguanidinium (288, Figure 87). 
Each of these compounds exhibited high quantum yields in DMSO; 287 (ɸf = 0.88) and 
288 (ɸf = 0.55). Both of these analogues exhibited MIC values of 4 μg/mL against MRSA. 
However, the NBD derivative (288) also showed antibacterial activity against a number 
of other Gram-negative bacterial pathogens including an MIC of 8 μg/mL against E. coli. 
 
Figure 87: Fluorescent norbornane diguanidinium analogues 287 and 288. 
Of the 31 analogues evaluated in this project, 14 compounds had activity ≤ 8 μg/mL 
against at least one bacterial pathogen. Moreover, MIC values of ≤ 1 μg/mL were 
observed against S. aureus strains for five analogues. Broad-spectrum antibacterial 
activity was observed across both the acetal and bisether family of compounds however 
Gram-positive bacteria seemed to be more susceptible than Gram-negative bacteria to 
both series of compounds. While a correlation between antibacterial activity and 
cytotoxicity was evident, the norbornane-based peptidomimetics assessed in this study 
were found to lyse bacterial cells more readily than human cells. 
Finally, in Chapter 6 a small collection of norbornene and norbornane compounds were 
evaluated for their organogelating properties. The most potent organogelator (311, Figure 
88) formed a gel in PhMe at 15.6 mg/mL within five minutes at ambient temperature. 
1H NMR spectroscopic analysis suggested that 311 relies on hydrogen bonding 
interactions to facilitate gelation. This particular gel was further characterised using AFM 
and TEM imaging which indicated that a longitudinal arrangement of fibrils 
(approximately 25 nm in diameter) underpinned the gel structure. 
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Figure 88: Norbornene-based organogelator 311. 
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Chapter 8 
Future Work 
A logical next step in this project is to elucidate the MOA employed by the norbornane-
based antibacterial agents. Many groups use isothermal titration calorimetry (ITC) and/or 
surface plasmon resonance (SPR) to investigate the MOA of antimicrobial agents. For 
example, Miller et al., used both of these techniques to help confirm that a series of 
pyridopyrimidine compounds, such as 322 (Figure 89), elicited antibacterial activity by 
binding to the biotin carboxylase enzyme which ultimately inhibits the synthesis of 
essential fatty acids.484 ITC measures the binding energies of host-guest systems and as a 
result the enthalpy, entropy and Gibbs free energy values can be determined.485,486 SPR 
is an optical analytical technique used to determine biomolecular interactions by 
measuring the change in the refractive index as analytes in solution interact with an 
immobilised ligand.487-489 Therefore, ITC and SPR can give an insight into the binding 
affinities of the charged norbornane-based antibacterial agents and the negatively charged 
groups of the bacterial cellular envelope. 
 
Figure 89: Biotin carboxylase inhibitor 322.484 
Given fluorescent naphthalimide (287) and NBD (288) analogues exhibited antibacterial 
activity, their use in fluorescence microscopy studies could be pursued. The Cooper group 
have previously used antibacterial agents tagged with the NBD fluorophore to label a 
range of Gram-positive bacterial strains which were visualised using confocal 
microscopy.490 Studies of this nature may reveal if these antibacterial agents act by 
penetrating the bacterial cellular membrane.  
Broadening the scope of the SAR data obtained in this study could also be pursued by 
synthesising additional analogues. For example, as the benzyl-substituted guanidine 
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compound 204 exhibited improved antibacterial activity when compared to its non-
substituted derivatives, different hydrophobic groups could be attached to the guanidine 
moiety. As such, analogues of the general structure 323 (Figure 90) which include 
substituted benzyl and alkyl derivatives could be investigated.  
 
Figure 90: General structure of proposed substituted guanidine targets. 
Boronic esters have previously found use in antimicrobial agents491 and are known to 
exhibit good chemical stability in acidic aqueous environments.492 A large selection of 
commercially available boronic acids exist and their transformation into boronic esters is 
well established within the literature.493 As such, the synthesis of boronic esters of the 
general structure 324 (Figure 91) could be explored which contain an aromatic group 
directly connected to the boronic ester. 
 
Figure 91: General structure of proposed boronic ester targets. 
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Chapter 9 
Experimental 
9.1 General  
All novel compounds synthesised were characterised by 1H NMR spectroscopy, 13C NMR 
spectroscopy and high-resolution mass spectrometry (HRMS). In addition melting points 
(m.p) were collected where possible. In instances when either the 1H or 13C resonance 
was coincidental with the deuterated solvent, the resonance was confirmed using HSQC 
analysis. Spectroscopic data for all previously reported compounds synthesised in this 
project were compared to literature values. 
All microwave reactions were conducted using a CEM Discover S-Class Explorer 48 
Microwave Reactor, operating on a frequency of 50/60 Hz and continuous irradiation 
power from 0–300 W. All reactions were performed in sealed reaction vessels (10 or 
35 mL). 
All melting points were obtained using Stuart Scientific SMP3 melting point apparatus 
and are uncorrected. 
Aqueous samples were lyophilized using an ilShin TFD5505 Freezedryer – Table Top 
Model. 
All 1H and 13C spectra were collected on either a JEOL JNM-GX 270 MHz FT-NMR 
spectrometer, a JEOL JNM-ECP 400 MHz FT-NMR spectrometer, or a BRUKER 
ADVANCE III 500 MHz FT-NMR spectrometer where indicated. All 19F NMR spectra 
were collected on a BRUKER ADVANCE III 500 MHz FT-NMR spectrometer. All 
NMR experiments were performed at 25 °C unless otherwise stated. All 2D NMR 
experiments were performed on a BRUKER ADVANCE III 500 MHz FT-NMR 
spectrometer. Variable temperature (VT) NMR experiments were performed on a JEOL 
JNM-GX 270 MHz FT-NMR spectrometer. Samples were dissolved in CDCl3, DMSO-
d6, CD3OD, D2O, CD2Cl2, or PhMe-d8 where specified with the residual solvent peak 
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used as the internal reference – CDCl3; 7.26 (1H) and 77.0 (13C), DMSO-d6; 2.50 (1H) and 
39.5 (13C), CD3OD; 3.31 (1H) and 49.0 (13C), D2O; 4.79 (1H), CD2Cl2; 5.32 (1H), CD3CN; 
1.94 (1H) and 1.3 (13C), PhMe-d8; 2.08 (1H), 20.4 (13C).494 Proton spectra are reported as 
chemical shift δ (ppm) (integral, multiplicity (s = singlet, br s = broad singlet, d = doublet, 
t = triplet, q = quartet, quin = quintet and m = multiplet), coupling constant) where 
appropriate. Carbon spectra are reported as chemical shift δ (ppm) and (integral, 
multiplicity) where appropriate. Fluorine spectra are reported as chemical shift δ (ppm) 
and multiplicity and were externally referenced using 0.05% α,α,α-trifluorotoluene in 
CDCl3; −63.8 (19F).495 
HRMS data was collected using a QTOF mass spectrometer (LC-1200 series) under the 
following conditions: gas temperature (300 °C), nitrogen drying gas (10.0 L min-1), 
capillary voltage (3500 V), fragmentor (140 V) and nebuliser (45 psi) in a 80% MeCN in 
H2O solvent system. Analyte solutions were prepared in HPLC grade MeOH or MeCN 
(concentration ≈ 1 mg/mL). HRMS data are reported as: molecular formula, calculated 
parent ion (m/z), observed parent ion (m/z). 
Absorbance spectra were obtained on a CARY 300 Bio UV-visible spectrophotometer 
and 10 μM solutions of the sample in either DMSO or H2O were analysed in quartz 
cuvettes of 1 cm path length.  
Emission spectra were collected on a CARY Eclipse fluorescence spectrometer and are 
uncorrected. The spectra were acquired using a quartz cuvette with a path length of 1 cm 
at right angle detection. 
Absolute quantum yields were collected using a 150 mm QuantaPhi integrating sphere 
and the Symphony II liquid nitrogen cooled Charge-Coupled Device (CCD) detector. 
Quantum yields were calculated using Fluorescence (Horiba JY) software and are the 
average of two replicated.  
Thin layer chromatography (TLC) was performed on aluminium-backed Merck TLC 
silica gel 60 F254 plates, and visualised using UV light (λ = 254 nm) and/or a KMnO4 
oxidising dip (KMnO4, H2O and K2CO3). Column chromatography was performed on 
silica gel 60 (230–400 mesh). 
All solvents used were AR grade. Pet. spirits refers to the fraction boiling between 40–
60 °C. Chemicals purchased from commercial sources were used without further 
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purification. Anhydrous CHCl3, DMF and THF were obtained using the Pure Solv solvent 
drying system (Innovative Technology, Inc., Amesbury, MA, USA). Solvents were 
degassed and passed through two drying chambers of alumina and stored/collected under 
a positive pressure of nitrogen gas. Anhydrous MeOH was prepared according to the 
method outlined by Armarego and Chai.496 
All norbornane-based compounds are named using the von-Baeyer system of 
nomenclature.497 All other parts of the structure are named following the IUPAC 
guidelines. Numbering of norbornane protons follows the general structures shown below 
(Figure 92). Protons on the bridge carbon are labelled either syn (s) or anti (a) in regards 
to the priority functional group. 
 
Figure 92: Numbering of norbornene 325 and norbornane compounds 326–330. 
 
9.2 Synthetic Procedures 
9.2.1: General Synthetic Procedures 
General procedure A - guanidinylation 
Boc-protected methylisothiourea 58 (1.0 equiv) in CH2Cl2 (40% of total solvent volume; 
0.27 M) was added in one portion to a stirred solution of the appropriate amine (2.5 equiv) 
in CH2Cl2 (60% of total solvent volume; 0.27 M). The reaction was stirred at ambient 
temperature for the time taken to consume all of 58 (as indicated by TLC analysis). The 
reaction mixture was washed with H2O (3 × 25 mL), brine (30 mL), dried (MgSO4), 
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filtered and concentrated in vacuo at ambient temperature, within the confines of a fume 
cupboard,‡‡‡ to afford the desired product. 
General procedure B – acetal formation 
A stirring suspension of the appropriate diol, TsOH·H2O (0.05 equiv), MgSO4 (1.0 equiv) 
and PhMe, was treated with the required aldehyde (1.5 equiv) at 110 °C for 3 h. Solid 
MgSO4 was removed by filtration and the filtrate was diluted with EtOAc (30 mL), 
washed with H2O (2 × 15 mL), brine (15 mL), dried (MgSO4), filtered and concentrated 
in vacuo to give the crude material which was purified by column chromatography (as 
specified) to afford the title compound. 
General procedure C – bisalkylation of norbornane diol 110 
Anhydrous DMF was added to a pre-dried round-bottom flask protected from light, 
containing diol 110 and Ag2O (1.6 equiv) at ambient temperature. To the stirring solution 
was added the appropriate alkylating agent (4.6 equiv) and the reaction was stirred for 
48 h before the reaction vessel was cooled to 4 °C (refrigerator) for a further 16 h without 
agitation. The resulting precipitate was removed by vacuum filtration and washed with 
EtOAc (15 mL). The filtrate was washed with H2O (3 × 10 mL), dried (MgSO4), filtered 
and concentrated in vacuo to afford the crude product which was purified by column 
chromatography (as specified) to give the desired bisether. 
General procedure D – hydrolysis 
A biphasic solution of the appropriate ester in 2 M NaOH/THF (1:4) was stirred at 
ambient temperature for 16 h. The reaction mixture was extracted with CH2Cl2 (2 × 8 mL) 
and the isolated aqueous phase was acidified to pH = 1 using 2 M HCl and extracted with 
EtOAc (3 × 15 mL). The combined organic phase was washed with brine (10 mL), dried 
(MgSO4), filtered and concentrated in vacuo to afford the title compound. 
General procedure E – amide coupling in DMF 
A microwave vial was charged with the appropriate carboxylic acid, EDCI (3.0 equiv), 
HOBt (0.1 equiv) and anhydrous DMF and was stirred at ambient temperature for 30 min. 
The appropriate amine (3.0 equiv) was added and the reaction was irradiated at 50 °C for 
                                                 
‡‡‡ The reaction produces methanethiol; a malodorous and noxious gas.498 As such, all evaporations were 
performed within the confines of a fume cupboard. All glassware that was used during these procedures 
was soaked in H2O/bleach for a period of no less than 2 h prior to regular cleaning. 
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30 min. The resulting mixture was diluted with EtOAc (15 mL), washed with H2O (3 × 
8 mL), brine (8 mL), dried (MgSO4), filtered and concentrated in vacuo to afford the 
crude product which was purified using column chromatography (as specified) to give 
the title compound. 
General procedure F – amide coupling in CHCl3 
A microwave vial was charged with the appropriate carboxylic acid, EDCI (3.0 equiv), 
HOBt (0.1 equiv) and anhydrous CHCl3 and was stirred at ambient temperature for 
30 min. The appropriate amine (3.0 equiv) was added and the reaction was irradiated at 
50 °C for 30 min. The resulting mixture was diluted with CHCl3 (20 mL), washed with 
H2O (2 × 10 mL), brine (10 mL), dried (MgSO4), filtered and concentrated in vacuo to 
afford the crude product which was purified using column chromatography (as specified) 
to give the title compound. 
General procedure G – removal of Boc-groups 
To a stirring solution of Boc-protected amine/guanidine and MeOH was added dropwise 
AcCl (10.0 equiv), and the reaction was stirred for 24 h at ambient temperature. The 
reaction mixture was concentrated in vacuo and co-evaporated with MeOH (2 × 0.5 mL), 
to afford the title compound as a hydrochloride salt. In instances when 1H NMR 
spectroscopy indicated the presence of Boc-groups the crude material was retreated using 
the same conditions. 
 
9.2.2: Chapter Two 
2-Methylisothiouronium iodide (68)224  
 
A mixture of thiourea (10.098 g, 0.133 mol), MeI (8.2 mL, 0.133 mol) and MeOH 
(100 mL) was heated at 65 °C for 90 min. The MeOH was removed in vacuo and the 
resulting yellow solid was transferred to a sintered glass funnel then washed with Et2O 
(5 × 100 mL) under vacuum to afford compound 68 (28.261 g, 99%) as an amorphous 
white powder. 
m.p 115–118 °C (lit. 117 °C).224  
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1H NMR (270 MHz, DMSO-d6) δ 2.56 (3H, s, CH3), 8.89 (4H, br s, NH2).  
13C NMR (67.5 MHz, DMSO-d6) δ 13.3, 171.1. 
 
N,Nʹ-Bis(tert-butoxycarbonyl)-S-methylisothiourea (58)225 
 
To a stirring solution of 2-methylisothiouronium iodide 68 (17.675 g, 81.06 mmol) in sat. 
NaHCO3 (80 mL) and CH2Cl2 (240 mL) was added Boc2O (35.380 g, 162.12 mmol) in 
CH2Cl2 (80 mL). After 48 h the reaction mixture was transferred to a separating funnel 
and the organic phase was isolated. The aqueous phase was extracted with CH2Cl2 (2 × 
150 mL). The combined organic phase was dried (MgSO4), filtered and concentrated in 
vacuo. The crude solid was stirred in EtOH/H2O (200 mL, 1:9) for 1 h before the mixture 
was cooled to 0 °C and the solid was collected by vacuum filtration. Washing with H2O 
gave the title compound (19.916 g, 85%) as a white powder. 
m.p 122–124 °C (lit. 127 °C).499 
1H NMR (270 MHz, CDCl3) δ 1.51 (9H, br s, t-Bu), 1.53 (9H, br s, t-Bu), 2.40 (3H, s, 
CH3), 11.61 (1H, br s, NH). 
13C NMR (100 MHz, CDCl3) δ 14.6, 28.18, 28.20, 81.1, 83.4, 150.9, 160.9, 171.6.  
HRMS (ESI, m/z) for C12H22N2O4S [M + Na]+ calc. 313.1193; found 313.1186. 
 
2-[2,3-Bis(tert-butoxycarbonyl)guanidino]ethylamine (41) 
 
Compound 41 was prepared by treating 58 (20.404 g, 70.27 mmol) with EDA (11.7 mL, 
176 mmol) for 90 min, according to general procedure A, and was isolated as a white 
solid (20.696 g, 97%). 
m.p 96–100 °C.  
1H NMR (270 MHz, CDCl3) δ 1.50 (9H, br s, t-Bu), 1.51 (9H, br s, t-Bu), 2.90 (2H, t, J 
= 6.2 Hz, CH2), 3.49 (2H, app. q, J = 5.5 Hz, CH2), 8.67 (1H, br s, NH), 11.51 (1H, br s, 
NH). 
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13C NMR (67.5 MHz, CDCl3) δ 28.2, 28.4, 41.1, 43.5, 79.4, 83.2, 153.3, 156.5, 163.7. 
HRMS (ESI, m/z) for C13H26N4O4 [M + H]+ calc. 303.2027; found 303.2032. 
 
2-[2,3-Bis(tert-butoxycarbonyl)guanidino]ethylamine hydrogen 4-
methylbenzenesulfonate (69) 
 
To a stirring homogenous solution of aminoethylguanidine 41 (174 mg, 0.575 mmol) in 
Et2O (5.8 mL) was added TsOH·H2O (110 mg, 0.58 mmol) and the reaction was stirred 
at 0 °C for 3 h. The white precipitate was collected by vacuum filtration and washed with 
cold Et2O (20 mL) to give a white solid (190 mg, 70%).  
m.p 158–160 °C. 
1H NMR (270 MHz, CDCl3) δ 1.43 (9H, s, t-Bu), 1.47 (9H, s, t-Bu), 2.35 (3H, s, Me), 
3.30 (2H, br s, CH2), 3.55 (2H, br s, CH2), 7.16 (2H, d, J = 8.0 Hz, ArH), 7.75 (2H, d, J 
= 8.0 Hz, ArH), 8.56 (3H, br s, NH3), 8.70 (1H, br s, NH), 11.25 (1H, br s, NH). 
13C NMR (67.5 MHz, CDCl3) δ 21.5, 28.1, 28.2, 40.1, 41.3, 80.6, 84.1, 126.0 (2 × C), 
129.0 (2 × C), 140.3, 142.0, 152.7, 157.3, 161.6. 
HRMS (ESI, m/z) for C13H26N4O4 [M + H]+ calc. 303.2027; found 303.2023.  
 
2-[2,3-Bis(tert-butoxycarbonyl)guanidino]ethylamine hydrogen methanesulfonate 
(70) 
 
To a stirring homogenous solution of aminoethylguanidine 41 (465 mg, 1.54 mmol) in 
Et2O (10 mL) was added MsOH (110 μL, 1.54 mmol) and the resulting white slurry was 
stirred at 21 °C for 2.5 h. The white precipitate was collected by vacuum filtration and 
washed with Et2O (40 mL) to give a fine white powder (593 mg, 97%).  
m.p 176–177 °C.  
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1H NMR (500 MHz, DMSO-d6) δ 1.40 (9H, s, t-Bu), 1.48 (9H, s, t-Bu), 2.33 (3H, s, Me), 
2.96–3.00 (2H, m, CH2), 3.51–3.53 (2H, m, CH2), 7.73 (3H, br s, NH3), 8.52 (1H, br s, 
NH), 11.49 (1H, br s, NH). 
13C NMR (125 MHz, DMSO-d6) δ 27.7, 28.0, 38.11, 38.15, 39.8, 78.6, 80.0, 151.7, 155.9 
(2 × C). 
HRMS (ESI, m/z) for C13H26N4O4 [M + H]+ calc. 303.2027; found 303.2027.  
 
2-[2,3-Bis(tert-butoxycarbonyl)guanidino]ethylamine hydrogen 2,2,2-
trifluoroacetate (71) 
 
To a stirring homogenous solution of aminoethylguanidine 41 (790 mg, 2.61 mmol) in 
Et2O (13 mL) was added TFA (200 μL, 2.61 mmol). Stirring was continued at 21 °C for 
2 h before the reaction mixture was concentrated at reduced pressure to give the title 
compound (1.08 g, 99%) as a white fluffy hygroscopic residue.  
1H NMR (500 MHz, DMSO-d6) δ 1.39 (9H, s, t-Bu), 1.48 (9H, s, t-Bu), 2.97–3.00 (2H, 
m, CH2), 3.52–3.53 (2H, m, CH2), 7.91 (3H, br s, NH3), 8.51 (1H, br s, NH), 11.49 (1H, 
br s, NH). 
13C NMR (125 MHz, DMSO-d6) δ 27.6, 29.0, 38.1, 38.2, 78.5, 82.9, 116.7 (q, JCF = 
295.1 Hz), 151.7, 155.9, 158.5 (q, JCF = 32.7 Hz), 162.9. 
19F NMR (470 MHz, DMSO-d6) δ −75.16 (s). 
HRMS (ESI, m/z) for C13H26N4O4 [M + H]+ calc. 303.2028; found 303.2027.  
 
3-[2,3-Bis(tert-butoxycarbonyl)guanidino]propyl-1-amine hydrogen 4-
methylbenzenesulfonate (72) 
 
To a stirring solution of 1,3-diaminopropane (2.2 mL, 25.8 mmol) in CH2Cl2 (23 mL) 
was added guanidinylating agent 58 (3.005 g, 10.35 mmol) in CH2Cl2 (15 mL). The 
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reaction was stirred at 21 °C for 90 min before being transferred to a separating funnel 
and diluted with CH2Cl2 (30 mL). The organic phase was washed with H2O (3 × 30 mL) 
and brine (30 mL), dried (MgSO4), filtered, and concentrated by rotary evaporation at 
21 °C. The resulting clear sticky oil was immediately dissolved in Et2O (24 mL) at 21 °C 
and TsOH·H2O (1.86 g, 9.80 mmol) was added with stirring. After 1 h the white 
precipitate was collected by vacuum filtration and washed with Et2O (20 mL) to give the 
title compound (4.291 g, 85%) as a white solid over two steps.  
m.p 157–158 °C.  
1H NMR (500 MHz, DMSO-d6) δ 1.40 (9H, s, t-Bu), 1.48 (9H, s, t-Bu), 1.74–1.80 (2H, 
m, CH2), 2.29 (3H, s, CH3), 2.77–2.83 (2H, m, CH2), 3.33–3.37 (2H, m, CH2), 7.11 (2H, 
d, J = 8.0 Hz, ArH), 7.48 (2H, d, J = 8.0 Hz, ArH), 7.72 (3H, br s, NH3), 8.54 (1H, br s, 
NH), 11.45 (1H, br s, NH). 
13C NMR (125 MHz, DMSO-d6) δ 20.8, 26.8, 27.6, 28.0, 36.4, 37.1, 78.5, 83.0, 125.5 (2 
× C), 128.1 (2 × C), 137.7, 145.6, 151.8, 155.6 (2 × C). 
HRMS (ESI, m/z) for C14H28N4O4 [M + H]+ calc. 317.2184; found 317.2184.  
 
4-[2,3-Bis(tert-butoxycarbonyl)guanidino]butyl-1-amine hydrogen 4-
methylbenzenesulfonate (73) 
 
To a stirring solution of 1,4-diaminobutane (2.6 mL, 25.8 mmol) in CH2Cl2 (23 mL) was 
added guanidinylating agent 58 (3.015 g, 10.38 mmol) in CH2Cl2 (15 mL). The reaction 
was stirred at 21 °C for 90 min before being transferred to a separating funnel and diluted 
with CH2Cl2 (30 mL). The organic phase was washed with H2O (3 × 30 mL) and brine 
(30 mL), dried (MgSO4), filtered, and concentrated by rotary evaporation at 21 °C. The 
resulting clear sticky oil was immediately dissolved in Et2O (24 mL) at 21 °C and 
TsOH·H2O (1.86 g, 9.80 mmol) was added with stirring. After 1 h the white precipitate 
was collected by vacuum filtration and washed with Et2O (20 mL) to give the title 
compound (3.851 g, 74%) as a white solid over two steps.  
m.p 109–110 °C.  
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1H NMR (500 MHz, DMSO-d6) δ 1.40 (9H, s, t-Bu), 1.47 (9H, s, t-Bu), 1.51–1.52 (4H, 
m, 2 × CH2), 2.29 (3H, s, CH3), 2.80–2.81 (2H, m, CH2), 3.29–3.30 (2H, m, CH2), 7.12 
(2H, d, J = 8.0 Hz, ArH), 7.48 (2H, d, J = 8.0 Hz, ArH), 7.66 (3H, br s, NH3), 8.42 (1H, 
br s, NH), 11.50 (1H, br s, NH). 
13C NMR (125 MHz, DMSO-d6) δ 20.8, 24.2, 25.5, 27.6, 28.0, 38.6, 39.5, 78.5, 83.1, 
125.5 (2 × C), 128.2 (2 × C), 137.8, 145.5, 152.0, 155.2 (2 × C). 
HRMS (ESI, m/z) for C15H30N4O4 [M + H]+ calc. 331.2342; found 331.2340.  
 
6-[2,3-Bis(tert-butoxycarbonyl)guanidino]hexyl-1-amine hydrogen 
methanesulfonate (74) 
 
To a stirring solution of 1,6-diaminohexane (475 mg, 4.09 mmol) in CH2Cl2 (3.6 mL) 
was added guanidinylating agent 58 (475 mg, 1.64 mmol) in CH2Cl2 (2.4 mL). The 
reaction was stirred at 21 °C for 90 min before being transferred to a separating funnel 
and diluted with CH2Cl2 (10 mL). The organic phase was washed with H2O (3 × 10 mL) 
and brine (10 mL), dried (MgSO4), filtered, and concentrated by rotary evaporation at 
21 °C. The resulting viscous yellow oil was immediately dissolved in Et2O (3.3 mL) at 
21 °C and MsOH (90 μL, 1.39 mmol) was added with stirring. After 1 h the reaction flask 
was cooled to 0 °C and the white precipitate was collected by vacuum filtration and 
quickly transferred to a vial. The precipitate was dried in vacuo to give the title compound 
(358 mg, 50%) as a white hygroscopic solid over two steps.  
m.p 107–108 °C.  
1H NMR (500 MHz, DMSO-d6) δ 1.27–1.33 (4H, m, 2 × CH2), 1.39 (9H, s, t-Bu), 1.47–
1.54 (13H, m, 2 × CH2, t-Bu), 2.33 (3H, s, Me), 2.73–2.80 (2H, m, CH2), 3.25–3.29 (2H, 
m, CH2), 7.65 (3H, br s, NH3), 8.30 (1H, br s, NH), 11.48 (1H, s, NH). 
13C NMR (125 MHz, DMSO-d6) δ 25.4, 25.8, 26.9, 27.6, 28.0, 28.3, 38.8, 39.8, 39.9, 
78.2, 82.9, 152.1, 155.2, 163.1. 
HRMS (ESI, m/z) for C17H34N4O4 [M + H]+ calc. 359.2653; found 359.2649.  
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2-[2,3-Bis(tert-butoxycarbonyl)guanidino]ethanol (75)212 
 
Compound 75 was prepared by treating 58 (97 mg, 0.33 mmol) with ethanolamine 
(50 μL, 0.83 mmol) for 16 h, according to general procedure A, and was isolated as a 
white powder (83 mg, 83%). 
m.p 125–126 °C (lit. 98–100 °C).230  
1H NMR (270 MHz, CDCl3) δ 1.47 (9H, s, t-Bu), 1.50 (9H, s, t-Bu), 3.54–3.59 (2H, m, 
CH2), 3.75–3.79 (2H, m, CH2), 4.59 (1H, br s, OH), 8.70 (1H, br s, NH), 11.45 (1H, br s, 
NH). 
13C NMR (67.5 MHz, CDCl3) δ 28.2, 28.3, 44.6, 63.4, 79.7, 83.7, 153.2, 157.6, 162.9. 
HRMS (ESI, m/z) for C13H25N3O5 [M + H]+ calc. 304.1867; found 304.1865.  
 
3-[2,3-Bis(tert-butoxycarbonyl)guanidino]propanol (76)500  
 
Compound 76 was prepared by treating 58 (474 mg, 1.63 mmol) with 3-amino-1-
propanol (310 μL, 4.08 mmol) for 24 h, according to general procedure A, and was 
isolated as a white powder (422 mg, 81%). 
m.p 115–116 °C (lit. 112.0–113.0 °C).501  
1H NMR (500 MHz, CDCl3) δ 1.47 (9H, s, t-Bu), 1.50 (9H, s, t-Bu), 1.67–1.72 (2H, m, 
CH2), 3.55–3.60 (4H, m, 2 × CH2), 8.48 (1H, br s, NH), 11.44 (1H, s, NH). 
13C NMR (125 MHz, CDCl3) δ 28.2, 28.3, 33.0, 37.0, 57.8, 79.8, 83.7, 153.3, 157.2, 
162.7. 
HRMS (ESI, m/z) for C14H27N3O5 [M + H]+ calc. 318.2024 found 318.2025. 
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3-[2,3-Bis(tert-butoxycarbonyl)guanidino]propene (77)232  
 
Compound 77 was prepared by treating 58 (477 mg, 1.64 mmol) with allylamine (310 μL, 
4.08 mmol) for 24 h, according to general procedure A, and was isolated as a white 
powder (421 mg, 86%). 
m.p 93–94 °C (lit. 87.0–89.0 °C).232 
1H NMR (270 MHz, CDCl3) δ 1.49 (9H, s, t-Bu), 1.50 (9H, s, t-Bu), 4.05–4.14 (2H, m, 
CH2NH), 5.14–5.27 (2H, m, CH2CH), 5.81–5.95 (1H, m, CH2CH), 8.41 (1H, br s, NH), 
11.51 (1H, s, NH). 
13C NMR (67.5 MHz, CDCl3) δ 28.2, 28.4, 43.5, 79.6, 83.4, 117.0, 133.4, 153.4, 156.1, 
163.5. 
HRMS (ESI, m/z) for C14H25N3O4 [M + Na]+ calc. 322.1737 found 322.1737. 
 
3-[2,3-Bis(tert-butoxycarbonyl)guanidino]propyne (78)237  
 
Compound 78 was prepared by treating 58 (476 mg, 1.64 mmol) with propargylamine 
(260 μL, 4.08 mmol) for 5 h, according to general procedure A, and was isolated as a 
white powder (404 mg, 83%). 
m.p 86–87 °C.  
1H NMR (500 MHz, CDCl3) δ 1.49 (9H, s, t-Bu), 1.50 (9H, s, t-Bu), 2.26 (1H, t, J = 
2.6 Hz, CH), 4.24 (2H, dd, J = 4.9, 2.6 Hz, CH2), 8.47 (1H, br s, NH), 11.44 (1H, s, NH). 
13C NMR (125 MHz, CDCl3) δ 28.2, 28.4, 30.9, 72.4, 79.0, 79.8, 83.6, 153.2, 155.7, 
163.3. 
HRMS (ESI, m/z) for C14H23N3O4 [M + H]+ calc. 298.1761 found 298.1765. 
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2-(2-[2,3-Bis(tert-butoxycarbonyl)guanidino]ethoxy)ethanol (79)238  
 
Compound 79 was prepared by treating 58 (476 mg, 1.64 mmol) with 2-(2-
aminoethoxy)ethanol (410 μL, 4.08 mmol) for 24 h, according to general procedure A, 
and was isolated as a clear viscous oil (476 mg, 84%). 
1H NMR (270 MHz, CDCl3) δ 1.48 (9H, s, t-Bu), 1.49 (9H, s, t-Bu), 2.45 (1H, s, OH), 
3.58–3.76 (8H, m, 4 × CH2), 8.78 (1H, br s, NH), 11.47 (1H, s, NH). 
13C NMR (67.5 MHz, CDCl3) δ 28.2, 28.4, 40.6, 62.0, 69.1, 72.5, 79.6, 83.6, 153.5, 
156.2, 163.4. 
HRMS (ESI, m/z) for C15H29N3O6 [M + Na]+ calc. 370.1949 found 370.1946. 
 
3-[2,3-Bis(tert-butoxycarbonyl)guanidino]propan-1,2-diol (80)  
 
Compound 80 was prepared by treating 58 (474 mg, 1.63 mmol) with 3-amino-1,2-
propandiol (320 μL, 4.13 mmol) for 2 d, according to general procedure A, and was 
isolated as a white fluffy solid (441 mg, 81%). 
m.p 132–136 °C. 
1H NMR (270 MHz, CDCl3) δ 1.47 (9H, s, t-Bu), 1.50 (9H, s, t-Bu), 3.44–4.61 (4H, m, 
2 × CH2), 3.71–3.78 (1H, m, CH), 3.91 (1H, br s, OH), 8.60 (1H, t, J = 6.2 Hz, NH), 11.41 
(1H, br s, NH). 
13C NMR (67.5 MHz, CDCl3) δ 28.2, 28.3, 43.7, 63.1, 71.5, 79.9, 83.9, 153.1, 157.6, 
162.6. 
HRMS (ESI, m/z) for C14H27N3O6 [M + H]+ calc. 334.1973 found 334.1971. 
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2-Chloro-1,3-dimethyl-4,5-dihydro-1H-imidazol-3-ium hexafluorophosphate (85)239  
 
To a stirring homogenous mixture of chloride salt 84 (3.17 g, 18.8 mmol) in MeCN 
(4.7 mL) under inert conditions, was added a solution of KPF6 (3.47 g, 18.8 mmol) in 
MeCN (24 mL). Stirring was maintained for 30 min at 21 °C before the reaction mixture 
was filtered through a Celite pad under N2. The filtrate was collected and concentrated 
under vacuum. The minimum amount of MeCN was used to redissolve the crude orange 
solid and the solution was added to cold Et2O. The precipitate was collected under 
vacuum and washed with cold Et2O (3 × 6 mL), under a stream of N2, to afford the title 
compound (3.39 g, 65%) as a white solid. 
m.p 195–199 °C (lit. 230–231 °C).239 
1H NMR (270 MHz, CD3CN) δ 3.11 (6H, s, 2 × CH3), 3.92 (4H, s, 2 × CH2). 
13C NMR (67.5 MHz, CD3CN) δ 35.2, 50.8, 118.4. 
HRMS (ESI, m/z) for C5H10ClN2 [M + H]+ calc. 133.0533; found 133.0531. 
 
2-Azido-1,3-dimethyl-4,5-dihydro-1H-imidazol-3-ium hexafluorophosphate (86)239  
 
To a stirring homogenous mixture of hexafluorophosphate salt 85 (1.51 g, 5.43 mmol) in 
MeCN (5.4 mL) under inert conditions at 0 °C, was added NaN3 (1.06 g, 16.3 mmol). The 
reaction was slowly warmed to ambient temperature and stirred for 1 h before the reaction 
mixture was filtered through a Celite pad under N2. The filtrate was collected and 
concentrated under vacuum. The minimum amount of MeCN was used to redissolve the 
crude orange solid and the solution was added to cold Et2O. The precipitate was collected 
by vacuum filtration and washed with cold Et2O (3 × 6 mL), under a stream of N2, to give 
the title compound (1.20 g, 77%) as a white solid. 
m.p 187–190 °C (lit. 203–205 °C).239 
1H NMR (270 MHz, CD3CN) δ 3.05 (6H, s, 2 × CH3), 3.78 (4H, s, 2 × CH2). 
13C NMR (67.5 MHz, CD3CN) δ 33.8, 50.0, 118.4. 
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HRMS (ESI, m/z) for C5H10N5 [M + H]+ calc. 140.0936; found 140.0937. 
 
N,Nʹ-Bis(tert-butoxycarbonyl)-Nʹ-(2-azidoethyl)guanidine (83)239  
 
ADMP 86 (113 mg, 0.40 mmol) was added in one portion to the stirred solution of 
aminoethylguanidine 41 (100 mg, 0.33 mmol) and Et3N (230 μL, 1.65 mmol) in CH2Cl2 
(330 μL). The reaction was stirred at 21 °C for 16 h before being quenched with sat. 
NaHCO3 (4 mL). The mixture was transferred to a separating funnel and extracted with 
CH2Cl2 (2 × 10 mL). The combined organic phase was washed with 0.5 M HCl (10 mL) 
and H2O (10 mL), then dried (MgSO4), filtered and concentrated in vacuo. The crude 
material was rinsed and decanted with Et2O (3 × 3 mL) and the combined organic phase 
was concentrated in vacuo to give the title compound (54 mg, 50%) as a white solid. 
m.p 77–79 °C (lit. 63 °C).239 
1H NMR (270 MHz, CDCl3) δ 1.50 (18H, br s, 2 × t-Bu), 3.49–3.54 (2H, m, CH2), 2.58–
2.64 (2H, m, CH2), 8.59 (1H, t, J = 5.7 Hz, NH), 11.48 (1H, s, NH). 
13C NMR (67.5 MHz, CDCl3) δ 28.2, 28.4, 40.2, 50.6, 79.8, 83.6, 153.3, 156.4, 163.2. 
HRMS (ESI, m/z) for C13H24N6O4 [M + H]+ calc. 329.1932 found 329.1934. 
 
9.2.3: Chapter Three 
2-(tert-Butoxycarbonylamino)ethylamine (51)226 
 
A solution of Boc2O (8.35 g, 38.3 mmol) in THF (75 mL) was added dropwise, over 
approximately 30 min, to a stirred solution of EDA (8.4 mL, 125 mmol) in THF (25 mL). 
The reaction was stirred for 4 h after which time the mixture was filtered and the solvent 
was then removed in vacuo to afford the desired product (5.65 g, 92%) as a viscous oil. 
1H NMR (270 MHz, CDCl3) δ 1.16 (2H, br s, NH2), 1.43 (9H, s, t-Bu), 2.78 (2H, t, J = 
6.0 Hz, CH2NH), 3.15 (2H, app. q, J = 6.0 Hz, NH2CH2), 4.83 (1H, br s, NH). 
13C NMR (67.5 MHz, CDCl3) δ 28.4, 40.7, 41.8, 43.4, 156.3. 
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HRMS (ESI, m/z) for C7H16N2O2 [M + H]+ calc. 161.1285; found 161.1290. 
 
3,4-Diethoxy-3-cyclobutene-1,2-dione (106)502 
 
A stirring solution of 3,4-dihydroxycyclobut-3-ene-1,2-dione (995 mg, 8.72 mmol) and 
EtOH (10 mL) was heated at 79 °C for 16 h. The reaction mixture was concentrated under 
reduced pressure before being diluted with CHCl3 (20 mL). The organic phase was 
washed with sat. NaHCO3 (2 × 10 mL), brine (10 mL), dried (MgSO4), filtered and 
concentrated in vacuo to give a pale yellow oil (979 mg, 65%). 
1H NMR (500 MHz, CDCl3) δ 1.47 (6H, t, J = 7.1 Hz, 2 × CH3), 4.73 (4H, q, J = 7.1 Hz, 
2 × CH2). 
13C NMR (125 MHz, CDCl3) δ 15.7, 70.6, 184.3, 189.4. 
HRMS (ESI, m/z) for C8H10O4 [M + Na]+ calc. 193.0471; found 193.0479.  
 
3,4-Dimethoxy-3-cyclobutene-1,2-dione (104)268 
 
To a stirring solution of 3,4-dihydroxycyclobut-3-ene-1,2-dione (1.00 g, 8.78 mmol) in 
MeOH (18 mL) was added trimethyl orthoformate (1.9 mL, 17.6 mmol) and the reaction 
was heated at 65 °C for 24 h. The reaction mixture was concentrated under reduced 
pressure before being diluted with CHCl3 (20 mL). The organic phase was washed with 
sat. NaHCO3 (2 × 10 mL), brine (10 mL), dried (MgSO4), filtered and concentrated in 
vacuo to give a yellow oil which was purified by a silica plug (10% EtOAc in CH2Cl2) to 
afford the title compound (896 mg, 72%) as a white solid. 
Rf = 0.33 (10% EtOAc in CH2Cl2). 
m.p 53–55 °C (lit. 55.0 °C).268 
1H NMR (270 MHz, CDCl3) δ 4.37 (6H, s, 2 × Me). 
13C NMR (67.5 MHz, CDCl3) δ 67.5, 184.6, 189.3. 
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HRMS (ESI, m/z) for C6H6O4 [M + H]+ calc. 143.0339; found 143.0340. 
 
3-Benzylamine-4-methoxycyclobut-3-ene-1,2-dione (105)269  
 
To a solution of squaric ester 104 (257 mg, 1.81 mmol) in MeOH (6.5 mL) was added 
BnNH2 (200 μL, 1.83 mmol) and the reaction was stirred for 1 h at ambient temperature. 
The reaction mixture was concentrated under reduced pressure before being purified by 
column chromatography (20% MeCN in CH2Cl2) to give the title compound (192 mg, 
49%) as a white solid. 
Rf = 0.5 (20% MeCN in CH2Cl2). 
m.p 123–124 °C (lit. 122–124 °C).269  
1H NMR (400 MHz, DMSO-d6, 40 °C) δ 4.29 (3H, s, OMe), 4.46 (1H, br s, CH2), 4.68 
(1H, br s, CH2), 7.29–7.39 (5H, m, ArH), 9.06–9.27 (1H, m, NH). 
13C NMR (67.5 MHz, DMSO-d6) δ 47.1, 60.1, 127.3, 127.4, 128.6, 138.2, 172.0, 177.5, 
182.4, 189.4.  
HRMS (ESI, m/z) for C12H11NO3 [M + H]+ calc. 218.0812; found 218.0818. 
 
Dimethyl bicyclo[2.2.1]hept-5-ene-3-endo-2-exo-dicarboxylate (112)  
 
Method A277 
Freshly distilled CPD (40 mL, 0.476 mol) was added to a solution of dimethyl fumarate 
(65.29 g, 0.453 mol) in THF (200 mL) and the reaction was stirred at ambient temperature 
for 16 h. The solvent was removed under reduced pressure to give the title compound 
(95.2 g, 99%) as a clear liquid. 
Method B278 
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A 35 mL microwave vial was charged with DCPD (2.0 mL, 15 mmol), dimethyl fumarate 
(2.88 g, 20 mmol) and hydroquinone (100 mg, 0.9 mmol), and heated to 150 °C for 2 h 
using microwave irradiation. The resulting orange oil was purified using flash column 
chromatography (10% EtOAc in pet. spirits) to give the title compound (4.14 g, 98%) as 
a colourless oil.  
Rf = 0.32 (10% EtOAc in pet. spirits).  
1H NMR (400 MHz, CDCl3) δ 1.45 (1H, dd, J = 8.8, 1.7 Hz, H7s), 1.61 (1H, d, J = 8.8 Hz, 
H7a), 2.68 (1H, dd, J = 3.1, 1.2 Hz, H2), 3.12 (1H, br s, H4), 3.25 (1H, br s, H1), 3.37 
(1H, app. t, J = 5.6 Hz, H3), 3.64 (3H, s, Me), 3.71 (3H, s, Me), 6.06 (1H, dd, J = 5.6, 
2.8 Hz, H6), 6.27 (1H, dd, J = 5.6, 3.1 Hz, H5).  
13C NMR (100 MHz, CDCl3) δ 45.5, 46.9, 47.2, 47.5, 47.7, 51.7, 51.9, 135.3, 137.7, 
174.0, 175.2. 
HRMS (ESI, m/z) for C11H14O4 [M + Na]+ calc. 233.0784; found 233.0785. 
 
Dimethyl 5,6-exo-dihydroxybicyclo[2.2.1]heptane-3-endo-2-exo-dicarboxylate (110)  
 
Method A185 
The dimethyl ester 112 (3.05 g, 14.53 mmol) and NMO·H2O (1.87 g, 15.98 mmol) were 
dissolved in a solution of H2O/acetone (1:4, 36 mL) before OsO4 (4% in H2O, 730 μL, 
0.40 mol%) was added. The reaction was stirred for 3 d and then quenched with sat. 
NaHSO3 (30 mL). The suspension was extracted with EtOAc (4 × 25 mL) and the 
combined organic phase was washed with brine (25 mL), dried (MgSO4), filtered and 
concentrated in vacuo to give the title compound (3.34 g, 94%) as a white solid. 
Method B301 
To a stirring solution of dimethyl ester 112 (270 mg, 1.28 mmol), t-BuOH (4.7 mL) and 
H2O (1.2 mL) at 0 °C, a solution of KMnO4 (405 mg, 2.56 mmol), K2CO3 (212 mg, 
1.54 mmol) in H2O (6.0 mL) was added dropwise. The reaction was stirred for a further 
25 min before consumption of starting material was observed by TLC analysis. The 
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reaction mix was quenched with sat. NaHSO3 (25 mL) and extracted with EtOAc (3 × 
20 mL). The combined organic phase was washed with brine (20 mL), dried (MgSO4), 
filtered and concentrated in vacuo to give the title compound (181 mg, 58%) as a white 
solid. 
m.p 90–92 °C (lit. 81-84 °C).185  
1H NMR (270 MHz, CDCl3) δ 1.33 (1H, d, J = 11.0 Hz, H7s), 1.78 (1H, dd, J = 11.0, 
1.2 Hz, H7a), 2.40 (1H, br s, H1), 2.46 (1H, dd, J = 4.5, 1.2 Hz, H4), 2.63 (1H, d, J = 
5.0 Hz, H2), 3.11 (1H, app. t, J = 5.0 Hz, H3), 3.62 (3H, s, Me), 3.64 (3H, s, Me), 3.71–
3.77 (1H, m, H6), 3.85 (1H, br s, H5).  
13C NMR (67.5 MHz, CDCl3) δ 31.8, 44.8, 46.2, 46.4, 48.2, 52.3, 52.5, 70.2, 73.3, 173.2, 
174.2. 
HRMS (ESI, m/z) for C11H16O6 [M + Na]+ calc. 267.0839; found 267.0836. 
 
Hexadecanal (129)307  
 
To the stirring solution of DMSO (710 μL, 10.0 mmol) in CH2Cl2 (40 mL) at −78 °C was 
added oxalyl chloride (440 μL, 5.0 mmol) under an inert atmosphere. After 20 min 1-
hexadecanol (484 mg, 2.0 mmol) in CH2Cl2 (6 mL) was added and the reaction was stirred 
for 5.5 h at −41 °C. The reaction was quenched with Et3N (3 mL, 21.5 mmol) and slowly 
warmed to ambient temperature over 30 min. The reaction mixture was washed with sat. 
NaHCO3 (50 mL) and extracted with CH2Cl2 (3 × 30 mL). The combined organic phase 
was washed with 2M HCl (2 × 20 mL), sat. NaHCO3 (20 mL), brine (20 mL), dried 
(MgSO4), filtered and concentrated in vacuo to afford a yellow solid (389 mg, 81%). 
m.p 36–38 °C (lit. 33.0–35.0 °C).503 
1H NMR (270 MHz, CDCl3) δ 0.87 (3H, t, J = 6.4 Hz, CH3), 1.25–1.30 (24H, m, 12 × 
CH2), 1.62 (2H, app. t, J = 7.4 Hz, CH2), 2.41 (2H, dt, J = 7.4, 1.9 Hz, CH2), 9.76 (1H, t, 
J = 1.9 Hz, CHO). 
13C NMR (100 MHz, CDCl3) δ 14.2, 22.2, 22.8, 29.3, 29.5, 29.6, 29.7, 29.8 (6 × C), 32.1, 
44.1, 203.1. 
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Methyl-3-(4-hydroxyphenyl)propionate (145)308  
 
To the stirring solution of 3-(4-hydroxyphenyl)propanoic acid (5.02 g, 30.23 mmol) in 
MeOH (50 mL), was added conc. H2SO4 (50 μL) and the reaction was heated at 65 °C for 
16 h. The reaction mixture was concentrated and the resulting yellow oil was dissolved 
in EtOAc (25 mL), washed with sat. NaHCO3 (20 mL), brine (20 mL), dried (MgSO4), 
filtered and concentrated in vacuo to give the title compound (4.78 g, 88%) as a viscous 
yellow oil.  
1H NMR (270 MHz, CDCl3) δ 2.58–2.64 (2H, m, ArCH2), 2.88 (2H, t, J = 7.4 Hz, 
CH2CO2Me), 3.67 (3H, s, Me), 5.85 (1H, br s, OH), 6.73–6.78 (2H, m, ArH), 7.01–7.07 
(2H, m, ArH). 
13C NMR (67.5 MHz, CDCl3) δ 30.2, 36.2, 51.9, 115.5 (2 × C), 129.5 (2 × C), 132.4, 
154.3, 174.2. 
HRMS (ESI, m/z) for C10H12O3 [M + H]+ calc. 181.0859; found 181.0857. 
 
Methyl 3-[4-(octyloxy)phenyl]propanoate (146)  
 
A mixture of phenol 145 (1.01 g, 5.63 mmol), K2CO3 (2.33 g, 8.45 mmol), 1-iodooctane 
(2.6 mL, 14.4 mmol) and DMF (8.7 mL), was stirred for 4 d at ambient temperature in a 
round bottom flask protected from light. The reaction was diluted with EtOAc (30 mL), 
and the organic phase was washed with H2O (3 × 25 mL), brine (25 mL), dried (MgSO4), 
filtered, and concentrated in vacuo to give a yellow oil. The crude material was purified 
using column chromatography (pet. spirits–5% EtOAc in pet. spirits) to afford the title 
compound (1.26 g, 77%) as a colourless oil. 
Rf = 0.44 (10% EtOAc in pet. spirits). 
1H NMR (400 MHz, CDCl3) δ 0.89 (3H, t, J = 6.7 Hz, CH3), 1.28–1.48 (10H, m, 5 × 
CH2), 1.74–1.78 (2H, m, CH2), 2.57–2.63 (2H, m, ArCH2), 2.89 (2H, t, J = 7.6 Hz, 
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CH2CO2Me), 3.67 (3H, s, Me), 3.92 (2H, t, J = 6.6 Hz, OCH2), 6.82 (2H, d, J = 8.6 Hz, 
ArH), 7.10 (2H, d, J = 8.6 Hz, ArH).  
13C NMR (67.5 MHz, CDCl3) δ 14.2, 22.8, 26.2, 29.4 (2 × C), 29.5, 30.3, 32.0, 36.2, 
51.7, 68.1, 114.6 (2 × C), 129.3 (2 × C), 132.5, 157.8, 173.6.  
HRMS (ESI, m/z) for C18H28O3 [M + H]+ calc. 293.2111; found 293.2117. 
 
3-[4-(Octyloxy)phenyl]propan-1-ol (147)  
 
Under an inert atmosphere, ester 146 (1.08 g, 3.68 mmol) was stirred in PhMe (18 mL), 
at 0 °C before Red-Al® (60% wt. in PhMe, 2.8 mL, 9.2 mmol) was slowly added. The 
reaction was warmed to ambient temperature over 30 min and then stirred for a further 
16 h. The reaction mixture was quenched with H2O (15 mL) and left to stir for 2 h. The 
crude product was extracted with EtOAc (2 × 20 mL), and the combined organic phase 
was washed with brine (20 mL), dried (MgSO4), filtered, and concentrated in vacuo. 
Purification was achieved by column chromatography (20% EtOAc in pet. spirits) to give 
the title compound (869 mg, 89%) as a white waxy solid. 
Rf = 0.25 (20% EtOAc in pet. spirits). 
1H NMR (270 MHz, CDCl3) δ 0.89 (3H, t, J = 6.6 Hz, CH3), 1.29–1.47 (10H, m, 5 × 
CH2), 1.51 (1H, s, OH), 1.72–1.91 (4H, m, 2 × CH2), 2.65 (2H, t, J = 7.3 Hz, ArCH2), 
3.66 (2H, t, J = 6.4 Hz, CH2OH), 3.93 (2H, t, J = 6.6 Hz, OCH2), 6.80–6.85 (2H, m, ArH), 
7.07–7.13 (2H, m, ArH).  
13C NMR (67.5 MHz, CDCl3) δ 14.2, 22.8, 26.2, 29.4, 29.5 (2 × C), 31.3, 31.9, 34.6, 
62.4, 68.2, 114.6 (2 × C), 129.4 (2 × C), 133.7, 157.4. 
HRMS (ESI, m/z) for C17H28O2 [M + H]+ calc. 265.2162; found 265.2170. 
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3-[4-(Octyloxy)phenyl]propanal (131)  
 
To the stirring solution of DMSO (1.1 mL, 15.3 mmol) in anhydrous CH2Cl2 (60 mL) at 
−78 °C was added oxalyl chloride (660 μL, 7.7 mmol) under an inert atmosphere. After 
20 min, alcohol 147 (809 mg, 3.06 mmol) in CH2Cl2 (16 mL) was added and the reaction 
was stirred for 5.5 h at −41 °C. The reaction mixture was quenched with Et3N (5 mL) and 
warmed slowly to ambient temperature over 1 h. The reaction mixture was washed with 
sat. NaHCO3 (50 mL) and extracted with CH2Cl2 (2 × 30 mL). The combined organic 
phase was washed with 2M HCl (30 mL), sat. NaHCO3 (30 mL), brine (30 mL), dried 
(MgSO4), filtered and concentrated in vacuo to give the title compound (668 mg, 83%) 
as a yellow oil that was used directly in ensuing reactions. 
 
Dimethyl 4-heptyl-3,5-dioxatricyclo[5.2.1.02,6]decane-8-endo-9-exo-dicarboxylate 
(148) 
 
Compound 148 was prepared from diol 110 (3.40 g, 14.32 mmol) and octanal (3.4 mL, 
21.5 mmol) according to general procedure B and was purified by column 
chromatography (10% EtOAc in pet. spirits) to give the title compound (4.66 g, 92%) as 
a colourless vicious oil. 
Rf = 0.26 (10% EtOAc in pet. spirits).  
1H NMR (400 MHz, CDCl3) δ 0.82 (3H, t, J = 6.6 Hz, CH3), 1.19–1.36 (11H, m, 5 × 
CH2, H10s), 1.56–1.59 (2H, m, CHCH2), 1.73 (1H, d, J = 10.8 Hz, H10a), 2.60 (2H, br 
s, H1, H7), 2.67 (1H, d, J = 4.7 Hz, H9), 3.18 (1H, app. t, J = 4.7 Hz, H8), 3.66 (6H, s, 2 
× Me), 3.85 (1H, d, J = 5.6 Hz, H6), 3.98 (1H, d, J = 5.6 Hz, H2), 4.61 (1H, t, J = 4.9 Hz, 
H4). 
13C NMR (100 MHz, CDCl3) δ 13.7, 22.3, 23.9, 28.9, 29.2, 31.3, 31.5, 32.5, 43.0, 43.4, 
44.8, 45.0, 51.9, 52.1, 78.7, 81.2, 104.2, 173.0, 174.2. 
HRMS (ESI, m/z) for C19H30O6 [M + Na]+ calc. 377.1935; found 377.1924. 
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Dimethyl 4-undecanyl-3,5-dioxatricyclo[5.2.1.02,6]decane-8-endo-9-exo-
dicarboxylate (149) 
 
Compound 149 was prepared from diol 110 (947 mg, 3.87 mmol) and dodecanal (1.3 mL, 
5.86 mmol) according to general procedure B and was purified by column 
chromatography (5–10% EtOAc in pet. spirits) to give the title compound (1.33 g, 83%) 
as a white waxy solid. 
Rf = 0.24 (10% EtOAc in pet. spirits). 
1H NMR (500 MHz, CDCl3) δ 0.87 (3H, t, J = 6.9 Hz, CH3), 1.24–1.39 (19H, m, 9 × 
CH2, H10s), 1.60–1.65 (2H, m, CHCH2), 1.78 (1H, dd, J = 10.9, 1.4 Hz, H10a), 2.40–
2.65 (2H, m, H1, H7), 2.72 (1H, d, J = 4.8 Hz, H9), 3.23 (1H, app. t, J = 4.8 Hz, H8), 
3.70 (6H, s, 2 × Me), 3.90 (1H, d, J = 5.6 Hz, H6), 4.03 (1H, d, J = 5.6 Hz, H2), 4.65 (1H, 
t, J = 4.9 Hz, H4). 
13C NMR (125 MHz, CDCl3) δ 14.3, 22.8, 24.4, 29.5, 29.6, 29.7 (2 × C), 29.8 (2 × C), 
31.8, 32.1, 32.9, 43.4, 43.8, 45.1, 45.4, 52.3, 52.5, 78.9, 81.4, 104.3, 172.9, 174.1.  
HRMS (ESI, m/z) for C23H38O6 [M + H]+ calc. 411.2741; found 411.2745. 
 
Dimethyl 4-pentadecyl-3,5-dioxatricyclo[5.2.1.02,6]decane-8-endo-9-exo-
dicarboxylate (150) 
 
Compound 150 was prepared from diol 110 (239 mg, 0.98 mmol) and hexadecanal 129 
(353 mg, 1.47 mmol) according to general procedure B and was purified by column 
chromatography (5% EtOAc in pet. spirits) to give the title compound (276 mg, 60%) as 
a white solid. 
Rf = 0.31 (10% EtOAc in pet. spirits).  
m.p 71–74 °C. 
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1H NMR (270 MHz, CDCl3) δ 0.88 (3H, t, J = 6.4 Hz, CH3), 1.25–1.41 (27H, m, 13 × 
CH2, H10s), 1.59–1.66 (2H, m, CHCH2), 1.78 (1H, dd, J = 10.7, 1.4 Hz, H10a), 2.64–
2.66 (2H, m, H1, H7), 2.72 (1H, d, J = 4.9 Hz, H9), 3.22 (1H, app. t, J = 4.9 Hz, H8), 
3.70 (6H, s, 2 × Me), 3.90 (1H, d, J = 5.4 Hz, H6), 4.03 (1H, d, J = 5.4 Hz, H2), 4.65 (1H, 
t, J = 4.8 Hz, H4). 
13C NMR (67.5 MHz, CDCl3) δ 14.3, 22.8, 24.4, 29.5, 29.6, 29.7 (2 × C), 29.8 (6 × C), 
31.8, 32.1, 32.9, 43.4, 43.8, 45.2, 45.4, 52.3, 52.5, 78.9, 81.4, 104.4, 172.9, 174.1.  
HRMS (ESI, m/z) for C27H46O6 [M + H]+ calc. 467.3367; found 467.3378. 
 
Dimethyl 4-ethylbenzene-3,5-dioxatricyclo[5.2.1.02,6]decane-8-endo-9-exo-
dicarboxylate (151) 
 
Compound 151 was prepared from diol 110 (1.01 g, 4.14 mmol) and 3-
phenylpropionaldehyde (820 μL, 6.21 mmol) according to general procedure B and was 
purified by column chromatography (10% EtOAc in pet. spirits) to give the title 
compound (1.18 g, 79%) as a yellow oil. 
Rf = 0.22 (10% EtOAc in pet. spirits).  
1H NMR (270 MHz, CDCl3) δ 1.38 (1H, dd, J = 10.8, 1.4 Hz, H10s), 1.82 (1H, dd, J = 
10.8, 1.4 Hz, H10a), 1.93–2.01 (2H, m, CHCH2), 2.65–2.77 (5H, m, H1, H7, H9, ArCH2), 
3.25 (1H, app. t, J = 5.1 Hz, H8), 3.71 (3H, s, Me), 3.72 (3H, s, Me), 3.94 (1H, d, J = 
5.6 Hz, H6), 4.06 (1H, d, J = 5.6 Hz, H2), 4.70 (1H, t, J = 4.8 Hz, H4), 7.16–7.31 (5H, 
m, ArH). 
13C NMR (67.5 MHz, CDCl3) δ 30.4, 31.8, 34.4, 43.4, 43.8, 45.2, 45.4, 52.3, 52.5, 79.0, 
81.5, 103.4, 126.1, 128.46 (2 × C), 128.53 (2 × C), 141.4, 172.9, 174.1.  
HRMS (ESI, m/z) for C20H24O6 [M + H]+ calc. 361.1646; found 361.1655. 
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Dimethyl 4-[4ʹ-(octyloxy)phenethyl]-3,5-dioxatricyclo[5.2.1.02,6]decane-8-endo-9-
exo-dicarboxylate (152) 
 
Compound 152 was prepared from diol 110 (275 mg, 1.13 mmol) and aldehyde 131 
(437 mg, 1.67 mmol) according to general procedure B and was purified by column 
chromatography (5–10–20% EtOAc in pet. spirits) to give the title compound (265 mg, 
48%) as a yellow oil. 
Rf = 0.62 (20% EtOAc in pet. spirits).  
1H NMR (500 MHz, CDCl3) δ 0.88 (3H, t, J = 7.1 Hz, CH3), 1.28–1.38 (9H, m, 4 × CH2, 
H10s), 1.41–1.47 (2H, m, CH2), 1.73–1.78 (2H, m, CH2), 1.81 (1H, dd, J = 10.8, 1.5 Hz, 
H10a), 1.91–1.95 (2H, m, CH2), 2.65–2.69 (4H, m, H1, H7, ArCH2), 2.74 (1H, d, J = 
4.8 Hz, H9), 3.24 (1H, app. t, J = 4.8 Hz, H8), 3.70 (3H, s, Me), 3.71 (3H, s, Me), 3.90–
3.93 (3H, m, H6, OCH2), 4.05 (1H, d, J = 5.7 Hz, H2), 4.68 (1H, t, J = 4.8 Hz, H4), 6.79–
6.82 (2H, m, ArH), 7.07–7.09 (2H, m, ArH). 
13C NMR (125 MHz, CDCl3) δ 14.2, 22.8, 26.2, 29.4, 29.5 (3 × C), 31.8, 32.0, 34.6, 43.4, 
43.8, 45.2, 45.4, 52.3, 52.5, 68.2, 79.0, 81.5, 103.5, 114.6 (2 × C), 129.3 (2 × C), 133.2, 
157.6, 172.9, 174.1.  
HRMS (ESI, m/z) for C28H40O7 [M + K]+ calc. 527.2406; found 527.2410. 
 
4-Heptyl-3,5-dioxatricyclo[5.2.1.02,6]decane-8-endo-9-exo-dicarboxylic acid (153) 
 
The title compound was prepared from diester 148 (1.00 g, 2.82 mmol) according to 
general procedure D and isolated as a white solid (795 mg, 86%). 
m.p 141–143 °C (lit. 153.0–154.0 °C).185  
1H NMR (270 MHz, DMSO-d6) δ 0.85 (3H, t, J = 6.4 Hz, CH3), 1.19–1.33 (11H, m, 5 × 
CH2, H10s), 1.50–1.61 (3H, m, CHCH2, H10a), 2.40 (1H, d, J = 5.2 Hz, H9), 2.45 (1H, 
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br s, H7), 2.54 (1H, br s, H1), 3.00 (1H, dd, J = 5.2, 0.6 Hz, H8), 3.88 (1H, d, J = 5.6 Hz, 
H6), 3.97 (2H, d, J = 5.6 Hz, H2), 4.62 (1H, t, J = 4.7 Hz, H4). 
13C NMR (67.5 MHz, CDCl3) δ 14.0, 22.1, 23.7, 28.6, 28.9, 31.2 (2 × C), 32.3, 42.6, 
43.3, 44.4, 45.0, 78.2, 80.7, 103.2, 173.3, 174.6. 
HRMS (ESI, m/z) for C17H26O6 [M + Na]+ calc. 349.1622; found 349.1627. 
 
4-Undecanyl-3,5-dioxatricyclo[5.2.1.02,6]decane-8-endo-9-exo-dicarboxylic acid 
(154) 
 
The title compound was prepared from diester 149 (137 mg, 0.33 mmol) according to 
general procedure D and isolated as a white powder (105 mg, 83%). 
m.p 138–140 °C. 
1H NMR (500 MHz, CD3OD) δ 0.90 (3H, t, J = 6.8 Hz, CH3), 1.29–1.42 (19H, m, 9 × 
CH2, H10s), 1.59–1.63 (2H, m, CHCH2), 1.75 (1H, dd, J = 10.6, 1.1 Hz, H10a), 2.56 (1H, 
dd, J = 5.3, 1.1 Hz, H9), 2.58 (1H, br s, H7), 2.64 (1H, app. t, J = 4.4 Hz, H1), 3.17 (1H, 
app. t, J = 5.3 Hz, H8), 3.99 (1H, d, J = 5.6 Hz, H6), 4.02 (1H, d, J = 5.6 Hz, H2), 4.67 
(1H, t, J = 4.8 Hz, H4). 
13C NMR (125 MHz, CD3OD) δ 14.5, 23.8, 25.2, 30.5 (2 × C), 30.7 (3 × C), 30.8, 32.4, 
33.1, 33.9, 44.4, 44.9, 46.4, 46.6, 80.2, 82.7, 105.2, 175.5, 176.9. 
HRMS (ESI, m/z) for C21H34O6 [M + Na]+ calc. 405.2248; found 405.2254. 
 
4-Pentadecyl-3,5-dioxatricyclo[5.2.1.02,6]decane-8-endo-9-exo-dicarboxylic acid (48) 
 
The title compound was prepared from diester 150 (258 mg, 0.56 mmol) according to 
general procedure D and isolated as an off-white solid (198 mg, 80%). 
m.p 127–134 °C (lit. 125.0–127.0 °C).185  
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1H NMR (270 MHz, DMSO-d6) δ 0.85 (3H, t, J = 6.2 Hz, CH3), 1.18–1.23 (27H, m, 13 
× CH2, H10s), 1.49–1.62 (3H, m, CHCH2, H10a), 2.40 (1H, d, J = 5.0 Hz, H9), 2.45 (1H, 
br s, H7), 2.53 (1H, br s, H1), 3.00 (1H, app. t, J = 5.0 Hz, H8), 3.89 (1H, d, J = 5.6 Hz, 
H6), 3.96 (1H, d, J = 5.6 Hz, H2), 4.62 (1H, t, J = 4.7 Hz, H4). 
13C NMR (100 MHz DMSO-d6) δ 13.9, 22.1, 23.6, 28.7, 28.9 (2 × C), 29.0 (7 × C), 31.2, 
31.3, 32.3, 43.6, 43.3, 44.4, 45.0, 78.2, 80.7, 103.2, 173.3, 174.6. 
HRMS (ESI, m/z) for C25H42O6 [M + Na]+ calc. 461.2874; found 461.2882. 
 
4-Ethylbenzene-3,5-dioxatricyclo[5.2.1.02,6]decane-8-endo-9-exo-dicarboxylic acid 
(155) 
 
The title compound was prepared from diester 151 (1.13 g, 3.12 mmol) according to 
general procedure D and isolated as a white solid (805 mg, 78%). 
m.p 180–181 °C.  
1H NMR (270 MHz, DMSO-d6) δ 1.24 (1H, d, J = 10.2 Hz, H10s), 1.66 (1H, d, J = 
10.2 Hz, H10a), 1.83–1.90 (2H, m, CHCH2), 2.42 (1H, d, J = 4.5 Hz, H9), 2.50–2.52 (1H, 
m, H1), 2.58 (1H, d, J = 4.7 Hz, H7), 2.64–2.69 (2H, m, ArCH2), 3.02 (1H, app. t, J = 
4.5 Hz, H8), 3.93 (1H, d, J = 5.2 Hz, H6), 4.01 (1H, d, J = 5.2 Hz, H2), 4.67 (1H, t, J = 
4.8 Hz, H4), 7.17–7.30 (5H, m, ArH), 12.59 (2H, br s, 2 × OH). 
13C NMR (67.5 MHz, DMSO-d6) δ 29.7, 31.2, 33.9, 42.6, 43.3, 44.4, 45.0, 78.3, 80.8, 
102.5, 125.9, 128.2 (2 × C), 128.3 (2 × C), 141.2, 173.3, 174.6.  
HRMS (ESI, m/z) for C18H20O6 [M + Na]+ calc. 355.1152; found 355.1150. 
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4-[4ʹ-(Octyloxy)phenethyl]-3,5-dioxatricyclo[5.2.1.02,6]decane-8-endo-9-exo-
dicarboxylic acid (156) 
 
The title compound was prepared from diester 152 (260 mg, 0.532 mmol) according to 
general procedure D and isolated as a white solid (197 mg, 80%). 
m.p 145–147 °C.  
1H NMR (270 MHz, DMSO-d6) δ 0.85 (3H, t, J = 5.9 Hz, CH3), 1.25–1.41 (11H, m, 5 × 
CH2, H10s), 1.62–1.72 (3H, m, CH2, H10a), 1.77–1.85 (2H, m, CH2), 2.42 (1H, d, J = 
5.2 Hz, H9), 2.52–2.60 (4H, m, CH2, H7, H1), 3.02 (1H, app. t, J = 5.2 Hz, H8), 3.89–
3.92 (3H, m, OCH2, H6), 4.00 (1H, d, J = 5.6 Hz, H2), 4.64 (1H, t, J = 4.7 Hz, H4), 6.80 
(2H, d, J = 8.5 Hz, ArH), 7.09 (2H, d, J = 8.5 Hz, ArH). 
13C NMR (67.5 MHz, DMSO-d6) δ 14.0, 22.1, 25.6, 28.7 (2 × C), 28.8 (2 × C), 31.2 (2 
× C), 34.2, 42.6, 43.3, 44.4, 45.0, 67.3, 78.3, 80.8, 102.5, 114.3 (2 × C), 129.1 (2 × C), 
132.9, 156.9, 173.3, 174.6. 
HRMS (ESI, m/z) for C26H36O7 [M + Na]+ calc. 483.2352; found 483.2364. 
 
8-endo-9-exo-Di[2ʹ-(2ʺ,3ʺ-bis-tert-butoxycarbonylguanidino)ethylcarbamoyl]-4-
heptyl-3,5-dioxatricyclo[5.2.1.02,6]decane (167) 
 
Compound 167 was prepared from diacid 153 (156 mg, 0.48 mmol) and 
aminoethylguanidine 41 (434 mg, 1.43 mmol) according to general procedure E and was 
purified using column chromatography (20–70% EtOAc in pet. spirits) to give the title 
compound (274 mg, 64%) as a white solid. 
Rf = 0.38 (70% EtOAc in pet. spirits).  
m.p 103–128 °C (slow decomposition). 
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1H NMR (270 MHz, CDCl3) δ 0.86 (3H, t, J = 6.7 Hz, CH3), 1.25 (12H, br s, 6 × CH2), 
1.48–1.63 (37H, m, 4 × t-Bu, H10s), 1.72–1.83 (1H, m, H10a), 2.44 (1H, d, J = 5.9 Hz, 
H1), 2.57 (1H, br s, H7), 2.70 (1H, d, J = 4.2 Hz, H9), 2.94 (1H, app. t, J = 4.2 Hz, H8), 
3.31–3.40 (4H, m, 2 × NHCH2), 3.51–3.61 (4H, m, 2 × NHCH2), 3.95 (1H, d, J = 5.5 Hz, 
H2), 4.03 (1H, d, J = 5.5 Hz, H6), 4.60 (1H, t, J = 4.8 Hz, H4), 6.87 (1H, t, J = 5.4 Hz, 
NH), 8.04 (1H, t, J = 4.1 Hz, NH), 8.51 (1H, t, J = 5.3 Hz, NH), 8.64 (1H, t, J = 5.7 Hz, 
NH), 11.45 (1H, s, NH), 11.48 (1H, s, NH). 
13C NMR (67.5 MHz, CDCl3) δ 14.2, 22.8, 24.3, 28.2, 28.4, 29.3, 29.7, 31.9, 32.5, 33.0, 
40.0, 40.1, 40.2, 42.3, 43.0, 44.3, 44.4, 47.8, 79.0, 79.6, 79.9, 81.7, 83.4, 83.7, 104.1, 
153.2 (2 × C), 157.1, 157.9, 163.0, 163.5, 172.0, 174.3.   
HRMS (ESI, m/z) for C43H74N8O12 [M + H]+ calc. 895.5499; found 895.5511. 
 
8-endo-9-exo-Di[2ʹ-(2ʺ,3ʺ-bis-tert-butoxycarbonylguanidino)ethylcarbamoyl]-4-
undecanyl-3,5-dioxatricyclo[5.2.1.02,6]decane (168) 
 
Compound 168 was prepared from diacid 154 (95 mg, 0.25 mmol) and 
aminoethylguanidine 41 (230 mg, 0.78 mmol) according to general procedure E and was 
purified using column chromatography (50–70% EtOAc in pet. spirits) to give the title 
compound (116 mg, 49%) as a colourless oil. 
Rf = 0.50 (70% EtOAc in pet. spirits).  
1H NMR (500 MHz, CDCl3) δ 0.87 (3H, t, J = 6.2 Hz, CH3), 1.24–1.37 (18H, m, 9 × 
CH2), 1.49–1.50 (37H, m, 4 × t-Bu, H10s), 1.57–1.62 (2H, m, CHCH2), 1.77 (1H, d, J = 
10.4 Hz, H10a), 2.45 (1H, d, J = 5.8 Hz, H1), 2.58 (1H, br s, H7), 2.69 (1H, d, J = 4.7 Hz, 
H9), 2.94 (1H, app. t, J = 4.7 Hz, H8), 3.34–3.44 (4H, m, 2 × NHCH2), 3.55–3.59 (4H, 
m, 2 × NHCH2), 3.95 (1H, d, J = 5.7 Hz, H2), 4.02 (1H, d, J = 5.7 Hz, H6), 4.60 (1H, t, 
J = 4.9 H4), 6.88 (1H, br s, NH), 8.04 (1H, t, J = 4.0 Hz, NH), 8.55 (1H, br s, NH), 8.65 
(1H, br s, NH), 11.45 (1H, s, NH), 11.48 (1H, s, NH). 
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13C NMR (125 MHz, CDCl3) δ 14.3, 22.8, 24.4, 28.18, 28.19, 28.4, 29.5 (2 × C), 29.66 
(2 × C), 29.72, 29.75, 29.80, 32.0, 32.5, 33.0, 40.0 (2 × C), 40.3, 42.2, 43.0, 44.2, 44.3, 
47.8, 79.0, 79.8, 80.1, 81.6, 83.5, 83.8, 104.1, 153.17, 153.19, 157.0, 157.8, 162.7, 163.2, 
172.0, 174.2.  
HRMS (ESI, m/z) for C47H82N8O12 [M + H]+ calc. 951.6125; found 951.6131. 
 
8-endo-9-exo-Di[2ʹ-(2ʺ,3ʺ-bis-tert-butoxycarbonylguanidino)ethylcarbamoyl]-4-
pentadecyl-3,5-dioxatricyclo[5.2.1.02,6]decane (49) 
 
Compound 49 was prepared from diacid 48 (69 mg, 0.16 mmol) and aminoethylguanidine 
41 (140 mg, 0.47 mmol) according to general procedure E and was purified using column 
chromatography (20–70% EtOAc in pet. spirits) to give the title compound (117 mg, 
74%) as a colourless oil. 
Rf = 0.47 (70% EtOAc in pet. spirits).  
1H NMR (500 MHz, CDCl3) δ 0.87 (3H, t, J = 6.8 Hz, CH3), 1.24–1.39 (27H, m, 13 × 
CH2, H10s), 1.49–1.50 (36H, m, 4 × t-Bu), 1.58–1.62 (2H, m, CHCH2), 1.78 (1H, d, J = 
9.6 Hz, H10a), 2.44 (1H, d, J = 5.6 Hz, H1), 2.57 (1H, br s, H7), 2.70 (1H, d, J = 5.4 Hz, 
H9), 2.94 (1H, app. t, J = 5.4 Hz, H8), 3.34–3.44 (4H, m, 2 × NHCH2), 3.52–3.58 (4H, 
m, 2 × NHCH2), 3.95 (1H, d, J = 5.6 Hz, H2), 4.03 (1H, d, J = 5.6 Hz, H6), 4.61 (1H, t, 
J = 4.8 Hz, H7), 6.87 (1H, t, J = 5.2 Hz, NH), 8.00 (1H, t, J = 4.2 Hz, NH), 8.50 (1H, t, J 
= 5.7 Hz, NH), 8.63 (1H, t, J = 6.1 Hz, NH), 11.45 (1H, s, NH), 11.47 (1H, s, NH). 
13C NMR (125 MHz, CDCl3) δ 14.3, 22.8, 24.4, 28.20, 28.21, 28.40, 28.41, 29.5, 29.67, 
29.69, 29.74, 29.80 (2 × C), 29.81, 29.84 (3 × C), 32.1, 32.5, 33.0, 40.0, 40.1, 40.2, 42.2, 
43.0, 44.3, 44.4, 47.8, 79.0, 79.7, 79.9, 81.7, 83.4, 83.7, 104.1, 153.2 (2 × C), 157.1, 
157.9, 163.0, 163.5, 172.1, 174.2.   
HRMS (ESI, m/z) for C51H90N8O12 [M + H]+ calc. 1007.6751; found 1007.6771. 
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8-endo-9-exo-Di[2ʹ-(2ʺ,3ʺ-bis-tert-butoxycarbonylguanidino)ethylcarbamoyl]-4-
ethylbenzene-3,5-dioxatricyclo[5.2.1.02,6]decane (169) 
 
Compound 169 was prepared from diacid 155 (203 mg, 0.61 mmol) and 
aminoethylguanidine 41 (550 mg, 1.83 mmol) according to general procedure F and was 
purified using column chromatography (50% EtOAc in pet. spirits) to give the title 
compound (242 mg, 44%) as a white waxy solid. 
Rf = 0.39 (70% EtOAc in pet. spirits).  
1H NMR (270 MHz, CDCl3) δ 1.49–1.51 (37H, m, 4 × t-Bu, H10s), 1.82 (1H, d, J = 
10.6 Hz, H10a), 1.90–1.98 (2H, m, CH2), 2.46 (1H, d, J = 6.2 Hz, H1), 2.61 (1H, br s, 
H7), 2.70–2.76 (3H, m, ArCH2, H9), 2.96 (1H, app. t, J = 5.9 Hz, H8), 3.35–3.62 (8H, m, 
4 × NHCH2), 3.98 (1H, d, J = 5.5 Hz, H2), 4.07 (1H, d, J = 5.5 Hz, H6), 4.66 (1H, t, J = 
4.7 Hz, H4), 6.88 (1H, t, J = 5.3 Hz, NH), 7.16–7.30 (5H, m, ArH), 8.05 (1H, t, J = 3.1 Hz, 
NH), 8.51 (1H, t, J = 5.9 Hz, NH), 8.65 (1H, t, J = 5.7 Hz, NH), 11.47 (1H, s, NH), 11.48 
(1H, s, NH). 
13C NMR (67.5 MHz, CDCl3) δ 28.2, 28.4, 30.4, 32.5, 34.5, 40.0, 40.2 (2 × C), 42.3, 
43.0, 44.3, 44.4, 47.8, 79.2, 79.7, 79.9, 81.8, 83.4, 83.7, 103.2, 126.1, 128.5 (4 × C), 
141.6, 153.2 (2 × C), 157.1, 158.0, 163.0, 163.5, 172.0, 174.8. 
HRMS (ESI, m/z) for C44H68N8O12 [M + H]+ calc. 901.5030; found 901.5052. 
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8-endo-9-exo-Di[2ʹ-(2ʺ,3ʺ-bis-tert-butoxycarbonylguanidino)ethylcarbamoyl]-4-[4ʹ-
(octyloxy)phenethyl]-3,5-dioxatricyclo[5.2.1.02,6]decane (170) 
 
Compound 170 was prepared from diacid 156 (89 mg, 0.19 mmol) and 
aminoethylguanidine 41 (180 mg, 0.57 mmol) according to general procedure E and was 
purified using column chromatography (50–70% EtOAc in pet. spirits) to give the title 
compound (81 mg, 41%) as a colourless oil. 
Rf = 0.38 (70% EtOAc in pet. spirits).  
1H NMR (500 MHz, CDCl3) δ 0.88 (3H, t, J = 6.4 Hz, CH3), 1.25–1.36 (8H, m, 4 × CH2), 
1.40–1.54 (39H, m, CH2, 4 × t-Bu, H10s), 1.73–1.78 (2H, m, CHCH2), 1.81 (1H, d, J = 
10.2 Hz, H10a), 1.87–1.92 (2H, m, CH2), 2.46 (1H, d, J = 5.5 Hz, H1), 2.60 (1H, s, H7), 
2.64–2.68 (2H, m, ArCH2), 2.74 (1H, d, J = 4.8 Hz, H9), 2.96 (1H, app. t, J = 4.8 Hz, 
H8), 3.35–3.45 (4H, m, 2 × NHCH2), 3.55–3.61 (4H, m, 2 × NHCH2), 3.91 (2H, t, J = 
6.6 Hz, OCH2), 3.98 (1H, d, J = 5.7 Hz, H6), 4.06 (1H, d, J = 5.7 Hz, H2), 4.64 (1H, t, J 
= 4.6 Hz, H4), 6.80 (2H, d, J = 8.5 Hz, ArH), 6.90 (1H, br s, NH), 7.07 (2H, d, J = 8.5 Hz, 
ArH), 8.03 (1H, t, J = 4.2 Hz, NH), 8.53 (1H, br s, NH), 8.65 (1H, t, J = 4.1 Hz, NH), 
11.47–11.48 (2H, m, 2 × NH). 
13C NMR (125 MHz, CDCl3) δ 14.2, 22.8, 26.2, 28.19, 28.21, 28.40, 28.41, 29.4, 29.5 (3 
× C), 32.0, 32.5, 34.8, 40.1 (2 × C), 40.3, 42.2, 43.0, 44.3, 44.4, 47.8, 68.2, 79.1, 79.9, 
80.1, 81.8, 83.5, 83.8, 103.3, 114.6 (2 × C), 129.3 (2 × C), 133.5, 153.2 (2 × C), 157.0, 
157.5, 157.9, 162.9, 163.3, 172.0, 174.1.  
HRMS (ESI, m/z) for C52H84N8O13 [M + H]+ calc. 1029.6231; found 1029.6253. 
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8-endo-9-exo-Di[3ʹ-(2ʺ,3ʺ-bis-tert-butoxycarbonylguanidino)propylcarbamoyl]-4-
heptyl-3,5-dioxatricyclo[5.2.1.02,6]decane (173) 
 
Compound 173 was prepared from diacid 153 (170 mg, 0.52 mmol) and 
aminopropylguanidine 171 (968 mg, 3.06 mmol) according to general procedure F and 
was purified using column chromatography (20–50% EtOAc in CH2Cl2) to give the title 
compound (234 mg, 49%) as a white residue. 
Rf = 0.41 (50% EtOAc in CH2Cl2).  
1H NMR (500 MHz, CDCl3) δ 0.86 (3H, t, J = 6.5 Hz, CH3), 1.23–1.27 (8H, m, 4 × CH2), 
1.36–1.41 (2H, m, CH2), 1.49–1.51 (36H, m, 4 × t-Bu), 1.57 (1H, d, J = 10.2 Hz, H10s), 
1.60–1.72 (6H, m, 3 × CH2), 1.77 (1H, d, J = 10.2 Hz, H10a), 2.54 (1H, br s, H7), 2.56 
(1H, d, J = 5.3 Hz, H1), 2.76 (1H, d, J = 4.2 Hz, H9), 3.05–3.19 (3H, m, NHCH2, H8), 
3.29–3.42 (4H, m, 2 × NHCH2), 3.47–3.63 (2H, m, NHCH2), 4.03 (1H, d, J = 5.7 Hz, 
H2), 4.05 (1H, d, J = 5.7 Hz, H6), 4.63 (1H, t, J = 4.8 Hz, H4), 6.85 (1H, t, J = 5.1 Hz, 
NH), 7.62 (1H, t, J = 5.7 Hz, NH), 8.45 (2H, br s, 2 × NH), 11.46 (1H, s, NH), 11.49 (1H, 
s, NH). 
13C NMR (125 MHz, CDCl3) δ 14.2, 22.7, 24.3, 28.2, 28.4, 28.5, 29.3, 29.7, 29.8, 30.0, 
31.9, 32.3, 33.0, 35.5, 36.5, 37.4, 38.0, 43.6, 44.1, 45.5, 47.3, 79.0, 79.9 (2 × C), 81.8, 
83.5, 83.6, 104.0, 153.29, 153.34, 156.7, 157.2, 163.2 (2 × C), 171.8, 174.0.   
HRMS (ESI, m/z) for C45H78N8O12 [M + H]+ calc. 923.5812; found 923.5822. 
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8-endo-9-exo-Di[4ʹ-(2ʺ,3ʺ-bis-tert-butoxycarbonylguanidino)butylcarbamoyl]-4-
heptyl-3,5-dioxatricyclo[5.2.1.02,6]decane (174) 
 
Compound 174 was prepared from diacid 153 (251 mg, 0.77 mmol) and 
aminobutylguanidine 172 (1.03 g, 3.12 mmol) according to general procedure F and was 
purified using column chromatography (20–50% EtOAc in CH2Cl2) to give the title 
compound (234 mg, 49%) as a white residue. 
Rf = 0.48 (50% EtOAc in CH2Cl2).  
1H NMR (500 MHz, CDCl3) δ 0.86 (3H, t, J = 6.8 Hz, CH3), 1.25–1.28 (10H, m, 5 × 
CH2), 1.37–1.63 (47H, m, 4 × t-Bu, 5 × CH2, H10s), 1.80 (1H, d, J = 9.7 Hz, H10a), 2.43 
(1H, d, J = 5.7 Hz, H9), 2.56–2.57 (2H, m, H1, H7), 2.93 (1H, dd, J = 5.7, 4.7 Hz, H8), 
3.19–3.47 (8H, m, 4 × NHCH2), 3.98 (1H, d, J = 5.6 Hz, H2), 4.09 (1H, d, J = 5.6 Hz, 
H6), 4.64 (1H, t, J = 4.8 Hz, H4), 6.25–6.44 (2H, m, 2 × NH), 8.38–8.43 (2H, m, 2 × NH), 
11.48 (1H, s, NH), 11.50 (1H, s, NH). 
13C NMR (125 MHz, CDCl3) δ 14.2, 22.8, 24.4, 26.5, 26.8, 26.9, 27.0, 28.2, 28.41, 28.42, 
29.3, 29.7, 31.9, 32.6, 33.0, 39.3, 39.5, 40.7, 40.8, 43.4, 44.4, 44.6, 47.9, 78.8, 79.9, 80.1, 
81.7, 83.5, 83.6, 104.2, 153.4 (2 × C), 156.2 (2 × C), 163.2 (2 × C), 171.9, 173.6.   
HRMS (ESI, m/z) for C47H82N8O12 [M + H]+ calc. 951.6125; found 951.6137. 
 
8-endo-9-exo-Di[2ʹ-(2ʺ,3ʺ-bis-tert-butoxycarbonylamino)ethylcarbamoyl]-4-heptyl-
3,5-dioxatricyclo[5.2.1.02,6]decane (175) 
 
Compound 175 was prepared from diacid 153 (333 mg, 1.02 mmol) and BocEDA 51 
(490 mg, 3.06 mmol) according to general procedure F and was purified using column 
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chromatography (50–70% EtOAc in pet. spirits–EtOAc) to give the title compound 
(357 mg, 57%) as a white solid. 
Rf = 0.21 (70% EtOAc in pet. spirits).  
m.p 122–123 °C. 
1H NMR (270 MHz, CDCl3) δ 0.87 (3H, t, J = 6.9 Hz, CH3), 1.25–1.44 (28H, m, 5 × 
CH2, 2 × t-Bu), 1.57–1.65 (3H, m, CHCH2, H10s), 1.80 (1H, d, J = 10.3 Hz, H10a), 2.43 
(1H, d, J = 5.0 Hz, H1), 2.53–2.57 (2H, m, H7, H9), 2.92 (1H, app. t, J = 5.1 Hz, H8), 
3.26–3.41 (8H, m, 4 × NHCH2), 3.96 (1H, d, J = 5.7 Hz, H2), 4.13 (1H, d, J = 5.7 Hz, 
H6), 4.64 (1H, t, J = 4.8 Hz, H4), 5.01–5.08 (2H, m, 2 × NH), 6.89 (1H, br s, NH), 6.86 
(1H, br s, NH). 
13C NMR (67.5 MHz, CDCl3) δ 14.2, 22.8, 24.4, 28.5, 29.3, 29.6, 29.8, 31.9, 32.6, 33.0, 
40.4, 40.6, 41.2, 43.4 (2 × C), 44.5, 44.7, 47.8, 78.8, 79.8, 80.0, 81.6, 104.2, 156.8, 157.1, 
172.5, 174.3.   
HRMS (ESI, m/z) for C31H54N4O8 [M + H]+ calc. 611.4014; found 611.4031. 
 
8-endo-9-exo-Di[2ʹ-(2ʺ,3ʺ-bis-tert-butoxycarbonylamino)ethylcarbamoyl]-4-
undecanyl-3,5-dioxatricyclo[5.2.1.02,6]decane (176) 
 
Compound 176 was prepared from diacid 154 (512 mg, 1.34 mmol) and BocEDA 51 
(670 mg, 4.18 mmol) according to general procedure F and was purified using column 
chromatography (50% EtOAc in pet. spirits–EtOAc) to give the title compound (542 mg, 
61%) as a white residue. 
Rf = 0.43 (EtOAc).  
1H NMR (500 MHz, CDCl3) δ 0.87 (3H, t, J = 7.1 Hz, CH3), 1.24–1.39 (18H, m, 9 × 
CH2), 1.43–1.44 (18H, m, 2 × t-Bu), 1.49 (1H, d, J = 10.2 Hz, H10s), 1.60–1.64 (2H, m, 
CHCH2), 1.81 (1H, d, J = 10.2 Hz, H10a), 2.40 (1H, d, J = 5.7 Hz, H9), 2.54 (1H, d, J = 
4.3 Hz, H7), 2.59 (1H, br s, H1), 2.88 (1H, dd, J = 5.7, 4.3 Hz, H8), 3.22–3.44 (8H, m, 4 
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× NHCH2), 3.96 (1H, d, J = 5.6 Hz, H2), 4.13 (1H, d, J = 5.6 Hz, H6), 4.64 (1H, t, J = 
4.8 Hz, H4), 4.92–5.02 (2H, m, 2 × NH), 6.63 (1H, br s, NH), 6.77 (1H, br s, NH). 
13C NMR (125 MHz, CDCl3) δ 14.3, 22.8, 24.4, 28.52, 28.53, 29.5, 29.67, 29.68, 29.71, 
29.76, 29.79, 32.1, 32.6, 33.0, 40.4, 40.5, 40.7, 41.2, 43.3, 44.4, 44.5, 48.0, 78.7, 79.9, 
80.1, 81.6, 104.2, 156.8, 157.1, 172.5, 174.3.   
HRMS (ESI, m/z) for C35H62N4O8 [M + H]+ calc. 667.4640; found 667.4656. 
 
8-endo-9-exo-Di[2ʹ-(2ʺ,3ʺ-bis-tert-butoxycarbonylamino)ethylcarbamoyl]-4-
pentadecyl-3,5-dioxatricyclo[5.2.1.02,6]decane (177) 
 
Compound 177 was prepared from diacid 48 (100 mg, 0.23 mmol) and BocEDA 51 
(110 mg, 0.68 mmol) according to general procedure F and was purified using column 
chromatography (50–70% EtOAc in pet. spirits) to give the title compound (76 mg, 46%) 
as a colourless oil. 
Rf = 0.07 (70% EtOAc in pet. spirits).  
1H NMR (500 MHz, CDCl3) δ 0.87 (3H, t, J = 6.9 Hz, CH3), 1.24–1.39 (27H, m, 13 × 
CH2, H10s), 1.43–1.44 (18H, m, 2 × t-Bu), 1.59–1.64 (2H, m, CHCH2), 1.81 (1H, d, J = 
9.8 Hz, H10a), 2.42 (1H, d, J = 5.3 Hz, H9), 2.54 (1H, d, J = 3.7 Hz, H7), 2.57 (1H, br s, 
H1), 2.91 (1H, app. t, J = 5.3 Hz, H8), 3.22–3.43 (8H, m, 4 × NHCH2), 3.96 (1H, d, J = 
5.2 Hz, H2), 4.13 (1H, d, J = 5.2 Hz, H6), 4.64 (1H, t, J = 4.9 Hz, H4), 5.01–5.08 (2H, 
m, 2 × NH), 6.69 (1H, br s, NH), 6.84 (1H, br s, NH). 
13C NMR (125 MHz, CDCl3) δ 14.3, 22.8, 24.4, 28.53, 28.55, 29.5, 29.67, 29.69, 29.72, 
29.80 (2 × C), 29.81 (2 × C), 29.84 (2 × C), 32.1, 32.6, 33.0, 34.0, 40.5, 40.6, 41.1, 43.4, 
44.5, 44.6, 47.8, 78.7, 79.8, 80.0, 81.6, 104.2, 156.8, 157.1, 172.5, 174.3.    
HRMS (ESI, m/z) for C39H70N4O8 [M + H]+ calc. 723.5266; found 723.5263. 
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8-endo-9-exo-Di[2ʹ-(2ʺ,3ʺ-bis-tert-butoxycarbonylamino)ethylcarbamoyl]-4-[4ʹ-
(octyloxy)phenethyl]-3,5-dioxatricyclo[5.2.1.02,6]decane (178) 
 
Compound 178 was prepared from diacid 156 (51 mg, 0.11 mmol) and BocEDA 51 
(78 mg, 0.49 mmol) according to general procedure F and was purified using column 
chromatography (50% EtOAc in CH2Cl2–EtOAc) to give the title compound (29 mg, 
35%) as a colourless oil. 
Rf = 0.34 (EtOAc).  
1H NMR (500 MHz, CDCl3) δ 0.88 (3H, t, J = 6.9 Hz, CH3), 1.25–1.36 (8H, m, 4 × CH2), 
1.42–1.43 (20H, m, CH2, 2 × t-Bu), 1.51 (1H, d, J = 10.1 Hz, H10s), 1.72–1.77 (2H, m, 
CH2), 1.81 (1H, d, J = 10.1 Hz, H10a), 1.88–1.92 (2H, m, CH2), 2.51 (1H, d, J = 5.1 Hz, 
H9), 2.56 (1H, s, H7), 2.59 (1H, d, J = 3.7 Hz, H1), 2.65 (2H, t, J = 8.1 Hz, ArCH2), 3.05 
(1H, app. t, J = 5.1 Hz, H8), 3.25–3.34 (8H, m, 4 × NHCH2), 3.91 (2H, t, J = 6.6 Hz, 
OCH2), 4.00 (1H, d, J = 5.4 Hz, H6), 4.13 (1H, d, J = 5.4 Hz, H2), 4.66 (1H, t, J = 4.7 Hz, 
H4), 5.27 (2H, br s, 2 × NH), 6.79 (2H, d, J = 8.6 Hz, ArH), 6.97 (1H, br s, NH), 7.06 
(2H, d, J = 8.6 Hz, ArH), 7.20 (1H, br s, NH). 
13C NMR (125 MHz, CDCl3) δ 14.2, 22.8, 26.2, 28.52, 28.53, 29.4 (2 × C), 29.5, 29.8, 
31.9, 32.4, 34.8, 40.4 (2 × C), 40.8 (2 × C), 43.7, 44.4, 45.5, 47.1, 68.1, 78.9, 79.7, 79.9, 
81.7, 103.2, 114.5 (2 × C), 129.2 (2 × C), 133.4, 156.8, 157.0, 157.5, 172.5, 174.4.  
HRMS (ESI, m/z) for C40H64N4O9 [M + H]+ calc. 745.4746; found 745.4768. 
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4-Pentadecyl-3,5-dioxatricyclo[5.2.1.02,6]decane-8-endo-9-exo-
dicarboxamidoethylguanidine hydrogen 2,2,2-trifluoroacetate (31)185 
 
To a stirring solution of Boc-protected guanidine 49 (58 mg, 0.06 mmol) in CH2Cl2 
(1.2 mL) was added TFA (420 μL, 5.5 mmol) and the reaction was stirred at ambient 
temperature for 48 h. The solvent was removed under reduced pressure and the crude 
material was co-evaporated with CHCl3 (2 × 1 mL) and concentrated in vacuo to give the 
title compound (29 mg, 60%) as a yellow resin. 
1H NMR (500 MHz, CD3OD) δ 0.90 (3H, t, J = 6.8 Hz, CH3), 1.29–1.41 (26H, m, 13 × 
CH2) 1.47 (1H, d, J = 10.1 Hz, H10s), 1.54–1.61 (2H, m, CHCH2), 1.74 (1H, d, J = 
10.1 Hz, H10a), 2.44 (1H, br s, H1), 2.60–2.61 (2H, m, H9, H7), 3.21 (1H, app. t, J = 
4.7 Hz, H8), 3.28–3.42 (8H, m, 4 × NHCH2), 3.99 (1H, d, J = 5.6 Hz, H2), 4.04 (1H, d, J 
= 5.6 Hz, H6), 4.56 (1H, t, J = 4.7 Hz, H4). 
13C NMR (125 MHz, CD3OD) δ 14.4, 23.7, 25.2, 28.2, 30.5, 30.7 (2 × C), 30.75 (4 × C), 
30.77 (2 × C), 32.7, 33.1, 33.9, 39.6, 39.7, 41.9 (2 × C), 44.9, 45.1, 46.8, 47.7, 79.9, 82.9, 
105.1, 158.9 (2 × C), 174.7, 176.6. 
HRMS (ESI, m/z) for C31H58N8O4 [M + 2H]2+ calc. 304.2363; found 304.2368.  
 
4-Heptyl-3,5-dioxatricyclo[5.2.1.02,6]decane-8-endo-9-exo-
dicarboxamidoethylguanidine hydrogen chloride (179)  
 
Compound 179 was synthesised from Boc-protected guanidine 167 (156 mg, 0.17 mmol) 
according to general procedure G and isolated as a white residue (94 mg, 95%). 
211 | P a g e  
 
1H NMR (270 MHz, CD3OD) δ 0.90 (3H, t, J = 6.5 Hz, CH3), 1.29 (10H, m, 5 × CH2), 
1.45–1.61 (3H, m, CHCH2, H10s), 1.74 (1H, d, J = 9.6 Hz, H10a), 2.45 (1H, br s, H9), 
2.61–2.63 (2H, m, H1, H7), 3.22 (1H, app. t, J = 4.9 Hz, H8), 3.30–3.39 (8H, m, 4  × 
NHCH2), 4.00 (1H, d, J = 5.6 Hz, H6), 4.05 (1H, d, J = 5.6 Hz, H2), 4.66 (1H, t, J = 
4.7 Hz, H4). 
13C NMR (67.5 MHz, CD3OD) δ 14.4, 23.7, 25.2, 28.2, 30.3, 30.6, 32.7, 32.9, 33.9, 39.6, 
39.7, 41.9, 44.9, 45.1, 46.9, 47.7, 80.0, 82.9, 105.1, 153.6, 158.9, 174.7, 176.6. 
HRMS (ESI, m/z) for C23H42N8O4 [M + 2H]2+ calc. 248.1737; found 248.1744. 
 
4-Undecanyl-3,5-dioxatricyclo[5.2.1.02,6]decane-8-endo-9-exo-
dicarboxamidoethylguanidine hydrogen chloride (4230)  
 
Compound 180 was synthesised from Boc-protected guanidine 168 (93 mg, 0.10 mmol) 
according to general procedure G and isolated as a colourless residue (52 mg, 85%). 
1H NMR (500 MHz, CD3OD) δ 0.90 (3H, t, J = 6.8 Hz, CH3), 1.29–1.40 (18H, m, 9 × 
CH2), 1.47 (1H, d, J = 10.2 Hz, H10s), 1.57–1.61 (2H, m, CHCH2), 1.73 (1H, d, J = 
10.2 Hz, H10a), 2.46 (1H, br s, H9), 2.62–2.63 (2H, m, H1, H7), 3.22 (1H, app. t, J = 
4.9 Hz, H8), 3.30–3.39 (8H, m, 4 × NHCH2), 4.00 (1H, d, J = 5.6 Hz, H6), 4.05 (1H, d, J 
= 5.6 Hz, H2), 4.66 (1H, t, J = 4.7 Hz, H4). 
13C NMR (125 MHz, CD3OD) δ 14.5, 23.7, 25.2, 30.5 (2 × C), 30.66 (2 × C), 30.74, 30.8, 
32.7, 33.1, 33.9, 39.6, 39.7, 41.9, 42.0, 44.9, 45.1, 46.9, 47.7, 79.9, 82.8, 105.1, 158.8, 
158.9, 174.6, 176.5. 
HRMS (ESI, m/z) for C27H50N8O4 [M + 2H]2+ calc. 276.2050; found 276.2057. 
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4-Pentadecyl-3,5-dioxatricyclo[5.2.1.02,6]decane-8-endo-9-exo-
dicarboxamidoethylguanidine hydrogen chloride (181)  
 
Compound 181 was synthesised from Boc-protected guanidine 49 (58 mg, 0.06 mmol) 
according to general procedure G and isolated as an off-white residue (34 mg, 87%). 
1H NMR (500 MHz, CD3OD) δ 0.90 (3H, t, J = 6.9 Hz, CH3), 1.29–1.45 (26H, m, 13 × 
CH2), 1.47 (1H, d, J = 10.1 Hz, H10s), 1.58–1.62 (2H, m, CHCH2), 1.74 (1H, d, J = 
10.1 Hz, H10a), 2.45 (1H, br s, H1), 2.61–2.62 (2H, m, H7, H9), 3.22 (1H, app. t, J = 
4.7 Hz, H8), 3.30–3.39 (8H, m, 4 × NHCH2), 3.99 (1H, d, J = 5.6 Hz, H2), 4.04 (1H, d, J 
= 5.6 Hz, H6), 4.66 (1H, t, J = 4.8 Hz, H4). 
13C NMR (125 MHz, CD3OD) δ 14.4, 23.7, 25.2, 28.2, 30.5, 30.6, 30.70 (2 × C), 30.73, 
30.74 (2 × C), 30.8 (2 × C), 32.7, 33.1, 33.9, 39.6, 39.7, 41.9, 42.0, 44.9, 45.1, 46.9, 47.7, 
80.0, 82.9, 105.1, 158.9 (2 × C), 174.6, 176.6. 
HRMS (ESI, m/z) for C31H58N8O4 [M + 2H]2+ calc. 304.2363; found 304.2374. 
 
4-Ethylbenzene-3,5-dioxatricyclo[5.2.1.02,6]decane-8-endo-9-exo-
dicarboxamidoethylguanidine hydrogen chloride (182)  
 
Compound 182 was synthesised from Boc-protected guanidine 169 (242 mg, 0.27 mmol) 
according to general procedure G and isolated as a white solid (145 mg, 93%). 
m.p 133–149 °C (slow decomposition). 
1H NMR (500 MHz, CD3OD) δ 1.50 (1H, d, J = 10.5 Hz, H10s), 1.78 (1H, d, J = 10.5 Hz, 
H10a), 1.88–1.92 (2H, m, CHCH2), 2.49 (1H, br s, H9), 2.62–2.66 (2H, m, H1, H7), 2.69–
2.72 (2H, m, ArCH2), 3.23 (1H, app. t, J = 5.0 Hz, H8), 3.29–3.40 (8H, m, 4  × NHCH2), 
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4.02 (1H, d, J = 5.6 Hz, H6), 4.08 (1H, d, J = 5.6 Hz, H2), 4.68 (1H, t, J = 4.8 Hz, H4), 
7.14–7.18 (3H, m, ArH), 7.23–7.27 (2H, m, ArH). 
13C NMR (125 MHz, CD3OD) δ 31.3, 32.8, 35.8, 39.6, 39.7, 41.9, 42.0, 44.9, 45.1, 47.0, 
47.7, 80.1, 83.0, 101.3, 127.0, 129.3 (2 × C), 129.5 (2 × C), 142.7, 158.9 (2 × C), 174.6, 
176.5. 
HRMS (ESI, m/z) for C24H36N8O4 [M + 2H]2+ calc. 251.1503; found 251.1510. 
 
4-[4ʹ-(Octyloxy)phenethyl]-3,5-dioxatricyclo[5.2.1.02,6]decane-8-endo-9-exo-
dicarboxamidoethylguanidine hydrogen chloride (183)  
 
Compound 183 was synthesised from Boc-protected guanidine 170 (78 mg, 0.08 mmol) 
according to general procedure G and isolated as a yellow oil (39 mg, 74%). 
1H NMR (500 MHz, CD3OD) δ 0.90 (3H, t, J = 6.9 Hz, CH3), 1.28–1.35 (8H, m, 4 × 
CH2) 1.44–1.53 (3H, m, CH2, H10s), 1.71–1.78 (3H, m, CH2, H10a), 1.84–1.88 (2H, m, 
CH2), 2.49 (1H, br s, H1), 2.62–2.65 (4H, m, ArCH2, H7, H9), 3.23 (1H, app. t, J = 5.0 Hz, 
H8), 3.30–3.39 (8H, m, 4 × NHCH2), 3.92 (2H, t, J = 6.5 Hz, OCH2), 4.02 (1H, d, J = 
5.6 Hz, H6), 4.07 (1H, d, J = 5.6 Hz, H2), 4.67 (1H, t, J = 4.4 Hz, H4), 6.79–6.81 (2H, 
m, ArH), 7.06–7.09 (2H, m, ArH). 
13C NMR (125 MHz, CD3OD) δ 14.4, 23.7, 27.2, 30.4, 30.46, 30.49, 30.7, 32.8, 33.0, 
36.0, 39.6, 39.7, 41.9, 42.0, 44.9, 45.1, 47.0, 47.6, 69.0, 80.1, 82.9, 104.3, 115.5 (2 × C), 
130.2 (2 × C), 134.6, 158.9 (3 × C), 174.6, 176.5. 
HRMS (ESI, m/z) for C32H52N8O5 [M + 2H]2+ calc. 315.2103; found 315.2109. 
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4-Heptyl-3,5-dioxatricyclo[5.2.1.02,6]decane-8-endo-9-exo-
dicarboxamidopropylguanidine hydrogen chloride (184)  
 
Compound 184 was synthesised from Boc-protected guanidine 173 (139 mg, 0.15 mmol) 
according to general procedure G and isolated as a white solid (66 mg, 74%). 
m.p 142–146 °C. 
1H NMR (500 MHz, CD3OD) δ 0.90 (3H, t, J = 6.8 Hz, CH3), 1.29–1.42 (10H, m, 5 × 
CH2), 1.48 (1H, d, J = 10.4 Hz, H10s), 1.58–1.62 (2H, m, CHCH2), 1.71–1.79 (5H, m, 2 
× CH2, H10a), 2.42 (1H, br s, H9), 2.59–2.60 (2H, m, H1, H7), 3.18–3.29 (9H, m, 4 × 
NHCH2, H8), 3.99 (1H, d, J = 5.6 Hz, H6), 4.05 (1H, d, J = 5.6 Hz, H2), 4.66 (1H, t, J = 
4.8 Hz, H4). 
13C NMR (125 MHz, CD3OD) δ 14.4, 23.7, 25.2, 29.90, 29.93, 30.3, 30.6, 32.7, 32.9, 
33.9, 37.69, 37.71, 40.1, 40.1, 44.9, 45.2, 46.9, 47.9, 80.0, 82.9, 105.1, 158.7 (2 × C), 
174.1, 176.1. 
HRMS (ESI, m/z) for C25H46N8O4 [M + 2H]2+ calc. 262.1894; found 262.1892. 
 
4-Heptyl-3,5-dioxatricyclo[5.2.1.02,6]decane-8-endo-9-exo-
dicarboxamidobutylguanidine hydrogen chloride (185)  
 
Compound 185 was synthesised from Boc-protected guanidine 174 (78 mg, 0.08 mmol) 
according to general procedure G and isolated as a white solid (48 mg, 94%). 
m.p 111–124 °C (slow decomposition). 
1H NMR (500 MHz, CD3OD) δ 0.90 (3H, t, J = 6.8 Hz, CH3), 1.29–1.40 (10H, m, 5 × 
CH2), 1.48 (1H, d, J = 10.3 Hz, H10s), 1.57–1.60 (10H, m, 5 × CH2), 1.71 (1H, d, J = 
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10.3 Hz, H10a), 2.39 (1H, br s, H9), 2.58–2.59 (2H, m, H1, H7), 3.15–3.27 (9H, m, 4 × 
NHCH2, H8), 3.99 (1H, d, J = 5.6 Hz, H6), 4.05 (1H, d, J = 5.6 Hz, H2), 4.65 (1H, t, J = 
4.8 Hz, H4). 
13C NMR (125 MHz, CD3OD) δ 14.4, 23.7, 25.2, 27.17, 27.23, 27.7 (2 × C), 30.3, 30.6, 
32.7, 32.9, 33.9, 39.9 (2 × C), 42.1 (2 × C), 44.9, 45.3, 46.9, 48.0, 80.0, 82.9, 105.1, 158.6 
(2 × C), 173.9, 175.9. 
HRMS (ESI, m/z) for C27H50N8O4 [M + 2H]2+ calc. 276.2050; found 276.2050. 
 
4-Heptyl-3,5-dioxatricyclo[5.2.1.02,6]decane-8-endo-9-exo-
dicarboxamidoethylamine hydrogen chloride (186)185  
 
Compound 186 was synthesised from Boc-protected amine 175 (650 mg, 1.06 mmol) 
according to general procedure G and isolated as a white solid (510 mg, 99%). 
m.p 242–243 °C. 
1H NMR (270 MHz, CD3OD) δ 0.90 (3H, t, J = 6.5 Hz, CH3), 1.29–1.48 (11H, m, 5 × 
CH2, H10s), 1.56–1.64 (2H, m, CHCH2), 1.75 (1H, d, J = 9.8 Hz, H10a), 2.51 (1H, br s, 
H9), 2.62–2.65 (2H, m, H1, H7), 3.03–3.10 (4H, m, 2 × NHCH2), 3.23 (1H, app. t, J = 
4.9 Hz, H8), 3.35–3.63 (4H, m, 2 × NHCH2), 4.00 (1H, d, J = 5.6 Hz, H6), 4.04 (1H, d, J 
= 5.6 Hz, H2), 4.66 (1H, t, J = 4.7 Hz, H4). 
13C NMR (67.5 MHz, CD3OD) δ 14.4, 23.7, 25.2, 28.2, 30.3, 30.6, 32.7, 32.9, 33.9, 38.4, 
38.5, 40.8, 44.9, 45.1, 47.1, 47.3, 80.0, 82.8, 105.1, 175.1, 177.0. 
HRMS (ESI, m/z) for C21H38N4O4 [M + 2H]2+ calc. 206.1519; found 206.1528. 
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4-Undecanyl-3,5-dioxatricyclo[5.2.1.02,6]decane-8-endo-9-exo-
dicarboxamidoethylamine hydrogen chloride (187)  
 
Compound 187 was synthesised from Boc-protected amine 176 (459 mg, 0.69 mmol) 
according to general procedure G and isolated as a white solid (364 mg, 98%). 
m.p 175–234 °C (slow decomposition). 
1H NMR (500 MHz, DMSO-d6) δ 0.85 (3H, t, J = 6.6 Hz, CH3), 1.23–1.30 (19H, m, 9 × 
CH2, H10s), 1.49–1.53 (3H, m, CHCH2, H10a), 2.41 (1H, br s, H1), 2.50 (1H, m, H7), 
2.61 (1H, d, J = 4.7 Hz, H9), 2.81–2.88 (4H, m, 2 × NHCH2), 3.10 (1H, app. t, J = 4.7 Hz, 
H8), 3.21–3.36 (4H, m, 2 × NHCH2), 3.85 (1H, d, J = 5.6 Hz, H6), 3.91 (1H, d, J = 5.6 Hz, 
H2), 4.59 (1H, t, J = 4.7 Hz, H4), 8.01 (6H, br s, 2 × NH3), 8.24 (1H, t, J = 5.4 Hz, NH), 
8.35 (1H, t, J = 5.1 Hz, NH). 
13C NMR (125 MHz, DMSO-d6) δ 14.0, 22.2, 23.8, 28.8, 28.99 (3 × C), 29.04, 29.1, 31.1, 
31.3, 32.4, 36.7, 36.8, 38.48, 38.52, 42.8, 43.2, 44.5, 46.1, 78.3, 81.1, 103.0, 171.6, 173.5. 
HRMS (ESI, m/z) for C25H46N4O4 [M + 2H]2+ calc. 234.1823; found 234.1826. 
 
4-Pentadecyl-3,5-dioxatricyclo[5.2.1.02,6]decane-8-endo-9-exo-
dicarboxamidoethylamine hydrogen chloride (188)  
 
Compound 188 was synthesised from Boc-protected amine 177 (76 mg, 0.11 mmol) 
according to general procedure G and isolated as a white powder (58 mg, 94%). 
m.p 156–200 °C (slow decomposition). 
1H NMR (500 MHz, DMSO-d6) δ 0.85 (3H, t, J = 7.1 Hz, CH3), 1.23–1.31 (27H, m, 13 
× CH2, H10s), 1.49–1.53 (3H, m, CHCH2, H10a), 2.41 (1H, br s, H1), 2.49–2.51 (1H, m, 
H7), 2.60 (1H, d, J = 4.7 Hz, H9), 2.81–2.86 (4H, m, 2  × NHCH2), 3.10 (1H, app. t, J = 
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4.7 Hz, H8), 3.19–3.32 (4H, m, 2 × NHCH2), 3.86 (1H, d, J = 5.6 Hz, H6), 3.91 (1H, d, J 
= 5.6 Hz, H2), 4.59 (1H, t, J = 4.7 Hz, H4), 7.96 (6H, br s, 2 × NH3), 8.23 (1H, t, J = 
5.4 Hz, NH), 8.33 (1H, t, J = 5.5 Hz, NH). 
13C NMR (125 MHz, DMSO-d6) δ 14.0, 22.1, 23.8, 28.7, 28.99 (3 × C), 29.04 (3 × C), 
29.1 (3 × C), 31.1, 31.3, 32.4, 36.7, 36.8, 38.4, 38.5, 42.8, 43.1, 44.5, 46.1, 78.2, 81.0, 
102.9, 171.5, 173.5. 
HRMS (ESI, m/z) for C29H54N4O4 [M + 2H]2+ calc. 262.2145; found 262.2150. 
 
4-[4ʹ-(Octyloxy)phenethyl]-3,5-dioxatricyclo[5.2.1.02,6]decane-8-endo-9-exo-
dicarboxamidoethylamine hydrogen chloride (189)  
 
Compound 189 was synthesised from Boc-protected amine 178 (28 mg, 0.04 mmol) 
according to general procedure G and isoalted as a white solid (23 mg, 99%). 
m.p 160–198 °C (slow decomposition). 
1H NMR (500 MHz, CD3OD) δ 0.90 (3H, t, J = 3.8 Hz, CH3), 1.29–1.34 (8H, m, 4 × 
CH2) 1.47–1.49 (3H, m, CH2, H10s), 1.73–1.79 (3H, m, CH2, H10a), 1.87–1.88 (2H, m, 
CH2), 2.53 (1H, br s, H1), 2.64–2.67 (4H, m, ArCH2, H9, H7), 3.06–3.09 (4H, m, 2 × 
NHCH2), 3.24 (1H, app. t, J = 5.0 Hz, H8), 3.37–3.40 (2H, m, NHCH2), 3.50–3.61 (2H, 
m, NHCH2), 3.90–3.93 (2H, m, OCH2), 4.02–4.03 (1H, m, H6), 4.06–4.07 (1H, m, H2), 
4.67 (1H, t, J = 4.4 Hz, H4), 6.79–6.81 (2H, m, ArH), 7.05–7.08 (2H, m, ArH). 
13C NMR (125 MHz, CD3OD) δ 14.4, 23.7, 27.2, 30.4, 30.46, 30.49, 30.7 (2 × C), 32.8, 
33.0, 36.0, 38.5 (2 × C), 40.9, 45.0, 45.1, 47.1, 47.3, 69.0, 80.1, 83.0, 104.3, 115.5 (2 × 
C), 130.2 (2 × C), 134.6, 158.9, 175.1, 177.0. 
HRMS (ESI, m/z) for C30H48N4O5 [M + 2H]2+ calc. 273.1855; found 273.1893. 
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8-endo-9-exo-Di[2ʹ-(2ʺ-bromoacetamide)ethylcarbamoyl]-4-heptyl-3,5-
dioxatricyclo[5.2.1.02,6]decane (190)  
 
To the stirring solution of diamine 186 (210 mg, 0.434 mmol), Et3N (320 μL, 2.26 mmol) 
and CH2Cl2 (4.3 mL) at −78 °C under an inert atmosphere, was added dropwise 
bromoacetyl bromide (110 μL, 1.22 mmol). The reaction was stirred for 5 h, before being 
warmed to −20 °C and quenched with H2O (5 mL) and diluted with CH2Cl2 (20 mL). The 
combined organic phase was washed with H2O (10 mL), sat. NH4Cl (10 mL), sat. 
NaHCO3 (10 mL) and brine (10 mL), dried (MgSO4), filtered and concentrated in vacuo 
to afford a white solid that was purified by column chromatography (EtOAc–10% MeOH 
in CH2Cl2) to give the title compound (185 mg, 65%) as a white powder.  
Rf = 0.36 (10% MeOH in CH2Cl2).  
m.p 66–70 °C. 
1H NMR (500 MHz, DMSO-d6) δ 0.85 (3H, t, J = 6.7 Hz, CH3), 1.23–1.31 (11H, m, 5 × 
CH2, H10s), 1.50–1.52 (3H, m, CHCH2, H10a), 2.32 (1H, br s, H7), 2.46 (1H, d, J = 
4.6 Hz, H1), 2.49–2.50 (1H, m, H9), 3.01–3.19 (9H, m, 4 × CH2, H8), 3.83 (2H, s, 
CH2Br), 3.84 (2H, s, CH2Br), 3.86 (1H, d, J = 5.6 Hz, H2), 3.90 (1H, d, J = 5.6 Hz, H6), 
4.59 (1H, t, J = 4.7 Hz, H4), 8.00 (1H, t, J = 5.4 Hz, NH), 8.04 (1H, t, J = 5.0 Hz, NH), 
8.29–8.30 (2H, m, 2 × NH). 
13C NMR (125 MHz, DMSO-d6) δ 14.0, 22.1, 23.7, 28.6, 28.9, 29.5 (2 × C), 31.1, 31.2, 
32.3, 38.1 (2 × C), 38.3 (2 × C), 42.7, 43.2, 44.5, 46.2, 78.2, 81.1, 102.9, 166.1, 166.2, 
171.2, 173.1.   
HRMS (ESI, m/z) for C25H4079Br2N4O6 [M + H]+ calc. 651.1387; found 651.1406. 
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4-Heptyl-3,5-dioxatricyclo[5.2.1.02,6]decane-8-endo-9-exo-di[2ʹ-
(ethylcarbamoyl)amidomethyl]di-1-methyl-1H-imidazol-3-ium bromide (191)  
 
To the stirring solution of 1-methylimidazole (16 μL, 0.19 mmol) in anhydrous THF 
(500 μL) at −78 °C under an inert atmosphere, was added α-bromo amide 190 (63 mg, 
0.10 mmol) in THF (500 μL) slowly. The reaction was warmed to −15 °C and stirred for 
1 h, before being warmed to ambient temperature and stirred for a further 2 d. The THF 
was decanted and the material was washed and decanted with Et2O (3 × 1 mL). The 
material was diluted with H2O (5 mL) and washed with CH2Cl2 (4 mL). The aqueous 
portion was lyophilised for 48 h to give the title compound (59 mg, 74%) as a light yellow 
residue. 
1H NMR (500 MHz, DMSO-d6) δ 0.85 (3H, t, J = 6.8 Hz, CH3), 1.23–1.29 (11H, m, 5 × 
CH2, H10s), 1.49–1.51 (3H, m, CHCH2, H10a), 2.32 (1H, br s, H7), 2.48–2.55 (2H, m, 
H1, H9), 3.01–3.23 (9H, m, 4 × NHCH2, H8), 3.85 (1H, d, J = 5.6 Hz, H2), 3.89 (6H, s, 
2 × NCH3), 3.92 (1H, d, J = 5.6 Hz, H6), 4.60 (1H, t, J = 4.7 Hz, H4), 4.97 (4H, s, 2 × 
CH2N), 7.68–7.71 (4H, m, 4 × ArH), 8.08–8.12 (2H, m, 2 × NH), 8.48–8.51 (2H, m, 2 × 
NH), 9.08 (2H, s, NCHN). 
13C NMR (125 MHz, DMSO-d6) δ 14.0, 22.1, 23.8, 28.7, 28.9, 31.1, 31.2, 32.4, 35.9 (2 
× C), 38.2, 38.4, 38.6, 38.7, 42.7, 43.4, 44.4, 46.2, 50.5, 50.6, 78.2, 81.1, 102.9, 123.1 (2 
× C), 123.8 (2 × C), 137.7 (2 × C), 165.1 (2 × C), 171.2, 173.1.   
HRMS (ESI, m/z) for C33H52N8O6 [M + 2H]2+ calc. 328.1999; found 328.1996. 
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4-Heptyl-3,5-dioxatricyclo[5.2.1.02,6]decane-8-endo-9-exo-di[2ʹ-
(ethylcarbamoyl)amidomethyl]dipyridin-1-ium bromide (192)  
 
To the stirring solution of α-bromo amide 190 (31 mg, 0.05 mmol) in anhydrous THF 
(480 μL) under an inert atmosphere was added pyridine (100 μL, 1.24 mmol) and the 
reaction was stirred at 66 °C for 16 h. The reaction mixture was concentrated under 
vacuum and the crude material was rinsed and decanted with Et2O (5 × 1 mL). The 
material was diluted with H2O (5 mL) and washed with CH2Cl2 (3 × 4 mL). The aqueous 
portion was lyophilised for 48 h to give the title compound (25 mg, 64%) as an orange 
spongy material. 
1H NMR (500 MHz, CD3OD) δ 0.90 (3H, t, J = 6.9 Hz, CH3), 1.29–1.45 (11H, m, 5 × 
CH2, H10s), 1.59–1.63 (2H, m, CHCH2) 1.70 (1H, dd, J = 10.3, 1.2 Hz, H10a), 2.44 (1H, 
br s, H1), 2.58–2.59 (2H, m, H9, H7), 3.18 (1H, app. t, J = 4.8 Hz, H8), 3.33–3.43 (8H, 
m, 4 × NHCH2), 4.01 (1H, d, J = 5.6 Hz, H6), 4.04 (1H, d, J = 5.6 Hz, H2), 4.66 (1H, t, 
J = 4.8 Hz, H4), 5.45 (2H, s, NCH2), 5.46 (2H, s, NCH2), 8.14–8.17 (4H, m, ArH), 8.65–
8.68 (2H, m, ArH), 8.93–8.94 (4H, m, ArH). 
13C NMR (125 MHz, CD3OD) δ 14.4, 23.7, 25.3, 30.4, 30.6, 32.8, 32.9, 33.9, 39.9, 40.0, 
40.6, 40.7, 45.1 (2 × C), 47.2, 47.5, 63.0 (2 × C), 78.0, 82.9, 105.1, 129.0 (4 × C), 147.5 
(2 × C), 147.55 (2 × C), 147.60 (2 × C), 166.3 (2 × C), 174.3, 176.2.   
HRMS (ESI, m/z) for C35H48N6O6 [M + 2H]2+ calc. 325.1890; found 325.1898. 
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8-endo-9-exo-Di[2ʹ-(2ʺ-benzylcarbamate-3ʺ-benzylguanidino)ethylcarbamoyl]-4-
undecanyl-3,5-dioxatricyclo[5.2.1.02,6]decane (199)  
 
To the stirring solution of diamine 187 (69 mg, 0.13 mmol) and DIPEA (110 μL, 
0.64 mmol) in CH2Cl2 (1 mL) at 0 °C, was added thiourea 195 (76 mg, 0.20 mmol) and 
EDCI (57 mg, 0.64 mmol) sequentially. The reaction was stirred at ambient temperature 
for 48 h before being transferred to a separatory funnel and diluted with CH2Cl2 (10 mL). 
The organic phase was washed with 0.5 M HCl (6 mL), H2O (6 mL) and brine (6 mL), 
dried (MgSO4), filtered and concentrated in vacuo, to give the desired product (84 mg, 
66%) as a white solid which was >90% pure according to 1H NMR spectroscopic analysis.  
1H NMR (500 MHz, CDCl3) δ 0.87 (3H, t, J = 6.5 Hz, CH3), 1.25–1.42 (18H, m, 9 × 
CH2), 1.53–1.58 (3H, m, CH2, H10s), 1.68 (1H, d, J = 9.8 Hz, H10a), 2.51 (1H, br s, H1), 
2.62 (1H, br s, H7), 2.76 (1H, br s, H9), 3.06 (1H, br s, H8), 3.28–2.40 (4H, m, 2 × 
NHCH2), 3.60–3.71 (4H, m, 2 × NHCH2), 3.90 (1H, br s, H2), 4.03 (1H, br s, H6), 4.49 
(1H, br s, H4), 4.71–4.73 (4H, m, 2 × ArCH2), 5.25 (4H, br s, 2 × OCH2Ar), 7.26–7.42 
(20H, m, ArH), 8.82–9.11 (2H, m, 2 × NH), 9.82 (2H, br s, 2 × NH), 11.70–11.78 (2H, 
m, 2 × NH). 
13C NMR (125 MHz, CDCl3) δ 14.2, 22.8, 24.3, 29.4, 29.67, 29.71 (2 × C), 29.8 (2 × C), 
31.0, 32.0, 32.1, 32.9, 39.6 (2 × C), 41.0, 41.4, 43.8, 44.0, 45.7, 47.1, 47.2, 47.5, 68.9, 
69.0, 78.7, 81.4, 103.9, 128.0, 128.09, 128.11, 128.2, 128.6, 128.7, 128.76, 128.80, 129.2, 
134.2, 134.4, 152.8, 154.6, 173.8, 173.9,  176.7, 176.8. 
HRMS (ESI, m/z) for C55H74N8O8 [M + H]+ calc. 999.5702; found 999.5709. 
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N,Nʹ-Bis(tert-butoxycarbonyl)-N-benzyl-S-methylisothiourea (201)  
 
To a stirring solution of methylisothiourea 58 (1.04 g, 3.58 mmol) in anhydrous THF 
(12.8 mL) at ambient temperature under an inert atmosphere, was added Ph3P (1.50 g, 
5.73 mmol) followed by BnOH (490 μL, 4.65 mmol). The homogenous solution was 
cooled to 0 °C, before DIAD (1.1 mL, 5.37 mmol) was added slowly. The yellow solution 
was warmed to ambient temperature and then heated to 66 °C for 16 h. The reaction 
mixture was concentrated under vacuum and the crude material was diluted with H2O 
(10 mL) and extracted with CH2Cl2 (3 × 15 mL). The combined organic phase was 
washed with brine (10 mL), dried (MgSO4), filtered and concentrated in vacuo to give a 
yellow oil which was triturated in pet. spirits (20 mL) at ambient temperature for 1 h. The 
white precipitate was collected using vacuum filtration and discarded. The filtrate was 
purified by column chromatography (10% EtOAc in pet. spirits) to give a light green oil 
(1.29 g, 95%).  
Rf = 0.38 (10% EtOAc in pet. spirits). 
1H NMR (270 MHz, CDCl3) δ 1.39 (9H, s, t-Bu), 1.52 (9H, s, t-Bu), 2.28 (3H, s, CH3), 
4.78 (2H, s, CH2), 7.24–7.36 (5H, m, ArH). 
13C NMR (67.5 MHz, CDCl3) δ 15.7, 28.1, 28.2, 52.6, 81.9, 82.8, 127.4, 127.6, 127.8, 
128.5, 128.7 137.5, 152.1, 158.1, 163.3. 
HRMS (ESI, m/z) for C19H28N2O4S [M + Na]+ calc. 403.1662; found 403.1664. 
 
8-endo-9-exo-Di[2ʹ-(2ʺ,3ʺ-bis-tert-butoxycarbonyl-3ʺ-
benzylguanidino)ethylcarbamoyl]-4-heptyl-3,5-dioxatricyclo[5.2.1.02,6]decane (203)  
 
A mixture of diamine 186 (80 mg, 0.165 mmol) and Et3N (60 μL, 0.41 mmol) in CH2Cl2 
(300 μL) was stirred for 30 min at ambient temperature before a solution of 
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methylisothiourea 201 (130 mg, 0.341 mmol) in CH2Cl2 (900 μL) was added in one 
portion and the reaction was heated to 39 °C for 2 d. The reaction mixture was diluted 
with CH2Cl2 (10 mL), transferred to a separatory funnel and washed with H2O (2 × 5 mL), 
brine (5 mL), dried (MgSO4) and filtered. The solvent was removed in vacuo and the 
crude mateiral was purified by flash column chromatography (20–70% EtOAc in pet. 
spirits) to give the title compound (53 mg, 30%) as a colourless viscous oil. 
Rf = 0.46 (70% EtOAc in pet spirits). 
1H NMR (500 MHz, CDCl3) δ 0.87 (3H, t, J = 6.8 Hz, CH3), 1.25–1.61 (49H, m, 6 × 
CH2, 4 × t-Bu, H10s), 1.76 (1H, d, J = 9.9 Hz, H10a), 2.32 (1H, d, J = 5.9 Hz, H1), 2.57 
(1H, br s, H7), 2.61 (1H, br s, H9), 2.87 (1H, app. t, J = 5.1 Hz, H8), 3.21–3.33 (8H, m, 
4 × NHCH2), 3.92 (1H, d, J = 5.5 Hz, H2), 4.10 (1H, br s, H6), 4.52 (1H, br s, H4), 4.79 
(4H, br s, ArCH2), 7.27–7.33 (10H, m, ArH). 
13C NMR (125 MHz, CDCl3) δ 14.2, 22.7, 24.3, 28.17, 28.21, 28.32, 28.33, 29.3, 29.6, 
29.8, 31.9, 32.5, 33.0, 38.8, 39.6, 43.0, 43.2, 44.3, 44.6, 47.8, 51.3, 51.4, 78.7, 79.7 (2 × 
C), 81.5, 83.1, 83.3, 104.0, 127.8, 128.0, 128.2, 128.3, 128.7 (6 × C), 137.8, 138.0, 153.5 
(2 × C), 172.6, 174.3. 
HRMS (ESI, m/z) for C57H84N8O12 [M + H]+ calc. 1075.6438; found 1075.6429. 
 
4-Heptyl-3,5-dioxatricyclo[5.2.1.02,6]decane-8-endo-9-exo-di[carboxamidoethyl-(3ʺ-
benzyl)guanidine] hydrogen chloride (204)  
 
Compound 204 was synthesised from Boc-protected guanidine 203 (40 mg, 0.04 mmol) 
according to general procedure G and isolated as a colourless oil (25 mg, 93%). 
1H NMR (270 MHz, CD3OD) δ 0.89 (3H, t, J = 6.8 Hz, CH3), 1.29–1.39 (10H, m, 5 × 
CH2), 1.45 (1H, d, J = 10.2 Hz, H10s), 1.56–1.60 (2H, m, CH2), 1.72 (1H, d, J = 10.2 Hz, 
H10a), 2.45 (1H, br s, H9), 2.61–2.62 (2H, m, H1, H7), 3.21 (1H, app. t, J = 4.8 Hz, H8), 
3.34–3.41 (8H, m, 4 × NHCH2), 3.98 (1H, d, J = 5.4 Hz, H6), 4.03 (1H, d, J = 5.4 Hz, 
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H2), 4.41–4.42 (4H, m, 2 × ArCH2), 4.61 (1H, t, J = 4.6 Hz, H4), 7.30–7.40 (10H, m, 
ArH). 
13C NMR (67.5 MHz, CD3OD) δ 14.4, 23.7, 25.2, 30.3, 30.6, 32.7, 32.9, 33.9, 39.6, 39.7, 
42.4 (2 × C), 44.9, 45.1, 46.1, 46.2, 47.0, 47.7, 79.9, 82.8, 105.1, 128.4 (2 × C), 128.5 (2 
× C), 129.0 (4 × C), 129.9 (4 × C), 157.7 (2 × C), 174.7, 176.7. 
HRMS (ESI, m/z) for C37H54N8O4 [M + 2H]2+ calc. 338.2207; found 338.2208. 
 
endo-3-Methoxycarbonylbicyclo[2.2.1]hept-5-ene-2-exo-carboxylic acid (205)335 
 
To the stirring solution of norbornene diester 112 (1.24 g, 5.91 mmol) in THF (13 mL) at 
0 °C was slowly added H2O (135 mL), followed by 0.25 M KOH (28 mL, 7.1 mmol) and 
the reaction was stirred for 3.5 h. Upon reaction completion, all organic impurities were 
extracted with CH2Cl2 (3 × 25 mL) and the remaining aqueous phase was acidified to pH 
= 1 (cold 1 M HCl) and salted with solid NaCl. The product was then extracted with 
EtOAc (4 × 30 mL), dried (MgSO4), filtered, and concentrated in vacuo to give the 
product (1.024 g, 88%) as a white solid in a 9:1 ratio of the exo-acid/endo-acid.  
1H NMR (270 MHz, CDCl3) δ 1.47 (1H, dd, J = 8.9, 3.4 Hz, H7s), 1.61 (1H, dd, J = 8.9, 
4.3 Hz, H7a), 2.72 (1H, dd, J = 4.3, 1.6 Hz, H2), 3.19 (1H, br s, H4), 3.27 (1H, br s, H1), 
3.37 (1H, app. t, J = 4.3 Hz, H3), 3.64 (3H, s, Me), 6.08 (1H, dd, J = 5.6, 2.8 Hz, H6), 
6.25 (1H, dd, J = 5.6, 3.4 Hz, H5). 
13C NMR (100 MHz, CDCl3) δ 45.7, 47.4, 47.5, 47.7, 47.8, 52.0, 135.4, 137.6, 173.7, 
180.5. 
HRMS (ESI, m/z) for C10H12O4 [M + Na]+ calc. 219.0628; found 219.0634. 
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Bicyclo[2.2.1]hepta-5-ene-3-endo-2-exo-dicarboxylic acid (50)337 
 
To the stirring solution of norbornene diester 112 (1.24 g, 5.88 mmol) in THF (24.5 mL) 
was added 2M NaOH (12.3 mL, 24.5 mmol) and the reaction was stirred for 16 h at 
ambient temperature. The THF was removed under reduced pressure before the remaining 
aqueous solution was acidified to pH = 1 (2 M HCl). The title compound (941 mg, 88%) 
was collected by vacuum filtration as a fine white powder. 
m.p 55–191 °C (slow decomposition) (lit. 186–187 °C).504  
1H NMR (270 MHz, DMSO-d6) δ 1.33 (1H, dd, J = 8.6, 1.4 Hz, H7s), 1.49 (1H, d, J = 
8.6 Hz, H7a), 2.42 (1H, d, J = 4.0 Hz, H2), 3.02–3.03 (1H, m, H4), 3.15–3.18 (2H, m, 
H3, H1), 6.05 (1H, dd, J = 5.6, 2.3 Hz, H6), 6.28 (1H, dd, J = 5.6, 3.1 Hz, H5), 12.28 
(2H, br s, CO2H). 
13C NMR (100 MHz, DMSO-d6) δ 45.0, 46.8, 47.0, 47.1, 47.5, 135.0, 137.5, 174.2, 175.3. 
HRMS (ESI, m/z) for C9H10O4 [M + Na]+ calc. 205.0468; found 205.0471. 
 
2-exo-Ioda-5-oxo-4-oxatricyclo[4.2.1.03,7]nonane-9-exo-carboxylic acid (207)336 
 
A solution of diacid 50 (2.34 g, 12.84 mmol), NaHCO3 (5.39 g, 64.2 mmol) and H2O 
(40 mL) at ambient temperature was stirred for approximately 45 min, after which an 
aqueous solution of I2/KI [0.2 M/ 0.6 M] was added until the solution maintained a dark 
brown colour. The mixture stirred for 20 min before addition of Na2S2O5 resulting in the 
decolourisation of the solution. The reaction mixture was acidified to pH = 1 (6M H2SO4), 
resulting in a colour change to light yellow. The product was extracted with CH2Cl2 (4 × 
30 mL), dried (MgSO4), filtered, and the solvent was removed in vacuo to give the title 
compound (3.76 g, 95%) as a white powder.  
m.p 129–133 °C (lit. 126.0–127.0 °C).505 
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1H NMR (270 MHz, CDCl3) δ 1.98 (1H, dd, J = 12.0, 2.3 Hz, H8s), 2.38 (1H, dd, J = 
12.0, 1.2 Hz, H8a), 2.91 (1H, s, H9), 3.10 (2H, m, H1, H6), 3.22–3.27 (1H, m, H7), 3.91 
(1H, d, J = 2.5 Hz, H2), 5.16 (1H, d, J = 5.0 Hz, H3), 10.65 (1H, br s, CO2H).  
13C NMR (100 MHz, CDCl3) δ 27.5, 35.3, 41.0, 46.3, 50.1, 50.5, 88.7, 174.9, 177.4. 
HRMS (ESI, m/z) for C9H9IO4 [M + Na]+ calc. 330.9438; found 330.9434. 
 
Methyl-2-exo-ioda-5-oxo-4-oxatricyclo[4.2.1.03,7]nonane-9-exo-carboxylate (208)336 
 
To the stirring solution of carboxylic acid 207 (7.63 g, 24.8 mmol) in MeOH (34 mL), 
was added conc. H2SO4 (300 μL, 5.63 mmol) and the reaction was heated to 65 °C for 
16 h. The reaction mixture was concentrated and the resulting yellow sludge was 
dissolved in CH2Cl2 (40 mL), washed with H2O (20 mL), sat. NaHCO3 (20 mL), brine 
(20 mL), dried (MgSO4), filtered and concentrated in vacuo. The resulting yellow viscous 
oil (7.15 g, 90%) required no further purification. 
1H NMR (270 MHz, CDCl3) δ 1.93–1.99 (1H, m, H8s), 2.32 (1H, dd, J = 12.0, 1.4 Hz, 
H8a), 2.84 (1H, br s, H9), 3.02 (1H, br s, H6), 3.08–3.10 (1H, m, H1), 3.19–3.24 (1H, m, 
H7), 3.73 (3H, s, Me), 3.88 (1H, d, J = 2.6 Hz, H2), 5.13 (1H, d, J = 5.0 Hz, H3).  
13C NMR (100 MHz, CDCl3) δ 27.9, 35.2, 41.1, 46.3, 50.3, 50.6, 53.0, 88.6, 170.7, 177.3. 
HRMS (ESI, m/z) for C10H11IO4 [M + H]+ calc. 322.9775; found 322.9773. 
 
exo-2-Methoxycarbonylbicyclo[2.2.1]hept-5-ene-3-endo-carboxylic acid (206)336 
 
Zinc (4.49 g, 68.7 mmol) was activated in 1M HCl (53 mL) until the solid turned from a 
dark black to a silvery grey (ca. 10 min). The HCl was decanted and the zinc was washed 
and decanted successively with H2O (3 × 10 mL) and EtOH (3 × 10 mL). A solution of 
iodolactone 208 (7.14 g, 68.7 mmol) in EtOH (67 mL) was added, followed by AcOH 
(67 mL), and the reaction was heated to 79 °C for 3 h. The zinc was removed by filtration 
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and the filtrate was concentrated in vacuo. The crude product was diluted with CHCl3 
(100 mL) and washed with H2O (2 × 50 mL), brine (50 mL), dried (MgSO4), filtered and 
concentrated in vacuo to afford the title compound (4.03 g, 93%) as a white solid. 
m.p 96–98 °C. 
1H NMR (270 MHz, CDCl3) δ 1.48 (1H, dd, J = 8.9, 1.6 Hz, H7s), 1.62 (1H, d, J = 8.9 Hz, 
H7a), 2.65 (1H, dd, J = 4.2, 1.5 Hz, H2), 3.13 (1H, br s, H4), 3.29 (1H, br s, H1), 3.42 
(1H, app. t, J = 4.2 Hz, H3), 3.72 (3H, s, Me), 6.13 (1H, dd, J = 5.6, 2.8 Hz, H6), 6.29 
(1H, dd, J = 5.6, 3.2 Hz, H5). 
13C NMR (67.5 MHz, CDCl3) δ 45.7, 47.1, 47.6, 47.7, 48.1, 52.4, 135.3, 137.9, 175.0, 
179.5. 
HRMS (ESI, m/z) for C10H12O4 [M − H]− calc. 195.0663; found 195.0667. 
 
Methyl endo-3-(heptylcarbamoyl)bicyclo[2.2.1]hept-5-ene-2-exo-carboxylate (209) 
 
Compound 209 was prepared from acid 206 (533 mg, 2.72 mmol) and heptylamine 
(620 μL, 4.07 mmol) according to general procedure F and after purification by column 
chromatography (20% EtOAc in CH2Cl2) was isolated as a clear oil (615 mg, 77%). 
Rf = 0.32 (20% EtOAc in CH2Cl2).  
1H NMR (500 MHz, CDCl3) δ 0.87 (3H, t, J = 6.9 Hz, CH3), 1.26–1.30 (8H, m, 4 × CH2), 
1.44–1.48 (3H, m, CH2, H7s), 1.55 (1H, d, J = 8.7 Hz, H7a), 2.58 (1H, dd, J = 5.0, 1.8 Hz, 
H2), 3.10–3.25 (5H, m, NHCH2, H1, H4, H3), 3.72 (3H, s, Me), 5.80 (1H, t, J = 6.0 Hz, 
NH), 6.17 (1H, dd, J = 5.7, 3.0 Hz, H6), 6.23 (1H, dd, J = 5.7, 3.4 Hz, H5). 
13C NMR (125 MHz, CDCl3) δ 14.2, 22.7, 27.0, 29.1, 29.8, 31.9, 39.7, 45.7, 46.9, 47.8, 
48.2, 49.8, 52.3, 135.7, 136.6, 172.5, 175.7. 
HRMS (ESI, m/z) for C17H27NO3 [M + H]+ calc. 294.2064; found 294.2056. 
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Methyl endo-3-(hexadecylcarbamoyl)bicyclo[2.2.1]hept-5-ene-2-exo-carboxylate 
(210) 
 
Compound 210 was prepared from acid 206 (835 mg, 4.26 mmol) and hexadecylamine 
(1.54 g, 6.39 mmol) according to general procedure F and after purification by column 
chromatography (5% EtOAc in CH2Cl2) was isolated as a white solid (1.39 g, 73%). 
Rf = 0.41 (20% EtOAc in CH2Cl2). 
m.p 84–85 °C. 
1H NMR (500 MHz, CDCl3) δ 0.87 (3H, t, J = 6.8 Hz, CH3), 1.25–1.29 (26H, m, 13 × 
CH2), 1.44–1.49 (3H, m, CH2, H7s), 1.55 (1H, d, J = 8.7 Hz, H7a), 2.58 (1H, dd, J = 5.0, 
1.7 Hz, H2), 3.10–3.26 (5H, m, NHCH2, H1, H3, H4), 3.73 (3H, s, Me), 5.79 (1H, t, J = 
5.5 Hz, NH), 6.17 (1H, dd, J = 5.6, 2.8 Hz, H6), 6.24 (1H, dd, J = 5.6, 3.5 Hz, H5). 
13C NMR (125 MHz, CDCl3) δ 14.3, 22.8, 27.0, 29.4, 29.5, 29.69, 29.72, 29.79 (2 × C), 
29.81 (2 × C), 29.83 (3 × C), 32.1, 39.7, 45.7, 46.9, 47.8, 48.2, 49.8, 52.3, 135.7, 136.6, 
172.5, 175.7. 
HRMS (ESI, m/z) for C26H45NO3 [M + H]+ calc. 420.3472; found 420.3483. 
 
Methyl-exo-5,6-dihydroxy-endo-3-(heptylcarbamoyl)bicyclo[2.2.1]heptane-2-exo-
carboxylate (211) 
 
The alkene 209 (1.12 g, 3.82 mmol) and NMO·H2O (570 mg, 4.20 mmol) were dissolved 
in a solution of H2O/acetone (9.3 mL, 1:4) before OsO4 (4% in H2O, 490 μL, 0.08 mol%) 
was added. The reaction was stirred for 3 d and then quenched with sat. NaHSO3 (15 mL). 
The suspension was extracted with EtOAc (3 × 30 mL) and the combined organic phase 
was washed with brine (30 mL), dried (MgSO4), filtered and concentrated in vacuo to 
give the title compound (1.06 g, 85%) as a yellow oil. 
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1H NMR (500 MHz, CDCl3) δ 0.87 (3H, t, J = 6.9 Hz, CH3), 1.25–1.31 (8H, m, 4 × CH2), 
1.36 (1H, d, J = 10.9 Hz, H7s), 1.47–1.50 (2H, m, CH2), 1.89 (1H, dd, J = 10.9, 1.2 Hz, 
H7a), 2.40 (1H, d, J = 4.0 Hz, H4), 2.52 (1H, br s, H1), 2.73 (1H, d, J = 5.6 Hz, H2), 2.92 
(1H, dd, J = 5.6, 4.0 Hz, H3), 3.19–3.24 (2H, m, NHCH2), 3.69 (3H, s, Me), 3.87 (1H, d, 
J = 5.4 Hz, H6), 4.02 (1H, d, J = 5.4 Hz, H5), 5.95 (1H, t, J = 5.4 Hz, NH).  
13C NMR (125 MHz, CDCl3) δ 14.2, 22.7, 27.0, 29.1, 29.7, 31.8, 32.4, 40.0, 45.1, 47.1, 
47.7, 48.1, 52.5, 69.8, 73.4, 171.6, 175.0. 
HRMS (ESI, m/z) for C17H29NO5 [M + H]+ calc. 328.2119; found 328.2114. 
 
Methyl-exo-5,6-dihydroxy-endo-3-(hexadecylcarbamoyl)bicyclo[2.2.1]heptane-2-
exo-carboxylate (212) 
 
The alkene 210 (1.34 g, 3.18 mmol) and NMO·H2O (475 mg, 3.50 mmol) were dissolved 
in a solution of CHCl3 (10 mL) and H2O/acetone (9.3 mL, 1:4) before OsO4 (4% in H2O, 
410 μL, 0.06 mol%) was added. The reaction was stirred for 16 h before being heated to 
50 °C for a further 48 h. The reaction was quenched with sat. NaHSO3 (15 mL). The 
suspension was extracted with EtOAc (3 × 25 mL) and the combined organic phase was 
washed with brine (25 mL), dried (MgSO4), filtered and concentrated in vacuo to give the 
title compound (1.28 g, 89%) as a dark green wax. 
1H NMR (500 MHz, CDCl3) δ 0.87 (3H, t, J = 6.9 Hz, CH3), 1.25–1.28 (26H, m, 13 × 
CH2), 1.37 (1H, d, J = 10.9 Hz, H7s), 1.47–1.50 (2H, m, CH2), 1.68 (2H, br s, 2 × OH), 
1.90 (1H, dd, J = 10.9, 1.2 Hz, H7a), 2.29 (1H, d, J = 3.2 Hz, H4), 2.52 (1H, br s, H1), 
2.74 (1H, d, J = 5.4 Hz, H2), 2.92 (1H, app. t, J = 5.4 Hz, H3), 3.18–3.24 (2H, m, NHCH2), 
3.70 (3H, s, Me), 3.89 (1H, d, J = 5.7 Hz, H5), 4.04 (1H, d, J = 5.7 Hz, H6), 5.85 (1H, t, 
J = 5.3 Hz, NH).  
13C NMR (125 MHz, CDCl3) δ 14.3, 22.8, 27.1, 29.4, 29.5 (2 × C), 29.69 (2 × C), 29.74, 
29.80 (2 × C), 29.84 (3 × C), 32.1, 32.4, 40.0, 45.1, 47.1, 47.7, 48.1, 52.4, 69.8, 73.5, 
171.5, 175.0. 
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HRMS (ESI, m/z) for C26H47NO5 [M + H]+ calc. 454.3520; found 454.3542. 
 
Methyl 4-heptyl-3,5-dioxatricyclo[5.2.1.02,6]decane-8-endo-(heptylcarbamoyl)-9-
exo-carboxylate (213) 
 
Compound 213 was prepared from diol 211 (196 mg, 0.60 mmol) and octanal (140 μL, 
0.90 mmol) according to general procedure B and was purified using column 
chromatography (10–20% EtOAc in pet. spirits) to give the title compound (247 mg, 
94%) as a colourless oil. 
Rf = 0.45 (20% EtOAc in pet. spirits). 
1H NMR (500 MHz, CDCl3) δ 0.85–0.89 (6H, m, 2 × CH3), 1.27–1.40 (19H, m, 9 × CH2, 
H10s), 1.47–1.50 (2H, m, NHCH2CH2), 1.60–1.65 (2H, m, CH2), 1.80 (1H, d, J = 
10.6 Hz, H10a), 2.53 (1H, d, J = 4.5 Hz, H7), 2.66 (1H, br s, H1), 2.77 (1H, d, J = 5.3 
Hz, H9), 2.98 (1H, app. t, J = 5.3 Hz, H8), 3.19–3.27 (2H, m, NHCH2), 3.69 (3H, s, Me), 
4.09 (1H, d, J = 5.7 Hz, H6), 4.14 (1H, d, J = 5.7 Hz, H2), 4.65 (1H, t, J = 4.9 Hz, H4), 
5.63 (1H, t, J = 5.0 Hz, NH). 
13C NMR (125 MHz, CDCl3) δ 14.22, 14.23, 22.7, 22.8, 24.4, 27.0, 29.0, 29.3, 29.66, 
29.74, 31.8, 31.9, 32.3, 33.0, 40.0, 43.6, 44.1, 45.1, 46.7, 52.5, 78.5, 81.4, 104.1, 170.8, 
174.8. 
HRMS (ESI, m/z) for C25H43NO5 [M + H]+ calc. 438.3214; found 438.3205. 
 
Methyl 4-heptyl-3,5-dioxatricyclo[5.2.1.02,6]decane-8-endo-(hexadecylcarbamoyl)-
9-exo-carboxylate (214) 
 
Compound 214 was prepared from diol 212 (76 mg, 0.17 mmol) and octanal (40 μL, 
0.26 mmol) according to general procedure B and was purified using column 
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chromatography (10–20% EtOAc in pet. spirits) to give the title compound (43 mg, 45%) 
as a colourless oil. 
Rf = 0.47 (20% EtOAc in pet. spirits).  
1H NMR (500 MHz, CDCl3) δ 0.85–0.89 (6H, m, 2 × CH3), 1.25–1.32 (35H, m, 17 × 
CH2, H10s), 1.35–1.44 (2H, m, CH2), 1.47–1.50 (2H, m, CH2), 1.60–1.64 (2H, m, CH2), 
1.80 (1H, dd, J = 10.7, 1.2 Hz, H10a), 2.52 (1H, d, J = 4.4 Hz, H1), 2.65 (1H, br s, H7), 
2.76 (1H, dd, J = 5.3, 1.2 Hz, H9), 2.98 (1H, app. t, J = 5.3 Hz, H8), 3.18–3.27 (2H, m, 
NHCH2), 3.69 (3H, s, Me), 4.08 (1H, d, J = 5.6 Hz, H2), 4.14 (1H, d, J = 5.6 Hz, H6), 
4.65 (1H, t, J = 4.9 Hz, H4), 5.66 (1H, t, J = 3.7 Hz, NH). 
13C NMR (100 MHz, CDCl3) δ 14.2, 14.3, 22.76, 22.83, 24.4, 27.0, 29.1, 29.2, 29.3, 29.4, 
29.5, 29.67, 29.72, 29.75, 29.80, 29.82, 29.84 (3 × C), 31.9, 32.0, 32.3, 33.0, 40.0, 43.6, 
44.1, 45.1, 46.7, 52.4, 78.6, 81.4, 104.1, 170.8, 174.8.  
HRMS (ESI, m/z) for C34H61NO5 [M + H]+ calc. 564.4623; found 564.4631. 
 
4-Heptyl-3,5-dioxatricyclo[5.2.1.02,6]decane-8-endo-(heptylcarbamoyl)-9-exo-
carboxylic acid (215) 
 
The title compound was prepared from ester 213 (240 mg, 0.55 mmol) according to 
general procedure D and isolated as a white solid (148 mg, 64%). 
m.p 137–140 °C.  
1H NMR (500 MHz, CD3OD) δ 0.89–0.91 (6H, m, 2 × CH3), 1.30–1.41 (19H, m, 9 × 
CH2, H10s), 1.50–1.53 (2H, m, NHCH2CH2), 1.58–1.62 (2H, m, CH2), 1.75 (1H, dd, J = 
10.5, 1.4 Hz, H10a), 2.55 (1H, d, J = 4.1 Hz, H7), 2.59 (1H, br s, H1), 2.68 (1H, d, J = 
5.0 Hz, H9), 3.05 (1H, app. t, J = 5.0 Hz, H8), 3.13 (1H, dt, J = 13.3, 7.0 Hz, NHCH2), 
3.25 (1H, dt, J = 13.3, 7.0 Hz, NHCH2), 4.01 (1H, d, J = 5.6 Hz, H6), 4.03 (1H, d, J = 
5.6 Hz, H2), 4.65 (1H, t, J = 4.8 Hz, H4). 
13C NMR (125 MHz, CD3OD) δ 14.4, 14.5, 23.66, 23.70, 25.2, 27.9, 30.1, 30.3, 30.4, 
30.6, 32.9, 33.0, 33.1, 33.9, 40.5, 44.3, 45.4, 46.3, 47.8, 79.9, 82.6, 105.1, 173.4, 177.2. 
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HRMS (ESI, m/z) for C24H41NO5 [M + H]+ calc. 424.3058; found 424.3044. 
 
4-Heptyl-3,5-dioxatricyclo[5.2.1.02,6]decane-8-endo-(hexadecylcarbamoyl)-9-exo-
carboxylic acid (216) 
 
The title compound was prepared from ester 214 (41 mg, 0.07 mmol) according to general 
procedure D and isolated as a brown wax (37 mg, 93%). 
1H NMR (270 MHz, CDCl3) δ 0.85–0.90 (6H, m, 2 × CH3), 1.25–1.52 (39H, m, 19 × 
CH2, H10s), 1.59–1.67 (2H, m, CH2), 1.83 (1H, d, J = 10.1 Hz, H10a), 2.54 (1H, d, J = 
4.1 Hz, H7), 2.71–2.73 (2H, m, H1, H9), 2.95 (1H, dd, J = 5.5, 4.1 Hz, H8), 3.19–3.28 
(2H, m, NHCH2), 4.07 (1H, d, J = 5.7 Hz, H6), 4.14 (1H, d, J = 5.7 Hz, H2), 4.66 (1H, t, 
J = 4.8 Hz, H4), 5.85 (1H, t, J = 4.1 Hz, NH). 
13C NMR (67.5 MHz, CDCl3) δ 14.2, 14.3, 22.75, 22.82, 24.3, 27.0, 29.3, 29.4, 29.5, 
29.6, 29.67 (2 × C), 29.73, 29.80 (2 × C), 29.83, 29.84 (3 × C), 31.9, 32.1, 32.5, 32.9, 
40.1, 43.7, 43.9, 44.6, 46.9, 78.5, 81.4, 104.3, 171.3, 177.9. 
HRMS (ESI, m/z) for C33H59NO5 [M + H]+ calc. 550.4466; found 550.4455. 
 
9-exo-[2ʹ-(2ʺ,3ʺ-Bis-tert-butoxycarbonylguanidino)ethylcarbamoyl]-8-endo-
(heptylcarbamoyl)-4-heptyl-3,5-dioxatricyclo[5.2.1.02,6]decane (217) 
 
Compound 217 was prepared from carboxylic acid 215 (43 mg, 0.10 mmol) and 
aminoethylguanidine 41 (50 mg, 0.17 mmol) according to general procedure E and was 
purified using column chromatography (10–50% EtOAc in CH2Cl2) to give the title 
compound (21 mg, 30%) as a colourless oil. 
Rf = 0.48 (50% EtOAc in CH2Cl2).  
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1H NMR (500 MHz, CDCl3) δ 0.85 (6H, m, 2 × CH3), 1.25–1.50 (39H, m, 10 × CH2, 2 
× t-Bu, H10s), 1.59–1.64 (2H, m, CH2), 1.78–1.80 (1H, m, H10a), 2.39 (1H, d, J = 5.6 Hz, 
H9), 2.52 (1H, d, J = 4.1 Hz, H1), 2.56 (1H, br s, H7), 2.94 (1H, dd, J = 5.6, 4.6 Hz, H8), 
3.15–3.26 (2H, m, NHCH2), 3.37–3.43 (2H, m, NHCH2), 3.50–3.62 (2H, m, NHCH2), 
3.98 (1H, d, J = 5.6 Hz, H2), 4.19 (1H, d, J = 5.6 Hz, H6), 4.63 (1H, t, J = 4.9 Hz, H4), 
6.17 (1H, t, J = 5.6 Hz, NH), 7.04 (1H, t, J = 4.9 Hz, NH), 8.53 (1H, t, J = 5.8 Hz, NH), 
11.48 (1H, s, NH). 
13C NMR (125 MHz, CDCl3) δ 14.20, 14.21, 22.7, 22.8, 24.4, 27.0, 28.2, 28.4, 29.0, 29.3, 
29.6, 29.7, 31.8, 31.9, 32.3, 34.0, 39.9, 40.0, 40.7, 43.3, 44.5, 44.9, 47.5, 78.8, 79.8, 81.6, 
83.6, 104.2, 153.3, 157.3, 163.4, 171.7, 174.1.   
HRMS (ESI, m/z) for C37H65N5O8 [M + H]+ calc. 708.4906; found 708.4921. 
 
9-exo-[2ʹ-(2ʺ,3ʺ-Bis-tert-butoxycarbonylguanidino)ethylcarbamoyl]-8-endo-
(hexadecylcarbamoyl)-4-heptyl-3,5-dioxatricyclo[5.2.1.02,6]decane (218) 
 
Compound 218 was prepared from carboxylic acid 216 (20 mg, 0.04 mmol) and 
aminoethylguanidine 41 (21 mg, 0.07 mmol) according to general procedure E and was 
purified using column chromatography (10–20% EtOAc in CH2Cl2) to give the title 
compound (22 mg, 79%) as a pale yellow oil. 
Rf = 0.32 (20% EtOAc in CH2Cl2).  
1H NMR (500 MHz, CDCl3) δ 0.85–0.88 (6H, m, 2 × CH3), 1.24–1.50 (57H, m, 19 × 
CH2, 2 × t-Bu, H10s), 1.59–1.63 (2H, m, CH2), 1.78 (1H, d, J = 9.6 Hz, H10a), 2.39 (1H, 
d, J = 5.7 Hz, H9), 2.52 (1H, d, J = 4.1 Hz, H1), 2.56 (1H, br s, H7), 2.94 (1H, dd, J = 
5.7, 4.6 Hz, H8), 3.13–3.27 (2H, m, NHCH2), 3.38–3.42 (2H, m, NHCH2), 3.51–3.64 
(2H, m, NHCH2), 3.98 (1H, d, J = 5.7 Hz, H2), 4.19 (1H, d, J = 5.7 Hz, H6), 4.63 (1H, t, 
J = 4.9 Hz, H4), 6.19 (1H, t, J = 5.6 Hz, NH), 7.06 (1H, t, J = 4.9 Hz, NH), 8.54 (1H, t, J 
= 5.7 Hz, NH), 11.49 (1H, s, NH). 
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13C NMR (125 MHz, CDCl3) δ 14.2, 14.3, 22.75, 22.83, 24.4, 27.1, 28.2, 28.4, 29.2, 29.3, 
29.4, 29.5, 29.67, 29.68, 29.73, 29.80, 29.83 (3 × C), 31.9 (2 × C), 32.1 (2 × C), 32.3, 
33.0, 39.9, 40.0, 40.7, 43.3, 44.5, 44.9, 47.4, 78.7, 79.8, 81.6, 83.6, 104.1, 153.2, 157.3, 
163.4, 171.7, 174.1.   
HRMS (ESI, m/z) for C46H83N5O8 [M + Na]+ calc. 856.6134; found 856.6134. 
 
4-Heptyl-3,5-dioxatricyclo[5.2.1.02,6]decane-8-endo-(heptylcarbamoyl)-9-exo-
carboxamidoethylguanidine hydrogen chloride (219)  
 
Compound 219 was synthesised from Boc-protected guanidine 217 (16 mg, 0.02 mmol) 
according to general procedure G and isolated as a colourless oil (10 mg, 99%). 
1H NMR (500 MHz, CD3OD) δ 0.88–0.91 (6H, m, 2 × CH3), 1.29–1.40 (18H, m, 9 × 
CH2), 1.47–1.52 (3H, m, CH2, H10s), 1.57–1.61 (2H, m, CH2), 1.72 (1H, d, J = 10.4 Hz, 
H10a), 2.42 (1H, br s, H9), 2.58–2.60 (2H, m, H1, H7), 3.07–3.13 (2H, m, NHCH2), 3.17 
(1H, app. t, J = 5.0 Hz, H8), 3.23–3.34 (4H, m, 2 × NHCH2), 3.98 (1H, d, J = 5.6 Hz, 
H6), 4.04 (1H, d, J = 5.6 Hz, H2), 4.65 (1H, t, J = 4.8 Hz, H4). 
13C NMR (125 MHz, CD3OD) δ 14.41, 14.44, 23.6, 23.7, 25.2, 27.9, 30.1, 30.3, 30.4, 
30.6, 32.7, 32.91, 33.0, 33.9, 39.7, 40.5, 42.0, 44.8, 45.3, 46.9, 47.8, 80.0, 82.9, 105.1, 
158.9, 173.5, 176.8. 
HRMS (ESI, m/z) for C27H49N5O4 [M + H]+ calc. 508.3857; found 508.3861. 
 
4-Heptyl-3,5-dioxatricyclo[5.2.1.02,6]decane-8-endo-(hexadecylcarbamoyl)-9-exo-
carboxamidoethylguanidine hydrogen chloride (220)  
 
Compound 220 was synthesised from Boc-protected guanidine 218 (21 mg, 0.03 mmol) 
according to general procedure G and isolated as an orange oil (16 mg, 80%). 
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1H NMR (500 MHz, CD3OD) δ 0.90 (6H, t, J = 6.5 Hz, 2 × CH3), 1.29–1.42 (36H, m, 18 
× CH2), 1.47–1.51 (3H, m, CH2, H10s), 1.57–1.61 (2H, m, CH2), 1.72 (1H, d, J = 10.2 Hz, 
H10a), 2.42 (1H, br s, H9), 2.59–2.61 (2H, m, H1, H7), 3.04–3.10 (2H, m, NHCH2), 3.17 
(1H, app. t, J = 5.1 Hz, H8), 3.26–3.35 (4H, m, 2 × NHCH2), 3.99 (1H, d, J = 5.6 Hz, 
H6), 4.04 (1H, d, J = 5.6 Hz, H2), 4.65 (1H, t, J = 4.8 Hz, H4). 
13C NMR (125 MHz, CD3OD) δ 14.4, 14.5, 23.69, 23.73, 25.3, 28.0, 30.1, 30.3, 30.35, 
30.39, 30.5, 30.6, 30.7 (2 × C), 30.76, 30.81 (2 × C), 32.7, 32.9, 33.1 (2 × C), 33.9 (2 × 
C), 39.7, 40.5, 42.0, 44.8, 45.3, 46.9, 47.8, 80.0, 82.9, 105.1, 158.9, 173.5, 176.8. 
HRMS (ESI, m/z) for C36H67N5O4 [M + H]+ calc. 634.5266; found 634.5283. 
 
8-endo-9-exo-Di[2ʹ-(phenylthioureido)ethylcarbamoyl]-4-heptyl-3,5-
dioxatricyclo[5.2.1.02,6]decane (208)  
 
Treatment of amine hydrochloride 186 (52 mg, 0.11 mmol) in CH2Cl2 (500 μL) with Et3N 
(50 μL, 0.109 mmol) was followed by addition of phenylisothiocyanate (13 μL, 
0.109 mmol) and the reaction was stirred at ambient temperature for 22 h. The reaction 
mixture was diluted with H2O (10 mL) and extracted with CH2Cl2 (2 × 10 mL). The 
combined organic phase was washed with 2 M HCl (10 mL), brine (10 mL), dried 
(MgSO4), filtered and concentrated in vacuo to give a white waxy solid which was 
purified using column chromatography (50% EtOAc in pet. spirits–EtOAc) to afford the 
title compound (35 mg, 95%) as a white paste. 
Rf = 0.37 (EtOAc).  
1H NMR (500 MHz, CDCl3) δ 0.87 (3H, t, J = 6.8 Hz, CH3), 1.25–1.42 (11H, m, 5 × 
CH2, H10s), 1.59–1.63 (2H, m, CHCH2) 1.75 (1H, d, J = 9.9 Hz, H10a), 2.35 (1H, d, J = 
5.8 Hz, H7), 2.52 (1H, br s, H1), 2.59 (1H, d, J = 4.4 Hz, H9), 2.85 (1H, app. t, J = 4.4 Hz, 
H8), 3.26–3.28 (2H, m, NHCH2) 3.45–3.51 (2H, m, NHCH2), 3.68–3.87 (4H, m, 2 × 
NHCH2), 3.89 (1H, d, J = 5.7 Hz, H6), 3.99 (1H, d, J = 5.7 Hz, H2), 4.60 (1H, t, J = 
4.9 Hz, H4), 6.68 (2H, br s, 2 × NH), 6.81 (1H, t, J = 5.6 Hz, NH), 7.06 (1H, t, J = 5.3 Hz, 
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NH), 7.21–7.31 (6H, m, ArH), 7.39–7.43 (4H, m, ArH), 8.06 (1H, br s, NH), 8.12 (1H, 
br s, NH). 
13C NMR (125 MHz, CDCl3) δ 14.2, 22.8, 24.4, 29.3, 29.7, 31.9, 32.6, 33.0, 39.4, 40.4, 
43.4, 44.3, 44.4, 44.9, 45.6, 48.0, 78.7, 81.5, 104.2, 125.5 (2 × C), 125.6 (2 × C), 127.5 
(2 × C), 130.3 (4 × C), 136.2 (2 × C), 172.9 (2 × C), 174.8 (2 × C). 
HRMS (ESI, m/z) for C35H48N6O4S2 [M + H]+ calc. 681.3251; found 681.3251.  
 
8-endo-9-exo-Di[2ʹ-([2ʺ-benzylaminocyclobut-1ʺ-ene-3ʺ,4ʺ-
dione]amino)ethylcarbamoyl]-4-heptyl-3,5-dioxatricyclo[5.2.1.02,6]decane (222)  
 
Treatment of amine hydrochloride 186 (99 mg, 0.204 mmol) in MeOH (730 μL) with 
Et3N (85 μL, 0.612 mmol) was followed by addition of squaric ester 105 (90 mg, 
0.408 mmol) and the reaction was stirred at ambient temperature for 2.5 h. The white 
slurry was concentrated under reduced pressure and then triturated in 2 M HCl (3 mL) for 
40 min at ambient temperature. The white solid was collected by vacuum filtration before 
being diluted with MeOH (600 μL), treated with EDA (20 μL) and stirred at ambient 
temperature for a further 2 h. Again, the resulting slurry was triturated in 2 M HCl (3 mL) 
for 20 min at ambient temperature and the off-white solid was collected and dried in vacuo 
to give the title compound (63 mg, 40%). 
m.p 166–205 °C (slow decomposition). 
1H NMR (500 MHz, DMSO-d6) δ 0.84 (3H, t, J = 6.7 Hz, CH3), 1.22–1.35 (11H, m, 5 × 
CH2, H10s), 1.48–1.49 (3H, CHCH2, H10a), 2.29 (1H, br s, H1), 2.46 (1H, d, J = 5.0 Hz, 
H7), 2.48–2.50 (1H, m, H9), 3.06 (1H, app. t, J = 3.8 Hz, H8), 3.10–3.27 (8H, m, 4 × 
NHCH2), 3.83 (1H, d, J = 5.6 Hz, H6), 3.87 (1H, d, J = 5.6 Hz, H2), 4.54 (1H, t, J = 
4.6 Hz, H4), 4.70 (4H, br s, 2 × ArCH2), 7.27–7.38 (10H, m, ArH), 7.49 (2H, br s, 2 × 
NH), 7.89 (2H, br s, 2 × NH), 8.11 (1H, t, J = 5.0 Hz, NH), 8.16 (1H, br s, NH). 
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13C NMR (125 MHz, DMSO-d6) δ 13.9, 22.1, 23.7, 28.6, 28.9, 31.1, 31.2, 32.4, 39.5 (4 
× C), 43.0, 43.1, 44.5, 46.2, 46.8 (2 × C), 78.2, 81.0, 102.9, 127.4 (2 × C), 127.5 (4 × C), 
128.6 (4 × C), 139.0 (2 × C), 167.5 (2 × C), 168.0 (2 × C), 171.3, 173.2, 182.5 (4 × C). 
HRMS (ESI, m/z) for C43H52N6O8 [M + H]+ calc. 781.3919; found 781.3904. 
 
Methyl-12-aminododecanoate hydrochloride (229)  
 
A solution of thionyl chloride (380 μL, 5.23 mmol) in MeOH (5 mL) at 0 °C was stirred 
for 20 min before 12-aminododecanoic acid 227 (504 mg, 2.34 mmol) was added. The 
reaction was slowly warmed to ambient temperature and stirring was maintained for 24 h. 
The reaction mixture was concentrated under reduced pressure to give the title compound 
(616 mg, 99%) as a white solid.  
m.p 156–157 °C (lit. 118–122 °C).506  
1H NMR (500 MHz, DMSO-d6) δ 1.24–1.28 (14H, m, 7 × CH2), 1.49–1.54 (4H, m, 2 × 
CH2), 2.28 (2H, t, J = 7.4 Hz, CH2CO2Me), 2.73 (2H, app. t, J = 7.5 Hz, CH2NH3), 3.57 
(3H, s, Me), 7.91 (3H, br s, NH3). 
13C NMR (125 MHz, DMSO-d6) δ 24.4, 25.8, 27.0, 28.4, 28.5, 28.7, 28.8, 28.9 (2 × C), 
33.3, 38.7, 51.2, 173.4. 
HRMS (ESI, m/z) for C13H27NO2 [M + H]+ calc. 230.2115; found 230.2111. 
 
N-(tert-Butoxycarbonyl)-12-aminododecanoic acid (230)342  
 
A 250 mL round-bottom flask was charged with 12-aminododecanoic acid 227 (6.00 g, 
27.86 mmol), Boc2O (6.08 g, 27.86 mmol), Et3N (4.7 mL, 33.62 mmol) and MeOH 
(90 mL) and stirred at 60 °C for 16 h. The colourless solution was concentrated under 
reduced pressure and the residue was dissolved in EtOAc (150 mL). The organic phase 
was washed with 0.25 M HCl (2 × 40 mL), brine (40 mL), dried (MgSO4), filtered and 
concentrated in vacuo to give the title compound (7.47 g, 85%) as a white solid. 
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m.p 85–86 °C (lit. 83.5–84.5 °C).506  
1H NMR (500 MHz, CDCl3) δ 1.26–1.34 (14H, m, 7 × CH2), 1.44–1.48 (11H, m, t-Bu, 
CH2), 1.62 (2H, app. quin, J = 7.5 Hz, CH2), 2.33 (2H, t, J = 7.5 Hz, CH2CO2H), 3.09–
3.10 (2H, m, NHCH2), 4.53 (1H, br s, NH). 
13C NMR (125 MHz, CDCl3) δ 24.8, 26.9, 28.6, 29.1, 29.3, 29.4, 29.46, 29.54, 29.6, 30.2, 
34.1, 40.8, 79.2, 156.2, 179.2. 
HRMS (ESI, m/z) for C17H33NO4 [M + Na]+ calc. 338.2302; found 338.2309.  
 
N-(tert-Butoxycarbonyl)-12-aminododecan-1-ol (231)342  
 
To a stirring solution of carboxylic acid 230 (7.33 g, 23.25 mmol) and anhydrous THF 
(110 mL) at 0 °C under an inert atmosphere, was added Red-Al® (18 mL, 59.97 mmol) 
dropwise over 25 min, and stirring was maintained for a further 60 min after warming the 
reaction to ambient temperature. The reaction was quenched with sat. Na2SO3 (30 mL) 
slowly (on ice) and stirred for a further 60 min. The precipitate was removed by vacuum 
filtration and the filtrate was concentrated under reduced pressure before being diluted 
with EtOAc (100 mL). The organic phase was washed with H2O (2 × 40 mL), brine 
(40 mL), dried (MgSO4), filtered and concentrated in vacuo to give the title compound 
(5.31 g, 76%) as a white solid. 
m.p 82–83 °C. 
1H NMR (270 MHz, CDCl3) δ 1.26–1.56 (29H, m, 10 × CH2, t-Bu), 3.09 (2H, t, J = 
7.0 Hz, NHCH2), 3.63 (2H, t, J = 6.6 Hz, CH2CO2H), 4.48 (1H, br s, NH). 
13C NMR (125 MHz, CDCl3) δ 25.9, 26.9, 28.6, 29.4, 29.5, 29.66 (3 × C), 29.70, 30.2, 
32.9, 40.8, 63.2, 79.2, 156.2. 
HRMS (ESI, m/z) for C17H35NO3 [M + Na]+ calc. 324.2509; found 324.2504.  
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tert-Butyl-[12-(methoxy[methyl]amino)-12-oxododecyl]carbamate (233)355  
 
A mixture of carboxylic acid 230 (5.46 g, 17.30 mmol), EDCI (4.02 g, 20.94 mmol), 
HOBt (241 mg, 1.78 mmol), N,O-dimethylhydroxylamine hydrochloride 232 (2.05 g, 
20.97 mmol), CHCl3 (80 mL) and DIPEA (15.4 mL, 86.5 mmol) was stirred at 65 °C for 
24 h. The reaction was cooled to ambient temperature and the mixture was washed with 
0.1 M HCl (40 mL), sat. NaHCO3 (40 mL), brine (40 mL), dried (MgSO4), filtered and 
concentrated in vacuo. The crude material was purified using column chromatography 
(20–50% EtOAc in pet. spirits) to afford the title compound (5.40 g, 87%) as a colourless 
viscous oil. 
Rf = 0.56 (50% EtOAc in pet. spirits). 
1H NMR (400 MHz, CDCl3) δ 1.26–1.29 (16H, m, 8 × CH2), 1.39–1.46 (9H, m, t-Bu), 
1.57–1.65 (2H, m, CH2), 2.40 (2H, t, J = 7.5 Hz, CH2CO), 3.08–3.09 (2H, m, NHCH2), 
3.17 (3H, s, NCH3), 3.67 (3H, s, OCH3), 4.51 (1H, br s, NH). 
 13C NMR (100 MHz, CDCl3) δ 24.8, 26.9, 28.6, 29.4, 29.5, 29.57, 29.58, 29.63, 29.64, 
30.2, 32.0, 32.3, 40.8, 61.3, 79.2, 156.1, 174.9. 
HRMS (ESI, m/z) for C19H38N2O4 [M + H]+ calc. 359.2904; found 359.2904. 
 
N-(tert-Butoxycarbonyl)-12-aminododecanal (226)  
 
Method A343 
To the stirring solution of oxalyl chloride (140 μL, 1.60 mmol) in anhydrous CH2Cl2 
(8 mL) at −78 °C, was added DMSO (230 μL, 3.19 mmol), alcohol 231 (400 mg, 
1.33 mmol) in anhydrous CH2Cl2 (1.5 mL) and Et3N (1 mL, 7.18 mmol) successively. 
Stirring was maintained under an inert atmosphere at −78 °C for 3 h before being warmed 
to ambient temperature and stirred for a further 16 h. The reaction was diluted with H2O 
(20 mL) and extracted with Et2O (2 × 20 mL). The combined organic phase was washed 
with brine (20 mL), dried (MgSO4), filtered and concentrated in vacuo. The crude 
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material was purified using column chromatography (10% EtOAc in pet. spirits) to give 
the title compound (140 mg, 35%) as a white solid. 
Method B348 
Alcohol  231 (1.035 g, 3.43 mmol) was added to the stirring mixture of neutral alumina 
(5.092 g, 49.97 mmol) and PCC (2.182 g, 10.12 mmol) in CH2Cl2 (33 mL) and stirring 
was maintained at ambient temperature for 3 h. The solid material was removed by 
filtration (rinsing with CH2Cl2) and the filtrate was concentrated in vacuo. The crude 
material was purified using column chromatography (20% EtOAc in pet. spirits) to give 
the product (808 mg, 79%) as a white solid. 
Method C351 
Alcohol 231 (209 mg, 0.693 mmol) was stirred in CH2Cl2 (1.4 mL) at ambient 
temperature before TEMPO (13 mg, 0.083 mmol) and iodobenzene diacetate (246 mg, 
0.762 mmol) were added. The pale orange solution was stirred at ambient temperature for 
a further for 24 h before more TEMPO (13 mg, 0.083 mmol) was added. Stirring was 
maintained for another 24 h then the reaction was quenched with sat. Na2SO3 (8 mL) and 
extracted with CH2Cl2 (3 × 5 mL). The combined organic phase was washed with sat. 
NaHCO3 (5 mL), brine (5 mL), dried (MgSO4), filtered and concentrated in vacuo. The 
crude material was purified using column chromatography (20% EtOAc in pet. spirits) to 
give the title compound (112 mg, 58%) as a white solid.  
Method D355 
A stirring solution of Weinreb amide 233 (994 mg, 2.77 mmol) in anhydrous THF 
(30 mL) was added LiAlH4 (4.2 mL, 4.16 mmol, 1 M solution in Et2O), at −78 °C under 
an inert atmosphere. Stirring was maintained for 2 h before the reaction was quenched 
with 1 M HCl (20 mL) and extracted with CH2Cl2 (3 × 30 mL). The combined organic 
phase was washed with brine (30 mL), dried (MgSO4), filtered and concentrated in vacuo 
to give a white solid (790 mg, 95%) that did not require further purification.  
Rf = 0.45 (20% EtOAc in pet. spirits).  
m.p 51–53 °C (lit. 51 °C).343 
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1H NMR (500 MHz, CDCl3) δ 1.26–1.29 (14H, m, 7 × CH2), 1.44–1.47 (11H, m, CH2, t-
Bu), 1.59–1.65 (2H, m, CH2), 2.41 (2H, dt, J = 7.4, 1.8 Hz, CH2CHO), 3.09 (2H, t, J = 
7.0 Hz, CH2NHBoc), 4.48 (1H, br s, NH), 9.76 (1H, t, J = 1.8 Hz, CHO). 
13C NMR (125 MHz, CDCl3) δ 22.2, 26.9, 28.6, 29.3, 29.4, 29.46, 29.51, 29.60, 29.63, 
30.2, 40.8, 44.1, 79.2, 156.2, 203.1. 
HRMS (ESI, m/z) for C17H33NO3 [M + Na]+ calc. 322.2353; found 322.2353.  
 
Dimethyl 4-[11ʹ-(tert-butoxycarbonylamino)undecyl]-3,5-
dioxatricyclo[5.2.1.02,6]decane-8-endo-9-exo-dicarboxylate (225) 
 
Compound 225 was prepared from diol 110 (323 mg, 1.32 mmol) and aldehyde 226 
(587 mg, 1.96 mmol) according to general procedure B and was purified using column 
chromatography (20% EtOAc in pet. spirits) to give the title compound (542 mg, 78%) 
as a colourless oil. 
Rf = 0.44 (20% EtOAc in pet. spirits). 
1H NMR (500 MHz, CDCl3) δ 1.24–1.39 (19H, m, 9 × CH2, H10s), 1.43 (9H, s, t-Bu), 
1.60–1.64 (2H, m, CH2), 1.77 (1H, dd, J = 10.9, 1.4 Hz, H10a), 2.63–2.64 (2H, m, H1, 
H7), 2.71 (1H, d, J = 4.8 Hz, H9), 3.08 (2H, app. t, J = 7.0 Hz, CH2NHBoc), 3.22 (1H, 
app. t, J = 4.8 Hz, H8), 3.69–3.70 (6H, m, 2 × Me), 3.89 (1H, d, J = 5.6 Hz, H6), 4.02 
(1H, d, J = 5.6 Hz, H2), 4.50 (1H, br s, NH), 4.65 (1H, t, J = 5.2 Hz, H4). 
13C NMR (125 MHz, CDCl3) δ 24.3, 26.9, 28.6, 29.4, 29.5, 29.59, 29.64, 29.78, 29.82, 
30.2, 31.7, 32.9, 40.8, 43.4, 43.8, 45.1, 45.4, 52.3, 52.5, 78.9, 79.1, 81.4, 104.3, 156.1, 
172.9, 174.1.  
HRMS (ESI, m/z) for C28H47NO8 [M + Na]+ calc. 548.3194; found 548.3171. 
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4-[11ʹ-(tert-butoxycarbonylamino)undecyl]-3,5-dioxatricyclo[5.2.1.02,6]decane-8-
endo-9-exo-dicarboxylic acid (234) 
 
The title compound was prepared from diester 225 (27 mg, 0.05 mmol) according to 
general procedure D and isolated as a colourless oil (22 mg, 88%). 
1H NMR (500 MHz, CDCl3) δ 1.25–1.51 (28H, m, 9 × CH2, t-Bu, H10s), 1.62–1.66 (2H, 
m, CH2), 1.82 (1H, d, J = 10.2 Hz, H10a), 2.65 (1H, d, J = 5.2 Hz, H9), 2.73 (1H, br s, 
H7), 2.78 (1H, d, J = 4.3 Hz, H1), 3.07 (2H, br s, NHCH2), 3.27 (1H, app. t, J = 5.2 Hz, 
H8), 4.04 (2H, s, H2, H6), 4.59 (1H, br s, NH), 4.68 (1H, t, J = 4.9 Hz, H4). 
13C NMR (125 MHz, CDCl3) δ 24.2, 26.9, 28.6, 29.4, 29.5 (2 × C), 29.56, 29.63, 29.8, 
30.1, 31.9, 32.7, 40.8, 43.4, 43.7, 45.2, 45.3, 78.8, 79.5, 81.4, 104.4, 177.2, 178.4. 
HRMS (ESI, m/z) for C26H43NO8 [M + H]+ calc. 498.3061; found 498.3054. 
 
8-endo-9-exo-Di[2ʹ-(2ʺ,3ʺ-bis-tert-butoxycarbonylguanidino)ethylcarbamoyl]-4-
[11ʹ-(tert-butoxycarbonylamino)undecyl]-3,5-dioxatricyclo[5.2.1.02,6]decane (235) 
 
Compound 235 was prepared from diacid 234 (21 mg, 0.04 mmol) and 
aminoethylguanidine 41 (38 mg, 0.13 mmol) according to general procedure F and was 
purified using column chromatography (20% EtOAc in pet. spirits–EtOAc) to give the 
title compound (14 mg, 32%) as a colourless oil. 
Rf = 0.75 (EtOAc).  
1H NMR (500 MHz, CDCl3) δ 1.24–1.36 (14H, m, 7 × CH2), 1.43–1.50 (50H, m, 2 × 
CH2, 5 × t-Bu, H10s), 1.57–1.62 (2H, m, CH2), 1.77 (1H, d, J = 9.7 Hz, H10a), 2.45 (1H, 
d, J = 5.3 Hz, H9), 2.57 (1H, br s, H7), 2.70 (1H, d, J = 4.1 Hz, H1), 2.94 (1H, app. t, J = 
5.3 Hz, H8), 3.07–3.11 (2H, m, BocNHCH2), 3.35–3.45 (4H, m, 2 × NHCH2), 3.56–3.60 
(4H, m, 2 × NHCH2), 3.95 (1H, d, J = 5.7 Hz, H2), 4.02 (1H, d, J = 5.7 Hz, H6), 4.50 
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(1H, br s, NH), 4.60 (1H, t, J = 4.8 Hz, H4), 6.92 (1H, br s, NH), 8.04 (1H, t, J = 4.1 Hz, 
NH), 8.56 (1H, br s, NH), 8.67 (1H, br s, NH), 11.44–11.47 (2H, m, 2 × NH). 
13C NMR (125 MHz, CDCl3) δ 22.8, 24.3, 27.0, 28.19, 28.20, 28.37, 28.38, 28.6, 29.4, 
29.6, 29.7, 29.8, 30.2, 32.1, 32.5, 33.0, 40.0, 40.1, 40.4, 40.8, 42.1, 43.0, 44.2, 44.4, 47.8, 
79.0, 79.1, 80.0, 80.1, 81.7, 83.6, 83.8, 104.1, 153.1, 153.2, 156.1, 157.0, 157.8, 162.7, 
163.1, 172.1, 174.2.  
HRMS (ESI, m/z) for C52H91N9O14 [M + H]+ calc. 1066.6758; found 1066.6775. 
 
4-[11ʹ-(Amino)undecyl]-3,5-dioxatricyclo[5.2.1.02,6]decane-8-endo-9-exo-
dicarboxamidoethylguanidine hydrogen chloride (224)  
 
Compound 224 was synthesised from 235 (14 mg, 0.01 mmol) according to general 
procedure G and was stirred for 48 h before being isolated as a colourless oil (9 mg, 99%). 
1H NMR (500 MHz, CD3OD) δ 1.29–1.40 (16H, m, 8 × CH2), 1.48 (1H, d, J = 10.3 Hz, 
H10s), 1.58–1.64 (4H, m, 2 × CH2), 1.73 (1H, d, J = 10.3 Hz, H10a), 2.45 (1H, br s,, H9), 
2.61–2.62 (2H, m, H1, H7), 2.85–2.96 (6H, m, 3 × NHCH2), 3.21 (1H, app. t, J = 5.0 Hz, 
H8), 3.26–3.37 (4H, m, 2 × NHCH2), 4.00 (1H, d, J = 5.5 Hz, H2), 4.05 (1H, d, J = 5.5 Hz, 
H6), 4.66 (1H, t, J = 4.6 Hz, H4). 
13C NMR (125 MHz, CD3OD) δ 25.2, 27.5, 29.2, 30.3, 30.5, 30.6, 30.67, 30.70, 30.8, 
32.7, 33.9, 39.6, 39.7, 40.0, 41.88, 41.93, 44.9, 45.1, 47.0, 47.7, 80.0, 82.8, 105.1, 158.9 
(2 × C), 174.6, 176.5. 
HRMS (ESI, m/z) for C27H51N9O4 [M + 3H]3+ calc. 189.4761; found 189.4766.  
 
 
 
 
244 | P a g e  
 
9.2.4: Chapter Four 
Benzyl acetate (246)507  
 
A 10 mL microwave vial was charged with benzyl alcohol (500 μL, 4.8 mmol) and Ac2O 
(906 μL, 9.6 mmol) and heated at 100 °C for 15 min using microwave irradiation. The 
crude material was diluted with CH2Cl2 (10 mL), washed with NaHCO3 (2 × 10 mL), 
brine (10 mL), dried (MgSO4), filtered, and concentrated in vacuo to afford the product 
(416 mg, 58%) as a colourless oil. 
1H NMR (270 MHz, CDCl3) δ 2.11 (3H, s, CH3), 5.12 (2H, s, CH2), 7.34–7.38 (5H, m, 
ArH). 
13C NMR (67.5 MHz, CDCl3) δ 21.1, 66.4, 100.3, 128.4 (2 × C), 128.7 (2 × C), 136.1, 
171.0. 
 
Dimethyl 5,6-bis(methoxy) bicyclo[2.2.1]heptane-3-endo-2-exo-dicarboxylate (239a) 
 
Compound 239a was prepared from diol 110 (915 mg, 3.74 mmol) and MeI (1.1 mL, 
17.7 mmol) according to general procedure C and was purified using column 
chromatography (20% EtOAc in pet. spirits) to give the title compound (682 mg, 67%) 
as a colourless viscous oil. 
Rf = 0.17 (20% EtOAc in pet. spirits).  
1H NMR (270 MHz, CDCl3) δ 1.37–1.41 (1H, m, H7s), 1.89 (1H, dd, J = 10.7, 1.2 Hz, 
H7a), 2.64–2.69 (3H, m, H1, H2, H4), 3.20 (1H, dd, J = 5.5, 1.2 Hz, H3), 3.29 (1H, dd, J 
= 6.0, 1.7 Hz, H5), 3.37 (3H, s, Me), 3.42 (3H, s, Me), 3.46 (1H, dd, J = 6.0, 1.7 Hz, H6), 
3.70 (3H, s, Me), 3.72 (3H, s, Me).  
13C NMR (67.5 MHz, CDCl3) δ 32.9, 43.3, 44.8, 45.0, 46.4, 52.2, 52.4, 58.7, 58.8, 81.0, 
84.1, 173.2, 174.2. 
HRMS (ESI, m/z) for C13H20O6 [M + H]+ calc. 273.1333; found 273.1328. 
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Dimethyl 5,6-bis(benzyloxy) bicyclo[2.2.1]heptane-3-endo-2-exo-dicarboxylate 
(239b) 
 
Compound 239b was prepared from diol 110 (917 mg, 3.75 mmol) and BnBr (2.1 mL, 
17.3 mmol) according to general procedure C and was purified using column 
chromatography (10% EtOAc in pet. spirits) to give the title compound (743 mg, 47%) 
as a colourless oil. 
Rf = 0.43 (20% EtOAc in pet. spirits).  
1H NMR (500 MHz, CDCl3) δ 1.45 (1H, dt, J = 10.7, 1.5 Hz, H7s), 2.10 (1H, dd, J = 
10.7, 1.6 Hz, H7a), 2.64–2.65 (2H, m, H1, H2), 2.70–2.71 (1H, m, H4), 3.19 (1H, app. t, 
J = 5.3 Hz, H3), 3.46 (1H, dd, J = 5.8, 1.6 Hz, H5), 3.60 (3H, s, Me), 3.62 (1H, dd, J = 
5.8, 1.4 Hz, H6), 3.69 (3H, s, Me), 4.54 (1H, d, J = 12.1 Hz, OCH2), 4.60 (1H, d, J = 
12.1 Hz, OCH2), 4.60 (1H, d, J = 12.1 Hz, OCH2), 4.63 (1H, d, J = 12.1 Hz, OCH2), 7.25–
7.38 (10H, m, ArH). 
13C NMR (125 MHz, CDCl3) δ 33.4, 44.2, 45.1, 45.9, 46.4, 52.2, 52.4, 72.5, 72.7, 77.9, 
81.7, 127.7 (2 × C), 127.9 (2 × C), 128.0 (2 × C), 128.4 (2 × C), 128.5 (2 × C), 138.4, 
138.5, 173.1, 174.3. 
HRMS (ESI, m/z) for C25H28O6 [M + Na]+ calc. 447.1778; found 447.1754 
 
Dimethyl 5,6-bis[(2-methylbenzyl)oxy] bicyclo[2.2.1]heptane-3-endo-2-exo-
dicarboxylate (239c) 
 
Compound 239c was prepared from diol 110 (321 mg, 1.31 mmol) and 2-methylbenzyl 
bromide (810 μL, 6.03 mmol) according to general procedure C and was purified using 
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column chromatography (10–20% EtOAc in pet. spirits) to give the title compound 
(115 mg, 19%) as a colourless oil. 
Rf = 0.50 (20% EtOAc in pet. spirits).  
1H NMR (500 MHz, CDCl3) δ 1.45 (1H, d, J = 10.6 Hz, H7s), 2.10 (1H, dd, J = 10.6, 
1.4 Hz, H7a), 2.27 (3H, s, ArMe), 2.30 (3H, s, ArMe), 2.67–2.68 (2H, m, H1, H2), 2.70–
2.71 (1H, m, H4), 3.19 (1H, app. t, J = 5.3 Hz, H3), 3.49 (1H, dd, J = 5.8, 1.4 Hz, H5), 
3.62 (3H, s, OMe), 3.64 (1H, dd, J = 5.8, 1.2 Hz, H6), 3.70 (3H, s, OMe), 4.50 (1H, d, J 
= 12.1 Hz, OCH2), 4.59 (1H, d, J = 12.1 Hz, OCH2), 4.60 (2H, s, OCH2), 7.10–7.20 (6H, 
m, ArH), 7.24–7.25 (1H, m, ArH), 7.31–7.33 (1H, m, ArH). 
13C NMR (125 MHz, CDCl3) δ 18.9, 19.0, 33.4, 44.4, 45.1, 45.7, 46.5, 52.2, 52.4, 70.9, 
71.0, 78.3, 82.0, 125.8, 125.9, 127.8 (2 × C), 128.8, 128.9, 130.2, 130.3, 136.3, 136.4, 
136.7, 136.9, 173.2, 174.3. 
HRMS (ESI, m/z) for C27H32O6 [M + Na]+ calc. 475.2091; found 475.2073. 
 
Dimethyl 5,6-bis[(4-trifluoromethyl)benzyloxy] bicyclo[2.2.1]heptane-3-endo-2-exo-
dicarboxylate (239d) 
 
Compound 239d was prepared from diol 110 (315 mg, 1.29 mmol) and 4-
(trifluoromethyl)benzyl bromide (910 μL, 5.93 mmol) according to general procedure C 
and was purified using column chromatography (10–20% EtOAc in pet. spirits) to give 
the title compound (461 mg, 64%) as a colourless oil. 
Rf = 0.26 (20% EtOAc in pet. spirits).  
1H NMR (500 MHz, CDCl3) δ 1.49 (1H, dt, J = 10.7, 1.4 Hz, H7s), 2.10 (1H, dd, J = 
10.7, 1.6 Hz, H7a), 2.66–2.68 (2H, m, H1, H2), 2.72–2.75 (1H, m, H4), 3.22 (1H, app. t, 
J = 5.2 Hz, H3), 3.52 (1H, dd, J = 5.8, 1.6 Hz, H5), 3.63 (3H, s, Me), 3.67 (1H, dd, J = 
5.8, 1.4 Hz, H6), 3.71 (3H, s, Me), 4.58 (1H, d, J = 12.7 Hz, OCH2), 4.62 (1H, d, J = 
12.7 Hz, OCH2), 4.64 (1H, d, J = 12.5 Hz, OCH2), 4.67 (1H, d, J = 12.5 Hz, OCH2), 7.38–
7.42 (4H, m, ArH), 7.54–7.57 (4H, m, ArH). 
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13C NMR (125 MHz, CDCl3) δ 33.3, 44.2, 45.0, 45.8, 46.3, 52.3, 52.5, 71.8, 71.9, 78.6, 
82.2, 124.2 (q, JCF = 270.6 Hz, 2 × C), 125.3 (q, JCF = 3.6 Hz, 2 × C), 125.4 (q, JCF = 
3.6 Hz, 2 × C), 127.7 (2 × C), 127.8 (2 × C), 129.9 (q, JCF = 32.3 Hz), 130.0 (q, JCF = 
32.3 Hz), 142.4 (2 × C), 173.1, 174.0. 
19F NMR (470 MHz, CDCl3) δ −63.00 (s), −63.02 (s). 
HRMS (ESI, m/z) for C27H26F6O6 [M + H]+ calc. 561.1706; found 561.1718. 
 
Dimethyl 5,6-bis[(3-fluorobenzyl)oxy] bicyclo[2.2.1]heptane-3-endo-2-exo-
dicarboxylate (239e) 
 
Compound 239e was prepared from diol 110 (333 mg, 1.36 mmol) and 3-fluorobenzyl 
bromide (770 μL, 6.26 mmol) according to general procedure C and was purified using 
column chromatography (10–20% EtOAc in pet. spirits) to give the title compound 
(326 mg, 52%) as a colourless oil. 
Rf = 0.31 (20% EtOAc in pet. spirits).  
1H NMR (500 MHz, CDCl3) δ 1.47 (1H, dt, J = 10.7, 1.5 Hz, H7s), 2.09 (1H, dd, J = 
10.7, 1.6 Hz, H7a), 2.65–2.67 (2H, m, H1, H2), 2.72–2.74 (1H, m, H4), 3.21 (1H, app. t, 
J = 5.3 Hz, H3), 3.47 (1H, dd, J = 5.9, 1.6 Hz, H5), 3.62–3.64 (4H, m, Me, H6), 3.70 (3H, 
s, Me), 4.54 (1H, d, J = 12.5 Hz, OCH2), 4.57 (1H, d, J = 12.5 Hz, OCH2), 4.58 (1H, d, J 
= 12.2 Hz, OCH2), 4.61 (1H, d, J = 12.2 Hz, OCH2), 6.94–7.13 (6H, m, ArH), 7.25–7.30 
(2H, m, ArH). 
13C NMR (125 MHz, CDCl3) δ 33.3, 44.1, 45.0, 45.8, 46.3, 52.2, 52.5, 71.7, 71.9, 78.2, 
81.9, 114.5 (d, JCF = 21.6 Hz, 2 × C), 114.59 (d, JCF = 21.1 Hz), 114.62 (d, JCF = 21.6 Hz), 
123.1 (d, JCF = 2.8 Hz), 123.2 (d, JCF = 2.8 Hz), 129.9 (d, JCF = 1.6 Hz), 130.0 (d, JCF = 
1.7 Hz), 140.98 (d, JCF = 2.4 Hz), 141.04 (d, JCF = 2.3 Hz), 163.0 (d, JCF = 244.6 Hz), 
163.1 (d, JCF = 244.4 Hz), 173.1, 174.1. 
19F NMR (470 MHz, CDCl3) δ −113.77 (s). 
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HRMS (ESI, m/z) for C25H26F2O6 [M + H]+ calc. 461.1770; found 461.1784. 
 
Dimethyl 5,6-bis[(4-fluorobenzyl)oxy] bicyclo[2.2.1]heptane-3-endo-2-exo-
dicarboxylate (239f) 
 
Compound 239f was prepared from diol 110 (308 mg, 1.26 mmol) and 4-fluorobenzyl 
bromide (720 μL, 5.80 mmol) according to general procedure C and was purified using 
column chromatography (10–20% EtOAc in pet. spirits) to give the title compound 
(157 mg, 27%) as a colourless oil. 
Rf = 0.30 (20% EtOAc in pet. spirits).  
1H NMR (500 MHz, CDCl3) δ 1.45 (1H, dt, J = 10.7, 1.5 Hz, H7s), 2.07 (1H, dd, J = 
10.7, 1.6 Hz, H7a), 2.64–2.65 (1H, m, H2), 2.66 (1H, br s, H1), 2.69 (1H, dd, J = 4.6, 
1.4 Hz, H4), 3.20 (1H, app. t, J = 5.1 Hz, H3), 3.47 (1H, dd, J = 5.8, 1.6 Hz, H5), 3.62 
(1H, dd, J = 5.8, 1.5 Hz, H6), 3.64 (3H, s, Me), 3.70 (3H, s, Me), 4.48 (1H, d, J = 11.9 Hz, 
OCH2), 4.52 (1H, d, J = 11.9 Hz, OCH2), 4.55 (2H, br s, OCH2), 6.96–7.01 (4H, m, ArH), 
7.23–7.30 (4H, m, ArH). 
13C NMR (125 MHz, CDCl3) δ 33.3, 44.2, 45.1, 45.9, 46.3, 52.2, 52.4, 71.8, 72.0, 78.1, 
81.8, 115.2 (d, J = 21.2 Hz, 2 × C), 115.3 (d, JCF = 21.1 Hz, 2 × C), 129.6 (d, JCF = 9.2 Hz, 
2 × C), 129.7 (d, JCF = 8.4 Hz, 2 × C), 134.1 (d, JCF = 3.4 Hz), 134.2 (d, JCF = 2.9 Hz), 
162.4 (d, JCF = 244.0 Hz), 162.5 (d, JCF = 244.3 Hz), 173.1, 174.1. 
19F NMR (470 MHz, CDCl3) δ −115.30 (s), −115.36 (s). 
HRMS (ESI, m/z) for C25H26F2O6 [M + Na]+ calc. 483.1590; found 483.1594. 
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Dimethyl 5,6-bis[(3-bromobenzyl)oxy] bicyclo[2.2.1]heptane-3-endo-2-exo-
dicarboxylate (239g) 
 
Compound 239g was prepared from diol 110 (315 mg, 1.29 mmol) and 3-bromobenzyl 
bromide (1.48 g, 5.93 mmol) according to general procedure C and was purified by 
column chromatography (10–20% EtOAc in pet. spirits) to give the title compound 
(266 mg, 35%) as a colourless oil. 
Rf = 0.27 (20% EtOAc in pet. spirits).  
1H NMR (500 MHz, CDCl3) δ 1.47 (1H, dt, J = 10.7, 1.3 Hz, H7s), 2.09 (1H, dd, J = 
10.7, 1.5 Hz, H7a), 2.66–2.67 (2H, m, H1, H2), 2.72 (1H, dd, J = 4.6, 1.3 Hz, H4), 3.21 
(1H, app. t, J = 4.9 Hz, H3), 3.48 (1H, dd, J = 5.8, 1.7 Hz, H5), 3.63 (1H, dd, J = 5.8, 
1.4 Hz, H6), 3.66 (3H, s, Me), 3.71 (3H, s, Me), 4.51 (1H, d, J = 12.5 Hz, OCH2), 4.54 
(1H, d, J = 12.5 Hz, OCH2), 4.55 (1H, d, J = 12.3 Hz, OCH2), 4.58 (1H, d, J = 12.3 Hz, 
OCH2), 7.15–7.29 (4H, m, ArH), 7.39–7.53 (4H, m, ArH). 
13C NMR (125 MHz, CDCl3) δ 33.3, 44.2, 45.1, 45.9, 46.3, 52.3, 52.5, 71.7, 71.9, 78.3, 
82.0, 122.6, 122.7, 126.2, 126.3, 130.1 (2 × C), 130.7, 130.8 (3 × C), 140.7, 140.8, 173.1, 
174.1. 
HRMS (ESI, m/z) for C25H2679Br2O6 [M + H]+ calc. 581.0169; found 581.0181. 
 
Dimethyl 5,6-bis[(4-bromobenzyl)oxy] bicyclo[2.2.1]heptane-3-endo-2-exo-
dicarboxylate (239h) 
 
Compound 239h was prepared from diol 110 (333 mg, 1.36 mmol) and 4-bromobenzyl 
bromide (1.57 g, 6.26 mmol) according to general procedure C and was purified using 
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column chromatography (10–20% EtOAc in pet. spirits) to give the title compound 
(279 mg, 35%) as a colourless oil. 
Rf = 0.36 (20% EtOAc in pet. spirits).  
1H NMR (500 MHz, CDCl3) δ 1.45 (1H, d, J = 10.7 Hz, H7s), 2.06 (1H, d, J = 10.7 Hz, 
H7a), 2.64–2.65 (2H, m, H1, H2), 2.68–2.69 (1H, m, H4), 3.20 (1H, app. t, J = 5.0 Hz, 
H3), 3.46 (1H, dd, J = 5.8, 1.6 Hz, H5), 3.61 (1H, dd, J = 5.8, 1.3 Hz, H6), 3.64 (3H, s, 
Me), 3.70 (3H, s, Me), 4.46 (1H, d, J = 12.2 Hz, OCH2), 4.50 (1H, d, J = 12.2 Hz, OCH2), 
4.53 (2H, br s, OCH2), 7.14–7.19 (4H, m, ArH), 7.42–7.45 (4H, m, ArH). 
13C NMR (125 MHz, CDCl3) δ 33.3, 41.2, 45.1, 45.9, 46.3, 52.3, 52.5, 71.8, 72.0, 78.3, 
81.9, 121.6 (2 × C), 129.4 (2 × C), 129.6 (2 × C), 131.5 (2 × C), 131.6 (2 × C), 137.4, 
137.5, 173.1, 174.1. 
HRMS (ESI, m/z) for C25H2679Br2O6 [M + H]+ calc. 581.0169; found 581.0182. 
 
Dimethyl 5,6-bis(allyloxy) bicyclo[2.2.1]heptane-3-endo-2-exo-dicarboxylate (239i) 
 
Compound 239i was prepared from diol 110 (302 mg, 1.24 mmol) and allyl bromide 
(530 μL, 5.70 mmol) according to general procedure C and was purified using column 
chromatography (20% EtOAc in pet. spirits) to give the title compound (107 mg, 29%) 
as a colourless oil. 
Rf = 0.44 (20% EtOAc in pet. spirits).  
1H NMR (270 MHz, CDCl3) δ 1.41 (1H, dd, J = 10.7, 1.5 Hz, H7s), 1.99 (1H, dd, J = 
10.7, 1.6 Hz, H7a), 2.58–2.59 (1H, m, H1), 2.64–2.68 (2H, m, H2, H4), 3.18 (1H, dd, J 
= 5.3, 4.8 Hz, H3), 3.43 (1H, dd, J = 5.9, 1.7 Hz, H5), 3.56 (1H, dd, J = 5.9, 1.6 Hz, H6), 
3.69 (3H, s, Me), 3.70 (3H, s, Me), 4.01 (2H, dt, J = 5.6, 1.4 Hz, OCH2), 4.06 (2H, dt, J 
= 5.6, 1.4 Hz, OCH2), 5.13–5.31 (4H, m, 2 × CH2CH), 5.81–5.98 (2H, m, 2 × CH2CH).  
13C NMR (67.5 MHz, CDCl3) δ 33.3, 44.2, 45.1, 46.0, 46.4, 52.2, 52.4, 71.8, 71.9, 78.3, 
81.8, 117.1 (2 × C), 135.0 (2 × C), 173.2, 174.3. 
HRMS (ESI, m/z) for C17H24O6 [M + Na]+ calc. 347.1465; found 347.1479. 
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5,6-Bis(methoxy) bicyclo[2.2.1]heptane-3-endo-2-exo-dicarboxylic acid (258a) 
 
The title compound was prepared from diester 239a (194 mg, 0.71 mmol) according to 
general procedure D and isolated as a white residue (127 mg, 73%). 
1H NMR (270 MHz, CDCl3) δ 1.43 (1H, d, J = 10.4 Hz, H7s), 1.96 (1H, d, J = 10.4 Hz, 
H7a), 2.67–2.76 (3H, m, H1, H2, H4), 3.25 (1H, app. t, J = 5.4 Hz, H3), 3.41 (3H, s, Me), 
3.44 (3H, s, Me), 3.45–3.50 (2H, m, H5, H6). 
 13C NMR (67.5 MHz, CDCl3) δ 33.1, 43.1, 44.8, 44.9, 46.3, 58.8, 58.9, 80.8, 84.1, 178.0, 
179.2.  
HRMS (ESI, m/z) for C11H16O6 [M + Na]+ calc. 267.0839; found 267.0842. 
 
5,6-Bis(benzyloxy) bicyclo[2.2.1]heptane-3-endo-2-exo-dicarboxylic acid (258b) 
 
The title compound was prepared from diester 239b (717 mg, 1.69 mmol) according to 
general procedure D and isolated as a white powder (525 mg, 78%). 
1H NMR (270 MHz, CDCl3) δ 1.48 (1H, d, J = 10.7 Hz, H7s), 2.17 (1H, d, J = 10.7 Hz, 
H7a), 2.63 (1H, d, J = 5.5 Hz, H2), 2.73 (1H, br s, H1), 2.79 (1H, d, J = 4.0 Hz, H4), 3.23 
(1H, app. t, J = 5.5 Hz, H3), 3.63 (2H, app. t, J = 6.4 Hz, H5, H6), 4.58 (2H, br s, OCH2), 
4.59 (1H, d, J = 11.9 Hz, OCH2), 4.65 (1H, d, J = 11.9 Hz, OCH2), 7.23–7.35 (10H, m, 
ArH). 
13C NMR (67.5 MHz, DMSO-d6) δ 32.9, 43.6, 44.7, 45.3, 46.1, 71.6, 71.7, 78.1, 81.5, 
127.4 (2 × C), 127.7 (4 × C), 128.12 (2 × C), 128.14 (2 × C), 138.5, 138.7, 173.6, 174.8. 
HRMS (ESI, m/z) for C23H24O6 [M − H]− calc. 395.1501; found 395.1504. 
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5,6-Bis[(2-methylbenzyl)oxy] bicyclo[2.2.1]heptane-3-endo-2-exo-dicarboxylic acid 
(258c) 
 
The title compound was prepared from diester 239c (121 mg, 0.27 mmol) according to 
general procedure D and isolated as a colourless oil (113 mg, 99%). 
1H NMR (500 MHz, DMSO-d6) δ 1.31 (1H, d, J = 9.7 Hz, H7s), 1.85 (1H, d, J = 9.7 Hz, 
H7a), 2.19 (3H, s, Me), 2.21 (3H, s, Me), 2.47 (1H, d, J = 5.5 Hz, H4), 2.55 (1H, br s, 
H1), 2.61 (1H, d, J = 4.2 Hz, H2), 2.99 (1H, app. t, J = 4.2 Hz, H3), 3.59 (1H, d, J = 
5.7 Hz, H5), 3.64 (1H, d, J = 5.7 Hz, H6), 4.45 (1H, d, J = 11.8 Hz, OCH2), 4.48 (1H, d, 
J = 11.8 Hz, OCH2), 4.53 (2H, br s, OCH2), 7.08–7.18 (6H, m, ArH), 7.22–7.27 (2H, m, 
ArH), 12.54 (2H, br s, 2 × CO2H). 
13C NMR (125 MHz, DMSO-d6) δ 18.3 (2 × C), 33.0, 43.6, 44.7, 45.2, 46.1, 70.0, 70.1, 
78.5, 81.8, 125.5 (2 × C), 127.5 (2 × C), 128.3 (2 × C), 129.8 (2 × C), 136.1 (2 × C), 
136.5, 136.6, 173.6, 174.8. 
HRMS (ESI, m/z) for C25H28O6 [M + Na]+ calc. 447.1778; found 447.1787. 
 
5,6-Bis[(4-trifluoromethyl)benzyloxy] bicyclo[2.2.1]heptane-3-endo-2-exo-
dicarboxylic acid (258d) 
 
The title compound was prepared from diester 239d (423 mg, 0.755 mmol) according to 
general procedure D and isolated as a white powder (316 mg, 79%). 
m.p 115–144 °C (slow decomposition). 
1H NMR (500 MHz, DMSO-d6) δ 1.34 (1H, d, J = 9.9 Hz, H7s), 1.90 (1H, d, J = 9.9 Hz, 
H7a), 2.46–2.49 (1H, m, H2), 2.58 (1H, br s, H1), 2.62–2.63 (1H, m, H4), 3.01 (1H, dd, 
J = 5.4, 4.8 Hz, H3), 3.62 (1H, d, J = 5.6 Hz, H6), 3.72 (1H, d, J = 5.6 Hz, H5), 4.58 (1H, 
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d, J = 12.7 Hz, OCH2), 4.62 (1H, d, J = 12.7 Hz, OCH2), 4.63 (1H, d, J = 12.5 Hz, OCH2), 
4.68 (1H, d, J = 12.5 Hz, OCH2), 7.46–7.50 (4H, m, ArH), 7.60–7.63 (4H, m, ArH), 12.58 
(2H, br s, 2 × CO2H). 
13C NMR (125 MHz, DMSO-d6) δ 33.0, 43.6, 44.6, 45.3, 46.0, 70.7, 70.8, 78.4, 81.7, 
124.4 (q, JCF = 270 Hz, 2 × C), 124.9 (q, JCF = 3.3 Hz, 2 × C), 125.0 (q, JCF = 3.3 Hz, 2 × 
C), 127.83, (2 × C), 127.84 (q, JCF = 31.6 Hz, 2 × C), 127.9 (2 × C), 143.5, 143.6, 173.6, 
174.8. 
19F NMR (470 MHz, DMSO-d6) δ −61.43 (s). 
HRMS (ESI, m/z) for C25H22F6O6 [M + Na]+ calc. 555.1213; found 555.1211. 
 
5,6-Bis[(3-fluorobenzyl)oxy] bicyclo[2.2.1]heptane-3-endo-2-exo-dicarboxylic acid 
(258e) 
 
The title compound was prepared from diester 239e (292 mg, 0.635 mmol) according to 
general procedure D and isolated as a white residue (206 mg, 75%). 
1H NMR (500 MHz, CD3OD) δ 1.45 (1H, d, J = 10.5 Hz, H7s), 2.04 (1H, dd, J = 10.5, 
1.2 Hz, H7a), 2.61 (1H, dd, J = 5.6, 1.2 Hz, H2), 2.65 (1H, br s, H1), 2.70 (1H, dd, J = 
4.7, 1.4 Hz, H4), 3.16 (1H, dd, J = 5.6, 4.7 Hz, H3), 3.67–3.71 (2H, m, H5, H6), 4.56 
(2H, s, OCH2), 4.61 (2H, s, OCH2), 6.96–7.00 (2H, m, ArH), 7.04–7.14 (4H, m, ArH), 
7.27–7.33 (2H, m, ArH). 
13C NMR (125 MHz, CD3OD) δ 33.9, 45.2, 46.2, 47.2, 47.6, 72.8 (d, 4JCF = 1.5 Hz), 73.7 
(d, 4JCF = 1.3 Hz), 80.0, 83.4, 115.2 (d, JCF = 21.1 Hz), 115.3 (d, JCF = 21.6 Hz), 115.4 (d, 
JCF = 22.3 Hz), 115.5 (d, JCF = 21.7 Hz), 124.4 (d, JCF = 2.7 Hz), 124.5 (d, JCF = 2.7 Hz), 
130.98, 131.04, 142.6 (d, JCF = 7.2 Hz), 142.7 (d, JCF = 7.2 Hz), 164.26 (d, JCF = 
242.9 Hz), 164.28 (d, JCF = 242.8 Hz), 175.7, 176.9.  
19F NMR (470 MHz, CD3OD) δ −116.03 (s), −116.06 (s). 
HRMS (ESI, m/z) for C23H22F2O6 [M + Na]+ calc. 455.1277; found 455.1264. 
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5,6-Bis[(4-fluorobenzyl)oxy] bicyclo[2.2.1]heptane-3-endo-2-exo-dicarboxylic acid 
(258f) 
 
The title compound was prepared from diester 239f (115 mg, 0.25 mmol) according to 
general procedure D and isolated as a white powder (103 mg, 94%). 
m.p 198–200 °C. 
1H NMR (270 MHz, CDCl3) δ 1.48 (1H, d, J = 10.7 Hz, H7s), 2.13 (1H, d, J = 10.7 Hz, 
H7a), 2.64 (1H, d, J = 5.7 Hz, H2), 2.72 (1H, br s, H1), 2.76–2.78 (1H, m, H4), 3.24 (1H, 
dd, J = 5.7, 4.8 Hz, H3), 3.56–3.64 (2H, m, H5, H6), 4.53 (2H, br s, OCH2), 4.56 (2H, br 
s, OCH2), 6.93–7.02 (4H, m, ArH), 7.23–7.31 (4H, m, ArH). 
13C NMR (67.5 MHz, DMSO-d6) δ 32.9, 43.6, 44.6, 45.3, 46.0, 70.8, 70.9, 78.0, 81.4, 
114.8 (d, JCF = 21.1 Hz, 2 × C), 114.9 (d, JCF = 21.0 Hz, 2 × C), 129.6 (d, JCF = 8.0 Hz, 2 
× C), 129.7 (d, JCF = 8.1 Hz, 2 × C), 134.7 (d, JCF = 3.0 Hz), 134.9 (d, JCF = 3.0 Hz), 161.5 
(d, JCF = 241.3 Hz, 2 × C), 173.5, 174.7. 
19F NMR (470 MHz, DMSO-d6) δ −116.68 (s). 
HRMS (ESI, m/z) for C23H22F2O6 [M + Na]+ calc. 455.1277; found 455.1270. 
 
5,6-Bis[(3-bromobenzyl)oxy] bicyclo[2.2.1]heptane-3-endo-2-exo-dicarboxylic acid 
(258g) 
 
The title compound was prepared from diester 239g (265 mg, 0.455 mmol) according to 
general procedure D and isolated as a white powder (171 mg, 68%). 
m.p 76–78 °C. 
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1H NMR (270 MHz, CDCl3) δ 1.50 (1H, d, J = 11.2 Hz, H7s), 2.16 (1H, d, J = 11.2 Hz, 
H7a), 2.67 (1H, d, J = 5.3 Hz, H2), 2.75 (1H, br s, H1), 2.79 (1H, d, J = 4.3 Hz, H4), 3.27 
(1H, app. t, J = 5.3 Hz, H3), 3.62–3.67 (2H, m, H5, H6), 4.55 (2H, s, OCH2), 4.58 (2H, 
s, OCH2), 7.14–7.24 (4H, m, ArH), 7.36–7.49 (4H, m, ArH). 
13C NMR (67.5 MHz, CDCl3) δ 33.5, 43.9, 44.9, 45.9, 46.2, 71.9, 72.0, 78.5, 81.9, 122.6, 
122.7, 126.2, 126.4, 130.1, 130.2, 130.7, 130.8, 130.9 (2 × C), 140.5, 140.6, 177.5, 178.6. 
HRMS (ESI, m/z) for C23H2279Br2O6 [M − H]− calc. 550.9710; found 550.9729. 
 
5,6-Bis[(4-bromobenzyl)oxy] bicyclo[2.2.1]heptane-3-endo-2-exo-dicarboxylic acid 
(258h) 
 
The title compound was prepared from diester 239h (159 mg, 0.273 mmol) according to 
general procedure D and isolated as a white powder (119 mg, 79%). Crystals suitable for 
X-ray analysis were obtained from recrystallisation with 10% EtOH in pet. spirits. 
m.p 120–125 °C.  
1H NMR (500 MHz, CD3OD) δ 1.43 (1H, d, J = 10.4 Hz, H7s), 2.02 (1H, dd, J = 10.4, 
1.2 Hz, H7a), 2.60 (1H, d, J = 5.4 Hz, H2), 2.63 (1H, br s, H1), 2.68 (1H, dd, J = 4.5, 
1.2 Hz, H4), 3.15 (1H, app. t, J = 5.4 Hz, H3), 3.65–3.68 (2H, m, H5, H6), 4.49 (1H, d, J 
= 12.1 Hz, OCH2), 4.51 (1H, d, J = 12.1 Hz, OCH2), 4.54 (2H, br s, OCH2), 7.19–7.24 
(4H, m, ArH), 7.42–7.44 (4H, m, ArH). 
13C NMR (125 MHz, CD3OD) δ 33.9, 45.2, 46.2, 47.2, 47.6, 72.7, 72.8, 79.8, 83.3, 122.3, 
122.4, 130.8 (2 × C), 130.9 (2 × C), 132.4 (4 × C), 138.9, 139.1, 173.6, 174.8. 
HRMS (ESI, m/z) for C23H2279Br2O6 [M − H]− calc. 550.9710; found 550.9723. 
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5,6-Bis(allyloxy) bicyclo[2.2.1]heptane-3-endo-2-exo-dicarboxylic acid (258i) 
 
The title compound was prepared from diester 239i (41 mg, 0.127 mmol) according to 
general procedure D and isolated as a yellow viscous oil (127 mg, 73%). 
1H NMR (270 MHz, CDCl3) δ 1.41–1.45 (1H, m, H7s), 2.04 (1H, d, J = 10.4 Hz, H7a), 
2.64–2.72 (3H, m, H1, H2, H4), 3.22 (1H, dd, J = 5.5, 4.7 Hz, H3), 3.56–3.61 (2H, m, 
H5, H6), 4.03–4.10 (4H, m, 2 × OCH2), 5.12–5.32 (4H, m, 2 × CH2CH), 5.82–5.99 (2H, 
m, CH2CH). 
 13C NMR (125 MHz, CDCl3) δ 33.2, 43.9, 44.9, 45.8, 46.2, 71.7, 71.8, 78.2, 81.6, 117.2, 
117.3, 134.6, 134.7, 178.1, 179.2. 
HRMS (ESI, m/z) for C15H20O6 [M + Na]+ calc. 319.1152; found 319.1152. 
 
Ethyl 4-(octyloxy)benzoate (260)508 
 
A mixture of 4-hydroxybenzoate 259 (1.54 g, 9.20 mmol), K2CO3 (3.81 g, 27.6 mmol), 
1-iodooctane (2.5 mL, 13.9 mmol) and DMF (14 mL) were stirred in a round-bottom flask 
protected from light at ambient temperature for 16 h. The reaction mixture was diluted 
with EtOAc (25 mL) and the organic phase was washed with H2O (3 × 20 mL), brine 
(20 mL), dried (MgSO4), filtered, and concentrated in vacuo to give a colourless oil which 
was purified using column chromatography (pet. spirits–5% EtOAc in pet. spirits) to 
afford the title compound (2.25 g, 88%) as a colourless oil. 
Rf = 0.45 (5% EtOAc in pet. spirits). 
1H NMR (270 MHz, CDCl3) δ 0.88 (3H, t, J = 7.0 Hz, CH3), 1.28–1.51 (13H, m, 5 × 
CH2, CH3), 1.77–1.81 (2H, m, CH2), 3.99 (2H, t, J = 6.6 Hz, OCH2), 4.34 (2H, t, J = 
7.2 Hz, OCH2), 6.87–6.92 (2H, m, ArH), 7.95–8.00 (2H, m, ArH).  
13C NMR (67.5 MHz, CDCl3) δ 14.2, 14.5, 22.8, 26.1, 29.2, 29.4, 29.5, 31.9, 60.7, 68.3, 
114.1 (2 × C), 122.7, 131.6 (2 × C), 163.0, 166.6. 
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HRMS (ESI, m/z) for C17H26O3 [M + H]+ calc. 279.1955 found 279.1954. 
 
4-[(Octyloxy)phenyl]methanol (261)405 
 
Under an inert atmosphere, ester 260 (2.21 g, 7.95 mmol) was stirred in PhMe (40 mL), 
at 0 °C before Red-Al® (65% wt. in PhMe, 6 mL, 20 mmol) was added slowly. The 
reaction was warmed to ambient temperature over 30 min, before stirring for a further 
16 h. The reaction mixture was diluted with EtOAc (25 mL), and H2O (25 mL) was added 
slowly over 2 h. The aqueous layer was extracted with EtOAc (2 × 25 mL), and the 
combined organic phase was washed with brine (25 mL), dried (MgSO4), filtered, and 
concentrated in vacuo. The resulting pale green waxy solid was stirred in pet. spirits 
(25 mL) at ambient temperature for 1 h. The product was collected using vacuum 
filtration (washing with cold pet. spirits) as a fluffy white solid (1.40 g, 75%). 
m.p 50–53 °C (lit. 46–47 °C).405 
1H NMR (270 MHz, CDCl3) δ 0.89 (3H, t, J = 6.9 Hz, CH3), 1.29–1.48 (10H, m, 5 × 
CH2), 1.56 (1H, s, OH), 1.78 (2H, dt, J = 6.6, 1.3 Hz, CH2), 3.95 (2H, t, J = 6.6 Hz, 
OCH2), 4.61 (2H, s, CH2OH), 6.86–6.88 (1H, m, ArH), 6.89–6.91 (1H, m, ArH), 7.25–
7.27 (1H, m, ArH), 7.29–7.31 (1H, m, ArH).  
13C NMR (67.5 MHz, CDCl3) δ 14.2, 22.8, 26.2, 29.4 (2 × C), 29.5, 32.0, 65.3, 68.2, 
114.7 (2 × C), 128.8 (2 × C), 133.0, 159.0. 
HRMS (ESI, m/z) for C15H24O2 [M + Na]+ calc. 259.1669; found 259.1660. 
 
1-(Bromomethyl)-4-(octyloxy)benzene (262)  
 
To a stirring solution of alcohol 261 (237 mg, 1.00 mmol) in PhMe (1.2 mL) at 40 °C, 
was added PBr3 (40 μL, 0.43 mmol) and the reaction was heated to 100 °C and stirred for 
16 h. The vessel was cooled to ambient temperature before i-PrOH (300 μL) was added 
over 1 h. The reaction mixture was diluted with CH2Cl2 (10 mL), and washed with H2O 
(2 × 8 mL), brine (8 mL), dried (MgSO4), filtered, and concentrated in vacuo to afford an 
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orange oil which was purified using flash column chromatography (20–50% EtOAc in 
pet. spirits) to afford the title compound (176 mg, 59%) as an orange oil.  
Rf = 0.40 (20% EtOAc in pet. spirits). 
1H NMR (500 MHz, CDCl3) δ 0.89 (3H, t, J = 7.1 Hz, CH3), 1.26–1.38 (8H, m, 4 × CH2), 
1.42–1.48 (2H, m, CH2), 1.78 (2H, dt, J = 6.6, 1.3 Hz, CH2), 3.95 (2H, t, J = 6.6 Hz, 
OCH2), 4.50 (2H, s, CH2Br), 6.84–6.88 (2H, m, ArH), 7.29–7.33 (2H, m, ArH).  
13C NMR (67.5 MHz, CDCl3) δ 14.3, 22.8, 26.2, 29.3, 29.4, 29.5, 31.9, 34.3, 68.2, 114.9 
(2 × C), 129.8, 130.5 (2 × C), 159.4. 
HRMS (ESI, m/z) for C15H2379BrO [M + Na]+ calc. 321.0824; found 321.0821. 
 
4-(Oct-1-ynyl)benzaldehyde (264)409  
 
A stirring solution under an inert atmosphere of 4-bromobenzaldehyde 263 (211 mg, 
1.14 mmol), PdCl2(PPh3)2 (10 mg, 0.01 mmol), Et3N (1.5 mL) and 1-octyne (190 μL, 
1.25 mmol), was heated at 50 °C for 3 d. The triethylammonium bromide salt was 
removed by filtration and the filtrate was collected and concentrated under vacuum. The 
crude material was purified using column chromatography (pet. spirits–5% EtOAc in pet. 
spirits) to give the title compound (164 mg, 67%) as an orange oil. 
Rf = 0.37 (5% EtOAc in pet. spirits). 
1H NMR (500 MHz, CDCl3) δ 0.90 (3H, t, J = 7.0 Hz, CH3), 1.30–1.35 (4H, m, 2 × CH2), 
1.42–1.48 (2H, m, CH2), 1.61–1.64 (2H, m, CH2), 2.43 (2H, t, J = 7.2 Hz, CH2), 7.51–
7.53 (2H, m, ArH), 7.79–7.80 (2H, m, ArH), 9.98 (1H, s, CHO). 
13C NMR (125 MHz, CDCl3) δ 14.2, 19.7, 22.7, 28.6, 28.7, 31.5, 80.2, 95.5, 129.7 (2 × 
C), 130.8, 132.2 (2 × C), 135.0, 191.7.   
HRMS (ESI, m/z) for C15H18O [M + H]+ calc. 215.1430; found 215.1435. 
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(4-Octylphenyl)methanol (265)409  
 
Under an inert atmosphere, aldehyde 264 (920 mg, 4.29 mmol) was stirred in EtOH 
(6.1 mL) at ambient temperature before Pd(OH)2 (60 mg, 0.43 mmol) was added. The 
reaction was backfilled and evacuated with N2 five times before exposing the reaction 
mixture to H2. The reaction was stirred for 16 h under a H2 atmosphere, before all 
insoluble material was removed by vacuum filtration through Celite and the filtrate was 
collected and concentrated in vacuo. The crude material was purified using flash column 
chromatography (CH2Cl2) to afford the product (198 mg, 21%) as a colourless oil.  
Rf = 0.53 (CH2Cl2). 
1H NMR (270 MHz, CDCl3) δ 0.88 (3H, t, J = 6.4 Hz, CH3), 1.27–1.31 (10H, m, 5 × 
CH2), 1.55–1.64 (3H, m, OH, CH2), 2.60 (2H, t, J = 7.5 Hz, CH2Ar), 4.65 (2H, s, CH2OH), 
7.18 (2H, d, J = 7.7 Hz, ArH), 7.28 (2H, d, J = 7.7 Hz, ArH).  
13C NMR (67.5 MHz, CDCl3) δ 14.2, 22.8, 29.4, 29.5, 29.6, 31.7, 32.0, 35.8, 65.5, 127.3 
(2 × C), 128.8 (2 × C), 138.2, 142.7. 
HRMS (ESI, m/z) for C15H24O [M + H]+ calc. 221.1900; found 221.1897. 
 
1-(Bromomethyl)-4-octylbenzene (266)410  
 
To a stirred solution of alcohol 265 (198 mg, 0.92 mmol) in anhydrous CH2Cl2 (6.1 mL), 
at 21 °C under an inert atmosphere, PBr3 (350 μL, 3.68 mmol) was added slowly and the 
reaction was stirred for 5 h. The reaction was quenched with i-PrOH (1.2 mL) and stirred 
for 1 h. The reaction mixture was diluted with CH2Cl2 (10 mL), washed with H2O (2 × 
10 mL), brine (10 mL), dried (MgSO4), filtered, and concentrated in vacuo to give the 
crude material which was purified using flash column chromatography (pet. spirits–10% 
EtOAc in pet. spirits) to afford the title compound (186 mg, 71%) as colourless oil. 
Rf = 0.39 (pet. spirits). 
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1H NMR (500 MHz, CDCl3) δ 0.88 (3H, t, J = 6.9 Hz, CH3), 1.26–1.31 (10H, m, 5 × 
CH2), 1.58–1.62 (2H, m, CH2), 2.59 (2H, t, J = 7.7 Hz, CH2Ar), 4.50 (2H, s, CH2Br), 7.15 
(2H, d, J = 7.7 Hz, ArH), 7.30 (1H, d, J = 7.7 Hz, ArH).  
13C NMR (125 MHz, CDCl3) δ 14.3, 22.8, 29.4, 29.5, 29.6, 31.5, 32.0, 34.0, 35.8, 129.0 
(2 × C), 129.1 (2 × C), 135.1, 143.6. 
HRMS (ESI, m/z) for C15H2379Br [M + H]+ calc. 283.1056; found 283.1060. 
 
8-endo-9-exo-Di[2ʹ-(2ʺ,3ʺ-bis-tert-
butoxycarbonylguanidino)ethylcarbamoyl]bicyclo[2.2.1]hept-5-ene (269)  
 
Compound 269 was prepared from diacid 50 (336 mg, 1.84 mmol) and 
aminoethylguanidine 41 (1.67 g, 5.53 mmol) according to general procedure F and was 
purified using column chromatography (50% EtOAc in CH2Cl2–EtOAc) to give the title 
compound (933 mg, 68%) as a white residue. 
Rf = 0.64 (EtOAc). 
1H NMR (270 MHz, CDCl3) δ 1.48–1.53 (37H, m, 4 × t-Bu, H7s), 1.70 (1H, d, J = 7.8 Hz, 
H7a), 2.39 (1H, dd, J = 5.8, 1.7 Hz, H2), 2.99 (1H, dd, J = 5.5, 3.0 Hz, H1), 3.11 (1H, br 
s, H4), 3.19 (1H, br s, H3), 3.36–3.68 (8H, m, 4 × NHCH2), 6.14 (1H, dd, J = 5.6, 2.9 Hz, 
H5), 6.23 (1H, dd, J = 5.6, 3.0 Hz, H6), 7.33 (1H, t, J = 4.9 Hz, NH), 7.62 (1H, t, J = 
4.9 Hz, NH), 8.53 (1H, t, J =5.6 Hz, NH), 8.65 (1H, t, J = 5.8 Hz, NH), 11.48 (1H, s, 
NH), 11.54 (1H, s, NH). 
13C NMR (67.5 MHz, CDCl3) δ 28.18, 28.19, 28.36, 28.43, 39.7, 39.8, 40.3, 41.9, 44.0, 
44.9, 48.6, 48.8, 51.3, 79.5, 79.9, 83.3, 83.8, 135.2, 137.9, 153.20, 153.22, 157.0, 157.9, 
163.3, 163.5, 174.3, 175.6. 
HRMS (ESI, m/z) for C35H58N8O10 [M + H]+ calc. 751.4349; found 751.4375. 
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5,6-exo-Dihydroxybicyclo[2.2.1]heptane (273)301  
 
Norbornene 272 (1.02 g, 10.83 mmol) and NMO·H2O (1.61 g, 11.91 mmol) were 
dissolved in a solution of H2O/acetone (25 mL, 1:4) before OsO4 (4% in H2O, 700 μL, 
0.11 mol%) was added. The reaction was stirred for 24 h and then quenched with sat. 
NaHSO3 (15 mL). The suspension was extracted with EtOAc (3 × 15 mL) and the 
combined organic phase was washed with brine (15 mL), dried (MgSO4), filtered and 
concentrated in vacuo to give the title compound (642 g, 46%) as an off-white solid. 
m.p 132–133 °C (lit. 142 °C).301  
1H NMR (500 MHz, CDCl3) δ 1.03–1.07 (2H, m, CH), 1.10 (1H, dt, J = 10.4, 1.5 Hz, 
CH), 1.43–1.48 (2H, m, CH), 1.76 (1H, dt, J = 10.4, 1.7 Hz, CH), 2.11–2.15 (2H, m, CH), 
2.53 (2H, br s, 2 × OH), 3.67 (1H, s, CH), 3.68 (1H, s, CH).  
13C NMR (125 MHz, CDCl3) δ 24.6 (2 × C), 31.7, 43.2 (2 × C), 75.0 (2 × C). 
HRMS (ESI, m/z) for C7H12O2 [M + H]+ calc. 129.0910; found 129.0909. 
 
3-endo-2-exo-Di[2ʹ-(2ʺ,3ʺ-bis-tert-butoxycarbonylguanidino)ethylcarbamoyl]-5,6-
bis(methoxy)bicyclo[2.2.1]heptane (271a) 
 
Compound 271a was prepared from diacid 258a (96 mg, 0.39 mmol) and 
aminoethylguanidine 41 (357 mg, 1.18 mmol) according to general procedure E and was 
purified using column chromatography (EtOAc) to give the title compound (230 mg, 
72%) as a colourless oil. 
Rf = 0.25 (EtOAc).  
1H NMR (500 MHz, CDCl3) δ 1.45–1.47 (36H, m, 4 × t-Bu), 1.56 (1H, d, J = 10.2 Hz, 
H7a), 1.89 (1H, d, J = 10.2 Hz, H7s), 2.45 (1H, d, J = 5.8 Hz, H2), 2.56 (1H, br s, H1), 
2.68 (1H, br s, H4), 2.82 (1H, app. t, J = 5.8 Hz, H3), 3.34 (3H, s, Me), 3.36 (3H, s, Me), 
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3.38–3.60 (10H, m, 4 × NHCH2, H5, H6), 6.69 (1H, t, J = 5.4 Hz, NH), 8.02 (1H, t, J = 
3.4 Hz, NH), 8.45 (1H, t, J = 5.5 Hz, NH), 8.65 (1H, t, J = 5.6 Hz, NH), 11.44 (1H, s, 
NH), 11.48 (1H, s, NH). 
13C NMR (125 MHz, CDCl3) δ 28.1, 28.2, 28.3, 28.4, 33.8, 39.4, 40.1, 40.3, 42.4, 42.9, 
43.7, 45.0,  49.3, 58.4, 58.6, 79.5, 80.0, 81.1, 83.3, 83.8, 84.2, 153.1, 153.2, 156.8, 157.9, 
163.0, 163.5, 172.3, 174.4. 
HRMS (ESI, m/z) for C37H64N8O12 [M + H]+ calc. 813.4717; found 813.4733. 
 
3-endo-2-exo-Di[2ʹ-(2ʺ,3ʺ-bis-tert-butoxycarbonylguanidino)ethylcarbamoyl]-5,6-
bis(benzyloxy)bicyclo[2.2.1]heptane (271b) 
 
Compound 271b was prepared from diacid 258b (343 mg, 0.87 mmol) and 
aminoethylguanidine 41 (786 mg, 1.60 mmol) according to general procedure F and was 
purified using column chromatography (70% EtOAc in pet. spirits) to give the title 
compound (563 mg, 57%) as a colourless oil. 
Rf = 0.43 (70% EtOAc in pet. spirits).  
1H NMR (270 MHz, CDCl3) δ 1.45–1.49 (36H, m, 4 × t-Bu), 1.63 (1H, d, J = 10.6 Hz, 
H7s), 2.12 (1H, d, J = 10.6 Hz, H7a), 2.43 (1H, d, J = 6.2 Hz, H2), 2.60 (1H, s, H1), 2.74–
2.76 (1H, m, H4), 2.79–2.83 (1H, m, H3), 3.16–3.57 (10H, m, 4 × NHCH2, H5, H6), 4.55 
(2H, s, OCH2), 4.59 (2H, s, OCH2), 6.56 (1H, t, J = 5.8 Hz, NH), 7.22–7.33 (10H, m, 
ArH), 7.99 (1H, t, J = 4.0 Hz, NH), 8.45 (1H, t, J = 5.6 Hz, NH), 8.69 (1H, t, J = 4.0 Hz, 
NH), 11.45 (1H, s, NH), 11.53 (1H, s, NH). 
13C NMR (67.5 MHz, CDCl3) δ 28.1, 28.2, 28.39, 28.42, 34.4, 39.2, 40.1, 40.4, 42.5, 
43.8, 44.6, 45.1, 49.5, 72.2, 72.3, 78.3, 79.5, 80.1, 81.6, 83.3, 83.8, 127.5, 127.6, 127.8 
(2 × C), 128.1 (2 × C), 128.3 (2 × C), 128.4 (2 × C), 138.6, 138.7, 153.18, 153.22, 156.7, 
158.0, 163.1, 163.6, 172.3, 174.5. 
HRMS (ESI, m/z) for C49H72N8O12 [M + H]+ calc. 965.5343; found 965.5371. 
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3-endo-2-exo-Di[2ʹ-(2ʺ,3ʺ-bis-tert-butoxycarbonylguanidino)ethylcarbamoyl]-5,6-
bis[(2-methylbenzyl)oxy]bicyclo[2.2.1]heptane (271c) 
 
Compound 271c was prepared from diacid 258c (62 mg, 0.15 mmol) and 
aminoethylguanidine 41 (140 mg, 0.45 mmol) according to general procedure E and was 
purified using column chromatography (50–70% EtOAc in pet. spirits) to give the title 
compound (36 mg, 54%) as a white solid. 
Rf = 0.71 (70% EtOAc in pet. spirits).  
m.p 118–121 °C. 
1H NMR (500 MHz, CDCl3) δ 1.46–1.48 (36H, m, 4 × t-Bu), 1.63 (1H, d, J = 9.8 Hz, 
H7s), 2.12 (1H, d, J = 9.8 Hz, H7a), 2.25 (3H, s, Me), 2.27 (3H, s, Me), 2.48 (1H, d, J = 
5.5 Hz, H2), 2.60 (1H, br s, H1), 2.73 (1H, d, J = 3.1 Hz, H4), 2.82 (1H, app. t, J = 5.5 Hz, 
H3), 3.23–3.55 (8H, m, 4 × NHCH2), 3.58 (1H, d, J = 5.7 Hz, H5), 3.61 (1H, d, J = 5.7 Hz, 
H6), 4.50–4.58 (4H, m, 2 × OCH2), 6.52 (1H, br s, NH), 7.08–7.19 (6H, m, ArH), 7.27–
7.31 (2H, m, ArH), 8.00 (1H, t, J = 4.1 Hz, NH), 8.48 (1H, br s, NH), 8.67 (1H, t, J = 
5.6 Hz, NH), 11.45 (1H, s, NH), 11.50 (1H, s, NH). 
13C NMR (125 MHz, CDCl3) δ 18.9, 19.0, 28.1, 28.2, 28.40, 28.42, 34.4, 39.2, 40.3, 40.5, 
42.3, 44.1, 44.7, 45.2, 49.5, 70.8, 70.9, 78.7, 79.6, 80.2, 82.1, 83.4, 83.8, 125.7, 125.8, 
127.6, 127.8, 128.7, 128.9, 130.1, 130.2, 136.6, 136.67, 136.69, 136.8, 153.19, 153.23, 
156.7 (2 × C), 157.9 (2 × C), 172.3, 174.6. 
HRMS (ESI, m/z) for C51H76N8O12 [M + H]+ calc. 993.5655; found 993.5654. 
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3-endo-2-exo-Di[2ʹ-(2ʺ,3ʺ-bis-tert-butoxycarbonylguanidino)ethylcarbamoyl]-5,6-
bis[(4-trifluoromethyl)benzyloxy]bicyclo[2.2.1]heptane (271d) 
 
Compound 271d was prepared from diacid 258d (151 mg, 0.28 mmol) and 
aminoethylguanidine 41 (260 mg, 0.85 mmol) according to general procedure E and was 
purified using column chromatography (EtOAc) to give the title compound (174 mg, 
56%) as a colourless oil. 
Rf = 0.45 (EtOAc).  
1H NMR (500 MHz, CDCl3) δ 1.44–1.52 (36H, m, 4 × t-Bu), 1.68 (1H, d, J = 9.8 Hz, 
H7s), 2.13 (1H, d, J = 9.8 Hz, H7a), 2.48 (1H, d, J = 5.9 Hz, H2), 2.65 (1H, br s, H1), 
2.79–2.80 (1H, m, H4), 2.85 (1H, dd, J = 5.9, 4.5 Hz, H3), 3.23–3.56 (8H, m, 4 × 
NHCH2), 3.58 (1H, d, J = 5.9 Hz, H5), 3.62 (1H, dd, J = 5.9, 1.2 Hz, H6), 4.55–4.67 (4H, 
m, 2 × OCH2), 6.68 (1H, m, NH), 7.38–7.40 (4H, m, ArH), 7.51–7.54 (4H, m, ArH), 8.16 
(1H, t, J = 4.0 Hz, NH), 8.49 (1H, m, NH), 8.72 (1H, t, J = 6.0 Hz, NH), 11.48 (1H, s, 
NH), 11.53 (1H, s, NH). 
13C NMR (125 MHz, CDCl3) δ 28.1, 28.2, 28.38, 28.39, 34.3, 39.4, 40.1, 40.4, 42.5, 43.8, 
44.6, 45.1, 49.4, 71.5, 71.6, 78.9, 79.7, 80.3, 82.1, 83.5, 84.0, 125.3 (q, JCF = 3.5 Hz, 4 × 
C), 126.4 (q, JCF = 270 Hz, 2 × C), 127.66 (2 × C), 127.72 (2 × C), 129.7 (q, JCF = 32.6 
Hz), 129.8 (q, JCF = 32.6 Hz), 142.7, 142.8, 153.2 (2 × C), 156.7, 158.1, 163.0, 163.4, 
172.2, 174.3. 
19F NMR (470 MHz, CDCl3) δ −63.97 (s). 
HRMS (ESI, m/z) for C51H70F6N8O12 [M + H]+ calc. 1101.5090; found 1101.5110. 
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3-endo-2-exo-Di[2ʹ-(2ʺ,3ʺ-bis-tert-butoxycarbonylguanidino)ethylcarbamoyl]-5,6-
bis[(3-fluorobenzyl)oxy]bicyclo[2.2.1]heptane (271e) 
 
Compound 271e was prepared from diacid 258e (184 mg, 0.43 mmol) and 
aminoethylguanidine 41 (290 mg, 1.28 mmol) according to general procedure E and was 
purified using column chromatography (50–70% EtOAc in pet. spirits) to give the title 
compound (111 mg, 26%) as a white solid. 
Rf = 0.58 (70% EtOAc in pet. spirits).  
m.p 215–258 °C (slow decomposition).  
1H NMR (500 MHz, CDCl3) δ 1.46–1.49 (36H, m, 4 × t-Bu), 1.66 (1H, d, J = 9.8 Hz, 
H7s), 2.12 (1H, d, J = 9.8 Hz, H7a), 2.47 (1H, d, J = 6.1 Hz, H2), 2.63 (1H, br s, H4), 
2.78–2.79 (1H, m, H1), 2.84 (1H, app. t, J = 6.1 Hz, H3), 3.25–3.60 (10H, m, 4  × NHCH2, 
H5, H6), 4.52 (1H, d, J = 12.6 Hz, OCH2), 4.55 (1H, d, J = 12.3 Hz, OCH2), 4.57 (1H, d, 
J = 12.6 Hz, OCH2), 4.60 (1H, d, J = 12.3 Hz, OCH2), 6.62 (1H, br s, NH), 6.91–7.07 
(6H, m, ArH), 7.22–7.28 (2H, m, ArH), 8.15 (1H, t, J = 4.0 Hz, NH), 8.50 (1H, br s, NH), 
8.72 (1H, br s, NH), 11.47 (1H, s, NH), 11.53 (1H, s, NH). 
13C NMR (125 MHz, CDCl3) δ 28.1, 28.2, 28.38, 28.39, 34.3, 39.3, 40.2, 40.6, 42.4, 43.7, 
44.7, 45.1, 49.4, 71.5, 71.6, 78.5, 80.0, 80.4, 81.9, 83.6, 84.0, 114.3 (d, JCF = 21.4 Hz), 
114.4 (d, JCF = 21.1 Hz), 114.5 (d, JCF = 21.2 Hz), 114.6 (d, JCF = 21.4 Hz), 123.1 (d, JCF 
= 2.8 Hz), 123.2 (d, JCF = 2.9 Hz), 129.8, 129.9, 141.3 (d, JCF = 7.0 Hz), 141.4 (d, JCF = 
7.1 Hz), 153.1, 153.2, 156.6, 158.0, 162.71, 162.73, 162.96 (d, JCF = 244.0 Hz), 163.02 
(d, JCF = 244.0 Hz), 172.3, 174.5. 
19F NMR (470 MHz, CDCl3) δ −113.86 (s), −113.92 (s). 
HRMS (ESI, m/z) for C49H70F2N8O12 [M + H]+ calc. 1001.5154; found 1001.5165. 
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3-endo-2-exo-Di[2ʹ-(2ʺ,3ʺ-bis-tert-butoxycarbonylguanidino)ethylcarbamoyl]-5,6-
bis[(4-fluorobenzyl)oxy]bicyclo[2.2.1]heptane (271f) 
 
Compound 271f was prepared from diacid 258f (86 mg, 0.20 mmol) and 
aminoethylguanidine 41 (181 mg, 0.60 mmol) according to general procedure F and was 
purified using column chromatography (50–70% EtOAc in pet. spirits) to give the title 
compound (90 mg, 45%) as a colourless oil. 
Rf = 0.13 (50% EtOAc in pet. spirits).  
1H NMR (270 MHz, CDCl3) δ 1.46–1.48 (36H, m, 4 × t-Bu), 1.62–1.66 (1H, m, H7s), 
2.12 (1H, d, J = 10.7 Hz, H7a), 2.46 (1H, d, J = 6.4 Hz, H2), 2.60 (1H, br s, H1), 2.72–
2.75 (1H, m, H4), 2.83 (1H, app. t, J = 6.4 Hz, H3), 3.28–3.60 (10H, m, 4 × NHCH2, H5, 
H6), 4.48 (2H, br s, OCH2), 4.50 (1H, d, J = 11.0 Hz, OCH2), 4.55 (1H, d, J = 12.1 Hz, 
OCH2), 6.58 (1H, t, J = 5.3 Hz, NH), 6.92–7.00 (4H, m, ArH), 7.22–7.29 (4H, m, ArH), 
8.07 (1H, t, J = 4.1 Hz, NH), 8.47 (1H, t, J = 5.7 Hz, NH), 8.70 (1H, t, J = 5.9 Hz, NH), 
11.48 (1H, s, NH), 11.52 (1H, s, NH). 
13C NMR (67.5 MHz, CDCl3) δ 28.1, 28.2, 28.41, 28.43, 34.3, 39.4, 40.2, 40.4, 42.6, 
43.8, 44.7, 45.2, 49.5, 71.6, 71.7, 78.6, 79.6, 80.2, 81.8, 83.4, 83.9, 115.0 (d, JCF = 
18.4 Hz, 2 × C), 115.3 (d, JCF = 18.5 Hz, 2 × C), 129.5 (d, JCF = 9.8 Hz, 2 × C), 129.7 (d, 
JCF = 9.9 Hz, 2 × C), 134.4 (d, JCF = 3.2 Hz), 134.5 (d, JCF = 3.2 Hz), 162.3 (d, JCF = 
243.7 Hz), 162.4 (d, JCF = 243.7 Hz), 153.2 (2 × C), 156.8, 158.1, 163.1, 163.6, 172.3, 
174.4. 
19F NMR (470 MHz, CDCl3) δ −115.10 (s), −115.17 (s). 
HRMS (ESI, m/z) for C49H70F2N8O12 [M + H]+ calc. 1001.5154; found 1001.5157. 
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3-endo-2-exo-Di[2ʹ-(2ʺ,3ʺ-bis-tert-butoxycarbonylguanidino)ethylcarbamoyl]-5,6-
bis[(3-bromobenzyl)oxy]bicyclo[2.2.1]heptane (271g) 
 
Compound 271g was prepared from diacid 258g (170 mg, 0.31 mmol) and 
aminoethylguanidine 41 (280 mg, 0.93 mmol) according to general procedure F and was 
purified using column chromatography (70% EtOAc in pet. spirits) to give the title 
compound (185 mg, 53%) as a colourless oil. 
Rf = 0.32 (70% EtOAc in pet. spirits).  
1H NMR (500 MHz, CDCl3) δ 1.46–1.49 (36H, m, 4 × t-Bu), 1.66 (1H, d, J = 10.4 Hz, 
H7s), 2.12 (1H, dd, J = 10.4, 1.2 Hz, H7a), 2.47 (1H, d, J = 6.0 Hz, H2), 2.61 (1H, br s, 
H1), 2.78–2.79 (1H, m, H4), 2.85 (1H, dd, J = 6.0, 4.5 Hz, H3), 3.30–3.61 (10H, m, 4  × 
NHCH2, H5, H6), 4.49 (1H, d, J = 12.3 Hz, OCH2), 4.53 (1H, d, J = 12.8 Hz, OCH2), 
4.55 (1H, d, J = 12.8 Hz, OCH2), 4.56 (1H, d, J = 12.3 Hz, OCH2), 6.59 (1H, t, J = 5.6 Hz, 
NH), 7.15–7.18 (2H, m, ArH), 7.22–7.24 (2H, m, ArH), 7.37–7.39 (2H, m, ArH), 7.44–
7.47 (2H, m, ArH), 8.11 (1H, t, J = 4.0 Hz, NH), 8.47 (1H, t, J = 5.5 Hz, NH), 8.71 (1H, 
t, J = 6.1 Hz, NH), 11.47 (1H, s, NH), 11.53 (1H, s, NH). 
13C NMR (125 MHz, CDCl3) δ 28.1, 28.2, 28.42, 28.44, 34.3, 39.4, 40.3, 40.4, 42.5, 43.6, 
44.8, 45.2, 49.4, 71.5, 71.7, 78.7, 79.6, 80.2, 82.1, 83.4, 83.9, 122.5, 122.6, 126.2, 126.3, 
130.0, 130.1, 130.66, 130.68, 130.72, 130.8, 141.0, 141.1, 153.2 (2 × C), 156.9, 158.1, 
163.1, 163.6, 172.2, 174.4. 
HRMS (ESI, m/z) for C49H7079Br2N8O12 [M + H]+ calc. 1121.3553; found 1121.3541. 
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3-endo-2-exo-Di[2ʹ-(2ʺ,3ʺ-bis-tert-butoxycarbonylguanidino)ethylcarbamoyl]-5,6-
bis[(4-bromobenzyl)oxy]bicyclo[2.2.1]heptane (271h) 
 
Compound 271h was prepared from diacid 258h (171 mg, 0.31 mmol) and 
aminoethylguanidine 41 (281 mg, 0.93 mmol) according to general procedure E and was 
purified using column chromatography (50–70% EtOAc in pet. spirits) to give the title 
compound (91 mg, 26%) as a colourless oil. 
Rf = 0.48 (70% EtOAc in pet. spirits).  
1H NMR (500 MHz, CDCl3) δ 1.46–1.48 (36H, m, 4 × t-Bu), 1.64 (1H, d, J = 9.9 Hz, 
H7s), 2.09 (1H, d, J = 9.9 Hz, H7a), 2.46 (1H, d, J = 5.4 Hz, H2), 2.60 (1H, br s, H1), 
2.74 (1H, m, H4), 2.83 (1H, app. t, J = 5.4 Hz, H3), 3.22–3.46 (4H, m, 2 × NHCH2), 3.52–
3.58 (6H, m, 2 × NHCH2, H5, H6), 4.46 (2H, br s, OCH2), 4.48 (1H, d, J = 12.2 Hz, 
OCH2), 4.53 (1H, d, J = 12.2 Hz, OCH2), 6.69 (1H, m, NH), 7.14–7.17 (4H, m, ArH), 
7.39–7.42 (4H, m, ArH), 8.09 (1H, t, J = 4.0 Hz, NH), 8.54 (1H, m, NH), 8.73 (1H, t, J = 
5.1 Hz, NH), 11.47 (1H, s, NH), 11.51 (1H, s, NH). 
13C NMR (125 MHz, CDCl3) δ 28.1, 28.2, 28.38, 28.39, 34.3, 39.3, 40.2, 40.5, 42.4, 43.8, 
44.6, 45.1, 49.4, 71.56, 71.61, 78.6, 80.0, 80.4, 81.8, 83.6, 84.0, 121.4, 121.5, 129.5 (2 × 
C), 129.6 (2 × C), 131.4 (2 × C), 131.5 (2 × C), 137.6, 137.7, 153.1, 153.2, 156.7, 158.0, 
162.8, 163.2, 172.2, 174.4. 
HRMS (ESI, m/z) for C49H7079Br2N8O12 [M + H]+ calc. 1121.3553; found 1121.3550. 
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3-endo-2-exo-Di[2ʹ-(2ʺ,3ʺ-bis-tert-butoxycarbonylguanidino)ethylcarbamoyl]-5,6-
bis(allyloxy]bicyclo[2.2.1]heptane (271i) 
 
Compound 271i was prepared from diacid 258i (70 mg, 0.24 mmol) and 
aminoethylguanidine 41 (214 mg, 0.71 mmol) according to general procedure E and was 
purified using column chromatography (50–70% EtOAc in pet. spirits) to give the title 
compound (128 mg, 63%) as a colourless oil. 
Rf = 0.34 (70% EtOAc in pet. spirits).  
1H NMR (500 MHz, CDCl3) δ 1.49–1.50 (36H, m, 4 × t-Bu), 1.60 (1H, d, J = 10.2 Hz, 
H7s), 2.02 (1H, d, J = 10.2 Hz, H7a), 2.48 (1H, d, J = 6.1 Hz, H2), 2.54 (1H, br s, H4), 
2.66 (1H, d, J = 2.9 Hz, H1), 2.82 (1H, dd, J = 6.1, 4.6 Hz, H3), 3.33–3.60 (10H, m, 4 × 
NHCH2, H5, H6), 3.98–4.04 (4H, m, 2 × OCH2), 5.10–5.14 (2H, m, CH2CH), 5.20–5.27 
(2H, m, CH2CH), 5.84–5.94 (2H, m, 2 × CH2CH), 6.58 (1H, t, J = 5.1 Hz, NH), 8.03 (1H, 
t, J = 3.9 Hz, NH), 8.48 (1H, br s, NH), 8.68 (1H, t, J = 5.8 Hz, NH), 11.46 (1H, s, NH), 
11.50 (1H, s, NH).  
13C NMR (125 MHz, CDCl3) δ 28.17, 28.21, 28.41, 28.44, 34.2, 39.3, 40.2, 40.5, 42.5, 
43.9, 44.9, 45.2, 49.4, 71.6, 71.7, 78.6, 80.2, 81.9, 83.4, 83.9 (2 × C), 116.6, 116.9, 135.2, 
135.3, 153.2, 153.3, 156.7, 158.0, 162.9, 163.0, 172.4, 174.6. 
HRMS (ESI, m/z) for C41H68N8O12 [M + H]+ calc. 865.5030; found 865.5027. 
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5,6-Bis(methoxy)bicyclo[2.2.1]heptane-3-endo-2-exo-dicarboxamidoethylguanidine 
hydrogen chloride (276a)  
 
Compound 276a was synthesised from Boc-protected guanidine 271a (42 mg, 
0.05 mmol) according to general procedure G and isolated as a white solid (24 mg, 96%). 
m.p 162–195 °C (slow decomposition). 
1H NMR (270 MHz, CD3OD) δ 1.50 (1H, d, J = 10.9 Hz, H7a), 1.80 (1H, d, J = 10.9 Hz, 
H7s), 2.46 (1H, br s, H2), 2.58–2.59 (1H, m, H1), 2.65 (1H, d, J = 5.3 Hz, H4), 3.17 (1H, 
app. t, J = 4.5 Hz, H3), 3.33 (3H, s, Me), 3.41 (3H, s, Me), 3.35–3.43 (9H, m, 4 × NHCH2, 
H5), 3.51 (1H, d, J = 6.3 Hz, H6), 8.22 (1H, t, J = 4.5 Hz, NH), 8.32 (1H, t, J = 4.6, NH). 
13C NMR (67.5 MHz, CD3OD) δ 33.9, 39.5, 39.7, 42.0, 42.2, 45.4, 46.1, 47.6, 47.8, 58.8, 
58.9, 81.8, 85.4, 158.9 (2 × C), 175.0, 176.7. 
HRMS (ESI, m/z) for C17H32N8O4 [M + 2H]2+ calc. 207.1346; found 207.1341. 
 
5,6-Bis(benzyloxy)bicyclo[2.2.1]heptane-3-endo-2-exo-
dicarboxamidoethylguanidine hydrogen chloride (276b)  
 
Compound 276b was synthesised from Boc-protected guanidine 271b (76 mg, 
0.08 mmol) according to general procedure G and isolated as a white residue (47 mg, 
96%). 
1H NMR (500 MHz, CD3OD) δ 1.56 (1H, d, J = 10.0 Hz, H7a), 2.02 (1H, d, J = 10.0 Hz, 
H7s), 2.53 (1H, br s, H2), 2.66–2.67 (2H, m, H1, H4), 3.18 (1H, app. t, J = 5.7 Hz, H3), 
3.21–3.39 (8H, m, 4 × NHCH2), 3.62 (1H, d, J = 5.4 Hz, H5), 3.73 (1H, d, J = 5.4 Hz, 
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H6), 4.51 (1H, d, J = 11.9 Hz, OCH2), 4.56 (1H, d, J = 11.9 Hz, OCH2), 4.62 (1H, d, J = 
12.5 Hz, OCH2), 4.64 (1H, d, J = 12.5 Hz, OCH2), 7.26–7.39 (10H, m, ArH). 
13C NMR (125 MHz, CD3OD) δ 34.3, 39.6, 39.7, 41.97, 42.01, 46.4 (2 × C), 47.8, 48.4, 
73.4, 73.7, 78.9, 83.2, 128.70, 128.72, 129.2 (2 × C), 129.32 (3 × C), 129.33 (3 × C), 
139.6, 139.7, 158.8, 158.9, 175.0, 176.7. 
HRMS (ESI, m/z) for C29H40N8O4 [M + 2H]2+ calc. 283.1659; found 283.1667. 
 
5,6-Bis[(2-methylbenzyl)oxy]bicyclo[2.2.1]heptane-3-endo-2-exo-
dicarboxamidoethylguanidine hydrogen chloride (276c)  
 
Compound 276c was synthesised from Boc-protected guanidine 271c (54 mg, 
0.05 mmol) according to general procedure G and isolated as a colourless oil (8 mg, 24%). 
1H NMR (500 MHz, CD3OD) δ 1.56 (1H, d, J = 9.9 Hz, H7a), 2.01 (1H, d, J = 9.9 Hz, 
H7s), 2.26 (3H, s, Me), 2.30 (3H, s, Me), 2.53 (1H, br s, H2), 2.63–2.69 (2H, m, H1, H4), 
3.14–3.38 (9H, m, 4 × NHCH2, H3), 3.64 (1H, d, J = 5.3 Hz, H5), 3.76 (1H, d, J = 5.3 Hz, 
H6), 4.49–4.67 (4H, m, 2 × OCH2), 7.08–7.20 (7H, m, ArH), 7.29 (1H, d, J = 7.3 Hz, 
ArH). 
13C NMR (125 MHz, CD3OD) δ 19.07, 19.09, 34.4, 39.6, 39.7, 41.98, 42.04, 46.2, 46.3, 
47.8, 48.4, 72.0, 72.1, 79.2, 83.6, 126.68, 126.73, 128.96, 128.99, 130.2, 130.3, 131.1, 
131.2, 137.4, 137.6, 138.1, 138.2, 158.86, 158.89, 175.1, 176.8. 
HRMS (ESI, m/z) for C31H44N8O4 calc. [M + 2H]2+ 297.1816; found 297.1820. 
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5,6-Bis[(4-trifluoromethyl)benzyloxy]bicyclo[2.2.1]heptane-3-endo-2-exo-
dicarboxamidoethylguanidine hydrogen chloride (276d)  
 
Compound 276d was synthesised from Boc-protected guanidine 271d (87 mg, 
0.08 mmol) according to general procedure G and isolated as a colourless oil (40 mg, 
66%). 
1H NMR (500 MHz, CD3OD) δ 1.60 (1H, d, J = 10.1 Hz, H7s), 2.06 (1H, d, J = 10.1 Hz, 
H7a), 2.59 (1H, br s, H2), 2.70–2.72 (2H, m, H1, H4), 3.21–3.38 (9H, m, 4 × NHCH2, 
H3), 3.69 (1H, d, J = 5.4 Hz, H5), 3.80 (1H, d, J = 5.4 Hz, H6), 4.63 (2H, s, OCH2), 4.70 
(1H, d, J = 12.3 Hz, OCH2), 4.75 (1H, d, J = 12.3 Hz, OCH2), 7.46–7.48 (2H, m, ArH), 
7.51–7.52 (2H, m, ArH), 7.55–7.58 (4H, m, ArH). 
13C NMR (125 MHz, CD3OD) δ 34.3, 39.6, 39.7, 41.9, 42.0, 46.1, 46.2, 47.8, 48.4, 72.6, 
72.7, 79.6, 83.6, 125.69 (q, JCF = 269.7 Hz), 125.71 (q, JCF = 269.7 Hz), 126.1 (q, JCF = 
3.4 Hz, 4 × C), 129.2 (4 × C), 130.58 (q, JCF = 31.8 Hz), 130.60 (q, JCF = 31.7 Hz), 144.46, 
144.54, 158.8, 158.9, 174.9, 176.6. 
19F NMR (470 MHz, CD3OD) δ −65.38 (s), −65.41 (s). 
HRMS (ESI, m/z) for C31H38F6N8O4 [M + 2H]2+ calc. 351.1533; found 351.1532. 
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5,6-Bis[(3-fluorobenzyl)oxy]bicyclo[2.2.1]heptane-3-endo-2-exo-
dicarboxamidoethylguanidine hydrogen chloride (276e)  
 
Compound 276e was synthesised from Boc-protected guanidine 271e (72 mg, 
0.07 mmol) according to general procedure G and isolated as a yellow solid (46 mg, 
99%). 
m.p 77–82 °C (slow decomposition). 
1H NMR (500 MHz, CD3OD) δ 1.58 (1H, d, J = 10.1 Hz, H7s), 2.02 (1H, d, J = 10.1 Hz, 
H7a), 2.57 (1H, br s, H2), 2.68–2.69 (2H, m, H1, H4), 3.19–3.38 (9H, m, 4 × NHCH2, 
H3), 3.65 (1H, d, J = 5.4 Hz, H5), 3.76 (1H, d, J = 5.4 Hz, H6), 4.49 (1H, d, J = 12.4 Hz, 
OCH2), 4.57 (1H, d, J = 12.4 Hz, OCH2), 4.64 (1H, d, J = 12.4 Hz, OCH2), 4.66 (1H, d, 
J = 12.4 Hz, OCH2), 6.97–7.00 (2H, m, ArH), 7.04–7.06 (1H, m, ArH), 7.10–7.11 (2H, 
m, ArH), 7.16 (1H, d, J = 7.6 Hz, ArH), 7.28–7.34 (2H, m, ArH). 
13C NMR (125 MHz, CD3OD) δ 34.3, 39.6, 39.7, 41.9, 42.0, 46.1 (2 × C), 47.8, 48.3, 
72.6, 72.7, 79.2, 83.4, 115.33 (d, JCF = 33.7 Hz), 115.26 (d, JCF = 26.6 Hz), 115.40 (d, JCF 
= 34.0 Hz), 115.43 (d, JCF = 27.0 Hz), 124.50 (d, JCF = 2.7 Hz), 124.52 (d, JCF = 2.6 Hz), 
131.0 (d, JCF = 7.8 Hz), 131.1 (d, JCF = 6.6 Hz), 142.6 (d, JCF = 7.2 Hz), 142.8 (d, JCF = 
7.1 Hz), 158.79, 158.81, 164.22 (d, JCF = 244.2 Hz), 164.23 (d, JCF = 242.8 Hz), 174.9, 
176.6. 
19F NMR (470 MHz, CDCl3) δ −115.86 (s), −116.03 (s). 
HRMS (ESI, m/z) for C29H38F2N8O4 [M + 2H]2+ calc. 301.1565; found 301.1576. 
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5,6-Bis[(4-fluorobenzyl)oxy]bicyclo[2.2.1]heptane-3-endo-2-exo-
dicarboxamidoethylguanidine hydrogen chloride (276f)  
 
Compound 276f was synthesised from Boc-protected guanidine 271f (90 mg, 0.09 mmol) 
according to general procedure G and isolated as a white solid (46 mg, 77%). 
m.p 94–110 °C (slow decomposition). 
1H NMR (500 MHz, CD3OD) δ 1.55 (1H, d, J = 9.6 Hz, H7a), 2.01 (1H, d, J = 9.6 Hz, 
H7s), 2.51 (1H, br s, H2), 2.62 (1H, m, H1), 2.67 (1H, d, J = 5.3 Hz, H4), 3.18–3.41 (9H, 
m, 4 × NHCH2, H3), 3.63 (1H, d, J = 5.6 Hz, H5), 3.73 (1H, d, J = 5.6 Hz, H6), 4.48 (1H, 
d, J = 11.7 Hz, OCH2), 4.52 (1H, d, J = 11.7 Hz, OCH2), 4.59 (2H, br s, OCH2), 7.00–
7.05 (4H, m, ArH), 7.29–7.31 (2H, m, ArH), 7.34–7.37 (2H, m, ArH). 
13C NMR (125 MHz, CD3OD) δ 34.3, 39.6, 39.7, 41.98, 42.04, 46.16, 46.20, 47.7, 48.6, 
72.7, 72.9, 79.0, 83.2, 115.96 (d, JCF = 21.0 Hz), 115.97 (d, JCF = 21.6 Hz), 131.1 (d, JCF 
= 8.1 Hz, 4 × C), 135.76 (d, JCF = 15.4 Hz), 135.78 (d, JCF = 15.6 Hz), 163.79 (d, JCF = 
243.2 Hz), 163.81 (d, JCF = 242.9 Hz), 158.9 (2 × C), 175.0, 176.7. 
19F NMR (470 MHz, CDCl3) δ −117.89 (s), −118.04 (s). 
HRMS (ESI, m/z) for C29H38F2N8O4 [M + 2H]2+ calc. 301.1565; found 301.1567. 
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5,6-Bis[(3-bromobenzyl)oxy]bicyclo[2.2.1]heptane-3-endo-2-exo-
dicarboxamidoethylguanidine hydrogen chloride (276g)  
 
Compound 276g was synthesised from Boc-protected guanidine 271g (169 mg, 
0.15 mmol) according to general procedure G and isolated as a white solid (115 mg, 
97%). 
m.p 100–133 °C (slow decomposition). 
1H NMR (500 MHz, CD3OD) δ 1.57 (1H, d, J = 10.5 Hz, H7a), 2.01–2.04 (1H, m, H7s), 
2.55 (1H, br s, H2), 2.66–2.69 (2H, m, H1, H4), 3.19–3.40 (9H, m, 4 × NHCH2, H3), 3.64 
(1H, d, J = 5.4 Hz, H5), 3.75 (1H, d, J = 5.4 Hz, H6), 4.51 (1H, d, J = 12.2 Hz, OCH2), 
4.54 (1H, d, J = 12.2 Hz, OCH2), 4.61 (1H, d, J = 12.1 Hz, OCH2), 4.63 (1H, d, J = 
12.1 Hz, OCH2), 7.21–7.27 (3H, m, ArH), 7.32 (1H, d, J = 7.7 Hz, ArH), 7.40–7.43 (3H, 
m, ArH), 7.48–7.52 (1H, m, ArH). 
13C NMR (125 MHz, CD3OD) δ 34.3, 39.6, 39.7, 41.96, 42.00, 46.1, 46.2, 47.7, 48.4, 
72.6, 72.7, 79.3, 83.5, 123.3, 123.4, 127.59, 127.62, 131.16, 131.21, 131.66, 131.70, 
131.8 (2 × C), 142.4, 142.5, 158.86, 158.87, 175.0, 176.7. 
HRMS (ESI, m/z) for C29H3879Br2N8O4 [M + 2H]2+ calc. 361.0764; found 361.0774. 
 
 
 
 
 
 
 
 
 
276 | P a g e  
 
5,6-Bis[(4-bromobenzyl)oxy]bicyclo[2.2.1]heptane-3-endo-2-exo-
dicarboxamidoethylguanidine hydrogen chloride (276h)  
 
Compound 276h was synthesised from Boc-protected guanidine 271h (57 mg, 
0.05 mmol) according to general procedure G and isolated as a colourless oil (40 mg, 
99%). 
1H NMR (500 MHz, CD3OD) δ 1.56 (1H, d, J = 10.1 Hz, H7s), 2.00 (1H, d, J = 10.1 Hz, 
H7a), 2.53 (1H, br s, H2), 2.64–2.67 (2H, m, H1, H4), 3.17–3.40 (9H, m, 4 × NHCH2, 
H3), 3.61 (1H, d, J = 5.6 Hz, H5), 3.73 (1H, d, J = 5.6 Hz, H6), 4.47 (1H, d, J = 12.1 Hz, 
OCH2), 4.51 (1H, d, J = 12.1 Hz, OCH2), 4.57 (1H, d, J = 11.9 Hz, OCH2), 4.60 (1H, d, 
J = 11.9 Hz, OCH2), 7.20–7.22 (2H, m, ArH), 7.26–7.28 (2H, m, ArH), 7.43–7.46 (4H, 
m, ArH). 
13C NMR (125 MHz, CD3OD) δ 34.3, 39.6, 39.7, 41.9, 42.0, 46.1, 46.2, 47.7, 48.4, 72.6, 
72.8, 79.1, 83.3, 122.36, 122.40, 131.0 (4 × C), 132.40 (2 × C), 132.41 (2 × C), 139.0, 
139.1, 158.81, 158.84, 174.9, 176.6. 
HRMS (ESI, m/z) for C29H3879Br2N8O4 [M + 2H]2+ calc. 361.0764; found 361.0769. 
 
5,6-Bis(allyloxy)bicyclo[2.2.1]heptane-3-endo-2-exo-dicarboxamidoethylguanidine 
hydrogen chloride (276i)  
 
Compound 276i was synthesised from Boc-protected guanidine 271i (126 mg, 
0.15 mmol) according to general procedure G and isolated as a yellow solid (24 mg, 
31%). 
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m.p 80–86 °C. 
1H NMR (500 MHz, CD3OD) δ 1.52 (1H, d, J = 9.8 Hz, H7a), 1.92 (1H, d, J = 9.8 Hz, 
H7s), 2.44 (1H, br s, H4), 2.59 (1H, d, J = 3.5 Hz, H1), 2.66 (1H, d, J = 5.1 Hz, H2), 3.16 
(1H, app. t, J = 5.1 Hz, H3), 3.30–3.46 (8H, m, 4 × NHCH2), 3.57 (1H, d, J = 5.7 Hz, 
H5), 3.63 (1H, d, J = 5.7 Hz, H6), 4.00–4.09 (4H, m, 2 × OCH2), 5.13–5.32 (4H, m, 2 × 
CH2CH), 5.86–5.98 (2H, m, 2 × CH2CH), 7.45–7.48 (2H, m, 2 × NH).  
13C NMR (125 MHz, CD3OD) δ 34.2, 39.6, 39.7, 42.0, 42.2, 46.1, 46.2, 47.9, 48.4, 72.7, 
72.8, 79.4, 83.3, 117.1, 117.2, 136.2 (2 × C), 158.87, 158.92, 175.0, 176.7. 
HRMS (ESI, m/z) for C21H36N8O4 [M + 2H]2+ calc. 233.1503; found 233.1502. 
 
9.2.5: Chapter Five 
12-Amino-1-dodecanol hydrochloride (295)  
 
Compound 295 was synthesised from Boc-protected amine 231 (332 mg, 1.10 mmol) 
according to general procedure G and isolated as a white solid (260 mg, 99%). 
m.p 150–151 °C. 
1H NMR (270 MHz, DMSO-d6) δ 1.24–1.42 (19H, m, 9 × CH2, OH), 1.47–1.58 (2H, m, 
CH2), 2.69–2.77 (2H, m, CH2NH3), 3.36 (2H, t, J = 6.4 Hz, CH2OH), 7.97 (3H, br s, 
NH3).  
13C NMR (100 MHz, DMSO-d6) δ 25.5, 25.8, 26.9, 28.5, 28.8, 28.9, 28.96, 29.00, 29.1, 
32.5, 38.7, 60.7. 
HRMS (ESI, m/z) for C12H27NO [M + H]+ calc. 202.2165; found 202.2165. 
 
6-Bromo-2-(12-hydroxydodecanyl)-1H-benzo[de]isoquinoline-1,3-(2H)-dione (293)  
 
278 | P a g e  
 
A 10 mL microwave vial was charged with 4-bromo-1,8-naphthalic anhydride 294 
(277 mg, 1.00 mmol), hydrochloride 295 (240 mg, 1.01 mmol), Et3N (140 μL, 
1.00 mmol) and EtOH (1.4 mL) and heated at 100 °C using microwave irradiation for 
45 min. The black solution was diluted with H2O (10 mL) and extracted with EtOAc 
(3 × 10 mL). The combined organic phase was washed with brine (10 mL), dried 
(MgSO4), filtered and concentrated in vacuo to give the title product (418 mg, 91%) as 
an orange solid. 
m.p 88–89 °C.  
1H NMR (500 MHz, CDCl3) δ 1.26–1.43 (17H, m, 8 × CH2, OH), 1.53–1.59 (2H, m, 
CH2), 1.69–1.75 (2H, m, CH2), 3.63 (2H, t, J = 6.7 Hz, CH2OH), 4.15 (2H, t, J = 7.7 Hz, 
NCH2), 7.84 (1H, dd, J = 8.5, 7.3 Hz, H8), 8.04 (1H, d, J = 7.9 Hz, H5), 8.41 (1H, d, J = 
7.9 Hz, H4), 8.56 (1H, dd, J = 8.5, 1.1 Hz, H7), 8.65 (1H, d, J = 7.3, 1.1 Hz, H9). 
13C NMR (125 MHz, CDCl3) δ 25.9, 27.2, 28.2, 29.46, 29.53, 29.62, 29.64, 29.66, 29.68, 
33.0, 40.8, 63.3, 122.4, 123.3, 128.2, 129.2, 130.3, 130.8, 131.2, 131.4, 132.2, 133.4, 
163.75, 163.78. 
HRMS (ESI, m/z) for C24H3079BrNO3 [M + H]+ calc. 460.1482; found 460.1493. 
 
2-(12-Hydroxydodecyl)-6-(propylamino)-1H-benzo[de]isoquinoline-1,3-(2H)-dione 
(292)  
 
A stirring solution of 4-bromo naphthalimide 293 (151 mg, 0.328 mmol), 
Pd2(dba)3·CHCl3 (14 mg, 0.013 mmol), Xantphos (8 mg, 0.013 mmol), propylamine 
(80 μL, 0.984 mmol) and Cs2CO3 (320 mg, 0.984 mmol) in PhMe (3.3 mL) was heated 
at 70 °C for 24 h. The solvent was removed in vacuo and the resulting residue was loaded 
onto SiO2 and purified using column chromatography (2% MeOH in 1:1 EtOAc in pet. 
spirits) to give the title compound (55 mg, 38%) as a yellow solid.  
m.p 131–134 °C. 
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1H NMR (500 MHz, CDCl3) δ 1.10–1.12 (3H, m, CH3), 1.25–1.41 (17H, m, 8 × CH2, 
OH), 1.53–1.58 (2H, m, CH2), 1.68–1.74 (2H, m, CH2), 1.80–1.87 (2H, m, CH2), 3.38 
(2H, t, J = 7.2 Hz, NHCH2), 3.63 (3H, t, J = 6.7 Hz, CH2OH), 4.14 (2H, t, J = 7.6 Hz, 
NCH2), 6.71 (1H, d, J = 6.4 Hz, H5), 7.60 (1H, dd, J = 8.3, 7.4 Hz, H8), 8.08 (1H, dd, J 
= 8.3, 0.8 Hz, H7), 8.45 (1H, d, J = 6.4 Hz, H4), 8.57 (1H, dd, J = 7.4, 0.8 Hz, H9). 
13C NMR (125 MHz, CDCl3) δ 11.8, 22.4, 25.8, 27.3, 28.3, 29.5 (2 × C), 29.62, 29.64, 
29.7, 29.8, 33.0, 40.4, 45.6, 63.2, 104.5, 110.5, 120.3, 123.4, 124.8, 125.8, 129.9, 131.2, 
134.5, 149.5, 164.3, 164.8. 
HRMS (ESI, m/z) for C27H38N2O3 [M + H]+ calc. 439.2955; found 439.2940. 
 
Dimethyl 4-(11ʹ-aminoundecanyl)-3,5-dioxatricyclo[5.2.1.02,6]decane-8-endo-9-exo-
dicarboxylate hydrogen chloride (6250) 
 
Compound 297 was synthesised from Boc-protected amine 225 (511 mg, 0.97 mmol) 
according to general procedure G and isolated as an off-white sticky residue (444 mg, 
99%). 
1H NMR (500 MHz, CD3OD) δ 1.29–1.41 (17H, m, 8 × CH2, H10s), 1.58–1.67 (4H, m, 
2 × CH2), 1.74 (1H, dd, J = 10.7, 1.5 Hz, H10a), 2.56 (1H, br s, H9), 2.62–2.64 (2H, m, 
H1, H7), 2.91 (2H, app. t, J = 7.6 Hz, CH2NH3), 3.21 (1H, app. t, J = 5.0 Hz, H8), 3.70 
(3H, s, Me), 3.71 (3H, s, Me), 3.90 (1H, d, J = 5.6 Hz, H6), 4.00 (1H, d, J = 5.6 Hz, H2), 
4.66 (1H, t, J = 4.8 Hz, H4). 
13C NMR (125 MHz, CD3OD) δ 25.2, 27.4, 28.6, 30.2, 30.5, 30.57 (3 × C), 30.62, 32.4, 
33.8, 40.8, 44.5, 44.9, 46.2, 46.6, 52.6, 52.8, 80.0, 82.5, 105.2, 174.0, 175.4. 
HRMS (ESI, m/z) for C23H39NO6 [M + H]+ calc. 426.2850; found 426.2847. 
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Dimethyl 4-[11ʹ-(6ʺ-bromo-1ʺ,3ʺ-dioxo-1H-benzo[de]isoquinoline-2(3H))undecyl]-
3,5-dioxatricyclo[5.2.1.02,6]decane-8-endo-9-exo-dicarboxylate (296) 
 
A 10 mL microwave vial was charged with 4-bromo-1,8-naphthalic anhydride 294 
(264 mg, 0.953 mmol), norbornane hydrochloride 297 (444 mg, 0.961 mmol), Et3N 
(140 μL, 1.00 mmol) and EtOH (3 mL) and heated to 100 °C using microwave irradiation 
for 45 min. The orange slurry was diluted with H2O (30 mL) and extracted with EtOAc 
(3 × 30 mL). The combined organic phase was washed with 0.1 M HCl (30 mL), sat. 
NaHCO3 (30 mL), brine (30 mL), dried (MgSO4), filtered and concentrated in vacuo to 
give the title compound (649 mg, 99%) as an orange oil. 
1H NMR (270 MHz, CDCl3) δ 1.25–1.42 (17H, m, 8 × CH2, H10s), 1.58–1.74 (4H, m, 
H1ʹ, H10ʹ), 1.78 (1H, dd, J = 11.0, 1.5 Hz, H10s), 2.64–2.65 (2H, m, H1, H7), 2.71 (1H, 
d, J = 4.9 Hz, H9), 3.23 (1H, app. t, J = 4.9 Hz, H8), 3.70 (6H, s, 2 × Me), 3.89 (1H, d, J 
= 5.5 Hz, H6), 4.02 (1H, d, J = 5.5 Hz, H2), 4.12–4.18 (2H, m, H11ʹ), 4.64 (1H, t, J = 
4.9 Hz, H4), 7.83 (1H, dd, J = 8.6, 7.4 Hz, H8ʺ), 8.02 (1H, d, J = 7.8 Hz, H5ʺ), 8.40 (1H, 
d, J = 7.8 Hz, H4ʺ), 8.55 (1H, dd, J = 8.6, 1.2 Hz, H7ʺ), 8.64 (1H, dd, J = 7.4, 1.2 Hz, 
H9ʺ). 
13C NMR (67.5 MHz, CDCl3) δ 24.3, 27.2, 28.2, 29.5 (2 × C), 29.60, 29.62, 29.7 (2 × C), 
31.8, 32.9, 40.7, 43.4, 43.8, 45.2, 45.4, 52.3, 52.5, 78.9, 81.4, 104.3, 122.4, 123.3, 128.2, 
129.1, 130.3, 130.8, 131.2, 131.3, 132.1, 133.3, 163.73, 163.74, 172.9, 174.1. 
HRMS (ESI, m/z) for C35H4279BrNO8 [M + Na]+ calc. 706.1986; found 706.1972. 
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Dimethyl 4-[11ʹ-(6ʺ-propylamino-1ʺ,3ʺ-dioxo-1H-benzo[de]isoquinoline-
2(3H))undecyl]-3,5-dioxatricyclo[5.2.1.02,6]decane-8-endo-9-exo-dicarboxylate (289) 
 
A stirring solution of 4-bromo naphthalimide norbornane 296 (28 mg, 0.041 mmol), 
Pd2(dba)3·CHCl3 (2 mg, 0.002 mmol), Xantphos (1 mg, 0.002 mmol), propylamine 
(5 drops) and Cs2CO3 (40 mg, 0.123 mmol) in PhMe (410 μL) was heated at 70 °C for 
24 h. The solvent was removed in vacuo and the resulting residue was loaded onto SiO2 
and purified using column chromatography (2% MeOH in 1:4 EtOAc in pet. spirits) to 
give the title compound (23 mg, 88%) as a yellow oil.  
Rf = 0.19 (2% MeOH in 1:4 EtOAc in pet. spirits). 
1H NMR (400 MHz, CDCl3) δ 1.11 (3H, t, J = 7.4 Hz, CH3), 1.24–1.43 (17H, m, 8 × 
CH2, H10s), 1.59–1.64 (2H, m, H1ʹ), 1.67–1.74 (2H, m, H10ʹ), 1.76–1.88 (3H, m, 
CH2CH3, H10a), 2.64–2.65 (2H, m, H1, H7), 2.72 (1H, d, J = 4.9 Hz, H9), 3.22 (1H, app. 
t, J = 5.1 Hz, H8), 3.35–3.40 (2H, m, NHCH2), 3.69 (3H, s, Me), 3.70 (3H, s, Me), 3.90 
(1H, dd, J = 5.7, 1.4 Hz, H6), 4.02 (1H, d, J = 5.7 Hz, H2), 4.12–4.16 (2H, m, H11ʹ), 4.65 
(1H, t, J = 4.9 Hz, H4), 5.25–5.26 (1H, m, NH), 6.72 (1H, d, J = 8.5 Hz, H5ʺ), 7.61 (1H, 
dd, J = 8.4, 7.4 Hz, H8ʺ), 8.08 (1H, dd, J = 8.4, 1.1 Hz, H7ʺ), 8.45 (1H, d, J = 8.5 Hz, 
H4ʺ), 8.57 (1H, dd, J = 7.4, 1.1 Hz, H9ʺ). 
13C NMR (100 MHz, CDCl3) δ 11.8, 22.4, 24.4, 27.3, 28.4, 29.5, 29.6 (2 × C), 29.67 (2 
× C), 29.69, 31.8, 32.9, 40.4, 43.4, 43.8, 45.2, 45.4, 45.6, 52.3, 52.5, 78.9, 81.4, 104.4, 
104.5, 110.5, 120.3, 123.4, 124.8, 125.8, 130.8, 131.2, 134.6, 149.5, 164.3, 164.8, 172.9, 
174.1. 
HRMS (ESI, m/z) for C38H50N2O8 [M + H]+ calc. 663.3640; found 663.3648. 
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4-[11ʹ-(6ʺ-Propylamino-1ʺ,3ʺ-dioxo-1H-benzo[de]isoquinoline-2(3H))undecyl]-3,5-
dioxatricyclo[5.2.1.02,6]decane-8-endo-9-exo-dicarboxylic acid (298) 
 
The title compound was prepared from diester 289 (434 mg, 0.655 mmol) according to 
general procedure D and isolated as an orange solid (366 mg, 88%). 
m.p 94–95 °C.  
1H NMR (500 MHz, CDCl3) δ 1.10 (3H, t, J = 7.4 Hz, CH3), 1.21–1.39 (17H, m, 8 × 
CH2, H10s), 1.59–1.72 (4H, m, 2 × CH2), 1.81–1.85 (3H, m, CH2, H10a), 2.66 (1H, d, J 
= 5.2 Hz, H9), 2.73 (1H, br s, H1), 2.79 (1H, d, J = 4.3 Hz, H7), 3.28 (1H, app. t, J = 
5.2 Hz, H8), 3.37 (2H, app. t, J = 7.3 Hz, NHCH2), 4.05 (2H, br s, H2, H6), 4.11–4.14 
(2H, m, H11ʹ), 4.68 (1H, t, J = 4.8 Hz, H4), 6.69 (1H, d, J = 8.5 Hz, H5ʺ), 7.58 (1H, dd, 
J = 8.5, 7.5 Hz, H8ʺ), 8.08 (1H, dd, J = 8.5, 1.1 Hz, H7ʺ), 8.44 (1H, d, J = 8.5 Hz, H4ʺ), 
8.56 (1H, dd, J = 7.5, 1.1 Hz, H9ʺ). 
13C NMR (125 MHz, CDCl3) δ 11.8, 22.4, 24.2, 27.3, 28.4, 29.4 (2 × C), 29.55, 29.58, 
29.64, 29.8, 31.9, 32.7, 40.5, 43.4, 43.7, 45.1, 45.2, 45.6, 78.8, 81.3, 104.4, 104.5, 110.1, 
120.2, 123.2, 124.8, 126.0, 129.9, 131.4, 134.8, 149.7, 164.5, 164.9, 176.9, 178.1. 
HRMS (ESI, m/z) for C36H46N2O8 [M − H]− calc. 633.3181; found 633.3190. 
 
8-endo-9-exo-Di[2ʹ-(2ʺ,3ʺ-bis-tert-butoxycarbonylguanidino)ethylcarbamoyl]-4-
[11ʹ-(6ʺ-propylamino-1ʺ,3ʺ-dioxo-1H-benzo[de]isoquinoline-2(3H))undecyl]-3,5-
dioxatricyclo[5.2.1.02,6]decane (299) 
 
Compound 299 was prepared from diacid 298 (285 mg, 0.449 mmol) and 
aminoethylguanidine 41 (423 mg, 1.40 mmol) according to general procedure E and 
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stirred at ambient temperature for 2 d before being purified using column chromatography 
(EtOAc) to give the title compound (444 mg, 82%) as a yellow solid. 
Rf = 0.50 (EtOAc).  
m.p 98–99 °C.  
ɸf = 0.89 (DMSO). 
1H NMR (500 MHz, CDCl3) δ 1.10 (3H, t, J = 7.4 Hz, CH3), 1.24–1.42 (16H, m, 8 × 
CH2), 1.48–1.50 (37H, m, 4 × t-Bu, H10s), 1.57–1.62 (2H, m, CH2), 1.67–1.72 (2H, m, 
CH2), 1.77 (1H, d, J = 9.5 Hz, H10a), 1.80–1.87 (2H, m, CH2), 2.44 (1H, d, J = 5.2 Hz, 
H9), 2.78 (1H, br s, H7), 2.70 (1H, d, J = 4.1 Hz, H1), 2.94 (1H, app. t, J = 5.2 Hz, H8), 
3.36–3.44 (6H, m, 3 × NHCH2), 3.52–3.60 (4H, m, 2 × NHCH2), 3.94 (1H, d, J = 5.5 Hz, 
H2), 4.02 (1H, d, J = 5.5 Hz, H6), 4.12–4.15 (2H, m, H11ʹ), 4.60 (1H, t, J = 4.9 Hz, H4), 
5.29 (1H, t, J = 5.0 Hz, NH), 6.72 (1H, d, J = 8.5 Hz, H5ʺ), 6.86 (1H, t, J = 5.3 Hz, NH), 
7.61 (1H, dd, J = 8.5, 7.4 Hz, H8ʺ), 8.01 (1H, t, J = 4.1 Hz, NH), 8.09 (1H, dd, J = 8.5, 
1.0 Hz, H7ʺ), 8.45 (1H, d, J = 8.5 Hz, H4ʺ), 8.51 (1H, t, J = 5.8 Hz, NH), 8.57 (1H, dd, J 
= 7.4, 1.0 Hz, H9ʺ), 8.63 (1H, t, J = 6.1 Hz, NH), 11.45 (1H, br s, NH), 11.48 (1H, br s, 
NH). 
13C NMR (125 MHz, CDCl3) δ 11.8, 22.4, 24.4, 27.3, 28.19, 28.20, 28.3, 28.38, 28.40, 
29.6, 29.66, 29.69, 29.71, 29.74, 32.5, 33.0, 39.97, 40.04, 40.2, 40.4, 42.3, 44.25, 44.30, 
45.6, 47.8, 79.0, 79.7, 79.9, 81.6, 83.4, 83.7, 104.2, 104.5, 110.5, 120.3, 123.4, 124.8, 
125.8, 129.9, 131.2, 134.6, 149.5, 153.21, 153.22, 157.1, 157.9, 163.0, 163.5, 164.3, 
164.8, 172.1, 174.2. 
HRMS (ESI, m/z) for C62H94N10O14 [M + H]+ calc. 1203.7024; found 1203.7040. 
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4-[11ʹ-(6ʺ-Propylamino-1ʺ,3ʺ-dioxo-1H-benzo[de]isoquinoline-2(3H))undecyl]-3,5-
dioxatricyclo[5.2.1.02,6]decane-8-endo-9-exo-dicarboxamidoethylguanidine 
hydrogen chloride (287)  
 
Compound 287 was synthesised from 299 (87 mg, 0.072 mmol) according to general 
procedure G and stirred for 48 h before being isolated as an orange solid (61 mg, 97%). 
m.p 122–159 °C (slow decomposition).  
ɸf = 0.88 (DMSO) and 0.16 (H2O). 
1H NMR (500 MHz, CD3OD) δ 1.07 (3H, t, J = 7.4 Hz, CH3), 1.28–1.40 (16H, m, 8 × 
CH2), 1.47 (1H, d, J = 10.0 Hz, H10s), 1.57–1.61 (2H, m, CH2), 1.66–1.70 (2H, m, CH2), 
1.73 (1H, d, J = 10.0 Hz, H10a), 1.78–1.85 (2H, m, CH2), 2.44 (1H, br s, H9), 2.61–2.62 
(2H, m, H1, H7), 3.23 (1H, app. t, J = 5.1 Hz, H8), 3.28–3.43 (10H, m, 5 × NHCH2), 3.99 
(1H, d, J = 5.7 Hz, H2), 4.05 (1H, d, J = 5.7 Hz, H6), 4.09–4.12 (2H, m, H11ʹ), 4.65 (1H, 
t, J = 4.7 Hz, H4), 6.78 (1H, d, J = 8.7 Hz, H5ʺ), 7.63 (1H, dd, J = 8.5, 7.5 Hz, H8ʺ), 8.35 
(1H, d, J = 8.7 Hz, H4ʺ), 8.50 (1H, dd, J = 7.5, 1.1 Hz, H7ʺ), 8.55 (1H, dd, J = 8.5, 1.1 Hz, 
H9ʺ). 
13C NMR (125 MHz, CD3OD) δ 11.9, 22.7, 25.2, 28.1, 29.1, 30.4, 30.5, 30.6 (4 × C), 
32.7, 33.9, 39.6, 39.7, 41.0, 41.9, 42.0, 44.9, 45.1, 46.2, 46.8, 47.8, 79.9, 82.8, 105.09, 
105.11, 109.1, 121.9, 123.4, 125.4, 129.4, 131.3, 132.2, 136.1, 152.8, 158.9 (2 × C), 
165.8, 166.3, 174.6, 176.5. 
HRMS (ESI, m/z) for C42H62N10O6 [M + 2H]2+ calc. 402.2500; found 402.2506. 
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Dimethyl 4-[11ʹ-(7ʺ-nitrobenzo[c][1,2,5]oxadiazol-4ʺ-amino)undecyl]-3,5-
dioxatricyclo[5.2.1.02,6]decane-8-endo-9-exo-dicarboxylate (290) 
 
A solution of norbornane hydrochloride 297 (371 mg, 0.803 mmol), 4-nitrobenz-2-oxa-
1,3-diazole chloride 300 (160 mg, 0.803 mmol) and Et3N (170 μL, 1.22 mmol) in MeOH 
(8 mL) was stirred at ambient temperature for 24 h. The reaction mixture was 
concentrated under reduced pressure then diluted with EtOAc (20 mL). The organic phase 
was washed with 0.1 M HCl (10 mL), sat. NaHCO3 (10 mL), brine (10 mL), dried 
(MgSO4), filtered and concentrated in vacuo. The orange residue was purified using 
column chromatography (10% EtOAc in CH2Cl2) to give the title compound (320 mg, 
68%) as a dark orange viscous oil. 
Rf = 0.9 (10% EtOAc in CH2Cl2). 
1H NMR (500 MHz, CDCl3) δ 1.26–1.39 (15H, m, H10s, 7 × CH2), 1.60–1.64 (2H, m, 
H9ʹ), 1.60–1.64 (2H, m, H1ʹ), 1.75–1.83 (3H, m, H10ʹ, H10a), 2.64–2.65 (2H, m, H1, 
H9), 2.71 (1H, d, J = 4.5 Hz, H7), 3.22 (1H, app. t, J = 5.2 Hz, H8), 3.46–3.50, (2H, m, 
H11ʹ), 3.69 (3H, s, Me), 3.70 (3H, s, Me), 3.94 (1H, d, J = 5.6 Hz, H2), 4.02 (1H, d, J = 
5.6 Hz, H6), 4.65 (1H, t, J = 4.8 Hz, H4), 6.17 (1H, d, J = 8.6 Hz, H5ʺ), 6.33 (1H, t, J = 
4.7 Hz, NH), 8.48 (1H, d, J = 8.6 Hz, H6ʺ). 
13C NMR (125 MHz, CDCl3) δ 24.3, 27.1, 28.6, 29.3, 29.5 (3 × C), 29.57, 29.60, 31.7, 
32.9, 43.4, 43.7, 44.1, 45.1, 45.4, 52.3, 52.5, 78.9, 81.3, 98.6, 104.3, 123.9, 136.7, 144.0, 
144.1, 144.4, 172.9, 174.1.   
HRMS (ESI, m/z) for C29H40N4O9 [M + H]+ calc. 589.2868; found 589.2883. 
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4-[11ʹ-(7ʺ-Nitrobenzo[c][1,2,5]oxadiazol-4ʺ-amino)undecyl]-3,5-
dioxatricyclo[5.2.1.02,6]decane-8-endo-9-exo-dicarboxylic acid (301) 
 
The title compound was prepared from diester 290 (259 mg, 0.440 mmol) according to 
general procedure D and isolated as an orange solid (193 mg, 78%). 
m.p 98–99 °C.  
1H NMR (400 MHz, DMSO-d6) δ 1.19–1.37 (17H, m, H10s, 8 × CH2), 1.49–1.54 (2H, 
m, H1ʹ), 1.59 (1H, d, J = 9.6 Hz, H10a), 1.63–1.70 (2H, m, H10ʹ), 2.40 (1H, d, J = 5.5 Hz, 
H9), 2.45 (1H, br s, H1), 2.52 (1H, d, J = 4.6 Hz, H7), 3.00 (1H, app. t, J = 5.5 Hz, H8), 
3.44–3.45, (2H, m, H11ʹ), 3.88 (1H, d, J = 5.8 Hz, H2), 3.96 (1H, d, J = 5.8 Hz, H6), 4.61 
(1H, t, J = 4.8 Hz, H4), 6.40 (1H, d, J = 9.1 Hz, H5ʺ), 8.50 (1H, d, J = 9.1 Hz, H6ʺ), 9.55 
(1H, t, J = 5.3 Hz, NH). 
13C NMR (100 MHz, DMSO-d6) δ 23.7, 26.4, 27.6, 28.7, 28.9 (5 × C), 31.2, 32.3, 42.6, 
43.2, 43.4, 44.4, 45.0, 78.2, 80.7, 99.1, 103.2, 120.5, 138.0, 144.2, 144.4, 145.2, 173.3, 
174.6.   
HRMS (ESI, m/z) for C27H36N4O9 [M − H]− calc. 559.2410; found 559.2424. 
 
8-endo-9-exo-Di[2ʹ-(2ʺ,3ʺ-bis-tert-butoxycarbonylguanidino)ethylcarbamoyl]-4-
[11ʹ-(7ʺ-nitrobenzo[c][1,2,5]oxadiazol-4ʺ-amino)undecyl]-3,5-
dioxatricyclo[5.2.1.02,6]decane (302) 
 
Compound 302 was prepared from diacid 301 (200 mg, 0.357 mmol) and 
aminoethylguanidine 41 (339 mg, 1.12 mmol) according to general procedure E and was 
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stirred at ambient temperature for 3 d before being purified using column chromatography 
(50% EtOAc in CH2Cl2) to give the title compound (263 mg, 65%) as an orange solid. 
Rf = 0.3 (50% EtOAc in CH2Cl2). 
m.p 117–124 °C (slow decomposition).  
ɸf = 0.55 (DMSO). 
1H NMR (500 MHz, CDCl3) δ 1.27–1.38 (16H, m, 8 × CH2), 1.43–1.53 (37H, m, H10s, 
4 × t-Bu), 1.58–1.61 (2H, m, H1ʹ), 1.76–1.83 (3H, m, H10ʹ, H10a), 2.45 (1H, d, J = 
5.2 Hz, H9), 2.58 (1H, br s, H7), 2.70 (1H, d, J = 4.1 Hz, H1), 2.93 (1H, app. t, J = 5.2 Hz, 
H8), 3.35–3.60 (10H, m, 5 × NHCH2), 3.95 (1H, d, J = 5.6 Hz, H2), 4.04 (1H, d, J = 
5.6 Hz, H6), 4.61 (1H, t, J = 4.7 Hz, H4), 6.17 (1H, d, J = 8.7 Hz, H5ʺ), 6.32 (1H, t, J = 
5.2 Hz, NH), 6.87 (1H, t, J = 5.2 Hz, NH), 8.03 (1H, t, J = 4.1 Hz, NH), 8.49–8.51 (2H, 
m, H6ʺ, NH), 8.64 (1H, t, J = 6.1 Hz, NH), 11.44 (1H, br s, NH), 11.48 (1H, br s, NH). 
13C NMR (125 MHz, CDCl3) δ 24.2, 27.1, 28.20, 28.21, 28.39, 28.41, 28.7, 29.3, 29.48, 
29.51, 29.54, 29.56, 29.61, 32.5, 32.9, 40.0, 40.1, 40.2, 42.3, 43.0, 44.1, 44.2, 44.3, 47.9, 
79.0, 79.7, 79.9, 81.7, 83.4, 83.7,  98.6, 104.1, 124.1, 136.6, 144.00, 144.04, 144.4, 153.2 
(2 × C), 157.1, 157.9, 163.0, 163.5, 172.0, 174.2.   
HRMS (ESI, m/z) for C53H84N12O15 [M + H]+ calc. 1129.6252; found 1129.6265. 
 
4-[11ʹ-(7ʺ-Nitrobenzo[c][1,2,5]oxadiazol-4ʺ-amino)undecyl]-3,5-
dioxatricyclo[5.2.1.02,6]decane-8-endo-9-exo-dicarboxamidoethylguanidine 
hydrogen chloride (288)  
 
Compound 288 was synthesised from 302 (89 mg, 0.079 mmol) according to general 
procedure G and was stirred for 48 h before being isolated as an orange solid (60 mg, 
95%). 
m.p 121–124 °C. 
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ɸf = 0.55 (DMSO) and 0.02 (H2O). 
1H NMR (500 MHz, CD3OD) δ 1.28–1.48 (17H, m, H10s, 8 × CH2), 1.55–1.59 (2H, m, 
H1ʹ), 1.72 (1H, d, J = 10.4 Hz, H10a), 1.75–1.80 (2H, m, H10ʹ), 2.44 (1H, br s, H9), 2.61–
2.62 (2H, m, H1, H7), 3.22 (1H, app. t, J = 5.0 Hz, H8), 3.29–3.40, (8H, m, 4 × CH2NH), 
3.52–3.55 (2H, m, H11ʹ), 3.99 (1H, d, J = 5.6 Hz, H2), 4.04 (1H, d, J = 5.6 Hz, H6), 4.64 
(1H, t, J = 4.7 Hz, H4), 6.35 (1H, d, J = 8.8 Hz, H5ʺ), 8.53 (1H, d, J = 8.8 Hz, H6ʺ). 
13C NMR (125 MHz, CD3OD) δ 25.2, 28.0, 29.2, 30.3, 30.49, 30.51 (2 × C), 30.57, 30.61, 
32.7, 33.9, 39.6, 39.7, 41.9, 42.0, 44.7, 44.9, 45.1, 46.9, 47.7, 79.9, 82.8, 99.5, 105.1, 
122.9, 138.6, 145.6, 145.9, 146.7, 158.8 (2 × C), 174.6, 176.5.   
HRMS (ESI, m/z) for C33H52N12O7 [M + 2H]2+ calc. 365.2114; found 365.2115. 
 
9.2.6: Chapter Six 
3-endo-2-exo-(Hetpylcarbamoyl)bicyclo[2.2.1]hept-5-ene (316) 
 
Compound 316 was prepared from diacid 50 (105 mg, 0.58 mmol) and heptylamine 
(260 μL, 1.74 mmol) according to general procedure E. Purification using column 
chromatography (10–50% EtOAc in pet. spirits) gave the title compound (274 mg, 64%) 
as a white solid. 
Rf = 0.64 (50% EtOAc in pet. spirits).  
m.p 127–128 °C. 
1H NMR (500 MHz, CDCl3) δ 0.85–0.88 (6H, m, 2 × CH3), 1.26–1.28 (16H, m, 8 × CH2), 
1.46–1.51 (4H, m, 2 × CH2), 1.54 (1H, dd, J = 8.5, 1.7 Hz, H7s), 1.73 (1H, d, J = 8.5 Hz, 
H7a), 2.37 (1H, dd, J = 5.4, 1.7 Hz, H2), 2.97 (1H, dd, J = 5.4, 3.3 Hz, H3), 3.03 (1H, br 
s, H1), 3.07 (1H, br s, H4), 3.12–3.29 (4H, m, 2 × NHCH2), 6.02 (1H, br s, NH), 6.13 
(1H, dd, J = 5.6, 2.8 Hz, H5), 6.27 (1H, dd, J = 5.6, 3.1 Hz, H6), 6.44 (1H, br s, NH). 
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13C NMR (125 MHz, CDCl3) δ 14.2 (2 × C), 22.7 (2 × C), 26.99, 27.02, 29.06, 29.09, 
29.7, 29.8, 31.9 (2 × C), 39.7, 39.8, 44.6, 45.5, 48.6, 48.9, 51.2, 134.5, 138.2, 173.6, 
174.7. 
HRMS (ESI, m/z) for C23H40N2O2 [M + H]+ calc. 377.3163 found 377.3169. 
 
3-endo-2-exo-(Hexadecylcarbamoyl)bicyclo[2.2.1]hept-5-ene (317) 
 
Compound 317 was prepared from diacid 50 (306 mg, 1.68 mmol), and hexadecylamine 
(1.22 g, 5.04 mmol) according to general procedure F. Purification using flash column 
chromatography (10–50% EtOAc in pet. spirits) gave the title compound (366 mg, 35%) 
as a white solid. 
Rf = 0.38 (20% EtOAc in pet. spirits).  
m.p 92–97 °C. 
1H NMR (270 MHz, CDCl3) δ 0.88 (6H, t, J = 6.5 Hz, 2 × CH3), 1.26–1.30 (52H, m, 26 
× CH2), 1.42–1.63 (5H, m, 2 × CH2, H7s), 1.73 (1H, d, J = 8.6 Hz, H7a), 2.37 (1H, dd, J 
= 5.5, 1.7 Hz, H2), 2.97 (1H, dd, J = 5.5, 3.3 Hz, H3), 3.05 (2H, br s, H1, H4), 3.12–3.29 
(4H, m, 2 × NHCH2), 5.95 (1H, t, J = 5.7 Hz, NH), 6.13 (1H, dd, J = 5.6, 2.5 Hz, H5), 
6.27 (1H, dd, J = 5.6, 3.2 Hz, H6), 6.40 (1H, t, J = 5.9 Hz, NH). 
13C NMR (67.5 MHz, CDCl3) δ 14.3 (2 × C), 22.8 (3 × C), 27.1 (3 × C), 29.4 (2 × C), 
29.5 (2 × C), 29.69 (2 × C), 29.72 (2 × C), 29.79 (4 × C), 29.81 (4 × C), 29.83 (3 × C), 
32.1 (3 × C), 39.7, 39.8, 44.6, 45.5, 48.7, 49.0, 51.2, 134.5, 138.2, 173.6, 174.7. 
HRMS (ESI, m/z) for C41H76N2O2 [M + H]+ calc. 629.5980 found 629.6008. 
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Methyl exo-2-(heptylcarbamoyl)bicyclo[2.2.1]hept-5-ene-3-endo-carboxylate (318) 
 
Compound 318 was prepared from carboxylic acid 205 (585 mg, 2.98 mmol), and 
heptylamine (680 μL, 4.47 mmol) according to general procedure F. Purification using 
column chromatography (30% EtOAc in pet. spirits) gave the title compound (427 mg, 
49%) as a viscous yellow oil. 
Rf = 0.60 (35% EtOAc in pet. spirits).  
1H NMR (270 MHz, CDCl3) δ 0.87 (3H, t, J = 6.6 Hz, CH3), 1.27–1.30 (8H, m, 4 × CH2), 
1.45–1.52 (3H, m, CH2, H7s), 1.86 (1H, d, J = 8.6 Hz, H7a), 2.33 (1H, dd, J = 4.5, 1.8 Hz, 
H2), 3.01 (1H, br s, H4), 3.17–3.29 (4H, m, NHCH2, H1, H3), 3.66 (3H, s, Me), 5.83 (1H, 
t, J = 5.1 Hz, NH), 6.09 (1H, dd, J = 5.6, 2.5 Hz, H6), 6.25 (1H, dd, J = 5.6, 3.2 Hz, H5). 
13C NMR (67.5 MHz, CDCl3) δ 14.2, 22.7, 27.0, 29.1, 29.8, 31.9, 39.8, 45.0, 47.0, 47.8, 
48.6, 49.4, 52.1, 135.5, 138.1, 174.0, 174.8. 
HRMS (ESI, m/z) for C17H27NO3 [M + Na]+ calc. 316.1883; found 316.1895. 
 
exo-2-(Heptylcarbamoyl)bicyclo[2.2.1]hept-5-ene-3-endo-carboxylic acid (320) 
 
The title compound was prepared from ester 318 (414 mg, 1.41 mmol) according to 
general procedure D and isolated as a fine white powder (309 mg, 77%). 
m.p 144–147 °C. 
1H NMR (270 MHz, CDCl3) δ 0.87 (3H, t, J = 6.5 Hz, CH3), 1.28–1.30 (8H, m, 4 × CH2), 
1.48–1.52 (3H, m, CH2, H7s), 1.81 (1H, d, J = 8.9 Hz, H7a), 2.32 (1H, dd, J = 4.5, 2.0 Hz, 
H2), 3.01 (1H, br s, H4), 3.22–3.30 (4H, m, NHCH2, H1, H3), 5.82 (1H, t, J = 6.0 Hz, 
NH), 6.19 (1H, dd, J = 5.6, 2.1 Hz, H6), 6.26 (1H, dd, J = 5.6, 3.2 Hz, H5). 
13C NMR (67.5 MHz, CDCl3) δ 14.2, 22.7, 27.0, 29.1, 29.7, 31.9, 40.0, 44.8, 46.7, 47.8, 
48.8, 49.4, 135.8, 138.0, 174.1, 178.0. 
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HRMS (ESI, m/z) for C16H25NO3 [M + H]+ calc. 280.1907; found 280.1906. 
 
Methyl exo-2-(hexadecylcarbamoyl)bicyclo[2.2.1]hept-5-ene-3-endo-carboxylate 
(319) 
 
Compound 319 was prepared from carboxylic acid 205 (641 mg, 3.27 mmol), and 
hexadecylamine (1.26 g, 5.22 mmol) according to general procedure E. Purification using 
column chromatography (20% EtOAc in pet. spirits) gave the title compound (431 mg, 
31%) as a white solid. 
Rf = 0.40 (20% EtOAc in pet. spirits).  
m.p 69–70 °C. 
1H NMR (270 MHz, CDCl3) δ 0.87 (3H, t, J = 6.4 Hz, CH3), 1.25–1.29 (26H, m, 13 × 
CH2), 1.44–1.52 (3H, m, CH2, H7s), 1.86 (1H, d, J = 8.7 Hz, H7a), 2.32 (1H, dd, J = 4.4, 
1.8 Hz, H2), 3.00–3.02 (1H, m, H4), 3.19–3.28 (4H, m, NHCH2, H1, H3), 3.66 (3H, s, 
Me), 5.84 (1H, t, J = 4.6 Hz, NH), 6.08 (1H, dd, J = 5.8, 2.7 Hz, H6), 6.24 (1H, dd, J = 
5.8, 3.2 Hz, H5). 
13C NMR (67.5 MHz, CDCl3) δ 14.3, 22.8, 27.0, 29.4, 29.5, 29.6, 29.7, 29.8 (7 × C), 
32.0, 39.8, 45.0, 47.0, 47.8, 48.6, 49.4, 52.1, 135.5, 138.1, 174.0, 174.8. 
HRMS (ESI, m/z) for C26H45NO3 [M + H]+ calc. 420.3472; found 420.3466. 
 
exo-2-(Hexadecylcarbamoyl)bicyclo[2.2.1]hept-5-ene-3-endo-carboxylic acid (310) 
 
The title compound was prepared from ester 319 (389 mg, 0.93 mmol) according to 
general procedure D and isolated as a white solid (261 mg, 69%). 
m.p 144–145 °C.  
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1H NMR (500 MHz, CDCl3) δ 0.88 (3H, t, J = 6.8 Hz, CH3), 1.25–1.29 (26H, m, 13 × 
CH2), 1.48–1.53 (3H, m, CH2, H7s), 1.80 (1H, d, J = 8.8 Hz, H7a), 2.33 (1H, dd, J = 4.9, 
1.7 Hz, H2), 3.00 (1H, br s, H4), 3.22–3.30 (4H, m, NHCH2, H1, H3), 5.80 (1H, t, J = 
4.8 Hz, NH), 6.20 (1H, dd, J = 5.6, 2.6 Hz, H6), 6.27 (1H, dd, J = 5.6, 3.1 Hz, H5). 
13C NMR (125 MHz, CDCl3) δ 14.3, 22.8, 27.0, 29.4, 29.5, 29.68, 29.73, 29.75, 29.81 (2 
× C), 29.83 (2 × C), 29.9 (2 × C), 32.1 40.0, 44.7, 46.5, 47.7, 49.0, 49.3, 135.9, 137.9, 
174.2, 176.8. 
HRMS (ESI, m/z) for C25H43NO3 [M + H]+ calc. 406.3316; found 406.3308. 
 
endo-3-(Heptylcarbamoyl)bicyclo[2.2.1]hept-5-ene-2-exo-carboxylic acid (322) 
 
The title compound was prepared from ester 209 (1.38 g, 3.29 mmol) according to general 
procedure D and isolated as a white solid (1.20 g, 87%). 
m.p 110–112 °C.  
1H NMR (270 MHz, CDCl3) δ 0.88 (3H, t, J = 6.3 Hz, CH3), 1.27–1.28 (8H, m, 4 × CH2), 
1.46–1.58 (4H, m, CH2, H7s, H7a), 2.53 (1H, d, J = 5.8 Hz, H2), 3.08–3.30 (5H, m, 
NHCH2, H1, H3, H4), 5.79 (1H, t, J = 5.8 Hz, NH), 6.16 (1H, dd, J = 5.6, 2.5 Hz, H6), 
6.31 (1H, dd, J = 5.6, 3.2 Hz, H5). 
13C NMR (67.5 MHz, CDCl3) δ 14.2, 22.7, 26.9, 29.0, 29.6, 31.8, 39.4, 44.7, 45.6, 48.6, 
48.7, 50.0, 134.4, 138.9, 173.5, 177.9. 
HRMS (ESI, m/z) for C16H25NO3 [M + H]+ calc. 280.1904; found 280.1907. 
 
endo-3-(Hexadecylcarbamoyl)bicyclo[2.2.1]hept-5-ene-2-exo-carboxylic acid (311) 
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The title compound was prepared from ester 210 (543 mg, 1.29 mmol) according to 
general procedure D and isolated as a white solid (464 mg, 90%). 
m.p 113–114 °C.  
1H NMR (270 MHz, CDCl3) δ 0.88 (3H, t, J = 6.0 Hz, CH3), 1.25–1.28 (26H, m, 13 × 
CH2), 1.48–1.52 (2H, m, CH2), 1.60–1.61 (2H, m, H7s, H7a), 2.49 (1H, dd, J = 6.0, 
0.8 Hz, H2), 3.06–2.29 (5H, m, NHCH2, H1, H3, H4), 5.70 (1H, t, J = 6.0 Hz, NH), 6.14 
(1H, dd, J = 5.8, 2.9 Hz, H6), 6.35 (1H, dd, J = 5.8, 2.7 Hz, H5). 
13C NMR (67.5 MHz, CDCl3) δ 14.3, 22.8, 27.0, 29.4, 29.5, 29.6, 29.67, 29.71, 29.78, 
29.81, 29.82 (2 × C), 29.84 (2 × C), 32.1 40.0, 44.1, 44.9, 48.8, 49.0, 50.2, 133.7, 138.7, 
173.9, 176.3. 
HRMS (ESI, m/z) for C25H43NO3 [M + H]+ calc. 406.3319; found 406.3316. 
 
9.3 General Procedures 
Some of the following procedures were kindly performed by experts in their respective 
fields and their contributions have been noted where appropriate. 
Disk diffusion assays 
All disk diffusion assays were performed courtesy of Professor Jian Li and Ms Heidi Yu 
at the Monash Institute of Pharmaceutical Sciences. 
A stock solution of 10 mg/mL was made for each compound under observation using 
DMSO as a solvent. Each of these stock solutions was then diluted by a factor of 1:2 to 
bring the concentration to 5 mg/mL. The diluted solutions were then filter-sterilised using 
a 0.2 μm nylon filter, and 10 μL of the 5 mg/mL stock was pipetted onto a blank disk (i.e. 
50 μg per disk). Suspensions of all bacterial isolates were adjusted to a 0.5 McFarland 
standard (in 0.9% NaCl) before they were swabbed onto nutrient agar plates. The controls 
used were a 10 μg Colistin disk (sulphate Oxoid), 10 μL of DMSO and a plate swabbed 
with saline from the dispenser used. 
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Micro-broth dilution assays 
All MIC determinations and cytotoxicity studies were performed by The Community for 
Antimicrobial Drug Discovery (CO-ADD), funded by the Wellcome Trust (UK) and The 
University of Queensland. Specifically, all MIC values were determined by Dr Alysha 
Elliott and all cytotoxicity studies were carried out by Dr Johnny Huang. 
Bacteria were obtained either from American Type Culture Collection (ATCC; Manassas, 
VA, USA), Network on Antimicrobial Resistance in Staphylococcus aureus (NARSA) or 
from a clinical isolate library at The University of Queensland, Centre for Clinical 
Research (UQCCR) as listed in Table 31. Bacteria were cultured in Nutrient broth (NB; 
Bacto Laboratories, catalogue no. 234000) or Muller-Hinton broth (MHB; Bacto 
Laboratories, catalogue no. 211443) at 37 °C overnight with shaking (≈ 180 RPM). A 
sample of each culture was diluted 50-fold in a fresh MHB and incubated at 37 °C for 
1.5–3 h with shaking (≈ 180 RPM). Compound stock solutions were prepared as 
10 mg/mL in DMSO and Colistin was dissolved in milli-Q water at 5.12 mg/mL. The 
compounds, at twice the final desired concentration, were serially diluted 2-fold across 
the wells of 96-well plates (Non-Binding Surface, Corning, catalogue no. 3641). Mid-log 
phase bacterial cultures (after 1.5–3 h incubation) were diluted to a final concentration of 
5 × 105 colony forming units (CFU) per mL, and 50 μL was added to each well giving a 
final compound concentration range of 32 μg/mL to 0.015 μg/mL (DMSO ≤ 1%). MICs 
were determined visually after 20 h of incubation 37 °C, with the MIC defined as the 
lowest compound concentration at which no bacterial growth was visible. Determined 
MIC values are the result of two independent experiments of n = 2, giving a final dataset 
of n = 4. 
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Table 31: Bacterial strains for disk diffusion and MIC assays 
Organism Strain Strain description Assay 
Escherichia  
coli 
ATCC 25922 FDA strain Seattle 
1946 
MIC 
Klebsiella  
pneumoniae 
ATCC 13883 Control strain DD 
Klebsiella  
pneumoniae 
ATCC 700603 MDR MIC 
Acinetobacter 
baumannii 
ATCC 19606 Type strain DD/MICa 
Pseudomonas 
aeruginosa 
ATCC 27853 Type strain DD/MIC 
Staphylococcus 
aureus 
ATCC 43300 MRSA DD/MIC 
Enterococcus 
 faecium 
ATCC 700221 VRE DD 
Staphylococcus 
aureus 
Clinical isolate from 
UQCCR collection 
mMRSA (multi-
resistant MRSA) 
MIC 
Staphylococcus  
aureus 
NARSA-NRS 17 GISA (glycopeptide 
intermediate S. aureus) 
MIC 
Staphylococcus  
aureus 
NARSA-NRS 1 VISA (Vancomycin-
intermediate S. aureus) 
MIC 
Streptococcus 
pneumoniae 
ATCC 700677 MDR MIC 
Enterococcus  
faecalis 
Clinical isolate from 
UQCCR collection 
VanA (Vancomycin 
resistant) 
MIC 
a DD = Disk diffusion. 
Cytotoxicity studies 
HEK293 (ATCC CRL-1573) and HepG2 (ATCC HB-8065) cells were seeded as 3000 
cells per well in a 384–well plate in DMEM medium (GIBCO-Invitrogen #11995-073), 
in which 10% of FBS was added. Cells were incubated for 24 h at 37 °C, 5% CO2 to allow 
cells to attach to the plates. A concentration series of compounds was then added into 
each well. The cells were incubated with the compounds for 24 h at 37 °C, 5% CO2. After 
the incubation, 10 μM resazurin (dissolved in PBS) was added to each well. The plates 
were then incubated for 2 h at 37 °C, 5% CO2. The fluorescence intensity was read using 
Polarstar Omega with excitation/emission 560/590 nm. The data was analysed by Prism 
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software. Results are presented as the average percentage of control ± SD for each set of 
duplicate wells using the following equation: 
Percentage Viability = (FITest − FINegative/FIUntreated – FINegative) × 100. 
Crystallography 
Crystal structures were solved by Professor Jonathan White at The University of 
Melbourne. 
Intensity data were collected with a CCD diffractometer using Cu-Kα radiation, the 
temperature during data collection was maintained at 130.0 °C using an Oxford 
Cryosystems cooling device. The structure was solved by direct methods and difference 
Fourier synthesis.509 Thermal ellipsoid plots were generated using the program ORTEP-
3510 integrated within the WINGX511 suite of programs. Disordered solvent, assumed to 
be EtOH was removed using the Squeeze procedure.512 
Formation of organogels 
All gels were formed by first heating a selected organogelator in organic solvent (1 mL) 
until a clear homogenous solution was formed, followed by cooling to room temperature 
and then to 4 °C for no more than 16 h. An organogelator was identified if the gel structure 
remained intact when samples were left upside-down, unagitated, at ambient temperature 
for 6 h.457 
Differential scanning calorimetry 
DSC and rheometry experiments were performed courtesy of Dr Richard Williams (RMIT 
University) and Ms Rui Li (Deakin University). 
A TA differential scanning calorimeter (DSC) Q200 instrument (TA Instruments, New 
Castle, DE, USA), a Tzero aluminium pan and a Tzero Hermetic lid were used for DSC 
experiments. Approximately, 10 mg of the sample was weighed into the pan, then covered 
with the lid and sealed using Tzero press. A small hole was made on the lid to allow for 
evaporation of solvent. Ramp 1 °C/min from 20–120 °C. An empty pan with lid (also 
with a hole) was used as a reference. 
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Rheometry 
A Discovery Hybrid Rheometer (TA Instruments) was operated at constant stress with a 
strain of 1%. An amplitude sweep was performed and then frequency sweeps were 
performed over a range from 1.0 to 100 rad/s. Temperature was maintained at 25 °C by 
means of Peltier plate controller. Soak time = 30 min. Organogels were performed on a 
cone-plate geometry (40 mm, 2°1ʹ 37ʺ) with a gap of 51 μm. A water trap was used to 
minimise evaporation. 
Atomic force microscopy 
AFM and TEM images were obtained by Dr Richard Williams (RMIT University) and Ms 
Rui Li (Deakin University). 
AFM images were obtained using a Multimode 8 (BRUKER BioSciences Corporation, 
Billerica, MA, USA). The tips used were Scanasyst-air probes with silicon tip on nitride 
lever (BRUKER BioSciences Corporation). The AFM was operated in peak force 
quantitative nanomechanical property mapping. Scan size was at 10 μm. Samples were 
prepared by diluting the organogels to a final concentration of 0.78 mg/mL and 15 μL of 
diluted samples were applied to highly ordered pyrolytic graphite (HOPG) substrates 
(SPI, Supplies, West Chester, PA, USA), the redundant samples were absorbed by pipette. 
Transmission electron microscopy 
JEOL-2100 LaB6 TEM (JEOL Ltd., Akishima, Tokyo, Japan) at an operation voltage of 
100 kV was used for TEM images. Holey carbon-coated films on 300 mesh copper grids 
(Emgrid Pty. Ltd., The Patch, VIC, Australia) were used as a sample holder. For sample 
preparation, 12 μL of diluted sample (3.1 mg/mL) was applied onto the grid and allowed 
to absorb for 30 s, then using split Whatman filter paper (No. 1) to wick off excess fluid. 
The sample was air-dried (carbon side up) overnight. 
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Chapter 11 
Appendix 
11.1 Conversion of μM to μg/mL 
Worked example: conversion of a 12 μM solution of compound 189 to μg/mL 
Molecular weight (189) = 617.65. 
1 M solution of 189 = 617.65 g in 1 L. 
Therefore, 1 μM solution of 189 = 617.65 μg in 1 L. 
Multiply mass by 12 to convert to 12 μM 
12 μM solution of 189 = 7411.8 μg in 1 L. 
Divide by 1000 to convert to mL 
12 μM solution of 189 = 7.41 μg in 1 mL 
Therefore, 12 μM of 189 ≈ 7 μg/mL. 
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11.2 NMR spectra of 187 
 
Figure 93: 1H and 13C NMR spectra of diamine 187 in CD3OD. 
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11.3 Photophysical data (Chapter 5) 
 
Figure 94: Normalised absorption and emission spectra of naphthalimide 299 in DMSO; λex = 
442 nm, λem = 526 nm and ɸf = 0.89. 
 
Figure 95: Normalised absorption and emission spectra of naphthalimide 287 in DMSO; λex = 
437 nm, λem = 528 nm and ɸf = 0.88. 
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Figure 96: Normalised absorption and emission spectra of naphthalimide 287 in H2O; λex = 449 
nm, λem = 549 nm and ɸf = 0.16. 
 
 
Figure 97: Normalised absorption and emission spectra of NBD 302 in DMSO; λex = 475 nm, 
λem = 538 nm and ɸf = 0.55. 
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Figure 98: Normalised absorption and emission spectra of NBD 288 in DMSO; λex = 472 nm, 
λem = 538 nm and ɸf = 0.55. 
 
Figure 99: Normalised absorption and emission spectra of NBD 288 in H2O; λex = 475 nm, λem 
= 550 nm and ɸf = 0.02. 
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11.4 Publications 
 
 
Abstract: This short report describes an improved, reliable, and high-yielding (>90%) 
synthesis of 2-[2,3-bis(tert-butoxycarbonyl)guanidino]ethylamine. The method is 
scalable (>5 g), and the product obtained directly from the reaction mixture requires no 
further purification. In addition, this methodology can be successfully applied to other 
diamine substrates (1,3-propyl and 1,4-butyl; 70% and 61% yield, respectively). 
 
 
 
 
 
 
 
 
 
 
Shane M. Hickey, Trent D. Ashton, Simren K. Khosa and Frederick M. Pfeffer, An 
optimised synthesis of 2-[2,3-Bis(tert-butoxycarbonyl)guanidine]ethylamine. Synlett 
2012, 23, 1779–1782. 
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Abstract: Using the rigid norbornane scaffold, a series of low molecular weight (LMW) 
organogelators have been synthesised and evaluated. Three separate compounds (16, 19 
and 20) were identified as organogelators in three aromatic organic solvents (PhMe, 
anisole and o-xylene). The formation of fibrillar assemblies at nanometre level were 
confirmed using AFM and TEM.  
 
 
 
 
 
 
Shane M. Hickey, Shani K. Tripcony, Rui Li, Richard J. Williams and Frederick M. 
Pfeffer, Organogelators based on the norbornane scaffold. Supramolecular Chemistry 
2015, 27, 425–435. 
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Abstract: Three useful developments in the preparation of guanidines are presented 
herein. A collection of bis(Boc)aminoalkylguanidines (n = 2, 3, 4 and 6; Boc = tert-
butoxycarbonyl), known to be prone to cyclisation, have been synthesised and isolated 
without chromatography as shelf stable sulfonate salts in good yield (up to 94%). 
Secondly, a selection of guanidines tethered to a range of other functional groups, 
including alkyne, alkene, alcohol and azide, have been prepared in good yields with no 
requirement for a purification step. Thirdly, an inexpensive, high-yielding (93%) and 
facile synthesis of N,Nʹ-bis(Boc)guanidine, a key precursor for N,Nʹ-bis(Boc)-Nʺ-
triflylguanidine, is described in which the need for chromatographic purification is again 
obviated. 
 
 
 
 
Shane M. Hickey, Trent D. Ashton and Frederick M. Pfeffer, Facile synthesis of 
guanidine functionalised building blocks. Asian Journal of Organic Chemistry 2015, 4, 
320–326. 
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Abstract: A small series of norbornane bisether diguanidines have been synthesized and 
evaluated as antibacterial agents. The key transformation—bisalkylation of norbornane 
diol 6—was not successful using Williamson methodology but has been accomplished 
using Ag2O mediated alkylation. Further functionalization to incorporate two 
guanidinium groups gave rise to a series of structurally rigid cationic amphiphiles; several 
of which (16d, 16g and 16h) exhibited antibiotic activity. For example, compound 16d 
was active against a broad range of bacteria including Pseudomonas aeruginosa (MIC = 
8 μg mL−1), Escherichia coli (MIC = 8 μg mL−1) and methicillin-resistant Staphylococcus 
aureus (MIC = 8 μg mL−1). 
 
 
 
Shane M. Hickey, Trent D. Ashton, Jonathan M. White, Jian Li, Roger L. Nation, Heidi 
Y. Yu, Alysha G. Elliott, Mark S. Butler, Johnny X. Huang, Matthew A. Cooper and 
Frederick M. Pfeffer, Synthesis of norbornane bisether antibiotics via silver-mediated 
alkylation. RSC Advances 2015, 5, 28582–28596. 
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Abstract: A series of structurally amphiphilic biscationic norbornanes have been 
synthesised as rigidified, low molecular weight peptidomimetics of cationic antimicrobial 
peptides. A variety of charged hydrophilic functionalities were attached to the norbornane 
scaffold including aminium, guanidinium, imidazolium and pyridinium moieties. 
Additionally, a range of hydrophobic groups of differing sizes were incorporated by an 
acetal linkage. The compounds were evaluated for antibacterial activity against both 
Gram-negative and Gram-positive bacteria. Activity was observed across the series; the 
most potent of which exhibited MIC’s ≤ 1 μg mL−1 against Streptococcus pneumoniae, 
Enterococcus faecalis and several strains of Staphylococcus aureus, including multi-
resistant methicillin resistant (mMRSA), glycopeptide-intermediate (GISA) and 
vancomycin-intermediate (VISA) S. aureus. 
 
Shane M. Hickey, Trent D. Ashton, Simren K. Khosa, Ryan N. Robson, Jonathan M. 
White, Jian Li, Roger L. Nation, Heidi Y. Yu, Alysha G. Elliott, Mark S. Butler, Johnny 
X. Huang, Matthew A. Cooper and Frederick M. Pfeffer, Synthesis and evaluation of 
cationic norbornanes as peptidomimetic antibacterial agents. Organic & Biomolecular 
Chemistry 2015, 13, 6225–6241. 
